2010 Roche Annual Report
Creating value
for patientsKey figures
Roche Group Index 2008 = 100
Sales mCHF Free cash flow mCHF
2010 47,473 4,699
2009 49,051 8,893
2008 45,617 4,979
Research and development 2 mCHF Total dividend mCHF
2010 9,050 5,6933
2009 9,509 5,175
2008 8,704 4,313
Operating profit 2 mCHF Number of employees
2010 16,591 80,653
2009 16,272 81,507
2008 15,068 80,080
Income taxes 2 mCHF Total employee remuneration mCHF
2010 3,135 11,934
2009 3,287 12,080
2008 3,604 11,129
Net income mCHF Patients on clinical trials 4
2010 8,891 327,804
2009 8,510 302,063
2008 10,844 277,674
Core Earnings per Share CHF Eco-efficiency rate 5
2010 12.78 0.414
2009 12.34 0.46
2008 11.17 0.387
Price development of non-voting equity security (Genussschein) | in CHF
2008 2009 2010
300
250
200
150
100
Roche non-voting equity security Swiss Market Index (rebased)
1 Key figures indexed to 2008 = 100. Figures for 2008 as in Annual Report 2009.
2 Core results. For a full index of Global Reporting Initiative (GRI)
3 Proposed by the Board of Directors. indicators used in the report see:
4 Development phase I to IV. www.roche.com/reporting_and_indices
5 For calculation of the Eco-Efficiency Rate see:
www.roche.com/environmentHighlights 2010
January January FEbruary
Eu Commission approves FDa approves actemra for the Roche Annual General Meeting votes
Herceptin for treatment of HER2- treatment of moderately to severely to increase shareholder dividend
positive advanced stomach cancer active rheumatoid arthritis by 20%
20
%
april JunE July
roche acquires medingo to expand FDa expands lucentis approval atHEna clinical trial demonstrates
its position in the growing insulin delivery to include treatment of macular edema high medical value of cobas 4800
systems market following retinal vein occlusion HpV test, which detects high-risk
genotypes 16 and 18, in screening for
cervical cancer
47,000
women
sEptEmbEr sEptEmbEr oCtobEr
FDa clearance for cobas 8000 roche named Healthcare super- Encouraging new clinical data for
modular analyser series for high- sector leader in Dow Jones Sustain- Avastin in ovarian, MetMAb in lung and
volume lab testing ability Indexes for second year running T–DM1 in breast cancer presented at
ESMO conference
october noVEmbEr RDG16E78 C— a Efirsmt-in-cblassE GRrI for schizophrenia
Creating value for patients means having
We report promising phase II results We launch the operational Excel- tPheh acosuer aIIg es ttuod gyo wwihtehr ef inresetd-si na-rec glaresast and
with rG7204 (brAF inhibitor), lence initiative to maintain long-term o cthoemrs phaovue nfadile rdG1678 shows
a new targeted medicine for innovation capabilities improvement in negative symptoms
advanced melanoma A———v oES Pbaf oeii gf tslena wic tib feift viil ecv ee nea s t n aah yst cmge s uar pi tia dn etcp oe s em itee p p sfs ifh soeooscfdi ttt es eiv inse zs s tiy lm l oop ct co um prs in thhe strabele phnasesi a R———— GEPFN1 efo ef w6 te we7c en t rm8 ti viseae icld a hteog a e a ntfri ifne semsacttt sons fue gb aao cttp ii ovtie nm sayllmy pctoonmtrsolled positive symptoms
Affecting nearly 24 million people worldwide, schizo- RG1678, a glycine reuptake inhibitor (GRI) developed
phrenia is a severe mental disorder that distorts at Roche, may be the first drug to treat the negative
the way a person thinks, acts, expresses emotions, per- symptoms of schizophrenia. Representing an entirely
ceives reality and relates to others. It is a lifelong novel approach, RG1678 normalises glutamate neu-
disease that cannot be cured. On average it shortens rotransmission by increasing synaptic levels of glycine,
life expectancy by 20 years due to the higher risk thereby targeting an important pathway in psychiatric
of suicide and also due to cardiovascular and pulmo- disorders. It has the potential to become first-in-class
nary events. Because of negative symptoms, which compound of this type for the treatment of schizophre-
usually have the greatest impact on quality of life, nia. In addition, RG1678 in combination with current
patients may be unable to live independently, hold jobs, treatments has the potential to treat suboptimally con-
establish personal relationships and manage every- trolled positive symptoms, with little or no increase
day social situations. Many drugs developed to treat in side effects. Its novel mode of action could also have
negative symptoms have failed in clinical trials, and the valu able therapeutic applications in other psychiatric
few available treatments offer only modest benefits. disorders.
07_Roche_AR10_ENG_Diagnostics.indd 72 28.01.2011 17:18:10|
Pharmaceuticals pipeline
Targeting areas of high unmet medical need
Phase I Phase II Phase III Registration
Project ID Project/Product Indication Project ID Project/Product Indication Project ID Project/Product Indication Project ID Project/Product Indication
Oncology Oncology Oncology Oncology
RG3639 dulanermin cancer RG1273 pertuzumab early BC, HER2+ RG105 MabThera/Rituxan NHL, fast infusion RG105 MabThera/Rituxan indolent NHL, 1st-line maint
RG7256 BRAF kinase inh metastatic melanoma RG1273 pertuzumab mBC, HER2+, 2nd-line RG105 MabThera/Rituxan NHL, SC formulation RG435* Avastin ovarian cancer, 1st-line
RG7112 MDM2 antag solid and hematologic tumours ADC RG3502 trastuzumab–DM1 early BC, HER2+ RG435 Avastin adj breast cancer, HER2+ RG435* Avastin+Xeloda met breast cancer, 1st-line
RG7160 anti-EGFR huMAb solid tumours RG3616 hedgehog pathway inh advanced basal cell carcinoma RG435 Avastin+Herceptin mBC, HER2+, 1st-line RG1415* Tarceva NSCLC, EGFR mutation-
RG7167 CIF/MEK dual inh solid tumours RG3616 hedgehog pathway inh operable basal cell carcinoma RG435 Avastin adj NSCLC positive, 1st-line
RG7304 RAF/ MEK dual inh solid tumours RG3638 anti-Met MAb metastatic NSCLC RG435 Avastin adj breast cancer, HER2-neg
RG7321 PI3 kinase inh solid tumours RG7159 anti-CD20 MAb NHL, CLL RG435 Avastin adj BC, triple negative Inflammation and autoimmune disorders
RG7334 anti-PlGF MAb solid tumours RG7204 BRAF inh met melanoma, 2nd-/3rd-line RG435 Avastin relapsed ovarian cancer RG105** MabThera/Rituxan ANCA-associated vasculitis
RG7414 anti-EGFL7 MAb solid tumours RG7433 navitoclax (ABT-263) solid and hematologic tumours RG435 Avastin high-risk carcinoid RG1569 Actemra/RoActemra JIA, systemic onset
RG7420 MEK inh solid tumours CHU topoisomerase I inh gastric cancer RG435 Avastin GBM, 1st-line
RG7421 MEK inh solid tumours RG435 Avastin met colorectal cancer, treat- Others
RG7422 PI3 kinase inh solid and hematologic tumours Inflammation and autoimmune disorders ment through multiple lines CHU Epogin (EPOCH) chemother.-induced anemia
RG7440 AKT inh solid tumours RG3637 lebrikizumab asthma RG435 Avastin met breast cancer, 2nd-line
RG7444 anti-FGFR3 MAb multiple myeloma RG4930 OX40L MAb asthma RG597 Herceptin BC, HER2+, SC formulation
RG7459 IAP antag solid tumours, lymphoma RG7415 rontalizumab systemic lupus erythematosus RG597 Herceptin adj BC, HER2+, 2-yr treatment
ADC RG7593 anti-CD22 hematologic malignancies RG7416 anti-LT α MAb rheumatoid arthritis RG1273 pertuzumab mBC HER2+, 1st-line
NME RG7594 antiangiogenic solid tumours RG3648 Xolair chronic idiopathic urticaria RG1415 Tarceva adj NSCLC
RG7597 anti-HER3 MAb metastatic epithelial tumours RG7449 anti-M1 prime MAb asthma RG1415 Tarceva NSCLC, EGFR mutation-
RG7686 anti-glypican MAb liver cancer positive, 1st-line
CHU ALK inh NSCLC Virology ADC RG3502 trastuzumab–DM1 mBC, HER2+, 1st-line
CHU – solid tumours RG3484 HPV16 immunotherapy cervical neoplasia ADC RG3502 trastuzumab–DM1 advanced mBC, HER2+
RG7128 nucleoside polymerase hepatitis C RG7159 anti-CD20 MAb chronic lymphocytic leukemia
Inflammation and autoimmune disorders inh prodrug RG7159 anti-CD20 MAb indolent NHL
RG4934 anti-IL-17 MAb rheumatoid arthritis RG7227 danoprevir hepatitis C RG7204 BRAF inh metastatic melanoma, 1st-line
RG7185 CRTH2 antag asthma
RG7413 anti-β7 rhuMAb ulcerative colitis Cardiovascular and metabolic diseases Inflammation and autoimmune disorders Selected abbreviations
RG1512 anti-P selectin MAb cardiovascular disease RG1569 Actemra/RoActemra ankylosing spondylitis adj adjuvant treatment HPV human papillomavirus
Virology RG7201 SGLT2 inh type 2 diabetes RG1569 Actemra/RoActemra RA, SC formulation ADC antibody-drug conjugate inh inhibitor
RG7432 nucleoside polymerase hepatitis C RG1569 Actemra/RoActemra early rheumatoid arthritis AMD age-related macular JIA juvenile idiopathic arthritis
inh Central nervous system RG1569 Actemra/RoActemra RA DMARD inadequate antag d aneg tae gn oe nra ist tion M maA ib n t m mo ain no tc el no an na cl ea n trt eib ao tmdy ent
CHU serine palmitoyltrans- hepatitis C RG1450 gantenerumab Alzheimer’s disease responders (head-to-head) BC breast cancer m, met metastatic (cancer)
ferase inh RG1594 ocrelizumab relapsing-remitting MS CLL chronic lymphocytic MS multiple sclerosis
leukemia NHL non-Hodgkin’s lymphoma
RG3487 nicotinic α7 receptor Alzheimer’s disease Cardiovascular and metabolic diseases DMARD disease-modifying NME new molecular entity
Cardiovascular and metabolic diseases agonist RG1439 aleglitazar cardiovascular risk reduction antirheumatic drug NSCLC non-small cell lung cancer
RG4929 11β-HSD inh metabolic diseases RG7090 mGluR5 antag treatment-resistant depression in type 2 diabetes G HB ERM 2 + g Hl Eio Rb 2la -pst oo sm itia v emultiforme R SCA r sh ue bu cm uta at no eid o ua srthritis
RG7236 Cat S antag cardiovascular risk in chronic EVO NMDA receptor antag treatment-resistant depression RG1658 dalcetrapib atherosclerosis, cardiovascular HER2-neg HER2-negative
kidney disease risk reduction
RG7273 ABCA1 inducer dyslipidemia
RG7418 anti-oxLDL MAb secondary prevention Central nervous system
of cardiovascular events RG1594 ocrezulimab primary progressive MS
RG7685 GIP/GLP-1 dual agonist type 2 diabetes RG1678 glycine reuptake inh schizophrenia, negative
symptoms Legend
Central nervous system RG1678 glycine reuptake inh schizophrenia, suboptimally Therapeutic protein, other biologic
RG1578 mGluR2 antag depression controlled Small molecule
RG1662 GABA-A α5 inverse cognitive disorders Blue type First indication
agonist Ophthalmology Black type Additional indications
RG7166 triple reuptake inh depression RG3645 Lucentis diabetic macular edema
RG7412 anti-amyloid β-peptide Alzheimer’s disease RG3645 Lucentis AMD, high dose RG-No. Roche and/or Genentech managed
MAb CHU Chugai managed
EVO Evotec
Ophthalmology
RG7417 anti-factor D MAb geographic atrophy Phase I Initial studies in healthy volunteers and possibly in patients
Phase II Efficacy, tolerability and dose-finding studies in patients
Phase III Large-scale studies in patients for statistical confirmation of safety
and efficacy
Registra- Marketing application(s) filed in EU, US and/or Japan
tion
* Filed in EU
** Filed in USA
Current as of January 2011|
Our business
Innovation is our answer
to medical challenges. Through our research
we create state-of-the-art diagnostics and
pioneering medicines that help millions of
people around the world.
Focus on personalised healthcare
At Roche we aim to develop novel medicines and
diagnostics that will help patients live longer, better
lives. We constantly strive for scientific excellence
so that we can continue developing effective thera-
peutic options where previously there were none.
As the world’s largest biopharmaceutical company
and the number one supplier of in vitro diagnostics,
Roche has brought many highly effective drugs to
market, including the industry’s leading portfolio of
cancer medicines. We were also one of the first
companies to recognise the potential of personalised
medicine. Today our expertise in molecular biology
is enabling us to develop targeted medicines for
specific patient groups. This contributes to better,
safer, more cost-effective healthcare.
02_Roche_AR10_ENG_Table of Contents.indd 2 28.01.2011 10:36:00Contents
Key figures
Inside cover
Pharmaceuticals pipeline
Inside cover
1
Highlights 2010
4
Letters to Shareholders
Letter from the Chairman
4
Letter from the CEO
8
12
Roche Group
Group Results and Outlook
13
Group Strategy
16
24
Pharmaceuticals
Results
27
Sales review
29
Development highlights
36
Research and development
45
56
Diagnostics
Results
62
Business area highlights
67
Research and development
74
80
Corporate Governance, Remuneration Report
Corporate Governance
81
Remuneration Report
91
102
Corporate Responsibility
Stakeholder engagement
104
Patients
105
People
115
Society
122
Responsible practices
124
Safety, security, health and
131
environmental protection
137
Independent Assurance Report
GRI statement
138
02_Roche_AR10_ENG_Table of Contents.indd 3 28.01.2011 10:36:004­
Roche Business Report 2010 Letter to Shareholders
Franz B. Humer
Dear Shareholders
2010­was­a­challenging­year­for­the­pharmaceutical­industry.­Market­conditions,­as­
anticipated­for­quite­some­time,­became­even­tougher.­In­the­wake­of­the­financial­
­crisis,­high­government­budget­deficits­added­to­pricing­pressures­in­the­global­health-
care­sector.­In­Europe­many­governments­cut­drug­prices­significantly,­while­healthcare­
reform­in­the­US­resulted­in­higher­rebates­on­prescription­drugs.­On­the­regulatory­
front,­the­hurdles­for­gaining­approval­of­new­medicines­were­raised­even­higher,­dra-
matically­increasing­the­cost­of­drug­development­and­delaying­access­to­innovative­
treatments.
Amid­these­challenges,­Roche­posted­good­full-year­results.­However,­we­also­felt­the­
effects­of­the­market­changes­I’ve­just­described.­In­July­the­US­Food­and­Drug­Admin-
istration­(FDA)­rejected­our­application­for­accelerated­approval­of­T–DM1,­even­
though­this­novel­compound­is­expected­to­significantly­improve­the­treatment­of­breast­
cancer.­This­will­increase­the­clinical­development­costs­for­T–DM1­and­delay­this­
03_Roche_AR10_ENG_Letter to Shareholders.indd 4 28.01.2011 10:37:045­
Letter to Shareholders Roche Business Report 2010
promising­drug’s­approval.­Late­in­the­year­the­FDA­announced­its­intention­to­withdraw­
approval­of­Avastin­in­combination­with­chemotherapy­for­first-line­treatment­of­meta-
static­HER2-negative­breast­cancer.­While­a­withdrawal­will­not­affect­US­patients’­
access­to­Avastin­in­its­other­approved­cancer­indications,­it­would­adversely­impact­
patients­with­this­very­serious­disease.­The­day­the­FDA­made­its­announcement,­­
the­European­Medicines­Agency­(EMA)­confirmed­Avastin’s­value­in­the­fight­against­
breast­cancer.­In­Europe­women­with­advanced­breast­cancer­will­thus­continue­to­
have­access­to­this­treatment­option.­
We­are­closely­monitoring­developments­in­healthcare­policy­around­the­world.­Precisely­
because­we­believe­our­highly­innovative­products­contribute­in­important­ways­to­­
more­effective,­cost-efficient­healthcare­delivery,­we­consider­it­vital­for­the­future­that­­
policymakers­and­health­officials­look­not­only­at­the­costs­of­new­medicines­but­also­­
at­the­innovation­they­embody­and­the­benefits­they­offer­patients.­Given­the­many­dis-
eases­that­still­cannot­be­treated­satisfactorily,­or­at­all,­medical­progress­should­be­
viewed­more­as­a­public­good­that­deserves­vigorous­political­support.
When­we­discuss­innovation­we­must­bear­in­mind­that­it­is­inherently­risky.­Pioneering­
research­and­development­efforts­sometimes­produce­breakthroughs,­but­they­also­can­
sometimes­not­achieve­the­desired­endpoints.­Taspoglutide­is­a­case­in­point.­We­sus-
pended­a­late-stage­development­programme­on­this­new­treatment­for­type­2­diabetes­
at­a­very­late­stage­of­development­after­careful­assessment­of­the­available­safety­and­
efficacy­data.
Our­intense­research­and­development­activities­also­yielded­some­very­strong­and­
promising­results­last­year.­We­currently­have­twelve­new­molecular­entities­in­late-stage­
development,­half­of­which­are­designed­for­targeted­use­in­specific­patient­populations­
with­the­help­of­companion­diagnostic­tests.­We­have­made­enormous­progress­in­
personalised­healthcare,­helped­by­the­close­interplay­between­our­Pharmaceuticals­
and­Diagnostics­Divisions.­These­developments­represent­major­strides­and­make­us­
confident­that­we­will­remain­an­industry­leader.­
Roche­convincingly­met­its­sales­and­earnings­targets­for­2010.­Excluding­sales­of­our­
influenza­medicine,­Tamiflu,­which­as­expected­were­down­sharply­for­the­year,­Group­
sales­rose­5%­in­local­currencies.­Net­income­attributable­to­Roche­shareholders­
showed­a­strong­increase,­advancing­11%­to­8.7­billion­Swiss­francs­despite­the­costs­
associated­with­the­‘Operational­Excellence’­programme­amounting­to­a­considerable­­
1.3­billion­Swiss­francs.­Core­Earnings­per­Share,­a­key­indicator­of­underlying­business­
performance,­increased­10%­in­local­currencies­(4%­in­Swiss­francs).
In­view­of­the­company’s­healthy­cash­flow­and­positive­outlook­the­Board­of­Directors­
will­propose­a­dividend­increase­for­2010­of­10%­to­6.60­Swiss­francs­per­share­and­
03_Roche_AR10_ENG_Letter to Shareholders.indd 5 28.01.2011 10:37:046­
Roche Business Report 2010 Letter to Shareholders
non-voting­equity­security­(up­from­6.00­Swiss­francs­for­2009).­Subject­to­your­
approval­at­the­Annual­General­Meeting­(AGM),­this­will­be­Roche’s­24­th­consecutive­
annual­dividend­increase.
Looking­ahead­to­the­Annual­General­Meeting­on­1­March­2011,­I­would­like­to­mention­
the­upcoming­changes­on­the­Board­of­Directors.­Walter­Frey­and­Wolfgang­Ruttens-
torfer­have­decided­not­to­stand­for­re-election.­On­behalf­of­the­entire­Board,­I­would­
like­to­thank­them­both­for­their­dedicated­service­to­Roche.­During­his­long­tenure­on­
the­Board­Mr­Frey,­who­runs­a­highly­successful­family­company,­has­made­significant­
contributions­to­the­Group’s­growth­and­success.­Among­the­strengths­Mr­Ruttenstorfer­
brought­to­the­Board,­his­expertise­on­the­growth­markets­in­Eastern­Europe­and­the­
Middle­East­has­been­particularly­valuable.
We­intend­to­use­this­opportunity­to­strengthen­the­Board­further­by­nominating­addi-­
tional­independent­directors.­As­announced­in­December,­Paul­Bulcke­(CEO­Nestlé­S.A.),­
­Christoph­Franz­(chairman­and­CEO­Deutsche­Lufthansa­AG)­and­Peter­R.­Voser­­
(CEO­Royal­Dutch­Shell­plc)­will­be­standing­for­election­as­new­members­of­the­Board.
At­the­Annual­General­Meeting­we­will­also­propose­that­the­term­of­Board­members­­
be­reduced­from­three­to­two­years.­This­will­enable­shareholders­to­influence­the­com-
position­of­the­Board­at­shorter­intervals­in­future.
After­ten­years­of­exceptional­service­on­the­Corporate­Executive­Committee,­Erich­
Hunziker­has­decided­to­retire­from­Roche­at­the­end­of­March­2011.­Erich­Hunziker­was­
appointed­Chief­Financial­Officer­in­2001,­becoming­Deputy­Head­of­the­Corporate­
Executive­Committee­in­2005.­During­his­long­career­at­Roche,­Erich­Hunziker­was­one­
of­the­key­architects­of­the­Group’s­successful­development.­I­would­like­to­take­this­
opportunity­to­thank­Erich­Hunziker­sincerely­for­his­outstanding­contribution­to­the­
Group’s­overall­success.­­
The­Board­of­Directors­has­appointed­Alan­Hippe­to­succeed­Erich­Hunziker­as­Chief­
Financial­Officer.­Alan­Hippe­will­join­Roche­as­a­member­of­the­Corporate­Executive­
Committee­as­of­April­2011.­Alan­Hippe­served­as­a­member­of­the­executive­board­of­
Continental­AG­from­2002­to­2009.­Since­April­2009­he­has­been­CFO­and­a­member­­
of­the­executive­board­of­ThyssenKrupp­AG.
Our­company­was­honoured­last­year­for­outstanding­achievements­in­a­number­of­
areas.­I­am­particularly­pleased­that­the­Dow­Jones­Sustainability­Indexes­named­us­the­
Supersector­Leader­in­healthcare­for­the­second­year­in­a­row,­ranking­Roche­as­the­
world’s­most­sustainable­healthcare­company.­We­firmly­believe­that­sustainable­corpo-
rate­policies­and­practices­ultimately­create­long-term­value­and­promote­innovation.­
03_Roche_AR10_ENG_Letter to Shareholders.indd 6 28.01.2011 10:37:047­
Letter to Shareholders Roche Business Report 2010
Our­success­as­a­company­is­built­on­scientific­excellence­that­benefits­patients.­The­
successful­integration­of­Genentech­has­further­strengthened­our­innovative­capa-
bilities­as­the­world’s­largest­biotech­company­and­the­leading­supplier­of­cancer­medi-
cines.­We­lead­in­personalised­healthcare,­are­the­world’s­number­one­supplier­of­­
in vitro­diagnostics­and­have­outstanding­product­portfolios­in­both­the­Pharmaceuticals­
and­the­Diagnostics­Division.
Our­ability­to­create­value­for­all­stakeholders­is­crucial­to­our­future­success­and­we­
will­continue­to­vigorously­pursue­this­strategy.
Franz­B.­Humer­
Chairman­of­the­Board
03_Roche_AR10_ENG_Letter to Shareholders.indd 7 28.01.2011 10:37:048­
Roche Business Report 2010 Letter to Shareholders
Severin Schwan
Dear Shareholders
Sandro­B.­had­been­recently­diagnosed­with­malignant­melanoma­—­shortly­after­his­28­th­
birthday.­Malignant­melanoma­is­one­of­the­deadliest,­most­aggressive­forms­of­skin­cancer,­
with­over­160,000­new­cases­reported­worldwide­each­year.­It­is­highly­likely­to­metastasise­
at­a­very­early­stage,­and­once­patients­have­developed­metastases­there­are­almost­no­
treatment­options­available­to­them.­Life­expectancy­following­diagnosis­is­typically­a­matter­
of­months.­His­doctors­gave­him­four­months­to­live.
Sandro­B.­met­the­inclusion­criteria­for­a­phase­II­clinical­trial­in­which­we­are­testing­our­
novel­investigational­drug­RG7204­in­patients­with­advanced­malignant­melanoma­whose­
cancer­cells­carry­a­specific­genetic­mutation.­A­diagnostic­test­confirmed­that­he­had­this­
mutation.
Before­reflecting­in­more­details­on­our­clinical­trials,­I­would­like­to­briefly­review­the­
Group’s­business­performance­in­2010.­Despite­strong­pressure­on­prices­in­the­US­and­in­
Europe,­the­Pharmaceuticals­and­Diagnostics­Divisions­both­posted­good­results.­Excluding­
Tamiflu­sales,­which­were­down­2.3­billion­Swiss­francs­for­the­year,­sales­in­the­Pharma-
ceuticals­Division­advanced­5%,­above­the­overall­market­growth.­Including­Tamiflu,­divisional­
sales­declined­2%­in­local­currencies­to­37.1­billion­Swiss­francs.­Growth­was­driven­by­key­
03_Roche_AR10_ENG_Letter to Shareholders.indd 8 28.01.2011 10:37:089­
Letter to Shareholders Roche Business Report 2010
products­for­oncology,­ophthalmology,­inflammatory­and­autoimmune­disease­and­anemia.­
Thanks­to­continued­strong­demand­for­our­anticancer­medicines,­we­expanded­our­lead­in­
this­important­market­segment.­In­the­Diagnostics­Division­sales­advanced­8%­in­local­
­currencies,­again­significantly­outpacing­the­market­and­solidifying­Roche’s­position­as­the­
leading­supplier­of­in vitro­diagnostics.­Professional­Diagnostics­and­Diabetes­Care­were­
the­division’s­primary­growth­drivers.
The­Group’s­core­operating­profit­grew­faster­than­sales,­rising­by­a­robust­7%­to­16.6­billion­
Swiss­francs­in­local­currencies.­Profitability­improved­further,­with­the­core­operating­mar-
gins­in­the­Pharmaceuticals­and­Diagnostics­Divisions­advancing­1.9­percentage­points­to­
39.9%­and­3.8­percentage­points­to­21.1%,­respectively.­Once­again,­the­earnings­power­­
of­our­operating­businesses­was­also­reflected­in­the­Group’s­operating­free­cash­flow,­which­
last­year­reached­a­strong­14.1­billion­Swiss­francs.­Thanks­to­our­strong­cash­flow,­by­
year’s­end­we­had­already­repaid­a­third­of­the­debt­incurred­in­connection­with­the­Genen-
tech­transaction­—­earlier­than­originally­planned.
Succeeding­in­our­industry­is­tougher­than­ever.­Pricing­pressures­are­rising­sharply­and­the­
requirements­for­approval­and­reimbursement­of­new­medicines­are­becoming­increasingly­
stringent.­At­Roche­we­additionally­experienced­setbacks­with­some­of­our­late-stage­devel-
opment­projects­last­year,­including­the­diabetes­drug­taspoglutide.
In­response­to­these­challenges,­my­colleagues­on­the­Executive­Committee­and­I­decided­­
to­take­appropriate­action­now­to­ensure­Roche’s­long-term­success.­In­November­2010­we­
launched­the­comprehensive­Group-wide­‘Operational­Excellence’­programme,­which­is­
designed­to­strengthen­the­Group’s­productivity­and­innovative­capacity­in­the­years­ahead.­
We­have­identified­a­wide­range­of­opportunities­to­improve­processes­and­raise­productivity­
and­efficiency.
Implementation­of­the­Operational­Excellence­programme­is­already­underway­and­will­con-
tinue­through­2012.­As­a­result­of­this­initiative,­the­workforce­of­roughly­82,000­(at­30­June­
2010)­will­be­reduced­by­4,800­positions,­almost­6%­of­the­global­workforce.­The­greatest­
changes­will­be­in­the­Pharmaceuticals­Division,­where­we­will­be­adjusting­our­global­sales­
organisation­and­taking­steps­to­improve­efficiency­and­productivity­in­product­development­
and­optimise­our­manufacturing­network.­In­the­Diagnostics­Division,­the­co-location­of­
related­business,­R­&­D­and­operational­functions­at­selected­sites­will­enable­the­division­to­
streamline­its­site­network.
We­are­taking­these­measures­proactively,­from­a­position­of­strength.­Roche­is­the­world’s­
biggest­biotech­company,­with­13­products­and­product­lines­that­generate­annual­sales­­
of­over­one­billion­Swiss­francs­each.­And­despite­last­year’s­setbacks,­our­research­and­
de­velopment­pipeline­remains­one­of­the­strongest­in­the­industry.­With­our­combined­
strengths­in­pharmaceuticals­and­diagnostics­and­proven­expertise­in­molecular­biology,­we­
03_Roche_AR10_ENG_Letter to Shareholders.indd 9 28.01.2011 10:37:0810­
Roche Business Report 2010 Letter to Shareholders
are­uniquely­positioned­to­realise­the­promise­of­personalised­healthcare­to­make­treatments­
safer­and­more­effective.­The­revolutionary­advances­we­are­starting­to­see­in­molecular­
biology­give­us­a­strategic­competitive­edge­across­a­number­of­areas,­including­our­ability­
to­raise­research­productivity.
Personalised­healthcare­paradigms­increasingly­shape­our­research­and­development­pro-
grammes.­We­currently­have­twelve­new­molecular­entities­in­late-stage­development,­half­­
of­which­are­tailored­to­specific­patient­populations.­Our­BRAF­inhibitor­for­malignant­
melanoma,­MetMAb­for­lung­cancer,­T–DM1­and­pertuzumab­for­breast­cancer­and­other­
projects­in­virology­and­inflammation­all­represent­potential­major­advances­for­patients.­­
Similarly,­our­Diagnostics­Division­is­developing­a­number­of­biomarkers­to­support­thera-
peutic­decision-making.­Targeted­therapies­and­diagnostic­tests­that­contribute­to­better­
medical­decisions­not­only­improve­patient­care­but­also­have­health­economic­benefits­that­
make­them­attractive­to­regulators­and­payers.
One­of­the­most­impressive­examples­of­personalised­healthcare­is­RG7204,­the­drug­used­
to­treat­malignant­melanoma­which­I­mentioned­earlier.­Thanks­to­insights­into­specific­
genetic­changes­in­tumour­cells,­huge­strides­are­being­achieved­now­in­clinical­trials­in­a­
disease­once­considered­virtually­untreatable.
Tumours­generally­develop­from­just­one­cell.­Every­cell­continuously­undergoes­changes,­
known­as­mutations,­that­affect­certain­signalling­pathways­within­the­cell.­Most­mutations­
are­corrected­spontaneously,­but­some­manage­to­evade­the­body’s­repair­mechanisms,­
causing­cells­to­divide­uncontrollably­and­thus­form­tumours.­Scientists­have­discovered­that­
in­over­half­of­all­melanoma­patients,­the­disease­is­triggered­by­a­highly­specific­mutation­­
of­the­gene­coding­for­the­BRAF­protein,­which­is­involved­in­cell­growth.­A­BRAF­V600E­
mutation­triggers­uncontrolled­cell­growth­and­these­cancer­patients­—­Sandro­B.­for­
e­xample­—­have­virtually­no­prospect­of­being­cured.
RG7204,­an­oral­cancer­drug­co-developed­with­our­partner­company­Plexxikon,­acts­via­­
a­highly­innovative­mechanism­to­inhibit­the­BRAF­protein­implicated­in­the­disease.­The­new­
drug­specifically­destroys­those­cells­carrying­the­V600E­mutation­and­does­not­attack­
healthy­cells­without­the­mutation.
We­have­developed­a­diagnostic­assay­for­use­with­the­drug­which­is­capable­of­detecting­
the­V600E­mutation­in­tumours,­and­will­thus­help­identify­patients­who­are­very­likely­to­
respond­to­the­new­drug.­This­means­the­new­drug­will­be­used­only­in­patients­likely­to­
benefit­from­the­new­treatment.
The­interim­results­of­a­phase­III­trial,­which­we­published­in­January­2011,­are­very­
e­ncouraging.­For­the­first­time,­a­personalised­investigational­medicine,­RG7204,­has­shown­
a­significant­survival­benefit­in­metastatic­melanoma.­This­is­an­important­advance­­11­
Letter to Shareholders Roche Business Report 2010
for­people­with­the­BRAF­V600­mutation-positive­form­of­the­disease­who­have­had­
extremely­limited­treatment­options.­Full­data­will­be­presented­at­a­medical­meeting­later­
this­year.­Roche­is­working­closely­with­global­health­authorities­so­that­patients­world-­
wide­can­already­be­treated­with­the­new­drug.
The­pursuit­of­treatments­offering­real­benefits­to­patients­is­the­core­of­our­corporate­
­strategy.­Consistent­with­that­strategy,­we­will­continue­to­drive­progress­on­our­promising­
development­portfolio.­We­expect­results­from­a­total­of­19­phase­II­and­phase­III­trials­­
in­2011­and­2012.­Based­on­our­current­late-stage­portfolio,­we­expect­to­submit­up­to­eight­
regu­latory­filings­for­approval­of­new­molecular­entities­by­the­end­of­2013.­Moreover,­­
we­are­currently­working­on­more­than­20­additional­indications­for­existing­products.
Going­forward,­innovations­that­benefit­patients­will­continue­to­drive­our­success.­Through­
excellence­in­science,­we­strive­to­develop­pioneering­treatments­and­diagnostic­tests­that­
prolong­patients’­lives­and­tangibly­improve­their­quality­of­life.
Roche­owes­its­success­to­its­employees.­Thanks­to­their­tremendous­dedication­and­hard­
work­we­once­again­achieved­our­goals­last­year,­despite­an­increasingly­challenging­market­
environment.­On­behalf­of­the­entire­Executive­Committee,­I­would­like­to­thank­all­our­
employees­for­their­important­contributions.
Making­sure­that­Roche­remains­an­employer­of­choice­is­an­important­priority­for­me.­So­­
I­am­especially­pleased­to­report­that­in­2010­our­company­was­again­voted­a­top­employer­­
in­polls­in­a­number­of­countries.­Being­a­top­employer­is­not­just­about­giving­as­many­
employees­as­possible­opportunities­to­develop­professionally­and­make­things­happen­in­
the­company.­Innovation­depends­on­a­diversity­of­views­and­approaches.­One­of­the­ways­
we’re­promoting­diversity­at­Roche­is­by­filling­more­managerial­positions­with­women.­At­the­
start­of­2010,­we­set­ourselves­the­goal­of­increasing­the­proportion­of­women­in­the­top­­
400­leadership­positions­by­half­to­20%­over­the­next­five­years.­I­am­happy­to­report­that­­
we­made­progress­on­this­front­as­well­last­year.­
What­happened­to­the­young­man­with­melanoma?­Like­many­of­the­other­trial­participants,­
Sandro­B.­has­responded­well­to­our­new­drug­for­skin­cancer.­He­is­still­alive­and­doing­well.­
This­is­exactly­what­we­have­in­mind­when­we­talk­about­helping­patients­through­excel-
lence­in­science.­
Severin­Schwan
Chief­Executive­Officer
03_Roche_AR10_ENG_Letter to Shareholders.indd 11 28.01.2011 10:37:09Roche Group |
Our Group posted
solid overall results in a challenging
market in 2010. Core operating profit
grew faster than sales, and Core Earnings
per Share increased at a double-digit rate.
We are steadily making progress in
personalised healthcare. Of the twelve
new molecular entities now in our
late-stage pipeline, half are targeted
at specific patient populations.
04_Roche_AR10_ENG_Group.indd 12 28.01.2011 13:02:5013­
Roche Group Roche Business Report 2010
Group Results and in­the­Diagnostics­Division­was­30%­in­local­curren-
cies,­mainly­resulting­from­sales­growth­due­to­­
Outlook new­product­launches­and­the­ongoing­operational­
efficiency­programmes.­The­Group’s­core­operating­
profit­margin­increased­by­1.7­percentage­points­to­
Overall results 34.9%,­with­the­Pharmaceuticals­Division­improving­
The­Roche­Group­posted­solid­overall­results­in­­ by­1.9 percentage­points­to­39.9%­and­the­Diagnos-
2010.­Group­sales­were­stable­in­local­currencies­­ tics­Division­by­3.8­percentage­points­to­21.1%.
at­47.5­billion­Swiss­francs­(–3%­in­Swiss­francs;­­
1%­in­US­dollars).­The­good­underlying­growth­of­ In­2010­the­Group’s­net­income­increased­by­4%­to­
both­divisions­compensated­for­the­expected­ 8.9­billion­Swiss­francs­compared­to­2009.­Net­
decline­in­Tamiflu­sales­and­the­impacts­of­health-­ income­attributable­to­Roche­shareholders­rose­11%­
care­reforms­and­austerity­measures.­Excluding­ to­8.7­billion­Swiss­francs.
­Tamiflu,­sales­increased­by­5%­in­local­currencies.­
The­Pharmaceuticals­Division­represented­78%­­ The­Group’s­operating­free­cash­flow­remained­strong­
of­Group­sales­and­the­Diagnostics­Division­con-­ at­14.1­billion­Swiss­francs.­A­free­cash­flow­of­
tributed­22%. 4.7 billion­Swiss­francs­was­achieved­in­2010­despite­
higher­interest,­tax­and­dividend­payments.
Sales­in­the­Pharmaceuticals­Division­declined­by­
2%­in­local­currencies­to­37.1­billion­Swiss­francs.­
Excluding­Tamiflu,­local­growth­was­5%,­above­mar-
The Board of Directors is
ket­growth.­Demand­for­the­oncology­drugs­Avastin,­
MabThera/Rituxan,­Herceptin,­Xeloda­and­Tarceva­
proposing an increase of 10%
continued­to­grow­strongly.­Additional­major­growth­
drivers­were­Actemra/RoActemra­in­rheumatoid­
in the dividend for 2010 to
arthritis,­Mircera­in­anemia­and­Lucentis­in­ophthal-
mology.­Actemra,­which­is­now­launched­in­some­
6.60 Swiss francs per share and
50 countries­including­the­United­States,­the­EU­and­
Japan,­reached­sales­of­397­million­Swiss­francs­in­ non-voting equity security for
2010.­These­positive­factors­compensated­for­most­of­
the­expected­strong­decline­in­Tamiflu­sales,­the­ approval at the Annual General
reduction­in­CellCept­sales­due­to­US­patent­expiry­
in­May­2009­and­the­impacts­of­the­US­healthcare­ Meeting.
reforms,­European­austerity­measures­and­price­cuts­
in­Japan.
The­Diagnostics­Division­increased­sales­to­10.4­bil- Of­the­debt­raised­in­early­2009,­33%­had­already­
lion­Swiss­francs­in­2010,­growing­8%­in­local­ been­repaid­by­31­December­2010.­In­addition,­the­
­currencies­(4%­in­Swiss­francs;­8%­in­US­dollars),­ Group­exercised­its­option­to­call­for­redemption­­
thereby­strengthening­its­leading­market­position.­ a­portion­of­the­US­dollar­notes­due­1­March­2014.­
Major­drivers­were­Professional­Diagnostics­with­11%­ Of­the­total­principal­amount­of­2.75­billion­US­dol-
sales­growth­and­Diabetes­Care­with­4%­sales­ lars,­1.0­billion­US­dollars­will­be­redeemed­in­March­
growth. 2011.­The­net­debt­position­of­the­Group­is­19.2 bil-
lion­Swiss­francs,­a­decrease­of­4.7­billion­Swiss­
The­Group’s­core­operating­profit­increased­by­7%­in­ francs­from­31­December­2009.
local­currencies­(2%­in­Swiss­francs).­The­Pharma-
ceuticals­Division­increased­its­core­operating­profit­ The­Board­of­Directors­is­proposing­an­increase­of­
by­4%­in­local­currencies,­driven­primarily­by­cost­ 10%­in­the­dividend­for­2010­to­6.60­Swiss­francs­­­
synergies­from­the­Genentech­integration­and­prod- per­share­and­non-voting­equity­security­for­approval­
uctivity­improvements.­Core­operating­profit­growth­ at­the­Annual­General­Meeting.
04_Roche_AR10_ENG_Group.indd 13 28.01.2011 13:02:5014­
Roche Business Report 2010 Roche Group
This­would­be­the­24­th­consecutive­increase­of­the­ Outlook 2011
dividend­and­corresponds­to­an­increase­in­payout­ In­2011,­Group­and­Pharmaceuticals­sales­(excluding­
ratio­from­49%­in­2009­to­52%­for­2010. Tamiflu)­are­expected­to­grow­at­low­single-digit­
rates­in­local­currencies,­reflecting­the­impact­of­US­
Financial implications of Operational Excellence healthcare­reform­and­European­austerity­measures.­­
On­17­November­2010­the­Group­announced­imple- Pharmaceuticals­sales­are­therefore­expected­to­­
mentation­plans­for­its­Operational­Excellence­pro- grow­in­line­with­the­market.
gramme,­which­is­aimed­at­adapting­cost­structures­
to­an­increasingly­challenging­market­environment­ In­2011,­Diagnostics­sales­are­again­expected­to­
and­achieving­significant­efficiency­and­productivity­ grow­significantly­ahead­of­the­market,­driven­by­fur-
gains.­The­initiative­is­expected­to­generate­savings­­ ther­rollout­of­new­products­in­all­business­areas.
of­1.8­billion­Swiss­francs­in­2011,­with­projected­
s­avings­of­2.4­billion­Swiss­francs­from­2012­onwards.­ In­spite­of­a­more­challenging­environment­and­the­
Implementation­is­scheduled­to­be­substantially­ introduction­of­an­excise­tax­in­the­United­States,­
­completed­by­the­end­of­2012.­During­the­period­ Roche­aims­for­Core­Earnings­per­Share­to­grow­at­a­
from­2010­through­2012­Roche­expects­to­incur­ high-single­digit­rate­in­2011­at­constant­exchange­
restructuring­costs­totalling­2.7­billion­Swiss­francs. rates.
As­a­consequence­of­implementing­the­respective­ Roche­aims­to­increase­the­dividend­in­line­with­­
restructuring­measures,­significant­costs­were­ Core­Earnings­per­Share­growth.
already­incurred­in­2010.­The­costs­in­2010­of­1.3­bil-
lion­Swiss­francs­mainly­relate­to­severance­payments­ Based­on­the­strong­operating­free­cash­flow,­Roche­
and­impairments­of­intangible­assets.­The­Pharma- expects­to­reduce­debt­progressively­and­to­return­to­
ceuticals­Division­accounts­for­1.2­billion­Swiss­francs­ a­net­cash­position­by­2015.
of­these­costs,­and­0.1­billion­Swiss­francs­relate­­
to­the­Diagnostics­Division.­Roughly­40%­of­the­
charges­are­non-cash,­being­mainly­impairments­of­
property,­plant­and­equipment­and­intangible­assets.­
The Group has expanded the presentation of its
core results for 2010. Previously only Core EPS
was shown, but now the full income statement for
the Group and the operating results of the divi-
sions are shown on both an IFRS and core basis.
This allows a transparent assessment of both the
actual results and the underlying performance
of the business. The core results concept is fully
described on pages 144–147 of the Finance Report
and reconciliations between the IFRS and core
results are given there.15­
Roche Group Roche Business Report 2010
Key achievements in 2010
Business/Finance Pharmaceuticals sales (excluding Tamiflu) increased above market growth
achievements Diagnostics sales growth significantly ahead of market
Core operating profit margin up significantly in both divisions
Double-digit rise in Core Earnings per Share (at constant exchange rates)
10% dividend increase proposed for reporting year 2010
Products and pipeline 18 key drug approvals, including approved new indications for Actemra, Herceptin,
Lucentis and MabThera/Rituxan
Twelve new molecular entities in late-stage development, six with a personalised
healthcare approach
Four new molecular entities moved into late-stage clinical development:
lebrikizumab (asthma), MetMAb (lung cancer) and RG7128 (hepatitis C),
Ocrelizumab (multiple sclerosis)
Fifty diagnostic tests and instruments launched in key markets
Patients and access Defined new pricing arrangements to increase patient access to our medicines
to healthcare in emerging markets
Expanded commitment not to file or enforce patents in Low Income Coutries (LIC)
as defined by the World Bank
Launched EDUCARE progamme in Africa with International Atomic Energy Agency (IAEA)
to establish online university to provide oncology training to doctors
People Genentech voted Science magazine’s top employer for the eighth time,
Roche rose from 17 th to 5 th place
Increased percentage of women in key positions from 13% to 16%
Published more than 1,200 scientific articles, nearly 60 in high-impact journals such as
Nature, Science and Cell
Society Employees generated over 1.2 million Swiss francs in annual ‘Children’s Walk’ to support
AIDS orphans in Malawi
Refurbished the primary health coach of the Phelophepa health train in South Africa
Responsible practices First year of the Roche SpeakUp line for reporting violations of our Code of Conduct
demonstrated responsible use by employees
Launched global marketing and sales compliance questionnaire to further promote good
business conduct
Rolled out Supplier Code of Coduct to over 500 suppliers and received their commitment
Introduced online procurement training, completed by over 3,000 employees
Roche named Healthcare Supersector Leader in Dow Jones Sustainability Indexes
for second year running
Safety, security, health Reduced our eco-balance measure of total environmental impact by 10%,
and environmental five years ahead of target
protection Kept greenhouse gas emissions stable despite significant growth of the company
To learn more about Roche’s achievements in the area of Corporate Responsibility see pages 102–137.
04_Roche_AR10_ENG_Group.indd 15 28.01.2011 13:02:5016­
Roche Business Report 2010 Roche Group
Group Strategy
A changing healthcare sector
The dynamic of the healthcare markets is more and more impacted by the tension
between steadily rising demand and limited financial resources. The growing
pressure on healthcare budgets means that increasingly new funds will only be
available for real innovations — products that offer patients significant added
value compared with conventional treatments. Despite the current challenges,
the pharmaceutical industry has excellent prospects over the long term. Key
drivers of this success include rising life expectancy, increasing prosperity in
developing countries, numerous diseases for which there are as yet no effective
therapies and, last but not least, rapid scientific and technological advances.
The­world’s­population­continues­to­expand,­and­ A­shift­in­the­growth­dynamic­from­Western­to­Far­
people­are­living­longer­on­average.­Greater­life­ Eastern­and­Latin­American­markets­has­been­appar-
expectancy­means­a­rise­in­age-related­diseases­ ent­for­some­time.­This­trend­will­become­even­
such­as­cancer,­diabetes,­rheumatoid­arthritis,­ stronger­in­future:­by­2013­the­emerging­markets­will­
­Parkinson’s­and­Alzheimer’s.­This­is­true­not­only­­ account­for­some­50%­of­the­growth­in­the­global­
of­the­industrialised­world­but­increasingly­of­­ pharmaceutical­market,­and­their­share­of­the­world­
developing­countries­and­emerging­markets­too.­ market­will­increase­to­around­25%.­The­Asian­phar-
Moreover,­there­are­still­no­effective­therapies­­ maceutical­market,­for­example,­has­grown­twice­­
for­some­5,000 diseases,­and­patient­response­to­ as­fast­as­the­overall­global­market­in­recent­years.­
existing­drugs­is­often­unsatisfactory.­There­is­­ China­—­where­Roche­again­expanded­its­pres-
consequently­substantial­unmet­medical­need­and­ ence­significantly­in­2010­—­has­become­the­third-
increasing­demand­for­more­targeted­diagnostics­­ largest­pharmaceutical­market­after­the­United­­
and­more­effective­and­better-tolerated­therapies.­­ States­and­Japan­in­2010.
Demographic­changes­and­growing­demands­on­
medical­care­are­placing­an­ever­greater­burden­on­
healthcare­systems.­The­recent­financial­and­eco-
nomic­crisis­and­the­resulting­government­deficits­in­
Europe­and­the­United­States­have­further­exacer-
bated­the­situation.­Political­pressure­to­curb­health-
care­costs­has­therefore­grown.­In­Europe,­several­
countries­imposed­significant­price­reductions­on­
pharmaceutical­products­in­2010.­Healthcare­reform­
in­the­United­States­has­led­to­an­increase­in­drug­
rebates­under­government­health­insurance­plans,­and­
a­new­consumption­tax­on­pharmaceutical­sales­is­
planned­for­2011.­In­addition,­US­and­European­regu-
latory­authorities­have­significantly­raised­the­bar­­
for­approval­of­new­products­and­are­taking­a­much­
more­critical­look­at­the­therapeutic­benefits­and­
safety­of­new­drugs.­Decisions­about­which­medi-
cines­to­administer­are­being­made­increasingly­­
by­public­agencies­and­health­insurers­rather­than­­
by­physicians.­
05_Roche_AR10_ENG_Strategy.indd 16 28.01.2011 10:39:1017­
Roche Group Roche Business Report 2010
Transforming the practice of medicine
Tapping the vast potential of Personalised healthcare:
modern science tailoring treatment to patients
In­order­to­remain­competitive­in­the­future­despite­a­ Patients­with­the­same­clinical­diagnosis­may­re­-
tougher­global­environment­in­the­healthcare­industry,­ spond­very­differently­to­the­same­medicines.­While­
Roche­is­pursuing­a­clear­innovation­strategy­based­ treatment­may­be­effective­and­successful­in­some­
on­outstanding­scientific­achievements.­We­have­con-­ patients,­others­may­experience­undesirable­side­
fidence­in­modern­science’s­vast­potential­for­devel- effects­or­the­desired­clinical­benefit­does­not­occur.­
oping­therapies­and­diagnostic­tests­that­will­reduce­ This­phenomenon­is­due­in­many­cases­to­genetic­
suffering­and­help­people­to­live­longer,­healthier­ and­other­molecular­differences­between­individual­
lives.­In­particular,­we­see­significant­opportunities­in­ patients.
the­fast-growing­body­of­knowledge­about­the­molec-
ular­basis­of­diseases.­A­deeper­understanding­of­ Treatments­tailored­to­different­patient­populations­
disease­mechanisms­and­the­growing­range­of­estab- have­medical­and­economic­advantages­and­are­con-
lished­and­new­therapeutic­approaches­is­enabling­­ sequently­not­only­important­for­patients­and­phy-­
us­to­develop­more­specific,­targeted­products. sicians­but­are­also­welcomed­by­regulatory­agencies­
and­health­insurers.­In­addition,­early­selection­of­
Through­our­medically­differentiated­therapies­we­ patients­who­are­highly­likely­to­respond­to­a­new­
want­to­offer­patients­and­doctors­significant­medical­ compound­increases­the­success­rate­in­drug­devel-
benefit­in­terms­of­effectiveness,­quality­and­safety,­ opment­while­also­lowering­development­costs.­
to­provide­laboratories­with­efficiency­gains­and­to­
give­payers­health­economic­benefits.­We­also­strive­ Combining­strengths­in­pharmaceuticals­and­diag-­
to­ensure­patients’­access­to­treatments. nostics­with­proven­expertise­in­molecular­biology,­
Roche­is­uniquely­positioned­to­make­its­personal-
Targeted,­cost-effective­therapies­can­play­a­key­role­ ised­healthcare­strategy­a­reality.­Thanks­to­the­close­
in­overcoming­current­challenges­in­the­healthcare­ cooperation­between­the­Pharmaceuticals­and­­
sector.­State-of-the-art­diagnostics­will­also­become­ Diagnostics­Divisions,­under­a­single­roof,­on­every-
increasingly­significant­in­a­rational­healthcare­sys- thing­from­research­to­sales,­Roche­is­committed­­
tem:­diagnostics­currently­account­for­only­around­2%­ to­the­systematic­pursuit­of­personalised­healthcare.­
of­healthcare­spending,­yet­around­70%­of­all­med-­ This­concept­is­becoming­a­reality­for­more­and­­
ical­decisions­depend­on­accurate,­fast­diagnosis.­ more­of­our­development­projects.
Here,­too,­there­is­vast­potential.­
05_Roche_AR10_ENG_Strategy.indd 17 28.01.2011 10:39:1018­
Roche Business Report 2010 Roche Group
Pairing targeted therapies with companion diagnostics
Roche already has a number of products that are custom-made for specific
patient populations and have become established standard treatments, including
therapies for HER2-positive breast and stomach cancer and for infections
caused by hepatitis B and hepatitis C viruses. Our late-stage pipeline contains
twelve new molecular entities, six of which are tailored to specific patient
groups and have a companion diagnostic test. These include new drugs for skin,
lung and breast cancer and for viral and infectious diseases (see features on
page 19 and 21).
Encouraging results in the battle against These­receptors­can­be­identified­using­molecular­tis-­
malignant melanoma sue­tests.­The­monoclonal­antibody­MetMAb­binds­
Roche’s­developmental­drug­RG7204­(BRAF­inhib- specifically­to­Met­receptors­and­prevents­activation­
itor)­is­currently­being­tested­in­patients­with­ of­a­cancer-promoting­growth­factor.­Roche­is­also­
advanced­malignant­melanoma­in­a­final­phase­III­­ developing­a­diagnostic­test­for­detecting­epidermal­
clinical­trial.­Diagnosed­worldwide­in­about­160,000­ growth­factor­receptor­(EGFR)­mutations­for­pa-­
people­each­year,­malignant­melanoma­is­the­most­ tients­with­NSCLC.­Patients­with­EGFR­mutations­re-­
aggressive­form­of­skin­cancer.­Thanks­to­insights­into­ spond­especially­well­to­the­anticancer­drug­Tarceva,­
specific­genetic­changes­in­tumour­cells,­huge­strides­ so­determining­EGFR­mutation­status­would­help­
are­being­achieved­now­in­a­disease­once­consid- oncologists­to­personalise­and­optimise­cancer­treat-
ered­virtually­untreatable.­Developed­on­the­basis­of­ ment­(see­also­personalised­healthcare­for­lung­­
biomolecular­findings,­RG7204­is­an­oral­drug­that­ cancer­on­page­22­and­23).­
specifically­inhibits­the­deadly­chain­of­events­asso-
ciated­with­the­development­of­melanoma.­ Progress in the fight against stomach cancer
Stomach­(gastric)­cancer­is­the­second-leading­­
In­roughly­half­of­all­melanoma­patients,­the­disease­ cause­of­cancer-related­deaths­in­the­world,­with­
is­triggered­by­a­dangerous­mutation­of­the­BRAF­ over­900,000­new­cases­diagnosed­each­year.­­
gene.­A­Roche­assay­developed­to­detect­this­muta- In­2010­European,­US­and­South­Korean­regulators­
tion­will­help­identify­patients­very­likely­to­respond­­ approved­Herceptin­for­use­in­HER2-positive­meta-
to­RG7204.­Initial­phase­II­trial­data­are­encouraging:­ static­stomach­cancer.­
disease­progression­was­significantly­delayed,­tu-­
mours­shrank­markedly­in­over­50%­of­patients­and­ Already­an­established­therapeutic­option­in­breast­
there­was­a­noticeable­improvement­in­patients’­ cancer,­Herceptin­is­one­of­the­most­successful­
quality­of­life.­ examples­of­personalised­healthcare­to­date.­The­
HER2­biomarker­is­detected­in­about­16–18%­of­­
Extending the lives of lung cancer patients gastric­tumours.­A­fast,­reliable­test­for­HER2­status­
Non-small­cell­lung­cancer­(NSCLC)­is­the­most­­ provides­critical­guidance­in­both­approved­Her-­
frequent­tumour-related­cause­of­death­in­the­world.­ ceptin­indications,­helping­doctors­to­identify­the­
According­to­preliminary­data­from­a­phase­II­trial,­ patients­most­likely­to­respond­to­the­drug.­Her-­
combining­the­novel­monoclonal­antibody­MetMAb­ ceptin­plus­chemotherapy­has­been­shown­to­prolong­
with­Tarceva­(erlotinib)­nearly­doubles­progres-­ the­lives­of­patients­with­stomach­cancer­by­up­to­
sion-free­survival­in­certain­patients­with­non-small­ 35%.­
cell­lung­cancer.­These­patients’­tumour­cells­­
carry­an­abnormally­high­concentration­of­a­cell­­
surface­protein­known­as­the­Met­receptor.­
05_Roche_AR10_ENG_Strategy.indd 18 28.01.2011 10:39:1019­
Roche Group Roche Business Report 2010
MAPK signalling Diagnostics Therapeutics
Molecular­test­*­(PCR)­­ Active­ingredient­(BRAF
identifies­patients­carrying­­ inhibitor RG7204)­targets­
a­mutated­BRAF­gene­ melanoma­cancer­cells­­
in­patients­with­mutated­­
BRAF­gene
Met signalling Diagnostics Therapeutics
Tissue­test­*­identifies­­ Antibody­(MetMAb
tumours­with­high­expression­ RG3638)­docks­on­Met­
of­the­Met­receptor­ receptor­and­inhibits­­
cancer-triggering­growth­
­factor
HER signalling Diagnostics Therapeutics
Tissue­test*­determines­­ Antibody-drug­conjugate­
HER2­receptors­or­HER2­­ binds­to­HER2­receptors­­
gene­expression (Herceptin)­and­linked­
chemo­therapy­agent­pene-
trates­cancer­cell­(T–DM1,
RG3502)
* These tests are being developed by Roche Diagnostics.
Precision two-pronged attack on breast cancer The­antibody­trastuzumab­binds­to­HER2-positive­
Preliminary­results­from­a­phase­II­study­of­trastuzu- cancer­cells­and­blocks­a­signalling­pathway­that­
mab-DM1­(T–DM1)­in­HER2-positive­metastatic­ makes­tumours­grow,­while­the­chemotherapy­agent­
breast­cancer­show­that­the­drug­shrank­tumours­in­ DM1­penetrates­and­destroys­the­cancer­cells.­
one-third­of­the­women­who­had­failed­prior­ther-­ Another­potential­new­weapon­against­breast­cancer­
apies.­Known­as­an­antibody-drug­conjugate,­T–DM1­ is­pertuzumab­(RG1273),­the­first­of­a­novel­class­­
links­trastuzumab,­the­active­ingredient­of­Hercep-­ of­targeted­therapeutics­known­as­HER­dimerisation­
tin,­with­the­potent­chemotherapeutic­agent­DM1.­ inhibitors.­RG1273­blocks­HER2­from­pairing­with­
This­represents­a­new­targeted­‘two-in-one’­ other­HER­proteins,­thus­preventing­the­abnormal­ac-­
approach­to­treating­cancer:­ tivation­of­signal­cascades­that­occurs­in­cancer­cells.­
05_Roche_AR10_ENG_Strategy.indd 19 28.01.2011 10:39:2120­
Roche Business Report 2010 Roche Group
Combining forces against hepatitis C Hope for asthma sufferers
Hepatitis­C­virus­(HCV)­causes­acute­and­chronic­ Asthma­still­represents­a­major­unmet­medical­need.­
liver­diseases­that­can­lead­to­liver­failure,­cirrhosis­ Moreover,­the­underlying­disease­mechanisms­are­
and­cancer.­There­are­currently­over­180­million­­ not­the­same­in­all­cases.­Our­scientists­have­discov-
people­infected­with­HCV­worldwide.­Diagnostic­tests­ ered­that,­in­a­particular­set­of­patients,­certain­
based­on­PCR­technology­can­now­measure­viral­ genes­are­activated­in­the­wrong­place­and­at­the­
load­in­the­blood­of­patients­with­chronic­hepatitis­C­ wrong­time­by­the­chemical­messenger­interleukin-13­
infection­and­determine­which­of­the­four­different­ (IL-13),­a­key­mediator­in­asthma­reactions.­Reduc-
HCV­subgroups­(genotypes)­is­present.­ ing­IL-13­levels­could­thus­be­a­way­of­relieving­
asthma­symptoms­in­this­patient­subpopulation.­­
The­disease­can­then­be­treated­by­pegylated­inter- This­approach­is­currently­being­tested­in­a­phase­II­
ferons­tailored­to­the­respective­genotype­and­viral­ trial­with­lebrikizumab­(RG3637),­involving­the­­
load­level,­such­as­the­Roche­product­Pegasys.­The­ measurement­of­a­key­biomarker­called­periostin.­­
viral­load­test­is­also­used­after­a­few­weeks­to­check­ It­may­make­it­possible­to­identify­the­patients­most­
treatment­response.­In­many­patients,­the­virus­can­ likely­to­respond­to­an­anti-IL-13­antibody­like­
be­completely­eliminated.­For­chronic­hepatitis­C­ RG3637.­Roche­Diagnostics­is­currently­developing­
patients­who­do­fail­to­benefit­from­interferon-based­ an­appropriate­assay.
therapy,­several­small­antiviral­molecules­are­in­clinical­
development­at­Roche.­ Once­just­a­vision,­personalised­healthcare­is­
increas­ingly­becoming­a­reality,­helped­by­pioneering­
The­focus­here­is­on­hepatitis­C­subtype­1­infection,­ efforts­at­Roche.­For­years­we­have­been­working­­
which­is­very­difficult­to­treat.­Initial­results­show­that­ to­advance­more­personalised­treatment­options­
in­patients­who­have­not­responded­to­interferons,­ across­all­our­therapeutic­areas­of­interest.­Going­for-­
the­new­combined­treatment­can­achieve­a­99.9%­ ward,­we­are­ideally­equipped­to­remain­at­the­fore-
reduction­in­blood­viral­load­within­just­two­weeks.­ front­of­this­groundbreaking­new­approach­to­health-
care­—­and­to­continue­realising­its­tremendous­
potential­for­all­our­stakeholders.
­
05_Roche_AR10_ENG_Strategy.indd 20 28.01.2011 10:39:2121­
Roche Group Roche Business Report 2010
HER signalling Diagnostics Therapeutics
Tissue­test*­determines­­ Antibody­(pertuzumab
HER2­receptors­or­HER2­ RG1273)­inhibits­pairing­of­
gene­expression HER1,­HER2­and­HER3­­
receptors­and­thus­prevents­
fatal­signalling­in­cancer­­
cells
Hepatitis C virus Diagnostics Therapeutics
Molecular­test*­(PCR)­to­ HCV­nucleoside­polymerase­
determine­levels­of­circulating­ inhibitor­(RG7128)­prevents­
Hepatitis­C­virus reproduction­of­hepatitis­C­
viruses
Lebrikizumab Diagnostics Therapeutics
Immunoassay*­measures­­ Antibody­(lebrikizumab
the­serum­level­of­the­protein­ RG3637)­inhibits­chemical­
periostin­(an­IL-13­gene­ messenger­interleukin-13­­
product)­and­thus­detects­ that­triggers­inflammation­in­
lung­inflammation­driven­­ asthmatic­reactions
by­IL-13
IL-13 molecule
* These tests are being developed by Roche Diagnostics.
05_Roche_AR10_ENG_Strategy.indd 21 28.01.2011 10:39:2522­
Roche Business Report 2010 Roche Group
From precise diagnosis to more personalised therapy
Non-small cell lung cancer (NSCLC) is the world’s number one cause of cancer-
related death, the most common form being adenocarcinoma. The illustrations
show how diagnostic tests can provide patients suffering from NSCLC and their
physicians with information about a tumour’s molecular profile, the likelihood
of response to drug therapy and the most appropriate therapeutic options.
Roche has developed
several immunohisto-
chemistry and in situ
The diagnosis of lung hybridisation tests to
cancer is complex. determine the exact
Imaging technologies type of tumour present.
are often used for an
initial examination.
2
1
1 Initial diagnosis 3 Prognosis
Tissue­samples­from­the­patient­are­first­examined­­ The­pathologist­then­characterises­the­tumour­on­­
in­the­pathology­laboratory­to­see­whether­cancer­ the­basis­of­cell­differentiation­and­other­criteria.­
cells­are­present.­If­irregularities­in­cellular­shape­or­ Roche­is­currently­developing­a­number­of­molecular­
structure­are­found,­more­extensive­tests­are­ biomarkers­that­will­enable­physicians­to­predict­­
required. the­course­of­cancers­as­accurately­as­possible.
2 Specific cancer diagnosis
Roche­has­developed­several­immunohistochemistry­
and­in situ­hybridisation­tests­for­use­on­the­Bench-
Mark­family­of­instruments­that­reliably­determine­the­
type­and­subtype­of­lung­tumour­present.­
05_Roche_AR10_ENG_Strategy.indd 22 28.01.2011 10:39:4223­
Roche Group Roche Business Report 2010
The pathologist grades Roche has tests on
the tumour by looking at the market and in
the individual cells and development to help
determining the extent physicians under-
of cell differentiation. stand the mecha-
nisms driving cancer
4 growth and thus
select the treatments
most likely to benefit Roche’s Avastin and
3 specific patients. Tarceva have become
pillars in the treat-
ment of lung cancer.
Roche continues to
develop new com-
pounds for targeted
cancer therapy.
5
4 Tests 5 Therapy
A­number­of­genes­have­been­identified­as­growth­ Roche’s­anticancer­medicines­Avastin­(bevacizumab)­
drivers­in­non-small­cell­lung­cancer­(NSCLC).­These­ and­Tarceva­(erlotinib)­play­a­crucial­role­in­the­­
include­the­EGFR­gene,­the­Met­receptors­and­the­ treatment­of­lung­cancer.­And­the­company­is­currently­
Pl3­kinase. developing­a­number­of­new­innovative­drugs­to­
address­cancer-specific­pathways­and­offer­patients­
Tests­from­Roche­help­doctors­understand­the­mech- targeted­therapies.­In­addition,­Roche­Diagnostics­
anisms­driving­tumour­growth­and­thus­to­select­ offers­a­blood­test­enabling­physicians­to­monitor­
drugs­most­likely­to­work­best­for­a­particular­patient.­ responses­to­cancer­treatment.
Roche­has­several­tests­on­the­market­or­in­devel-
opment­which­use­three­key­technologies­—­immuno-
histochemistry­(IHC),­in situ­hybridisation­(ISH)­
and­the­polymerase­chain­reaction­(PCR).
05_Roche_AR10_ENG_Strategy.indd 23 28.01.2011 10:39:45Pharmaceuticals |
Solid local-
currency growth in sales of strategic products
and core operating profit despite lower
Tamiflu revenues and a tougher market
environment, additional approvals for
key medicines and progress with promising
projects in our late-stage development
pipeline made 2010 a successful year.
The Pharmaceuticals Division is focused on
translating excellence in science into effective
medicines for patients. It combines cutting-
edge research at Roche, Genentech in the
US, Chugai in Japan and over 150 partners
worldwide with global scale and reach
in clinical development, manufacturing and
commercial operations.
06_Roche_AR10_ENG_Pharmaceuticals.indd 24 28.01.2011 14:50:4025­
Pharmaceuticals Roche Business Report 2010
Pharmaceuticals Division in brief
Sales | in millions of CHF Core operating profit | in millions of CHF Number of employees
38,996
37,058 54,141 54,813 53,187
35,961
14,836 14,776
13,594
08 09 10 08 09 10 08 09 10
Key figures
% change % change in
In millions of CHF in CHF local currencies % of sales
Sales 37,058 –5 –2 100
— United States 14,071 –5 –1 38
— Western Europe 9,467 –13 –5 25
— Japan 4,319 –9 –12 12
— International (Asia—Pacific, CEMAI 1, 9,201 7 8 25
Latin America, Canada, Others)
Core operating profit 14,776 0 4 39.9
Operating free cash flow 12,933 –13 –9 34.9
Research and development (core basis) 8,160 –5 –2 22.0
1 CEMAI: Central and Eastern Europe, Middle East, Africa, Central Asia, Indian Subcontinent.
Pharmaceuticals Management Team | 31 December 2010
Pascal Soriot 1, 2 Chief Operating Officer Pharmaceuticals, Head of Pharma Medicines
Hal Barron 2 Global Product Development, Chief Medical Officer
Ian Clark 2 Commercial Operations, North America and CEO, Genentech
Tuygan Göker 2 Commercial Operations, CEMAI
Meeta Gulyani 2 Global Portfolio Management
Peter Hug 2 Commercial Operations, Western Europe
Michael Knierim 2 Human Resources
David Loew 2 Global Product Strategy
Luke Miels 2 Commercial Operations, Asia—Pacific
Patrick Mongrolle 2 Finance
Jörg Rupp 2 Commercial Operations, Latin America
Patrick Yang 2 Global Technical Operations
Jean-Jacques Garaud 1 Pharma Research and Early Development (pRED)
Osamu Nagayama 1 President and CEO, Chugai
Richard Scheller 1 Genentech Research and Early Development (gRED)
Dan Zabrowski 1 Roche Partnering
1 Member of the Corporate Executive Committee — see Corporate Governance, p. 84–85.
2 Member of the Pharma Medicines Leadership Team.
06_Roche_AR10_ENG_Pharmaceuticals.indd 25 28.01.2011 14:50:4126­
Roche Business Report 2010 Pharmaceuticals
Pharmaceuticals Division Sales by region
Solid­local-currency­growth­1­in­sales­of­strategic­
products­and­core­operating­profit,­additional­mar- United States 38% (–1%)
keting­approvals­for­strategic­products,­and­progress­ Asia—Pacific 6% (+8%)
with­a­range­of­promising­projects­in­our­late-stage­ Latin America 7% (+20%)
R­&­D­pipeline­made­2010­a­successful­year­overall­ Other regions 3% (–9%)
for­the­Pharmaceuticals­Division.­Growth­was­driven­ CEMAI 9% (+4%)
primarily­by­strong­demand­for­key­medicines­from­
the­Group’s­oncology­and­inflammatory­disease­port-
folios.­Following­the­end­of­the­influenza­A­(H1N1)­ Western Europe 25% (–5%)
pandemic­and­completion­of­government­stockpiling­ Japan 12% (–12%)
orders,­sales­of­Tamiflu­declined­strongly.­
Italics = growth rates (local currencies).
CEMAI: Central and Eastern Europe, Middle East, Africa,
We­achieved­important­product­development­suc- Central Asia, Indian Subcontinent.
cesses­in­2010,­including­expanded­marketing­
ap­prov­als­for­Actemra/RoActemra­for­rheumatoid­
arthritis­in­the­US­and­the­EU,­Herceptin­for­stomach­ bursement­prices­or­higher­rebates­on­medicines­
cancer­(EU­and­US),­MabThera/Rituxan­for­chronic­ under­statutory­health­insurance­or­government-
lymphocytic­leukemia­(US)­and­maintenance­treat- funded­programmes.­These­developments­already­
ment­of­follicular­lymphoma­(EU),­and­Lucentis­for­ had­a­noticeable­impact­on­sales­in­2010,­and­­
macular­edema­following­retinal­vein­occlusion­(US).­ we­expect­this­to­continue­into­2011­and­beyond.­­
Key­regulatory­filings­included­marketing­applica- In­addition,­we­experienced­several­product­devel-
tions­for­Actemra/RoActemra­for­juvenile­idiopathic­ opment­setbacks­in­2010.­The­most­serious­of­­
arthritis­in­the­EU­and­US,­Herceptin­for­stomach­ these­were­the­decision­to­suspend­phase­III­testing­
cancer­in­Japan­and­Avastin­for­advanced­ovarian­ of­taspoglutide­for­type­2­diabetes,­and­regulatory­
cancer­in­the­EU.­ developments­in­the­US­and­EU­concerning­Avastin­
as­a­treatment­for­advanced­breast­cancer.
During­the­year­we­made­decisions­to­move­several­
projects­into­late-stage­development,­including­ In­December­the­European­and­US­health­authorities­
­ocrelizumab­for­multiple­sclerosis,­RG7128­for­hep-­ announced­decisions­that­are­pivotal­in­determining­
atitis­C,­lebrikizumab­for­asthma­and­RG3638­­ whether­Avastin­remains­available­as­a­treatment­­
(MetMAb)­for­lung­cancer.­Positive­results­from­clin-­ for­metastatic­breast­cancer.­We­believe­strongly­that­
ical­trials­with­other­late-stage­compounds­such­­ patients­should­have­this­option­and­are­pleased­­
as­RG7204­(BRAF­inhibitor)­for­melanoma,­RG7159­ that­the­European­authorities­continue­to­support­the­
(GA101)­for­non-Hodgkin’s­lymphoma­and­chronic­ use­of­Avastin­in­this­indication.­It­is­disappointing­
lymphocytic­leukemia,­and­T–DM1­and­pertuzumab­ that­the­US­Food­and­Drug­Administration­(FDA)­has­
for­HER2-positive­breast­cancer­were­published­or­ come­to­a­different­conclusion­after­reviewing­the­
presented­at­major­medical­conferences­during­2010.­ same­set­of­data.­We­believe­that­women­with­HER2-
These­targeted­compounds­are­designed­to­move­­ negative­metastatic­breast­cancer­living­in­the­US­
the­standard­of­care­for­these­diseases­and­improve­ should­also­have­Avastin­as­a­treatment­option,­and­
patient­survival.­Roche’s­pharmaceutical­pipeline­ we­have­requested­a­hearing­with­the­FDA­accord-
­currently­includes­12­new­molecular­entities­in­late- ingly­(see­p.­37).
stage­development.
Responding­to­the­tougher­operating­environment­
At­the­same­time,­2010­was­a­year­of­significant­ and­setbacks­outlined­above,­we­continued­to­
­challenges.­Pressure­on­healthcare­budgets­in­many­ strengthen­our­Pharmaceuticals­organisation­to­
countries­and­healthcare­reforms­in­the­United­
States,­the­world’s­largest­market­for­pharmaceuti-
cals,­translated­into­mandatory­reductions­in­reim- 1 Unless otherwise stated, all growth rates are in local currencies.
06_Roche_AR10_ENG_Pharmaceuticals.indd 26 28.01.2011 14:50:4227­
Pharmaceuticals Roche Business Report 2010
increase­efficiency­and­maintain­its­focus­on­inno-
vation.­We­believe­that­the­measures­now­being­
Excluding Tamiflu, Pharma-
implemented­through­the­Group’s­Operational­Excel-
lence­programme­will­enhance­Roche’s­ability­to­
ceuticals Division sales grew 5%,
deliver­breakthrough­medicines­for­patients,­allowing­
us­to­expand­further­in­high-growth­emerging­econ- above the global market.
omies­while­strengthening­our­presence­in­estab-
lished­markets.
healthcare­reforms­in­the­United­States­and­austerity­
Results and main measures­in­Europe­had­a­negative­impact­on­total­
sales­of­approximately­530­million­Swiss­francs­or­­
business developments
1.5­percentage­points.­Excluding­Tamiflu,­sales­in­the­­
US­and­Western­Europe­increased­4%­and­2%,­
Sales­by­the­Pharmaceuticals­Division­in­2010­ respectively,­compared­with­market­growth­2­of­3%­
declined­2%­in­local­currencies­(–5%­in­Swiss­francs,­ and­2%.­A­decline­in­sales­of­12%­in­Japan­reflects­
–1%­in­US­dollars)­compared­with­2009­to­37.1 bil- both­significantly­lower­demand­for­Tamiflu­and­­
lion­Swiss­francs.­Excluding­Tamiflu,­the­division’s­ the­impact­of­revised­National­Health­Insurance­reim-
local-currency­sales­grew­5%,­above­the­global­­ bursement­prices­that­came­into­effect­in­April.­
market.­In­addition­to­the­Group’s­five­main­cancer­ Excluding­Tamiflu,­Japanese­sales­grew­3%­in­a­vir-
medicines,­the­primary­sales­drivers­were­Lucentis,­ tually­flat­market.
Actemra/RoActemra­and­Mircera.­Growth­from­these­
and­other­pharmaceuticals­largely­compensated­­ Core­operating­profit­3­grew­4%­in­local­currencies­
for­lower­sales­of­Tamiflu,­CellCept­and­NeoRecor- and­was­stable­in­Swiss­francs­at­14.8­billion­Swiss­
mon/Epogin.­Together,­the­top­six­sales­drivers­—­ francs.­The­corresponding­margin­increased­1.9­
Avastin,­MabThera/Rituxan,­Herceptin,­Lucentis,­ ­percentage­points­to­39.9%,­driven­by­synergies­from­
Actemra/RoActemra­and­Xeloda­—­contributed­over­ the­merger­with­Genentech­and­productivity­improve-
1.3 billion­Swiss­francs­in­additional­sales­in­2010.­ ments.­This­was­achieved­despite­the­expected­sharp­
Due­to­the­passing­of­the­influenza­A­(H1N1)­pan- decline­in­Tamiflu­sales­and­the­impact­of­health­­-­­
demic,­a­relatively­mild­influenza­season­and­the­ care­reforms­and­austerity­measures.­A­reduction­of­
completion­of­most­government­stockpiling­orders,­ 1%­in­marketing­expenses­was­achieved­through­
sales­of­Tamiflu­declined­strongly,­to­873 million­ tight­cost­management,­which­more­than­covered­­
Swiss­francs­(2.3 billion­francs­lower­than­in­2009). an­increase­in­allowances­for­bad­debts­in­Southern­
Europe.­Research­and­development­expenses­
Sales­expanded­fastest­in­the­International­region­ declined­2%­versus­2009­thanks­to­resource­priori-­
(8%,­or­11%­excluding­Tamiflu),­driven­by­demand­for­ tisation­while­securing­long-term­growth­through­­
MabThera,­Herceptin,­Avastin­and­other­key­medi- the­rich­R­&­D­pipeline.­In­addition­to­investments­in­
cines­in­emerging­markets.­Particularly­strong­growth­ phase­III­initiations,­the­metabolism­franchise­and­­
was­recorded­in­Latin­America­(20%),­led­by­Brazil­ the­earlier-stage­neurology­portfolio,­research­and­
and­Venezuela.­Solid­growth­in­the­Asia—Pacific­ development­expenses­included­costs­associated­
region­(8%)­was­led­by­China­and­Taiwan.­A­slight­ with­the­discontinuation­of­the­ocrelizumab­rheuma-
decrease­in­the­United­States­(–1%)­reflects­sig- toid­arthritis­programme­(see­p.­51,­below)­and­
nificantly­lower­sales­of­Tamiflu­and­CellCept,­as­well­ project­termination­costs­associated­with­the­Opera-
as­healthcare­reform­impacts­affecting­all­major­ tional­Excellence­programme.
products.­A­5%­decline­in­sales­in­Western­Europe­
was­due­primarily­to­markedly­lower­sales­of­Tamiflu­
and­NeoRecormon­and­the­effects­of­government­
austerity­measures­introduced­in­a­number­of­coun- 2 Pharmaceutical market growth according to IMS
(to end of September 2010).
tries,­including­Greece­and­Spain­in­the­second­
3 Unless otherwise stated all results are on a core basis
quarter­and­Germany­in­the­third­quarter.­Together,­ (see p. 14, above, and p. 144 of the Finance Report).
06_Roche_AR10_ENG_Pharmaceuticals.indd 27 28.01.2011 14:50:4228­
Roche Business Report 2010 Pharmaceuticals
­Germany­and­Switzerland.­In­addition,­expansion­­
of­the­Kentucky­Distribution­Center­was­completed­
The core operating profit
in­2010.­The­facility­now­serves­as­the­primary­
­distribution­centre­for­all­products­marketed­in­the­
margin increased 1.9 percentage
United­States.
points to 39.9%.
In­all,­Global­Technical­Operations­facilities­passed­
more­than­30­health­authority­inspections­in­2010.­
Our­biotech­production­facility­in­Singapore­received­
The­division’s­full-year­operating­free­cash­flow­ its­first­approvals­by­the­US­Food­and­Drug­Admin-
remained­strong­at­12.9­billion­Swiss­francs.­The­ istration­(FDA),­to­manufacture­Lucentis­and­Avastin­
decrease­of­9%­compared­with­2009­primarily­ biologic­bulk­drug­substance­for­commercial­use­­
reflects­the­payment­in­2010­of­certain­large­2009­ in­the­US.­Approval­by­the­EU­authorities­is­targeted­
year-end­accruals,­including­employee­retention­­ for­2011.­Our­Kaiseraugst­(Switzerland)­facility­
and­severance­payments,­and­high­royalty­payments­ ­successfully­launched­Actemra­product­for­commer-
relating­to­strong­Tamiflu­sales­in­the­second­half­­ cialisation­in­the­United­States­14­days­after­FDA­
of­2009.­The­Pharmaceuticals­Division­is­on­track­to­ approval.­Our­bulk­drug­manufacturing­facilities­in­
achieve­its­goal­of­pre-tax­annual­synergies­from­­ South­San­Francisco,­Vacaville­and­Oceanside­­
the­Genentech­merger­of­approximately­1­billion­ (California,­USA)­received­Class­A­certification,­an­
Swiss­francs­by­2011.­Synergies­of­over­800­million­ international­business­award­recognising­system­-­­
Swiss­francs­were­achieved­in­2010.­For­more­ atic­process­improvements.­
­information­on­the­division’s­operating­results,­­
see­the­Finance­Report­(Part­2­of­this­Annual­­ As­part­of­the­continuous­evaluation­of­our­global­
Report). manufacturing­network,­we­are­always­reviewing­and­
analysing­our­structures,­organisations,­processes­
In­the­year­under­review­the­Pharmaceuticals­­ and­operations.­In­2010­we­sold­facilities­located­in­
Division­incurred­significant­non-core­costs­associ- Isando­(South­Africa)­and­Karachi­(Pakistan).­In­
ated­with­restructuring­measures­implemented­­ addition,­plants­in­Montevideo­(Uruguay)­and­Nutley­
under­the­Operational­Excellence­programme.­Most­ (New­Jersey,­USA)­were­closed,­and­we­continue­­
of­these­costs­relate­to­severance­payments­fol- to­plan­for­the­closure­of­certain­operations­in­Mann-
lowing­reductions­in­positions­in­sales­and­market- heim­(Germany)­and­Basel­(Switzerland).
ing,­global­manufacturing,­global­development,­­
and­research­and­early­development,­as­well­as­ Following­a­detailed­analysis­of­organisational­
impairments­of­intangible­assets. ­structures­and­processes­as­part­of­the­Group-wide­
Operational­Excellence­programme,­Global­Technical­
Operations­will­further­refine­its­organisational­
Manufacturing infrastructure ­structure­to­improve­operational­efficiencies,­opti-
mise­manufacturing­assets­and­consolidate­the­
Integration­of­the­Roche­and­Genentech­manufactur- ­technical­development­and­clinical­supply­network.­
ing­and­supply­networks­continued­in­2010,­as­ Some­activities­will­be­reorganised­in­California,­
­initiatives­were­implemented­to­ensure­that­global­ Mannheim­and­other­sites­by­the­end­of­2013,­result-
demand­for­commercial­and­clinical­supplies­of­­ ing­in­a­reduction­of­approximately­750­positions.­­
our­medicines­can­be­met­and­that­necessary­adap- In­addition,­Roche­intends­to­seek­buyers­for­its­US­
tations­to­our­growing­pipeline­are­made­in­time. sites­in­Florence,­South­Carolina,­and­Boulder,­
­Colorado,­potentially­affecting­an­additional­600­jobs.­
A­number­of­important­milestones­were­achieved­­ Together­with­activities­initiated­in­the­last­two­­
in­2010.­In­April­Hillsboro­Operations­(Oregon,­USA)­ years,­these­changes­will­reduce­the­number­of­
was­officially­inaugurated.­By­2013­Hillsboro­will­­ ­manufacturing­locations­from­21­to­15­by­the­­
be­the­US­commercial­filling­and­packaging­facility­ end­of­2013.
for­our­medicines,­supplementing­facilities­in­
06_Roche_AR10_ENG_Pharmaceuticals.indd 28 28.01.2011 14:50:4229­
Pharmaceuticals Roche Business Report 2010
Sales by therapeutic area
Oncology 57% (+7%)
Inflammatory and autoimmune diseases, transplantation 8% (+3%)
Central nervous system 3% (+2%)
Respiratory 3% (+7%)
Metabolic diseases, bone diseases 7% (–1%)
Infectious diseases 1% (–2%)
Cardiovascular diseases 3% (–3%)
Virology 10% (–39%)
Others 1% (–10%)
Renal anemia 3% (–6%)
Ophthalmology 4% (+27%)
Italics = growth rates (local currencies).
Partnering activities Network­(EIN)­project,­which­is­designed­to­create­
and­deepen­relations­with­leading­academic­insti-­
Collaboration­with­external­partners­has­long­been­­ tutions­worldwide.­Under­a­new­EIN­partnership­with­
a­cornerstone­of­Roche’s­R­&­D­strategy.­Access­­ Harvard­University,­Roche­provides­strategic­ques-
to­external­innovation­through­licensing­and­targeted­ tions­and­know-how­to­Harvard,­with­Harvard­provid-
acquisitions­is­a­significant­means­of­strengthening­ ing­innovative­solutions.
the­R­&­D­portfolio­and­expanding­the­Group’s­tech-
nology­capabilities.­In­2010­Roche­Partnering­signed­ Genentech­Partnering­completed­four­product­trans-
a­total­of­52­new­agreements,­including­one­prod­­­-­­ actions­and­16­research­and­technology­collabo-
uct­transaction­and­40­research­and­technology­col- rations­in­2010,­supporting­the­cutting-edge­work­­
laborations.­In­addition,­ten­product­outlicensing­ of­Genentech­Research­and­Early­Development.­
agreements­were­signed. Among­these­is­an­expansion­of­the­antibody-drug­
conjugate­collaboration­with­Seattle­Genetics­in­
Among­Roche­Partnering’s­main­transactions­in­2010­ oncology.­New­collaborations­in­immunology­
were­an­agreement­with­Belgian­company­reMYND­ included­an­exclusive­licensing­agreement­with­
to­develop­novel­therapeutics­that­could­slow­down­ Swiss-based­antibody­specialist­NovImmune,­cover-
neurodegeneration­in­Parkinson’s­and­Alzheimer’s­ ing­an­anti-IL-17­antibody­that­has­the­potential­­
patients.­A­new­collaboration­was­agreed­with­Aileron­ to­benefit­patients­across­a­range­of­autoimmune­dis-
Therapeutics­to­discover,­develop­and­commercial-­ eases.­A­novel­research­programme­was­agreed­­
ise­a­novel­class­of­drugs­called­stapled­peptide­ther-­ with­US­company­Adimab,­which­will­use­its­propri-
apeutics,­a­potentially­transfor­mative­technology­­ etary­discovery­platform­to­identify­fully­human­anti-
to­create­drugs­for­important­disease­targets­that­are­ bodies­against­two­targets­selected­by­Genentech.­
intractable­to­currently­available­modalities.­In­ Under­the­agreement,­Genentech­has­rights­to­
December­Roche­acquired­Marcadia­Biotech,­a­pri- ­commercialise­antibodies­generated­from­the­collab-
vately­owned­US­company­focusing­on­the­devel-­ oration.
opment­of­innovative­therapeutics­for­­metabolic­­
diseases.­Marcadia’s­research­and­development­pro-
grammes­on­new­peptide­therapies­for­the­treatment­ Sales review —
of­type­2­diabetes­and­obesity­will­be­integrated­­
selected key products
into­Roche’s­R­&­D­portfolio.­These­include­next­gener-­
ation­peptides­such­as­MAR701,­currently­in­phase­I­
development­for­type­2­diabetes.­Several­partners­ The­Pharmaceuticals­Division’s­broad-based­portfolio­
were­added­to­Roche’s­Expanding­the­Innovation­ of­marketed­products­includes­ten­medicines­from­
06_Roche_AR10_ENG_Pharmaceuticals.indd 29 28.01.2011 14:50:4330­
Roche Business Report 2010 Pharmaceuticals
Top-selling pharmaceuticals — Roche Group | in millions of CHF
6,461 6,356 5,429 1,645 1,458
Avastin MabThera/Rituxan Herceptin Pegasys Lucentis **
+9% * +9% * +7% * +2% * +27% *
Active substance: Active substance: Active substance: Active substance: Active substance:
bevacizumab 1 rituximab 1 trastuzumab 1 peginterferon alfa-2a 1 ranibizumab 1
Indications: Indications: Indications: Indications: Indications:
colorectal cancer, non-Hodgkin’s lymphoma, HER2-positive breast can- hepatitis B and C wet age-related macular
breast cancer, non-small chronic lymphocytic cer, advanced HER2-posi- degeneration, macular
cell lung cancer, kidney leukemia, rheumatoid tive stomach cancer edema following retinal
cancer, glioblastoma arthritis vein occlusion
06_Roche_AR10_ENG_Pharmaceuticals.indd 30 28.01.2011 14:50:4631­
Pharmaceuticals Roche Business Report 2010
Thanks to the Pharmaceuticals Division’s broad-based
portfolio, Roche is one of the world’s leading providers of
clinically differentiated medicines for cancer, viral
and inflammatory diseases, and metabolic disorders.
1,426 1,325 1,290 1,285 1,013
Xeloda Tarceva CellCept NeoRecormon, Epogin Bonviva/Boniva
+17% * +6% * –15% * –15% * +1% *
Active substance: Active substance: Active substance: Active substance: Active substance:
capecitabine 2 erlotinib 2 mycophenolate mofetil 2 epoetin beta 1 ibandronate 2
Indications: Indications: Indications: Indications: Indications:
colorectal cancer, breast advanced non-small cell transplantation anemia osteoporosis
cancer, stomach cancer lung cancer, advanced
pancreatic cancer
1,2 T he images above show molecular diagrams representing the active
substance of each medicine (1 = therapeutic protein, 2 = small molecule).
* Year-on-year sales growth in local currencies.
** US sales. Lucentis is marketed outside the United States by Novartis.
06_Roche_AR10_ENG_Pharmaceuticals.indd 31 28.01.2011 14:50:5032­
Roche Business Report 2010 Pharmaceuticals
six­therapeutic­areas­that­generated­sales­of­over­­ Latin­America­(42%).­In­the­third­quarter­Avastin­­
1­billion­Swiss­francs­each­in­2010.­Of­these,­the­top­ was­launched­in­China­in­its­first­indication,­first-line­
three­recorded­sales­of­well­over­5­billion­Swiss­ treatment­of­metastatic­colorectal­cancer;­initial­
francs­each.­Combined­sales­of­the­Group’s­top­20­ uptake­has­been­very­encouraging.
pharmaceuticals­amounted­to­32.6­billion­Swiss­
francs,­or­88%­of­divisional­sales. Full-year­sales­(oncology­and­autoimmune­diseases)­
of­MabThera/Rituxan­(rituximab),­for­non-Hodgkin’s­
Sales­of­the­division’s­oncology­portfolio­rose­7%­to­ lymphoma­(NHL),­chronic­lymphocytic­leukemia­
21.3­billion­Swiss­francs­in­2010,­led­by­key­products­ (CLL)­and­rheumatoid­arthritis­(RA),­totalled­6.4 bil-
Avastin,­MabThera/Rituxan,­Herceptin,­Xeloda­and­ lion­Swiss­francs­in­2010,­an­increase­of­9%­versus­
Tarceva.­Together,­these­five­medicines­accounted­for­ 2009.­Sustained­growth­in­the­oncology­segment­was­
over­half­of­total­pharmaceutical­sales.­Sales­of­ driven­by­uptake­in­CLL­and­continued­strong­use­­
a­ntiviral­medicines­declined­39%,­for­a­full-year­total­ in­NHL­in­Western­Europe­and­the­US.­Solid­double-
of­3.5­billion­Swiss­francs,­due­mainly­to­the­sharp­ digit­growth­in­the­International­region,­including­
decline­in­sales­of­Tamiflu.­Overall­sales­of­the­renal­ strong­gains­in­key­emerging­markets,­reflects­uptake­
anemia­portfolio­declined­by­6%­to­1.2­billion­francs,­ of­the­medicine­in­its­NHL­indications.­The­European­
with­strong­demand­for­Mircera­outweighed­by­ rollout­of­MabThera­in­a­new­indication,­first-line­
decreasing­sales­of­NeoRecormon/Epogin.­Sales­in­ maintenance­treatment­of­patients­with­follicular­lym-
the­combined­inflammation/autoimmune/transplan- phoma,­commenced­in­the­fourth­quarter.­Estimated­
tation­portfolio­rose­3%­to­3.0­billion­francs:­growing­ sales­of­MabThera/Rituxan­in­the­RA­segment­
demand­for­MabThera/Rituxan­for­rheumatoid­­ reached­the­1­billion­Swiss­franc­mark­in­2010­(16%­
arthritis­and­strong­uptake­of­Actemra/RoActemra­ of­the­product’s­total­sales),­17%­higher­than­in­
offset­continued­generic­erosion­of­CellCept­in­the­ 2009.­Growth­is­being­driven­by­increased­use­in­
United­States.­ patients­with­an­inadequate­response­to­one­or­more­
tumour­necrosis­factor­inhibitors­and­by­growing­
Oncology acceptance­of­six-month­repeat­treatment­intervals.
Global­sales­of­Avastin­(bevacizumab),­for­advanced­
colorectal,­breast,­lung­and­kidney­cancer,­and­for­ Global­sales­of­Herceptin­(trastuzumab),­for­HER2-
relapsed­glioblastoma­(a­type­of­brain­tumour),­rose­ positive­breast­cancer­and­HER2-positive­metastatic­
9%­to­6.5­billion­Swiss­francs,­reflecting­continued­ stomach­cancer,­rose­7%­to­5.4­billion­Swiss­francs­
positive­uptake­of­the­product­overall.­Sales­growth­ on­sustained,­solid­single-digit­growth­in­the­United­
in­Western­Europe­(7%)­was­driven­primarily­by­ States­and­Western­Europe,­and­double-digit­gains­­
­continued­uptake­for­breast­cancer­and­improved­ in­the­International­region.­Herceptin­maintained­­
uptake­for­colorectal­and­lung­cancer.­Austerity­ its­high­market­penetration­in­breast­cancer,­with­­
measures­introduced­during­the­year­in­Greece,­ sales­also­benefitting­from­initial­uptake­for­stomach­
Spain,­Germany­and­other­markets­resulted­in­a­pro- ­cancer­in­EU­countries­and­other­markets.­In­addi-
gressive­flattening­of­growth­in­the­region­as­a­­ tion,­improvements­in­the­quality­of­HER2­testing­­
whole­that­was­particularly­noticeable­in­the­fourth­ are­expanding­the­population­of­patients­eligible­for­
quarter.­Sales­in­the­US­were­flat­for­the­year,­reflect- treatment­with­Herceptin.­In­Japan,­where­Herceptin­
ing­reserve­adjustments­due­to­the­healthcare­ has­a­market­share­of­approximately­90%­in­its­­
reforms­enacted­in­2010­and­regulatory­and­reim- breast­cancer­indications,­a­stable­sales­volume­and­
bursement­uncertainty­regarding­the­metastatic­ revised­reimbursement­prices­from­April­resulted­­
breast­cancer­indication­(see­p.­37);­together­these­ in­a­significant­decline­in­sales­revenue­compared­
factors­led­to­a­decline­in­sales­in­the­second­ with­2009.
h­alf-year,­especially­the­fourth­quarter.­Avastin­main-
tained­its­high­US­market­share­in­its­metastatic­ Xeloda­(capecitabine),­for­colorectal,­stomach­
colorectal­and­lung­cancer­indications.­Very­strong­ and­breast­cancer,­generated­total­sales­of­1.4­billion­
sales­growth­in­Japan­(51%)­was­driven­by­continued­ Swiss­francs,­an­increase­of­17%­compared­with­
good­uptake­in­colorectal­and­non-small­cell­lung­ 2009.­Growth­was­driven­primarily­by­strong­gains­in­
cancer.­Very­strong­growth­was­also­recorded­in­ the­United­States,­Japan­and­China,­the­product’s­33­
Pharmaceuticals Roche Business Report 2010
three­largest­markets.­Global­sales­of­Xeloda­are­ Swiss­francs­in­2010,­73%­(2.3­billion­francs)­lower­
benefitting­from­a­number­of­new­indications,­ than­in­2009.­With­government­stockpiling­orders­
­including­stomach­cancer­in­China,­an­expanded­ largely­completed­by­early­2010­and­the­influenza­A­
metastatic­colorectal­cancer­indication­in­Japan,­­ (H1N1)­pandemic­passing­its­peak,­sales­fell­sharply­
and­adjuvant­4­colon­cancer­in­Europe,­as­well­as­ in­the­last­three­quarters.­Sales­were­also­affected­­
increased­patient­share­in­metastatic­breast­­ by­relatively­mild­influenza­seasons­in­both­hemi-
cancer­in­the­US­and­EU. spheres­during­2010.­Roche­remains­ready­to­address­
­potential­threats­posed­by­influenza­and­is­main-
Sales­of­Tarceva­(erlotinib),­for­advanced­lung­ taining­production­capacity­in­cooperation­with­
and­pancreatic­cancer,­increased­6%­to­1.3­billion­ ­exter­nal­manufacturing­partners­to­enable­a­rapid­
Swiss­francs,­driven­mainly­by­increased­use­in­­ response­to­future­significant­outbreaks­or­govern-
the­second-line­non-small­cell­lung­cancer­setting.­ ment­stockpiling­orders.
The­main­contributions­to­growth­came­from­the­
International­region,­Japan­and­the­US.­Mid-single- Ophthalmology
digit­growth­in­the­US­reflects­steady­demand­in­­ US­sales­of­Lucentis­(ranibizumab),­for­wet­age-
the­lung­and­pancreatic­cancer­indications­and­the­ related­macular­degeneration­and­macular­edema­
impact­of­government­healthcare­reforms.­Against­­ following­retinal­vein­occlusion,­rose­27%­to­­
a­background­of­stable­demand,­sales­in­Western­ 1.5­billion­Swiss­francs.­Strong­growth­throughout­
Europe­declined­slightly,­mainly­as­a­result­of­govern- 2010­was­driven­primarily­by­increases­in­the­­
ment-mandated­price­reductions­and­rebates­in­ total­number­of­patients­receiving­Lucentis­and­the­
­several­major­markets.­Sustained­strong­sales­growth­ time­patients­are­on­treatment.­The­US­launch­of­
in­Japan­(37%)­reflects­continued­market­pene­- Lucentis­for­the­treatment­of­macular­edema­(swell-
tration­and­oncologists’­increasing­confidence­in­the­ ing­in­the­retina)­following­retinal­vein­occlusion­
benefits­of­treatment­with­Tarceva. began­in­late­June,­and­initial­uptake­is­encouraging.­
Lucentis­was­­discovered­by­Genentech,­which­
Virology retains­commer­­cial­rights­in­the­United­States.­
Worldwide­sales­of­Pegasys­(peginterferon­alfa-2a),­ Novartis­has­exclusive­commercial­rights­for­the­­
for­hepatitis­B­and­C,­increased­2%­to­1.6­billion­ rest­of­the­world.
Swiss­francs­in­2010.­Flat­sales­in­the­United­States­
and­sales­decreases­in­Western­Europe,­Japan­­ Inflammation and autoimmune disorders
and­certain­other­mature­markets­were­offset­by­ As­the­global­rollout­of­the­novel­rheumatoid­­
growth­in­the­International­region,­especially­­ arthritis­medicine­Actemra­(tocilizumab,­known­as­
Asia—Pacific­and­CEMAI­5­countries.­The­product’s­ RoActemra­in­the­EU)­continued,­sales­in­2010­
market­share­continued­to­expand­in­the­main­ totalled­397 million­Swiss­francs,­a­rise­of­177%­over­
­European­markets,­the­US­and­Japan.­Global­sales­ 2009.­Uptake­of­Actemra/RoActemra­in­the­EU,­­
continued­to­benefit­from­clinical­data­reinforcing­­ the­United­States­and­other­launch­markets­remains­
the­superiority­of­Pegasys­over­other­treatment­ very­encouraging.­Around­60%­of­US­rheumatol-
options­and­increased­use­in­hepatitis­B.­The­hepatitis­ ogists­have­already­prescribed­the­medicine.­Contin-
C­market­is­poised­for­major­expansion,­with­the­ ued­strong­sales­growth­in­Japan­reflects­increas­­-­­
introduction­of­a­new­generation­of­direct-acting­ ing­use­of­Actemra­as­a­first-line­biologic.­Chugai­
antiviral­agents­expected­from­2011­onwards.­ announced­in­August­that­the­Japanese­health­
Because­Pegasys­—­the­leading­pegylated­interferon­ authorities­had­removed­the­approval­conditions­for­
—­is­used­in­most­hepatitis­treatment­development­ Actemra­for­the­rheumatoid­arthritis­and­polyar­tic-
programmes­today,­it­is­expected­to­become­the­ ular-course­juvenile­idiopathic­arthritis­indica­tions.­
backbone­of­future­combination­therapies­with­the­
new­antivirals­(see­also­p.­51,­below).­
Following­exceptional­demand­in­2009­due­to­the­ 4 Adjuvant treatment is given after surgical removal of the
tumour to lower the risk of relapse.
influenza­A­(H1N1)­pandemic,­sales­of­Tamiflu­(osel-
5 CEMAI: Central and Eastern Europe, Middle East, Africa,
tamivir),­for­influenza­A­and­B,­totalled­873­million­ Central Asia, Indian Subcontinent.
06_Roche_AR10_ENG_Pharmaceuticals.indd 33 28.01.2011 14:50:50Clinical development — a long process that continues even after market launch
Creating value for patients means
investing skill and resources in a long,
uncertain journey
10,000
molecules
10
investment
molecules
≤ 50
volunteers or patients
Preclinical development Phase I
3–6 years 1–2 years
Preclinical testing evaluates a drug’s safety profile and pharma- Phase I trials test the safety of
cological effects in the laboratory. Every promising new compound various doses of a new drug. Dur-
must pass rigourous preclinical testing before it can be studied in ing phase I trials researchers are
humans. New drugs usually undergo both in vitro (in test tubes, cell looking at how the drug is absorbed,
cultures and isolated organs) and in vivo (animal) testing. Computer distributed and changed (metabo-
models are playing an increasingly important role in preclinical devel- lised) in the body, how it is eliminated,
opment. Data from preclinical tests are essential for determining how long these processes take, and
whether a drug is safe enough to be administered to people in clinical whether there are any unwanted
trials. effects. These trials involve only a
small number of people — usually
healthy volunteers. In some cases
people whose disease is very
advanced (cancer, for example) may
also participate.
06_Roche_AR10_ENG_Pharmaceuticals.indd 34 28.01.2011 14:50:53100–1,000 *
patients
≤ 15 ,000
patients
≤ 500
patients
2–3
1–2
molecules
1
molecules
molecule
Phase II Phase III Phase IV
1.5–2 years 3–3.5 (or more) years from market entry on
Phase II trials test the new drug A new drug moves into phase III Phase IV trials are conducted after
in people who have the disease it clinical trials only if the phase I a drug has been approved by regu-
is designed to treat. The number and phase II trial results suggest latory agencies and launched on
of patients in phase II trials is limited it might benefit patients in signfi- the market. Also known as post-mar-
but usually larger than in phase I cant ways. Phase III trials compare keting trials, they are designed to
studies. In addition to further safety the new drug with current treatments gather broader, ‘real-world’ experience
testing, these trials identify appropri- or, in some trials, with a placebo. with the new drug in routine medical
ate dose ranges and test whether Many phase III trials last a long time, practice. Phase IV trials generate addi-
the drug demonstrates clinical effi- typically a year or more, and may tional data on safety and efficacy in
cacy (proof of concept). Many new involve several thousand patients in large numbers of patients and in par-
drugs fail in phase II testing. several countries. ticular patient subgroups. They can
also provide further information on
Phase III trials must include a large how the drug works in comparison or
number of patients so that investiga- in combination with other treatments.
tors can evaluate the differences
between types of treatment. Regula- Even large phase III trials cannot iden-
tory agencies normally require results tify all potential side effects: this is
from phase III trials before approving another area where phase IV trials pro-
a new drug. vide essential additional information.
Roche maintains a system of risk
assessment programmes to identify
and evaluate side effects that did not
appear in phase I–III trials.
* Patients per trial; 5–20 (or more) trials.
06_Roche_AR10_ENG_Pharmaceuticals.indd 35 28.01.2011 14:50:5636­
Roche Business Report 2010 Pharmaceuticals
Development highlights —
Further major approvals for key marketed products
Actemra/RoActemra, Herceptin,
In­2010­the­Pharmaceuticals­Division­filed­20­major­
MabThera/Rituxan and new­marketing­applications­and­gained­18­major­
­regulatory­approvals­(see­tables,­pp.­38­and­39).­The­
Lucentis. following­summaries­present­approvals,­filings­and­
major­clinical­trial­results­for­key­marketed­products,­
by­indication.
The­decision­gives­more­patients­access­to­Actemra­ Actemra/RoActemra
and­follows­positive­results­from­a­routine­post-­ Approvals |­In­January­2010­the­US­Food­and­Drug­
marketing­surveillance­programme.­Actemra/ Administration­(FDA)­approved­Actemra­for­­
RoActemra­is­now­available­in­some­50­countries­ the­treatment­of­adult­patients­with­moderately­to­
worldwide. severely­active­rheumatoid­arthritis­(RA)­who­­
have­had­an­inadequate­response­to­one­or­more­
Anemia and transplantation tumour­necrosis­factor­(TNF)­inhibitors.­Actemra,­­
Sales­of­the­renal­anemia­medication­Mircera­(me­- the­first­interleukin-6­receptor-inhibiting­monoclonal­
thoxy­polyethylene­glycol-epoetin­beta)­rose­51%­to­ antibody­approved­to­treat­RA,­may­be­used­alone­­
255­million­Swiss­francs.­Demand­for­Mircera,­which­ or­in­combination­with­methotrexate­or­other­disease­
is­now­available­in­over­100­countries­worldwide,­­ modifying­antirheumatic­drugs.­In­June­the­Euro­­-
is­coming­mainly­from­the­predialysis­segment­and­ pean­Commission­extended­the­product’s­existing­
new­patient­commencements.­Combined­sales­of­­ marketing­approval­to­include­treatment­with­
the­Group’s­established­anemia­medicines,­Roche’s­ RoActemra­plus­methotrexate­to­reduce­the­rate­of­
NeoRecormon­and­Chugai’s­Epogin­(epoetin­beta),­ progression­of­joint­damage­and­improve­physical­
declined­15%­to­1.3­billion­Swiss­francs.­Roche­ function­in­patients­with­rheumatoid­arthritis.­The­
­Pharmaceuticals’­overall­share­of­the­European­ane- new­indication,­which­is­based­on­two-year­data­from­
mia­market­remained­stable­despite­increasing­ a­global­phase­III­study­(LITHE),­came­just­over­a­
biosimilar­competition,­due­mainly­to­the­strong­per- year­after­the­medicine’s­initial­EU­approval,­further­
formance­of­Mircera­in­the­major­EU­countries­­ reinforcing­its­value­as­an­effective­treatment­for­­
and­a­robust­market­share­by­volume­for­NeoRecor- RA.­In­January­2011­the­FDA­approved­Actemra­for­­
mon­in­the­renal­indication.­A­10%­decline­in­sales­­ a­similar­indication­(inhibition­and­slowing­of­
of­Epogin­in­Japan­was­due­mainly­to­competition­in­ ­structural­joint­damage,­improvement­of­physical­
the­dialysis­market­and­a­lower­National­Health­ function,­and­achievement­of­major­clinical­response­
Insurance­reimbursement­price,­factors­which­out- in­adults­with­moderately­to­severely­active­RA),­
weighed­increased­demand­for­the­medicine­in­­ based­on­a­supplemental­Biologics­License­Appli-
the­predialysis­segment. cation­(sBLA)­submitted­by­Genentech­in­March­
2010.
At­1.3­billion­Swiss­francs­for­the­full­year,­sales­
­revenue­from­CellCept­(mycophenolate­mofetil),­for­ Filings |­In­October­Genentech­submitted­a­second­
the­prevention­of­solid­organ­transplant­rejection,­ sBLA­to­the­FDA­and­Roche­submitted­an­Accel-
remained­significant.­The­sales­decrease­of­15%­was­ erated­Assessment­application­to­the­European­
due­primarily­to­the­loss­of­patent­exclusivity­in­­ ­Medicines­Agency­(EMA),­seeking­to­extend­the­
the­United­States­in­2009.­The­resulting­losses­to­ approved­indications­of­Actemra/RoActemra­to­
competition­from­generic­versions­were­partly­offset­ include­treatment­of­systemic­juvenile­idiopathic­
by­sales­growth­in­Japan­and­the­International­ arthritis­(sJIA).­Both­applications­are­based­on­posi-
region.­ tive­data­from­the­global­phase­III­TENDER­study.­
There­are­currently­no­approved­therapies­in­the­EU­
or­US­for­sJIA,­a­debilitating­and­difficult-to-treat­
06_Roche_AR10_ENG_Pharmaceuticals.indd 36 28.01.2011 14:50:5637­
Pharmaceuticals Roche Business Report 2010
disease­that­affects­the­whole­body­and­represents­ the­FDA’s­‘Notice­of­Opportunity­for­Hearing’.­We­
an­area­of­high­unmet­medical­need. believe­this­would­provide­an­opportunity­to­present­
our­views­that­the­data­are­clinically­meaningful­­
Avastin and­meet­the­applicable­legal­and­regulatory­stan-
Since­its­initial­approval­in­2004­in­the­United­States­ dards­for­continued­approval.­Until­the­conclusion­­
for­advanced­colorectal­cancer,­Avastin­has­made­ of­these­proceedings,­Avastin­remains­FDA-approved­
anti-angiogenic­therapy­a­fundamental­pillar­of­cancer­ for­use­in­combination­with­paclitaxel­for­metastatic­
treatment.­Avastin­is­approved­in­many­countries­­ HER2-negative­breast­cancer.­At­the­same­time­the­
for­the­treatment­of­advanced­stages­of­colorectal,­ FDA­issued­complete­responses­for­all­other­pending­
breast,­non-small­cell­lung­and­kidney­cancer.­It­is­ applications­concerning­Avastin­in­metastatic­breast­
also­available­in­the­US­and­29­other­countries­for­the­ cancer,­saying­that­the­applications­failed­to­support­
treatment­of­patients­with­glioblastoma­(a­type­of­ the­extension­of­the­proposed­indications:­for­first-
brain­cancer).­Nearly­a­million­patients­have­been­ line­treatment­in­combination­with­docetaxel­(based­
treated­with­Avastin­so­far.­More­than­1,000­ongoing­ on­AVADO)­and­in­combination­with­standard­chemo-
Roche-sponsored­or­-supported,­or­independently­ therapy­(based­on­RIBBON-1),­and­for­second-­
conducted­clinical­trials­are­investigating­the­use­of­ line­treatment­in­combination­with­standard­chemo-
Avastin­in­over­50­tumour­types­(including­colorec- therapy­(based­on­RIBBON-2).­These­decisions­do­
tal,­breast,­non-small­cell­lung,­brain,­gastric,­ovarian­ not­affect­the­availability­of­Avastin­for­its­approved­
and­others)­and­different­settings­(advanced­or­ uses­in­other­types­of­cancer­in­the­United­States.
early-stage­disease).
Approvals |­In­February­the­Chinese­health­author-
Breast cancer |­In­December,­following­a­review­ ities­approved­Avastin­for­the­treatment­of­metastatic­
of­all­relevant­data,­the­European­Committee­for­ colorectal­cancer,­its­first­indication­in­this­important­
Medicinal­Products­for­Human­Use­(CHMP)­sup- market.
ported­the­continued­first-line­use­of­Avastin­in­
­combination­with­paclitaxel­chemotherapy,­describ- Filings |­In­December­Roche­filed­an­application­
ing­it­as­a­valuable­treatment­option­for­patients­ with­the­EU­authorities­for­approval­of­Avastin­­
­suffering­from­metastatic­breast­cancer.­Paclitaxel­is­ as­frontline­treatment­for­ovarian­cancer,­based­on­
the­chemotherapy­most­frequently­used­and­also­ the­results­of­the­phase­III­GOG218­and­ICON-7­
most­frequently­partnered­with­Avastin­to­control­the­ ­trials­(see­below,­Clinical Milestones).
disease.­The­committee­also­considered­combina-
tions­of­Avastin­with­two­other­types­of­chemother- Clinical milestones |­Two­large­phase­III­trials­
apy,­based­on­data­from­the­AVADO­and­RIBBON-1­ involving­some­3,400­patients­have­demonstrated­the­
trials.­The­CHMP­recommended­that­the­combination­ potential­of­Avastin­in­ovarian­cancer.­Results­from­
with­docetaxel­be­removed­from­the­Avastin­label­ GOG218­were­presented­at­the­annual­meeting­of­the­
and­that­the­combination­with­capecitabine­(Xeloda)­ American­Society­of­Clinical­Oncology­(ASCO)­in­
not­be­approved.­A­decision­by­the­European­Com- June.­The­trial­met­its­primary­endpoint­of­extending­
mission­on­these­recommendations­is­expected­early­ progression-free­survival­(the­period­a­patient­­
in­2011.­The­CHMP­opinion­does­not­affect­the­­ lives­without­the­disease­getting­worse)­in­women­
other­approved­uses­of­Avastin­in­the­European­Union­ with­previously­untreated­advanced­ovarian­cancer.­
for­advanced­colorectal,­kidney­and­lung­cancer. ICON-7,­a­further­trial­with­Avastin­in­ovarian­cancer,­
reported­positive­results­in­early­July.­The­data­­
Also­in­December­the­FDA­announced­a­number­­ were­presented­at­the­European­Society­for­Medical­
of­regulatory­decisions­concerning­the­use­of­Avastin­ Oncology­(ESMO)­conference­in­October.­In­addition­
for­metastatic­breast­cancer­in­the­US.­The­most­ to­the­EU­filing­in­December,­Roche­plans­to­use­­
important­of­these­is­the­agency’s­decision­to­initiate­ the­results­of­both­trials­to­support­a­regulatory­appli-
the­process­to­withdraw­the­current­conditional­ cation­for­this­additional­indication­in­the­US­in­2011.­
(‘accelerated’)­approval­for­Avastin­for­first-line­
treatment­of­metastatic­breast­cancer.­Roche­and­ Clinical­trial­results­led­to­a­number­of­adjustments­­
Genentech­have­requested­a­hearing­pursuant­to­­ in­the­Avastin­development­programme­in­2010.­As­
06_Roche_AR10_ENG_Pharmaceuticals.indd 37 28.01.2011 14:50:5638­
Roche Business Report 2010 Pharmaceuticals
Major regulatory filings in 2010­1
Clinical data supporting
Product filing Indication and/or dosage form Country
Actemra/ LITHE (2-year data) rheumatoid arthritis, reduction or inhibition of progression USA
RoActemra of joint damage and improvement of physical function
ML21753 rheumatoid arthritis signs and symptoms, China (refiled)
progressive joint damage
TENDER systemic onset juvenile idiopathic arthritis EU, USA
Avastin RIBBON-2 metastatic breast cancer, second-line treatment USA
ICON-7, GOG 218 metastatic ovarian cancer EU
Herceptin ToGA advanced HER2-positive gastric cancer USA, China
Herceptin ToGA advanced HER2-positive gastric cancer Japan
+ Xeloda
MabThera/ PRIMA advanced follicular lymphoma, first-line maintenance EU, USA,
Rituxan following induction treatment with MabThera/Rituxan Switzerland
plus chemotherapy
RAVE ANCA-associated vasculitis USA
Mircera ML20680 renal anemia China
CORDATUS correction of symptomatic anemia in adults with chronic EU, Switzerland
(NH20052) kidney disease who do not yet need dialysis, once-monthly
administration
Tarceva emerging data metastatic non-small cell lung cancer with EGFR- EU
from clinical trials, activating mutations, first-line treatment
ongoing clinical
experience
Xeloda NO16968 (XELOXA) adjuvant colon cancer, combination with oxaliplatin Switzerland
data in the public advanced or refractory gastric cancer in patients who Japan
domain are not candidates for curative surgery
XELOX (NO16966) metastatic colorectal cancer, combination with oxaliplatin China (refiled)
1 Includes supplemental indications.
phase­III­trials­with­Avastin­in­stomach­(AVAGAST)­ meaningful­progression-free­and­overall­survival­
and­prostate­(CALGB­90401)­cancer­did­not­meet­ ­benefit­in­both­first-­and­second-line­treatment.­
their­primary­endpoints­of­extending­overall­survival,­ Avastin­has­shown­a­positive­benefit–risk­ratio­in­
Roche­has­decided­not­to­pursue­regulatory­filings­ these­and­all­other­approved­metastatic­cancer­
for­these­indications.­A­phase­III­programme­inves- ­indications.
tigating­the­addition­of­Avastin­to­standard­treat-
ment­with­MabThera/Rituxan­plus­chemotherapy­­ Herceptin
for­diffuse­large­B­cell­lymphoma,­an­aggressive­­ Approvals |­The­European­Commission­approved­
form­of­non-Hodgkin’s­lymphoma,­was­discontinued­ Herceptin­in­combination­with­chemotherapy­for­use­
after­a­safety­and­efficacy­analysis­showed­an­unfa- in­patients­with­metastatic­stomach­(gastric)­cancer­
vourable­benefit–risk­assessment.­Following­eval- exhibiting­high­levels­of­HER2,­in­January­2010.­
uation­of­phase­III­data­(AVANT),­Roche­has­discon- Approvals­for­the­same­indication­were­received­in­
tinued­development­of­Avastin­in­adjuvant­colorectal­ Switzerland­in­May­and­the­US­in­October,­following­
cancer.­The­results­and­decision­on­adjuvant­colo- priority­review­by­the­FDA.
rectal­cancer­do­not­affect­the­use­of­Avastin­in­­
the­metastatic­(advanced)­colorectal­cancer­setting,­ Filings |­In­June­the­Japanese­health­authorities­
where­the­medicine­has­demonstrated­a­clinically­ gave­priority­review­status­to­an­application­sub­-­
06_Roche_AR10_ENG_Pharmaceuticals.indd 38 28.01.2011 14:50:5639­
Pharmaceuticals Roche Business Report 2010
Major regulatory approvals in 2010 1
Clinical data supporting
Product filing Indication and/or dosage form Country
Actemra/ OPTION, TOWARD, rheumatoid arthritis signs and symptoms USA
RoActemra RADIATE, AMBITION,
LITHE (6-month data)
LITHE (2-year data) rheumatoid arthritis, reduction or inhibition of progression EU, Switzerland,
of joint damage and improvement of physical function USA 2
Avastin AVF 2107, E3200, metastatic colorectal cancer China
NO16966 (global);
ARTIST (China)
Herceptin ToGA advanced HER2-positive gastric cancer EU, USA, Switzerland
Lucentis CRUISE, BRAVO macular edema following retinal vein occlusion USA
MabThera/ CLL-8 first-line chronic lymphocytic leukemia USA
Rituxan
REACH relapsed or refractory chronic lymphocytic leukemia USA
PRIMA advanced follicular lymphoma, first-line maintenance EU, Switzerland
following induction treatment with MabThera/Rituxan plus
chemotherapy
REFLEX rheumatoid arthritis, inhibition of progression of joint EU
damage and improvement of physical function
Mircera CORDATUS correction of symptomatic anemia in adults with EU, Switzerland
(NH20052) chronic kidney disease who do not yet need dialysis,
once-monthly administration
Tarceva SATURN non-small cell lung cancer, first-line maintenance after USA, EU
chemotherapy
Xeloda NO16968 (XELOXA) adjuvant colon cancer, combination with oxaliplatin EU
1 Includes supplemental indications.
2 January 2011.
mitted­in­March­by­Chugai,­for­approval­of­Herceptin­ Lucentis
for­advanced­HER2-positive­stomach­cancer.­In­­ Approvals |­In­June­the­US­Food­and­Drug­Admin-
June­Roche­submitted­an­application­for­approval­­ istration­(FDA)­approved­Lucentis­for­the­treatment­­
of­the­same­indication­in­China. of­patients­with­macular­edema­(swelling­in­the­
­retina)­following­retinal­vein­occlusion­(RVO).­The­
Clinical milestones |­In­December­patient­enrol- approval­followed­a­six-month­priority­review­by­­
ment­was­completed­for­a­phase­III­study­with­a­new­ the­FDA.­RVO­occurs­when­blood­flow­through­a­ret-
subcutaneous­formulation­of­Herceptin­in­women­ inal­vein­becomes­blocked,­causing­swelling­(macu-
with­HER2-positive­breast­cancer.­Herceptin­is­cur- lar­edema)­and­hemorrhages­in­the­retina,­which­may­
rently­given­intravenously­over­30­to­90­minutes.­­ result­in­blurring­or­vision­loss­in­all­or­part­of­one­
The­innovative­subcutaneous­formulation,­which­is­ eye.
based­on­Halozyme’s­Enhanze­technology­(see­­
p.­128),­is­expected­to­take­less­than­five­minutes­­ MabThera/Rituxan (oncology)
to­administer­and­may­allow­patients­with­HER2-­ Approvals |­In­February­the­FDA­approved­Rituxan­
positive­breast­cancer­to­receive­treatment­in­their­ combined­with­fludarabine­and­cyclophosphamide­
physician’s­office­or­at­home,­without­having­to­­ chemotherapy­for­people­with­either­previously­
go­to­a­hospital. untreated­(first-line)­or­previously­treated­(relapsed­­
06_Roche_AR10_ENG_Pharmaceuticals.indd 39 28.01.2011 14:50:56Will it
Disease area Oncology
Indication Second-line HER2-positive metastatic breast cancer
Trials EMILIA (TDM4370g / BO21977)
No. of patients 551 (recruited as of December 2010)
No. of study sites 216
No. of countries 22
Jone F., participant in the EMILIA study (T–DM1), Houston
06_Roche_AR10_ENG_Pharmaceuticals.indd 40 28.01.2011 14:51:34work ?
Wayne C., T–DM1 Medical Director, Genentech, South San Francisco
06_Roche_AR10_ENG_Pharmaceuticals.indd 41 28.01.2011 14:51:57T–DM1 — an antibody–drug conjugate
Creating value for patients means building
on good treatments to make them even better
1970s 2000 The future?
Non-specific chemo- Herceptin (trastuzumab) ADC targets chemo-
therapy agents — the new standard of therapy specifically
care for HER2-positive to tumour cells
metastatic breast cancer
Points of attack
Cancer cell
Chemotherapy Trastuzumab + chemo T–DM1
Healthy cell Attacks both healthy The monoclonal antibody Attacks cancer cells
and cancerous cells trastuzumab specifically only, no conventional
targets HER2-positive chemotherapy burden
tumour cells
As the first therapeutic antibody targeting a specific cancer-related biomarker
to receive FDA approval, Herceptin (trastuzumab) launched a revolution in the
treatment of breast cancer. We continue to build on that breakthrough with tras-
tuzumab–DM1 (T–DM1), a novel antibody-drug conjugate (ADC) being developed
T–DM1
to treat HER2-positive breast cancer. T–DM1 combines two powerful anticancer
approaches in one medicine. The trastuzumab antibody component
Trastuzumab blocks the signals that make HER2-positive cancer cells more
aggressive and sends a message to the patient’s immune system
to destroy the cancer cells. It also delivers DM1, a potent chemo-
DM1 therapy agent, directly to the tumour cells to induce cell death.
T–DM1 may offer patients with HER2-positive breast cancer effective treatment
Stable linker
that spares them the burden and side effects of conventional chemotherapy.
EMILIA is a phase III registration trial comparing single-agent T–DM1 treatment
with combined lapatinib (another HER2-targeted drug) plus capecitabine
(Xeloda) chemotherapy in women with advanced HER2-positive breast cancer.
Further trials are testing T–DM1 in combination with Roche’s pertuzumab,
another next-generation HER-targeting antibody therapy.
06_Roche_AR10_ENG_Pharmaceuticals.indd 42 28.01.2011 14:51:5943­
Pharmaceuticals Roche Business Report 2010
or­refractory)­CD20-positive­chronic­lymphocytic­ MabThera/Rituxan (inflammation)
leukemia,­based­on­the­results­of­the­CLL-8­and­ Approvals |­Roche­received­regulatory­approval­
REACH­trials.­Following­regulatory­applications­by­ in­October­for­two­additions­to­the­existing­EU­­
Roche­and­Genentech­in­the­first­quarter,­in­Octo-­ marketing­authorisation­for­MabThera­in­rheumatoid­
ber­the­European­Medicines­Agency­(EMA)­ arthritis:­based­primarily­on­data­from­the­REFLEX­
approved­MabThera­as­maintenance­treatment­for­ study,­the­indications­were­expanded­to­include­
people­with­follicular­lymphoma­who­have­re-­ ­inhibition­of­progression­of­joint­damage­and­im-­
sponded­to­induction­therapy;­the­FDA­is­currently­ prove­ment­of­physical­function;­and­information­­
reviewing­Genentech’s­sBLA­for­the­same­indica-­ on­enhanced­treatment­responses­in­seropositive­­
tion­and­has­set­an­action­date­in­late­January­2011.­ RA­patients­(see­below,­Clinical milestones)­
Both­submissions­were­based­on­the­results­of­­ was­added­to­the­product’s­prescribing­information.
the­PRIMA­study,­which­showed­that­­continuing­
MabThera/Rituxan­for­two­years­(maintenance­­ Filings |­In­October,­based­on­data­from­the­phase­
therapy)­in­patients­who­responded­to­initial­treat- II/III­RAVE­study,­Genentech­and­Biogen­Idec­
ment­with­MabThera/Rituxan­plus­chemotherapy­ ­submitted­a­supplemental­Biologics­License­Appli-
nearly­doubled­progression-free­survival,­compared­ cation­to­the­FDA­for­approval­of­Rituxan­for­ANCA-
with­those­who­did­not­receive­maintenance­­ associated­vasculitis,­a­group­of­rare,­severe,­life-
treatment. threatening­autoimmune­diseases­characterised­by­
inflammation­of­blood­vessels­leading­to­organ­
Clinical milestones |­Based­on­positive­results­ ­damage.­There­are­currently­no­approved­therapies­
from­a­phase­Ib­study­in­patients­with­follicular­lym- for­the­condition,­and­treatment-associated­toxicities­
phoma,­in­July­Roche­decided­to­advance­a­new­ are­common­with­the­unapproved­standard­of­care,­
subcuta­ne­ous­formulation­of­MabThera,­also­based­ cyclophosphamide.
on­­Halozyme’s­Enhanze­technology,­into­phase­­
III­development.­Subcutaneous­administration­has­ Clinical milestones |­An­analysis­of­samples­from­
the­potential­to­significantly­simplify­treatment­­ patients­with­RA­who­participated­in­two­phase­III­
by­shortening­administration­time­to­less­than­ten­ trials­was­presented­at­the­European­League­Against­
minutes­and­improving­patient­comfort.­A­phase­­ Rheumatism­(EULAR)­annual­congress­in­June.­It­
III­trial­is­expected­to­start­in­the­first­quarter­of­2011.­ showed­that­testing­for­specific­blood­markers­at­the­
Positive­data­from­a­phase­III­study­of­MabThera/ time­of­diagnosis­could­have­a­significant­impact­­
Rituxan­in­patients­with­advanced­follicular­lym- on­treatment­decisions­and­lead­to­improved­patient­
phoma­who­did­not­have­symptoms­(asymptomatic­ quality­of­life.­Approximately­80%­of­RA­patients­­
disease)­were­presented­at­the­annual­meeting­­ have­at­least­one­of­two­characteristic­biomarkers­
of­the­American­Society­of­Hematology­in­December.­ produced­by­autoreactive­B­cells­—­rheumatoid­
The­study­showed­that­immediate­administration­­ ­factor­(RF)­and­anticyclic­citrullinated­peptide­(anti-
of­single-agent­MabThera/Rituxan­as­induction­ther- CCP)­—­in­their­blood.­Such­patients­are­referred­
apy­followed­by­continued­(maintenance)­treatment­ to­as­‘seropositive’.­Data­from­a­pooled­cohort­of­the­
with­MabThera/Rituxan­delayed­the­need­for­chemo-­ two­studies­showed­that,­while­both­seropositive­­
or­radiotherapy­and­extended­progression-free­ and­seronegative­patients­benefitted­from­treatment­
­survival,­compared­with­watchful­waiting.­These­are­ with­MabThera/Rituxan,­the­response­was­enhanced­
the­first­phase­III­data­to­show­that­initial­use­­ in­the­seropositive­population.­Additional­biomarker­
of­MabThera/Rituxan­monotherapy­as­induction­fol- analyses­from­other­phase­III­studies­are­pending.­
lowed­by­maintenance­can­provide­clinical­benefit­­ MabThera/Rituxan­is­the­first­and­only­selective­B­cell­
for­patients­with­asymptomatic­follicular­lymphoma,­­ targeted­therapy­available­for­RA.
a­disease­that­is­commonly­treated­only­when­
­symptoms­appear­(an­approach­known­as­‘watchful­ Tarceva
waiting’). Approvals |­In­April­the­US­Food­and­Drug­Adminis-
tration­(FDA)­approved­Tarceva­as­a­maintenance­
treatment­for­patients­with­locally­advanced­or­meta-
static­non-small­cell­lung­cancer­(NSCLC)­whose­
06_Roche_AR10_ENG_Pharmaceuticals.indd 43 28.01.2011 14:51:5944­
Roche Business Report 2010 Pharmaceuticals
EGFR-activating­mutations­would­continue­to­benefit­
from­treatment­with­Tarceva­in­later­lines­of­therapy.
Roche has 12 innovative new
Clinical milestones |­Results­from­a­randomised­
molecular entities in late-stage
phase­III­study­(OPTIMAL)­presented­at­the­
­European­Society­for­Medical­Oncology­(ESMO)­
development, including six
congress­in­October­demonstrated­that­first-line­
potential personalised healthcare treatment­with­Tarceva­extended­progression-­­
free­survival­in­patients­with­advanced­NSCLC­with­
medicines with planned EGFR-activating­mutations­to­more­than­one­year,­
almost­three­times­longer­than­patients­who­received­
companion diagnostic tests. conventional­chemotherapy.­Interim­results­from­­
a­second­trial­investigating­Tarceva­in­this­indication­
(EURTAC)­are­expected­in­the­first­quarter­of­2011.­
As­many­as­30%­of­Asian­patients­with­lung­cancer­
disease­has­not­progressed­after­four­cycles­of­ and­an­estimated­10%­of­lung­cancer­patients­in­
­platinum-based­first-line­chemotherapy.­In­April­the­ Western­countries­have­this­distinct­form­of­NSCLC.
European­Commission­approved­Tarceva­as­mono-
therapy­for­maintenance­treatment­in­patients­with­ Xeloda
advanced­non-small­cell­lung­cancer­(NSCLC)­ Approvals |­In­March­the­EU­authorities­approved­
whose­disease­remains­largely­unchanged­(known­­ Xeloda­in­combination­with­oxaliplatin­(a­com­-­
as­stable­disease)­after­platinum-based­initial­ bin­­ation­known­as­XELOX)­for­the­adjuvant­(post-
­chemotherapy.­Both­approvals­are­based­on­data­ surgical)­treatment­of­patients­with­early­colon­
from­the­phase­III­SATURN­study,­which­showed­ ­cancer.­The­approval­was­based­on­results­from­­
that,­compared­with­placebo,­Tarceva­significantly­ the­NO16968­(XELOXA)­study,­one­of­the­largest­­
improved­overall­survival­in­patients­with­stable­ studies­of­patients­with­stage­III­(early)­colon­cancer,­
­disease.­Patients­with­advanced­NSCLC­and­stable­ which­showed­that­patients­taking­XELOX­imme-
disease­after­initial­chemotherapy­have­tumours­­ diately­after­surgery­lived­disease-free­for­longer­
that­progress­faster,­are­more­resistant­to­further­ ­compared­with­those­treated­with­a­chemotherapy­
lines­of­chemotherapy­and­have­a­poorer­prognosis­ regimen­consisting­of­5-fluorouracil­plus­leucovorin.­
compared­with­patients­who­have­a­complete­or­­
partial­response­to­initial­chemotherapy. Filings |­In­Japan­Chugai­filed­marketing­applica-
tions­with­the­Ministry­for­Health,­Labour­and­­
Filings |­In­June­Roche­submitted­an­application­to­ Welfare­in­March­for­approval­of­Xeloda­combined­
the­European­Medicines­Agency­(EMA)­to­extend­ with­­Herceptin­for­the­treatment­of­advanced­­
the­current­marketing­approval­for­Tarceva­to­include­ HER2-positive­stomach­cancer­and­in­September­­
first-line­treatment­of­patients­with­advanced­NSCLC­ for­Xeloda­in­advanced­or­refractory­gastric­
with­EGFR-activating­mutations.­The­application­­ ­(stomach)­cancer­in­patients­who­are­not­candi­-­
is­supported­by­emerging­data­from­clinical­trials­and­ dates­for­­curative­surgery.
ongoing­clinical­experience,­including­new­data­­
from­the­OPTIMAL­trial­presented­at­ESMO­(see­ Clinical milestones |­A­data­analysis­completed­
below).­Tarceva­is­the­only­epidermal­growth­factor­ in­June­showed­that­NO17629,­a­phase­III­trial­inves-
receptor­(EGFR)­inhibitor­approved­for­use­in­ tigating­Xeloda­in­combination­with­docetaxel­for­­
­maintenance­and­second-line­treatment­settings­­ the­adjuvant­(postsurgical)­treatment­of­women­with­
in­patients­with­advanced­or­metastatic­NSCLC,­­ early­breast­cancer,­did­not­meet­its­primary­end-
irrespective­of­the­presence­of­EGFR-activating­ point­of­extending­disease-free­survival­but­did­meet­
mutations.­A­licence­for­Tarceva­for­use­in­the­first- the­secondary­endpoint­of­extending­overall­sur­-
line­setting­would­allow­physicians­to­personalise­ vival.­Roche­has­decided­not­to­pursue­regulatory­
early­treatment­according­to­EGFR­activating­muta- ­filings­for­this­indication.­
tion­status,­while­people­with­NSCLC­without­
06_Roche_AR10_ENG_Pharmaceuticals.indd 44 28.01.2011 14:51:5945­
Pharmaceuticals Roche Business Report 2010
Research and development lations.­Roche’s­research­on­antibody–drug­conju-
gates­as­a­means­of­treating­cancer­is­another­
Roche’s­Pharmaceuticals­Division­is­committed­­ ­example­of­a­highly­targeted­approach­with­the­
to­discovering­and­commercialising­innovative­medi- potential­of­improving­outcomes­while­reducing­­
cines­that­represent­true­medical­value­in­areas­­ the­side­­effects­of­treatment.­T–DM1,­for­HER2-­
of­high­unmet­need.­To­ensure­a­strong­flow­of­suit- positive­breast­cancer,­is­the­most­advanced­­
able­candidate­molecules­into­its­development­pipe- of­these­projects.­For­more­information,­see­below,­
line,­Roche­has­built­a­unique­innovation­network­of­ Oncology,­and­also­pp.­18­and­19­of­this­report.
independent­research­and­development­centres.­In­
addition­to­Roche­and­Genentech,­it­includes­Chugai­ As­part­of­the­Group’s­Operational­Excellence­pro-
in­Japan­and­alliances­with­more­than­150­partner­ gramme,­the­Pharmaceuticals­Division­is­prioritising­
organisations­worldwide.­This­promotes­a­diversity­­ its­R­&­D­investments­in­order­to­dedicate­resources­
of­research­approaches­and­enables­access­to­new­ to­projects­with­the­highest­potential.­Following­­
technologies­and­promising­drug­candidates. a­comprehensive­portfolio­review,­Roche­decided­to­
discontinue­R­&­D­activities­in­RNA­interference,­
Close­cooperation­between­the­Pharmaceuticals­ ­consolidate­internal­functional­resources­and­reduce­
Division­and­Roche­Diagnostics­is­a­key­strategic­ the­number­of­Pharma­Research­and­Early­Devel-
advantage­for­our­company.­It­ensures­that­diagnos- opment­sites­from­11­to­seven,­thereby­reducing­
tics­expertise­is­seamlessly­integrated­into­all­parts­ fixed­costs­and­making­funds­available­for­additional­
of­the­pharmaceutical­R­&­D­process.­This­is­central­ external­research­partnerships­and­promising­new­
to­Roche’s­goal­of­advancing­personalised­healthcare­ programmes­entering­phase­II­clinical­development.
(PHC),­an­approach­that­seeks­to­tailor­treatments­­
to­specific­patient­subpopulations­based­on­growing­ At­the­beginning­of­2011­the­division’s­R­&­D­pipe-­
scientific­understanding­of­biology­and­disease­at­­ line­included­102­projects­in­clinical­development­­
the­molecular­level. (phase­I­to­III­and­filed­for­regulatory­review).­Of­
these,­62­involved­new­molecular­entities­(NMEs)­
Two­recent­examples­of­the­progress­that­Roche­is­ and­40­involved­additional­indications.­Twelve­­
making­towards­PHC­in­the­development­of­therapies­ NMEs­are­in­late-stage­development­(see­table,­­
for­difficult-to-treat­diseases­are­RG3638­(MetMAb)­ p.­47).­Twenty-two­projects­investigating­additional­
for­lung­cancer­and­RG7204­(BRAF­inhibitor)­for­ indications­for­existing­products­are­in­phase­III.­­
malignant­melanoma.­Roche­Diagnostics­is­develop- The­Pharmaceuticals­pipeline­is­shown­in­the­fold-out­
ing­diagnostic­tests­designed­to­guide­appropriate­ inside­the­front­cover­of­this­report.­Further­details­
use­of­both­compounds­in­their­target­patient­popu- are­available­at­www.roche.com.
Roche and Genentech — 376 projects Roche and Genentech — 39 projects
in research and early development in phase III (or marketing applications
(discovery, phases 0–II) | January 2011 filed) | January 2011
Inflammation 65 Oncology 26
Metabolic 29 Metabolic 2
Others 12 CNS 3
Ophthalmology 3
Virology 65 Ophthalmology 2
Inflammation 6
CNS 63
Oncology 139
06_Roche_AR10_ENG_Pharmaceuticals.indd 45 28.01.2011 14:52:0046­
Roche Business Report 2010 Pharmaceuticals
target­HER2-positive­tumours­(see­p.­42).­Data­from­­
a­randomised­phase­II­trial­(TDM4450g)­with­T–DM1­
Four additional NMEs advance
in­previously­untreated­HER2-positive­metastatic­
breast­cancer­presented­at­the­ESMO­conference­in­
into late-stage development:
October­showed­efficacy­comparable­to­Herceptin­
plus­chemotherapy,­the­standard­of­care,­along­with­
MetMAb (lung cancer), lebriki-
a­significantly­reduced­side­effect­burden.­Final­
zumab (asthma), RG7128 results­from­this­study­are­expected­in­2011.
(hepatitis C), ocrelizumab (MS). Two­phase­III­registration­studies­in­metastatic­
HER2-­positive­breast­cancer­are­ongoing,­and­we­
plan­to­submit­global­marketing­applications­in­­
2012.­EMILIA,­investigating­T–DM1­in­pretreated­
Oncology patients,­is­expected­to­yield­data­on­progression-
Roche’s­clinical­development­pipeline­in­oncology­ free­survival­in­2012­and­overall­survival­in­2013.­
includes­29­new­molecular­entities.­The­Pharma- MARIANNE,­a­comparative­trial­of­first-line­treat-
ceuticals­Division­is­further­strengthening­its­oncol- ment­with­either­T–DM1­alone­or­T–DM1­plus­
ogy­portfolio­through­new­targeted­therapeutic­ ­pertuzumab­versus­Herceptin­plus­chemotherapy,­
options­and­expanding­into­new­indications.­Six­ began­in­July.­Both­trials­are­investigating­therapeu-­
oncology­NMEs­are­now­in­late-stage­clinical­testing.­ tic­options­that­target­HER2-positive­tumours­­
while­sparing­patients­the­burden­and­side­effects­­
Pertuzumab­(RG1273)­is­a­HER2­dimerisation­inhi­b- of­conventional­chemotherapy.
itor­that­is­being­studied­with­the­current­standard­­
of­care,­Herceptin­plus­chemotherapy,­in­HER2-­ RG7204­(PLX4032,­collaboration­with­Plexxikon)­
positive­breast­cancer.­Data­from­a­phase­II­trial­ is­a­first-in-class­molecule­designed­to­selectively­
(NEOSPHERE)­investigating­pertuzumab­and­ inhibit­a­cancer-causing,­mutated­form­of­the­BRAF­
­Herceptin­plus­docetaxel­chemotherapy­in­HER2- protein­found­in­approximately­half­of­metastatic­
positive­early­breast­cancer­were­presented­at­­ melanoma­tumours.­Promising­results­from­a­phase­­
the­San­Antonio­Breast­Cancer­Symposium­in­De-­ II­clinical­trial­(BRIM2)­were­presented­in­November­­
cem­ber.­The­results­showed­that­the­two­antibodies­ at­the­International­Melanoma­Research­Congress.­
plus­docetaxel­given­in­the­neoadjuvant­setting­ The­data­showed­that­RG7204­shrank­tumours­­
(before­surgery)­improved­the­rate­of­complete­ in­over­half­of­patients­with­previously­treated­BRAF­
tumour­­disappearance­in­the­breast­by­more­than­ V600E­mutation-positive­metastatic­melanoma.­
half­compared­with­Herceptin­plus­docetaxel­chemo- Median­progression-free­survival­in­the­study­was­
therapy.­Based­on­the­encouraging­efficacy­results­ 6.2­months.­Typically,­progression-free­survival­for­
from­NEOSPHERE,­pertuzumab­will­also­be­studied­ these­patients­is­approximately­two­months.­A­phase­
as­adjuvant­(postsurgical)­therapy­in­HER2-positive­ III­trial­(BRIM3)­in­previously­untreated­BRAF­
early­breast­cancer.­The­phase­III­clinical­programme­ ­mutation-positive­metastatic­melanoma­patients­met­
in­this­setting­is­scheduled­to­start­in­late­2011.­ its­primary­endpoints­in­January­2011,­with­an­­
Results­and­related­regulatory­filings­are­expected­­ interim­analysis­showing­significantly­improved­over-
in­2011­from­a­phase­III­study­(CLEOPATRA)­eval- all­and­progression-free­survival­in­patients­who­
uating­the­addition­of­pertuzumab­to­Herceptin­and­ received­RG7204­compared­with­those­treated­with­
chemotherapy­in­the­first-line­treatment­of­patients­ dacarbazine,­the­current­standard­of­care.­Roche­
with­advanced­(metastatic)­disease. Molecular­Diagnostics­is­developing­a­companion­
diagnostic,­cobas­4800­BRAF­V600­Mutation­­
Trastuzumab–DM1­(T–DM1,­RG3502)­is­a­novel­ Test­(see­pp.­59,­69,­78),­to­identify­patients­whose­
anti­body–drug­conjugate­that­combines­the­thera- tumours­carry­the­abnormal­BRAF­gene­and­are­
peutic­effect­of­trastuzumab­(the­active­substance­­ therefore­appropriate­for­treatment­with­RG7204.
of­­Herceptin)­with­intracellular­delivery­of­DM1,­­
a­highly­potent­chemotherapy­agent,­to­specifically­
06_Roche_AR10_ENG_Pharmaceuticals.indd 46 28.01.2011 14:52:0047­
Pharmaceuticals Roche Business Report 2010
Twelve new molecular entities in ongoing or planned late-stage studies
Compound Indication Status Expected first filing
pertuzumab HER2-positive metastatic phase III started in 2008 2011
breast cancer, first line
trastuzumab–DM1 HER2-positive metastatic phase III started in first quarter 2009 2012
breast cancer, first and
second line
RG7204 (BRAF metastatic melanoma phase III trial in first-line treatment met primary 2011
inhibitor) endpoints in January 2011
RG3616 (hedgehog advanced basal cell pivotal phase II started in first quarter 2009 2011
pathway inhibitor) carcinoma
RG7159 (GA101) chronic lymphocytic phase III started in fourth quarter 2009 2013
leukemia, non-Hodgkin’s (chronic lymphocytic leukemia)
lymphoma
RG3638 (MetMAb) solid tumours LIP 1 decision made, preparing for phase III post-2013
lebrikizumab asthma LIP 1 decision made, preparing for phase III post-2013
aleglitazar cardiovascular risk reduc- phase III initiated in first quarter 2010 post-2013
tion in type 2 diabetes
dalcetrapib dyslipidemia, cardio- phase III enrolment completed in second quarter 2013
vascular high risk 2010
RG7128 (HCV po- hepatitis C LIP 1 decision made, preparing for phase III 2013
lymerase inhibitor)
RG1678 (glycine negative symptoms of phase III started November 2010 2013
reuptake inhibitor) schizophrenia, subopti-
mally controlled positive
symptoms of schizophrenia
ocrelizumab multiple sclerosis phase III planned to start in first quarter (PPMS) post-2013
(RRMS and PPMS) and second quarter (RRMS) 2011
1 Lifecycle investment point (decision to commence late-stage development leading to submission of marketing applications).
RG3616­(GDC-0499;­collaboration­with­Curis)­is­ cells­by­activating­other­immune­cells­to­attack­­
a­novel­compound­targeting­the­hedgehog­signalling­ the­cancer­cells­and­by­inducing­direct­cell­death.­­
pathway,­which­is­thought­to­be­implicated­in­ In­two­phase­II­studies­presented­at­the­American­
­sev­eral­cancers.­A­pivotal­phase­II­study­with­reg- ­Society­of­Hematology­annual­meeting­in­Decem-­
istration­potential­is­currently­investigating­RG3616­ ber,­treatment­with­RG7159­produced­promising­
as­a­potential­treatment­for­advanced­basal­cell­ response­rates­in­very­difficult-to-treat­patients­with­
­carcinoma­(BCC).­RG3616­is­also­being­evaluated­­ either­indolent­or­aggressive­NHL­who­had­not­
in­a­phase­II­study­as­a­therapy­for­operable­BCC.­­ responded­to­multiple­prior­treatments,­including­
In­the­fourth­quarter­Roche­decided­to­discontinue­ MabThera/Rituxan.­Further­clinical­data­for­RG7159­
development­of­the­compound­in­ovarian­and­colo- in­NHL­and­CLL­are­expected­in­2011.­Phase­III­
rectal­cancer­due­to­lack­of­benefit­in­phase­II­trials. studies­of­RG7159­versus­MabThera/Rituxan­in­
aggressive­and­indolent­NHL­are­scheduled­to­start­
RG7159­(GA101)­is­the­first­type­II,­glycoengineered,­ in­2011.
anti-CD20­monoclonal­antibody­being­investigated­­
in­late-stage­clinical­trials­as­a­potential­treatment­for­ RG3638­(MetMAb)­is­a­unique­monoclonal­antibody­
non-Hodgkin’s­lymphoma­(NHL)­and­chronic­lym- that­binds­specifically­to­the­c-Met­protein­receptor.­
phocytic­leukemia­(CLL).­It­has­been­specifically­ The­Met­pathway­can­be­inappropriately­activated­­
designed­to­enhance­the­destruction­of­cancerous­B­ in­cancer­and­lead­to­invasive­growth.­New­phase­II­
06_Roche_AR10_ENG_Pharmaceuticals.indd 47 28.01.2011 14:52:00What are the
Disease area Metabolic and cardiovascular diseases
Indication CV risk reduction in patients with type 2 diabetes
Trials ALECARDIO
No. of patients 6,000
No. of study sites 750
No. of countries 24
Ragnar B., participant in the ALECARDIO (aleglitazar) trial, Stockholm
06_Roche_AR10_ENG_Pharmaceuticals.indd 48 28.01.2011 14:52:43implications ?
Anita M.-W., Operations Program Leader, Roche Basel
06_Roche_AR10_ENG_Pharmaceuticals.indd 49 28.01.2011 14:53:21Aleglitazar
Creating value for patients means focusing
on the unsolved issues
For patients with type 2 diabetes (T2D), blood glucose Aleglitazar, a dual PPAR α/γ co-agonist developed
control is no longer the biggest concern. More than 60% at Roche, may become the first compound with the
of patients with diabetes die from heart disease and potential to reduce cardiovascular morbidity and
stroke, not from an inability to control blood glucose. mortality specifically in high-risk patients with T2D.
And 10% of patients who experience an acute coronary Aleglitazar is an excellent example of translational
syndrome (ACS) event, such as a heart attack, die within medicine: biochemical parameters, animal data,
one year. Currently, there are no drugs on the market and biomarkers of efficacy and safety consistently
that specifically and effectively control their high risk of supported hypotheses that were later proven in
cardiovascular disease. clinical settings.
Increased risk of heart attack and stroke ALECARDIO, an innovative global, randomised,
associated with T2D controlled phase III clinical trial with some 6,000
patients, is now testing the hypothesis that alegli-
Healthy people
tazar can reduce cardiovascular morbidity and
mortality in patients with T2D who have suffered
People who have had a
heart attack or stroke a recent ACS event.
People with T2D
People with T2D who
have had a heart attack
or stroke
Risk
Demonstrating the multiple effects of aleglitazar
1–2 years
Conventional trial in people with T2D
Reduction of
blood glucose
levels
5 years
Trial with aleglitazar in T2D high-risk subpopulation
Blood glucose Blood fats Hypertension
Focused on reducing
cardiovascular risk
in people with type 2 diabetes
Saving lives
06_Roche_AR10_ENG_Pharmaceuticals.indd 50 28.01.2011 14:53:2251­
Pharmaceuticals Roche Business Report 2010
data­presented­at­the­annual­European­Society­for­ Metabolic and cardiovascular diseases
Medical­Oncology­(ESMO)­conference­in­October­ Roche­has­nine­new­compounds­in­development­for­
showed­a­significant­increase­in­progression-free­ metabolic­and­cardiovascular­diseases.­­Dalcetrapib­
survival­for­patients­with­high­Met-expressing­non- (RG1658,­JTT-705;­licensed­from­Japan­Tobacco)­is­­
small­cell­lung­cancer­(NSCLC)­who­were­treated­ a­novel­cholesteryl­ester­transfer­protein­(CETP)­
with­MetMAb­plus­Tarceva.­Based­on­this­data,­in­ modulator­being­tested­for­its­ability­to­reduce­cardio-
September­Roche­advanced­the­compound­into­late- vascular­events­in­patients­with­­stable­coronary­
stage­development­for­the­second-­and­third-line­ heart­disease­following­a­recent­acute­coronary­syn-
treatment­of­NSCLC.­A­phase­III­study­in­patients­ drome­event.­The­phase­III­dal-HEART­programme­­
with­high­Met-expressing­NSCLC­is­expected­to­ is­on­track:­recruitment­for­the­phase­III­dal-OUT-
start­in­2011.­Roche­Tissue­Diagnostics­is­developing­ COMES­trial­has­been­completed,­with­over­15,600­
a­companion­diagnostic­test­to­identify­patients­­ participants­enrolled.­Results­from­two­phase­IIb­
with­high­Met-expressing­NSCLC­who­are­most­likely­ studies­(dal-VESSEL­and­dal-PLAQUE)­are­expected­
to­respond­to­treatment­with­RG3638­(see­pp.­19,­ in­2011,­and­recruitment­for­a­further­phase­III­study­
59,­74).­A­phase­II­study­to­investigate­the­addition­ (dal-PLAQUE­2)­is­ongoing.­These­supporting­studies­
of­MetMAb­to­chemotherapy,­with­or­without­Avastin,­ are­investigating­the­potential­impact­of­dalcetrapib­
for­the­treatment­of­triple­negative­metastatic­breast­ treatment­on­atherosclerotic­plaque­burden,­using­
cancer­is­expected­to­enrol­its­first­patient­in­the­­ imaging­techniques­and­functional­tests.
first­quarter­of­2011.
Aleglitazar­(RG1439)­is­an­innovative­investigational­
Inflammation and autoimmune disorders treatment­designed­to­reduce­the­incidence­and­
Roche­has­eight­new­compounds­in­development­­ impact­of­cardiovascular­mortality,­non-fatal­heart­
for­chronic­and­progressive­autoimmune­and­inflam- attack­and­stroke­in­patients­with­a­recent­acute­cor-
matory­diseases­such­as­rheumatoid­arthritis­(RA)­ onary­syndrome­and­type­2­diabetes.­A­global­phase­
and­asthma,­five­of­which­are­in­phase­II­clinical­test- III­programme­(ALECARDIO)­began­recruitment­
ing.­Lebrikizumab­is­a­humanised­monoclonal­anti- early­in­2010.­Aleglitazar­has­the­potential­to­be­the­
body­designed­to­bind­specifically­to­interleukin-13,­ first­therapy­to­specifically­reduce­cardiovascular­­
a­protein­thought­to­play­a­key­role­in­the­airway­ risk­in­people­with­type­2­diabetes.
inflammation,­hyperresponsiveness­and­obstruction­
experienced­by­asthma­patients.­The­compound­­ Taspoglutide­(RG1583,­BIM51077;­licensed­from­
is­being­developed­for­the­treatment­of­moderate­to­ Ipsen)­is­a­once-weekly­human­glucagon-like­pep-
severe­persistent­asthma.­Patient­recruitment­for­­ tide-1­(GLP-1)­hormone­analogue­in­development­­
two­key­phase­II­trials­(MOLLY­and­MILLY)­has­been­ for­the­treatment­of­type­2­diabetes.­In­September­
completed.­Based­on­promising­phase­II­results­with­ Roche­communicated­its­decision­to­stop­administer-
lebrikizumab­in­patients­whose­symptoms­remained­ ing­taspoglutide­to­patients­in­global­phase­III­
uncontrolled­on­inhaled­corticosteroids,­with­or­ ­clinical­trials,­based­on­higher­than­expected­patient­
­without­a­second­controller,­Roche­has­decided­to­ discontinuation­rates­observed­in­analyses­of­data­
advance­the­molecule­into­late-stage­clinical­testing.­ from­the­T-emerge­programme,­and­also­due­to­­
In­May­Roche­and­Biogen­Idec­announced­their­ the­antibody-monitoring­plan­implemented­to­address­
decision­to­discontinue­development­of­ocrelizumab­ serious­hypersensitivity­reactions.­After­careful­
(RG1594)­for­rheumatoid­arthritis­(RA).­Following­­ assessment­of­the­relevance­of­the­T-emerge­safety­
a­detailed­analysis­of­the­efficacy­and­safety­results­ and­efficacy­data­to­support­future­regulatory­
from­the­RA­programme,­the­companies­concluded­ approval­in­type­2­diabetes,­including­consideration­
that­the­overall­benefit–risk­profile­of­ocrelizumab­ of­the­current­portfolio­evaluation­initiative,­­
was­not­favourable­in­RA,­taking­into­account­ Roche­has­decided­to­discontinue­the­taspoglutide­
­currently­available­treatment­options,­including­ T-emerge­development­programme.
MabThera/Rituxan.­Development­of­ocrelizumab­­
as­a­therapy­for­multiple­sclerosis­is­continuing­­
(see­p.­52).
06_Roche_AR10_ENG_Pharmaceuticals.indd 51 28.01.2011 14:53:2352­
Roche Business Report 2010 Pharmaceuticals
there­are­currently­no­approved­treatments.­The­­
first­of­six­planned­trials­began­in­November­2010.­
As the first in a new class of
As­the­first­in­a­new­class­of­medicines,­RG1678­­
has­the­potential­to­redefine­the­therapeutic­
medicines, RG1678 has the
approach­to­a­range­of­psychiatric­disorders­and­
deliver­clinical­benefits­beyond­those­achievable­­
potential to redefine the thera-
with­current­treatment­options.
peutic approach to a range
In­October­Roche­and­Biogen­Idec­reported­posi­-­
of psychiatric disorders. tive­results­from­a­phase­II­trial­with­the­humanised­
anti-CD20­monoclonal­antibody­ocrelizumab­
(RG1594)­in­patients­with­relapsing-remitting­mul-
tiple­sclerosis­(RRMS),­one­of­the­leading­causes­­
Virology of­neurological­disability­in­young­adults.­Data­pre-
Roche­currently­has­two­direct-acting­antiviral­agents­ sented­at­the­annual­meeting­of­the­European­
in­late-stage­development­for­hepatitis­C:­the­nucle- ­Committee­for­Treatment­and­Research­in­Multiple­
oside­polymerase­inhibitor­RG7128­(partnered­with­ Sclerosis­(ECTRIMS)­showed­that,­compared­with­
Pharmasset)­and­the­protease­inhibitor­danoprevir­ placebo,­ocrelizumab­significantly­reduced­signs­of­
(RG7227).­Both­of­these­oral­agents­are­being­inves- disease­activity,­as­measured­by­brain­lesions­and­
tigated­in­combination­with­Pegasys­and­ribavirin,­ annualised­relapse­rate,­with­no­opportunistic­infec-
and­in­combination­with­each­other­in­an­interferon- tions­reported.­Two­phase­III­­studies­will­begin­in­the­
free­regimen.­RG7128­interim­phase­IIb­results­ ­second­quarter­of­2011­to­explore­the­drug’s­efficacy­
showed­good­efficacy­and­tolerability,­with­no­evi- in­RRMS­compared­with­interferon,­the­current­
dence­of­viral­resistance­after­three­months’­therapy­ standard­of­care.­A­phase­III­study­investigating­the­
in­combination­with­Pegasys­and­ribavirin.­A­phase­I­ potential­of­ocrelizumab­in­patients­with­primary­
trial­(INFORM-1)­of­RG7128­and­danoprevir­as­an­ ­progressive­multiple­sclerosis­(PPMS)­is­planned­to­
interferon-free­combination­showed­significant­viral­ start­in­the­first­quarter­of­2011.­In­October­Genen-
suppression.­A­phase­III­programme­with­RG7128­­ tech­and­Biogen­Idec­amended­their­collaboration­on­
is­expected­to­begin­in­2011.­In­October­2010­Roche­ antibodies­targeting­CD20­and­agreed­that­Genen-
acquired­the­global­rights­to­danoprevir,­to­increase­ tech­will­have­respon­sibility­for­the­further­develop-
the­strategic­flexibility­of­the­Group’s­hepatitis­C­ ment­of­ocrelizumab­in­multiple­sclerosis­in­the­US.
portfolio.
Central nervous system
The­Roche­portfolio­has­10­novel­compounds­in­
development­for­disorders­of­the­central­nervous­sys-
tem,­including­schizophrenia,­multiple­sclerosis­and­
other­serious­conditions.­One­of­these­compounds­is­
RG1678,­a­novel­glycine­reuptake­inhibitor­being­
developed­for­the­treatment­of­schizophrenia,­an­area­
of­high­unmet­medical­need.­Promising­data­from­­
a­phase­II­proof-of-concept­study­with­RG1678­in­
patients­with­negative­symptoms­of­schizophrenia­
were­presented­at­the­annual­meeting­of­the­Amer-
ican­College­of­Neuropsychopharmacology­in­
December.­A­global­phase­III­programme­has­been­
initiated­to­investigate­RG1678­in­combination­­
with­antipsychotics­in­patients­with­either­negative­
symptoms­or­suboptimally­controlled­positive­
­symptoms­of­schizophrenia,­indications­for­which­
06_Roche_AR10_ENG_Pharmaceuticals.indd 52 28.01.2011 14:53:2353­
Pharmaceuticals Roche Business Report 2010
Focus on unmet medical Breast cancer |­The­most­common­cancer­among­
women­worldwide.­Over­1.4­million­women­are­newly­
needs
diagnosed­and­over­450,000­die­from­the­disease­
each­year.­As­there­are­several­different­types­of­
Cancer |­According­to­the­latest­International­ breast­cancer,­knowledge­of­tumour­characteristics­
Agency­for­Research­on­Cancer­(IARC)­estimate,­in­ is­important­for­treatment­decisions.­Some­15–25%­
2008­over­12­million­people­worldwide­were­diag- of­women­with­breast­cancer­have­tumours­with­
nosed­with­cancer,­and­some­7.6­million­died­of­the­ abnormally­high­levels­of­a­protein­known­as­HER2.­
disease.­The­IARC­anticipated­then­that­cancer­ HER2-positive­tumours­are­particularly­aggressive,­
would­surpass­heart­disease­as­the­leading­cause­­ fast-growing­and­likely­to­recur.
of­death­worldwide­in­2010.­The­agency­also­fore-
casts­that­by­2030­there­will­be­over­26­million­new­ Lung cancer |­The­most­common­form­of­cancer­
cases­and­17­million­deaths­per­year­from­cancer.­­ worldwide­6­and­the­leading­cause­of­cancer­deaths.­
In­Europe­alone,­one­in­three­people­can­expect­to­ There­are­an­estimated­1.4­million­new­cases­annually.­
develop­cancer­in­their­lifetime.­Cancer­is­not­one­ Non-small­cell­lung­cancer­is­the­most­common­­
disease­but­a­group­of­more­than­100­distinct­disor- form,­accounting­for­approximately­80%­of­all­cases.­
ders,­each­with­its­own­medical­challenges.
Malignant melanoma |­The­deadliest­and­most­
Non-Hodgkin’s lymphoma |­A­group­of­over­30­ aggressive­form­of­skin­cancer.­The­life­expectancy­
cancers­that­affect­the­lymphatic­system.­This­class­ of­people­with­advanced­melanoma­is­usually­­
of­cancer­currently­affects­over­1.5­million­people­ short,­with­less­than­one­in­four­expected­to­be­­
worldwide,­and­some­350,000­new­diagnoses­­ alive­one­year­after­diagnosis.­Every­year­an­
are­made­each­year.­Follicular­lymphoma­accounts­ ­estimated­40,000­people­worldwide­die­from­the­
for­about­one­in­four­of­all­cases­of­non-Hodgkin’s­ ­disease;­the­number­of­new­cases­in­developed­
lymphoma.­It­can­occur­at­any­time­during­adulthood,­ countries­is­expected­to­double,­to­227,000­per­year,­
though­people­are­typically­diagnosed­during­their­ by­2019.­Approximately­50%­of­melanomas­carry­
sixties,­and­it­affects­as­many­men­as­it­does­women. activating­mutations­in­the­BRAF­protein,­a­key­com-
ponent­of­the­RAS–RAF­signalling­pathway­involved­
Chronic lymphocytic leukemia |­The­most­common­ in­normal­cell­growth­and­survival.­These­mutations­
type­of­leukemia­in­adults,­accounting­for­25–30%­­ cause­the­pathway­to­be­overactive,­which­may­­
of­all­forms­of­leukemia.­The­incidence­of­CLL­in­ lead­to­excessive­growth­and­cancer.­It­is­estimated­
Western­countries­is­approximately­3­per­100,000,­ that­approximately­8%­of­all­solid­tumours­carry­
and­it­is­twice­as­common­in­men­as­in­women. BRAF­V600­mutations.
Colorectal cancer |­Cancer­of­the­large­intestine­ Pancreatic cancer |­A­particularly­aggressive­dis-
or­rectum,­which­accounts­for­over­1­million­new­ ease­that­is­extremely­difficult­to­treat.­It­kills­a­higher­
cases­(around­10%­of­all­newly­diagnosed­cancers)­ proportion­of­patients­in­the­first­year­after­diagnosis­
worldwide­each­year.­It­is­the­second­most­common­ than­any­other­cancer.­The­fifth­leading­cause­of­
cause­of­cancer­deaths­in­Europe­and­the­third­­ cancer­deaths­in­the­developed­world,­pancreatic­
most­common­worldwide. cancer­claims­nearly­80,000­lives­every­year.
Kidney cancer |­This­type­of­cancer­is­newly­diag-
nosed­in­around­200,000­people­and­causes­100,000­
deaths­worldwide­every­year,­rates­that­are­expected­
to­increase.­Renal­cell­carcinoma­accounts­for­90%­
of­all­kidney­cancers.
6 Excluding non-melanoma skin cancers, most of which are easily
treated and not life-threatening.
06_Roche_AR10_ENG_Pharmaceuticals.indd 53 28.01.2011 14:53:2354­
Roche Business Report 2010 Pharmaceuticals
Gastric (stomach) cancer |­Stomach­cancer­is­the­ Hepatitis B and C |­The­hepatitis­B­and­C­viruses­
second­most­common­cause­of­cancer-related­ (HBV,­HCV),­which­are­commonly­transmitted­
deaths­in­the­world­and­the­fourth­most­commonly­ through­blood-to-blood­contact,­cause­acute­and­
diagnosed­cancer.­It­accounts­for­over­1­million­­ chronic­liver­disease,­potentially­leading­to­liver­
new­cases­and­some­800,000­deaths­each­year.­The­ ­failure,­cirrhosis­liver­cancer,­and­death.­Worldwide,­
vast­majority­of­cases­occur­in­Asia,­where,­with­­ 350­million­people­are­thought­to­be­chronically­
lung­cancer,­it­is­the­leading­malignancy.­Advanced­ infected­with­HBV,­a­highly­infectious­virus­that­is­
(metastatic)­stomach­cancer­is­associated­with­a­ responsible­for­an­estimated­one­million­deaths­
poor­prognosis:­the­median­survival­time­after­diag- annually.­More­than­170­million­people­around­the­
nosis­is­10–11­months­with­currently­available­ther- world­are­infected­with­HCV,­and­three­to­four­­
apies.­Early­diagnosis­of­this­disease­is­challenging­ million­new­cases­occur­each­year.­Hepatitis­C­is­­
because­most­patients­with­early-stage­disease­do­ the­main­reason­for­liver­transplantation.­A­recent­
not­show­symptoms. study­on­the­HCV-related­burden­of­disease­in­­
22­European­countries­estimated­that­between­seven­
Age-related macular degeneration (AMD) |­A­ and­nine­million­people,­or­over­1%­of­the­popula­-
major­cause­of­gradual­or­sudden,­painless,­central­ tion,­are­infected­with­HCV.
visual­loss­in­the­elderly­and­a­leading­cause­of­­
vision­loss­in­people­aged­60­and­older.­There­are­ Autoimmune disorders |­Occur­as­a­result­of­a­mis-
two­forms­of­AMD­—­wet­and­dry.­All­cases­begin­ taken­immune­response­to­the­body’s­own­tissues.­
as­the­dry­form,­but­10–15%­progress­to­the­wet­ The­causes­are­unknown.­Rheumatoid­arthritis,­mul-
form,­which­can­result­in­sudden­and­severe­central­ tiple­sclerosis­and­lupus­erythematosus­are­among­­
vision­loss.­In­wet­AMD,­new­blood­vessels­grow­ the­most­common­autoimmune­disorders,­which­affect­
under­the­retina­and­leak­blood­and­fluid,­causing­ millions­of­people­worldwide.
deterioration­of­the­macula,­the­portion­of­the­­
eye­responsible­for­fine,­detailed­central­vision.­More­ Rheumatoid arthritis (RA) |­An­autoimmune­dis-
than­1.7­million­Americans­have­the­advanced­form­­ ease­characterised­by­inflammation­that­leads­to­stiff,­
of­this­condition. swollen­and­painful­joints,­ultimately­resulting­in­
­irreversible­joint­damage­and­disability.­More­than­­
Anemia |­Occurs­when­the­number­of­red­blood­ 20­million­people­worldwide­and­twice­as­many­
cells­or­the­hemoglobin­molecules­they­contain­­ women­as­men­suffer­from­RA.­In­addition­to­inflam-
falls­below­normal,­resulting­in­insufficient­oxygen­ mation­of­the­joints,­such­as­the­hands,­feet­and­
reaching­organs­and­tissues.­It­is­seen­in­up­to­­ wrists,­RA­can­cause­fatigue,­heart­disease­and­
80%­of­patients­with­chronic­kidney­(renal)­disease,­ increase­the­likelihood­of­developing­other­complica-
which­affects­more­than­500­million­people­world- tions­such­as­osteoporosis,­anemia,­and­problems­
wide.­In­addition,­anemia­affects­three­out­of­four­ with­the­lungs­and­eyes.­It­can­shorten­life­expec-
cancer­patients­undergoing­chemotherapy.­Patients­ tancy­by­6–10­years.­B­cells­(a­type­of­immune­cell)­
with­untreated­anemia­may­need­blood­transfusions.­ are­known­to­play­a­key­role­in­the­inflammation­
The­potential­long-term­effects­of­anemia­include­ associated­with­RA.­Several­key­cytokines,­or­proteins,­
cardiovascular­disease­in­renal­patients,­while­in­ are­also­involved,­including­interleukin-6­(IL-6),­TNF­
patients­with­cancer­it­is­associated­with­diminished­ alfa­and­interleukin-1­(IL-1).­IL-6­has­been­identified­
quality­of­life. as­having­a­pivotal­role­in­the­­inflammation­process.
06_Roche_AR10_ENG_Pharmaceuticals.indd 54 28.01.2011 14:53:2355­
Pharmaceuticals Roche Business Report 2010
Multiple sclerosis (MS) |­An­often­debilitating­ Glossary
autoimmune­disease­in­which­nerve­impulses­passing­
through­the­central­nervous­system­are­disrupted­ Adjuvant treatment |­Treatment­given­after­surgical­
due­to­damage­to­the­brain­and­spinal­chord.­This­ removal­of­a­tumour­to­lower­the­risk­of­relapse.
leads­to­unpredictable­and­highly­variable­symptoms­
ranging­from­abnormal­sensations­and­reduced­coor- Disease-free survival |­The­length­of­time­after­
dination­to­pain,­paralysis,­visual­impairment­and­a­ treatment­for­a­specific­disease­during­which­­
decline­in­cognitive­and­other­functions.­According­ a­patient­survives­with­no­sign­of­the­disease.
to­WHO­estimates,­approximately­1.3­million­people­
worldwide­are­living­with­the­disorder,­which­is­ First-line treatment |­The­initial­treatment­given­
­usually­diagnosed­in­adults­aged­between­20­and­­ after­diagnosis,­including­the­first­treatment­­
40­years.­Relapsing-remitting­multiple­sclerosis­ given­after­metastatic­cancer­has­been­diagnosed.
(RRMS),­the­most­common­form,­is­characterised­by­
acute­exacerbations­with­full­or­partial­recovery­ Maintenance treatment |­Treatment­given­to­­pre-
between­attacks.­Primary­progressive­multiple­scle- vent­a­disease­getting­worse­or­to­prevent­a­cancer­
rosis­(PPMS)­is­characterised­by­neurological­ from­recurring­when­it­has­disappeared­following­
­disability­from­onset,­with­symptoms­gradually­wors- ­initial­therapy.
ening­over­time.
Metastatic disease |­Cancer­that­has­spread­
Diabetes |­Recognised­as­a­global­epidemic­by­ from­the­original­site­of­a­tumour­to­other­parts­of­­
the­World­Health­Organization.­The­International­­ the­body.­Also­referred­to­as­advanced­disease.
Diabetes­Federation­estimates­that­some­360­million­
people­worldwide­will­have­diabetes­by­2030.­ Neoadjuvant treatment |­Treatment­given­to­
According­to­the­WHO,­type­2­(adult­onset)­diabetes­ reduce­the­size­of­a­tumour­before­surgical­removal­­
accounts­for­around­90%­of­all­cases.­Uncontrolled­ is­attempted.
type­2­­diabetes­can­lead­to­severe­complications­
such­as­cardiovascular­disease,­stroke,­blindness,­ Overall survival |­The­time­from­the­start­of­
amputations,­and­kidney­failure,­resulting­in­signifi- ­treatment­until­the­patient­dies.
cant­healthcare­burdens­to­society.
Progression-free survival |­The­length­of­time­
Schizophrenia |­A­severe­mental­disorder­that­ ­during­and­after­treatment­during­which­a­patient­
­distorts­the­way­a­person­thinks,­acts,­expresses­ lives­without­the­disease­getting­worse.
emotions,­perceives­reality­and­relates­to­others.­
According­to­WHO­estimates,­schizophrenia­affects­ Second-line treatment |­Treatment­given­if­the­
approximately­24­million­people­worldwide­and­is­ ­initial,­or­first-line,­treatment­does­not­work,­or­if­­
usually­diagnosed­in­adults­aged­between­15­and­35­ the­cancer­stops­responding­to­it.
years.­The­symptoms­of­schizophrenia­are­broadly­
categorised­as­positive,­negative­and­cognitive.­Posi-
tive­symptoms­are­psychotic­behaviours­such­as­­
hallucinations­and­delusions.­Negative­symptoms­
include­apathy,­social­withdrawal,­lack­of­drive­­
and­reduced­ability­to­feel­pleasure­in­everyday­life.­
Cognitive­deficits­include­difficulty­concentrating­­
or­following­instructions,­difficulty­completing­tasks,­
memory­problems,­and­disorganised­thinking.­
­Persistent­negative­symptoms­are­a­major­cause­of­
burden­for­patients­and­caregivers.
06_Roche_AR10_ENG_Pharmaceuticals.indd 55 28.01.2011 14:53:23Diagnostics |
In 2010 sales again
grew well ahead of the market, with
market share gains in key segments such
as immunoassays and tissue diagnostics.
Efforts to enhance operational efficiency
continue throughout the division and
contributed to higher operating profit in
2010. All business areas launched new
products that will help drive above-
market growth in 2011.
07_Roche_AR10_ENG_Diagnostics.indd 56 28.01.2011 11:13:3557­
Diagnostics Roche Business Report 2010
Diagnostics Division in brief
Sales | in millions of CHF Core operating profit | in millions of CHF Number of employees
10,055 10,415 2,202 25,404 25,508 26,194
9,656
1,754 1,742
08 09 10 08 09 10 08 09 10
Key figures
% change % change in
In millions of CHF in CHF local currencies % of sales
Sales 10,415 4 8 100
— Professional Diagnostics 4,858 7 11 47
— Diabetes Care 2,959 0 4 28
— Molecular Diagnostics 1,189 1 4 12
— Applied Science 868 0 4 8
— Tissue Diagnostics 541 13 17 5
Core operating profit 2,202 26 30 21.1
Operating free cash flow 1,634 42 48 15.7
Research and development (core basis) 890 –6 –2 8.6
Diagnostics Leadership Team | 31 December 2010
Daniel O’Day Chief Operating Officer Roche Diagnostics
Manfred Baier Applied Science
Colin Brown * (Dirk H. Ehlers) Professional Diagnostics
Paul Brown Molecular Diagnostics
Roland Diggelmann Asia—Pacific
Peter Finckh Platforms & Support
Christian Hebich Finance and Services
Michael Heuer EMEA (Europe, Middle East, Africa) and Latin America
David LaPré Operations
Annette Luther Communications
Kent Kost Quality and Regulatory
Hany Massarany Tissue Diagnostics
Wataru Ogawa Japan
Jack Phillips North America
Burkhard G. Piper ** Diabetes Care
Claus-Joerg Ruetsch Legal
Cris Wilbur Human Resources
Robert Yates Business Development
* From 1 June 2010.
** To 31 December 2010.
07_Roche_AR10_ENG_Diagnostics.indd 57 28.01.2011 11:13:3558­
Roche Business Report 2010 Diagnostics
Diagnostics Division Sales by region
Roche’s­Diagnostics­Division­is­the­world’s­leading­
supplier­of­in vitro­diagnostics­(IVDs).­Performed­in­­ Europe/Middle
a­laboratory­or­at­the­point­of­care­on­blood,­tissue­ East/Africa 50% (+6%)
and­other­samples­from­patients,­IVD­tests­are­a­­crit-­ Japan 5% (+4%)
ical­source­of­objective­information­helping­doctors­ Asia—Pacific 12% (+20%)
detect­diseases,­select­appropriate­treatments­and­
monitor­patients’­responses­to­care.­In­addition,­sci- Latin America 7% (+16%)
entists­use­the­division’s­research­products­to­gain­­
a­better­understanding­of­the­causes­of­disease­and­ North America 26% (+5%)
to­discover­new­treatments.­In­over­130­countries­
Italics = growth rates (in local currencies).
Roche­Diagnostics­serves­customers­spanning­the­
entire­healthcare­spectrum­—­from­hospitals­and­
commercial­medical­labs,­to­physicians,­to­patients­
with­conditions­requiring­them­to­self-test.­The­ nologies­and­simplify­processes,­meeting­the­
­division­offers­a­wide­range­of­technologies­allowing­ requirements­of­all­customers­regardless­of­lab­
­the­detection­and­analysis­of­DNA,­RNA­and­­ size,­location­or­testing­experience.
proteins­­­on­a­large­base­of­instruments­installed­ • Demonstrating medical value­is­becoming­
worldwide.­Already­among­the­broadest­in­the­­ the­main­driver­of­differentiation­in­the­diagnostics­
industry,­Roche’s­IVD­test­menu­is­steadily­expand-­ market,­contributing­to­the­revaluation­of­IVDs.­
ing­and­drawing­on­the­latest­scientific­advances.­­ Despite­their­fundamental­impact­on­the­majority­
In­2010­Roche­had­approximately­a­20%­share­of­the­ of­clinical­decisions,­IVDs­currently­account­for­
global­IVD­market,­which­is­valued­at­an­estimated­ less­than­2%­of­medical­spending­and­are­clearly­
44­billion­US­dollars­in­annual­sales.­1­ undervalued.­There­are­two­main­categories­of­
diagnostics­that­contribute­to­better­healthcare­
decisions.­Stand-alone diagnostics­offer­value­
Strategic priorities by­enabling­the­precise­and­timely­diagnosis­­
of­diseases­and­facilitating­early­screening­for­dis-­
Scientific­progress,­new­technologies­and­changing­ ease­predisposition­and­prognosis.­Examples­
demographics­are­among­the­trends­expanding­­­ include­the­molecular­human­papillomavirus­(HPV)­
the­healthcare­market.­On­the­other­hand,­there­is­ test­in­screening­for­cervical­cancer,­the­MRSA­
mounting­pressure­on­healthcare­budgets­and­­ test­to­diagnose­infection­with­methicillin-resistant­
costs­worldwide.­Diagnostics­can­capitalise­on­all­ Staphylococcus aureus,­and­the­PIGF­and­sFlt-1­
these­trends­by­translating­scientific­insights­into­ immunoassays­in­testing­for­pre­eclampsia.­
products­that­bring­patients­real­medical­benefit­and,­ Companion diagnostics­are­tests­that­enable­
at­the­same­time,­contribute­to­significant­cost­­ doctors­to­identify­the­patients­most­likely­to­
savings.­Enabling­precise­and­timely­disease­diagno- benefit­from­a­particular­treatment­or­to­monitor­
sis­and­treatments­to­be­targeted­at­the­patients­ responses­to­it.­Roche­already­markets­com-
most­likely­to­benefit­is­of­great­value,­both­for­the­ panion­diagnostics­for­a­number­of­indications,­
well-being­­of­the­patient­and­in­allocating­medical­ with­more­in­late­stage­development­(see­list­­
resources­where­they­will­be­most­effective.­ on­page­59).
• Deploying diagnostic tests in drug develop-
The­Diagnostics­Division’s­strategic­priorities: ment­is­crucial­to­help­increase­R­&­D­productivity­
• Improving testing efficiency is­one­pillar­of­the­ and­develop­more­targeted­medicines.­Roche­
division’s­strategy.­Roche’s­automated­diagnostic­ Diagnostics­is­collaborating­closely­with­the­
systems­embody­decades­of­engineering­inno-­ ­Pharmaceuticals­Division­and­external­pharma­
vation.­Testing­components,­visualisation­and­ana­-­
lysis­units­and­workflow­management­systems­
have­continuously­improved­to­include­new­tech-­ 1 Market size based on company and independent reports.
07_Roche_AR10_ENG_Diagnostics.indd 58 28.01.2011 11:13:3559­
Diagnostics Roche Business Report 2010
Roche companion diagnostics on the market or in late development
Disease Area Disease Drug Diagnostic Test * Technology Application
Virology CMV Valcyte CMV viral load PCR Monitoring
HBV Pegasys and other HBV viral load PCR Monitoring
antivirals
HBV Pegasys, peginterferon HBsAg levels Immunoassay Monitoring
alpha-2b (Merck/SP)
HCV Pegasys, peginterferon HCV viral load PCR Monitoring
alpha-2b (Merck/SP)
HCV Polymerase inhibitor (R7128) HCV viral load PCR Monitoring
HCV Protease inhibitor (R7227) HCV viral load PCR Monitoring
HIV Antivirals HIV viral load PCR Monitoring
HIV abacavir HLA-B 5701 PCR Screening
(GlaxoSmithKline) genotype
Oncology Breast cancer Herceptin, lapatinib HER2 expression/ IHC, ISH Selection
(GlaxoSmithKline) gene amplification
Breast cancer Tamoxifen and other ER/PgR expression IHC Selection
hormonal therapies
Breast cancer pertuzumab (RG1273) HER2 expression/ IHC, ISH Selection
gene amplification
Breast cancer T–DM1 (RG3502) HER2 expression/ IHC, ISH Selection
gene amplification
Cancer compound (Merck) p53 mutations Microarray Selection
Colon cancer cetuximab (Merck), KRAS mutations PCR Selection
panitumumab (Amgen) (TheraScreen)
Colon cancer cetuximab (Merck), KRAS mutations PCR Selection
panitumumab (Amgen)
Gastric cancer Herceptin HER2 expression/ IHC, ISH Selection
gene amplification
Melanoma BRAF inhibitor BRAF V600E mutation PCR Selection
(RG7204)
NSCLC gefitinib (AstraZeneca), EGFR mutations PCR Selection
Tarceva ** (TheraScreen)
NSCLC Tarceva **, EGFR mutations PCR Selection
gefitinib (AstraZeneca)
NSCLC MetMAb (RG3638) MET expression IHC Selection
NSCLC TG4010 (Transgene) MUC1 expression IHC Selection
Pancreatic CP-4126 hENT1 expression IHC Selection
cancer (Clovis Oncology)
Inflammation Asthma lebrikizumab (RG3637) Serum periostin levels, Immunoassay Selection
CEA, IgE
Rheumatoid MabThera/Rituxan RF, anti-CCP Ab Immunoassay Selection
arthritis
SLE rontalizumab (RG7415) IFN-induced genes PCR Selection
Others Osteoporosis Bonviva/Boniva and other B-Crosslaps; Immunoassay Monitoring
bisphosphonates P1NP levels
Transplantation CellCept MPA levels Immunoassay Monitoring
black type = on the market, grey type = in development; * not available in all markets.
monitoring = monitoring of patient’s response to a particular treatment; screening = screening of patients for a particular genetic
variation of HLA-associated with hypersensitivity to abacavir; selection = selection of patients eligible for a particular treatment
(** = selection of patients eligible for earlier treatment).
anti-CCP = antibodies against cyclic citrullinated peptide; BRAF = B-isoform of the rapidly growing fibrosarcoma oncogene;
CEA = carcinoembryonic antigen; CMV = cytomegalovirus; HBV = hepatitis B; HBsAg = HBV surface antigen; HCV = hepatitis C;
HER2 = human epidermal growth factor receptor 2; HIV = human immunodeficiency virus; hENT1 = human equilibrative nucleoside
transporter; EGFR = epithelial growth factor receptor; ER = estrogene receptor; IHC = immunohistochemistry; ISH = in situ hybridisation;
IFN = interferon; KRAS = member of the Ras family of oncogenes; MPA = mycophenolic acid; NSCLC = non-small cell lung cancer;
PCR = polymerase chain reaction; P1NP = procollagen type 1 N-terminal propeptide; PgR = progesterone receptor;
RF = rheumatoid factor; SLE = systemic lupus erythematosus; SP = Schering Plough.
07_Roche_AR10_ENG_Diagnostics.indd 59 28.01.2011 11:13:3560­
Roche Business Report 2010 Diagnostics
Roche’s top-selling diagnostics | sales in millions of CHF
Accu-Chek­Aviva­Nano cobas­e­602 cobas­c­502 cobas­TaqMan­48 Ventana­IHC­reagents
2,718 1,957 1,475 561 452
Accu-Chek cobas e modules, cobas c modules, Cobas AmpliPrep/ immunohistochemistry
monitoring systems Modular Analytics, Modular Analytics, Cobas TaqMan and in situ hybridisation
Elecsys Cobas Integra
+4% * +17% * +5% * +2% * +17% *
Market segment: Market segment: Market segment: Market segment: Market segment:
Blood glucose monitoring Immunoassays Clinical chemistry Virology (hepatitis C, Advanced tissue staining
hepatitis B, HIV)
Business unit: Business area: Business area: Business area: Business area:
Diabetes Care Professional Diagnostics Professional Diagnostics Molecular Diagnostics Tissue Diagnostics
07_Roche_AR10_ENG_Diagnostics.indd 60 28.01.2011 11:13:3861­
Diagnostics Roche Business Report 2010
An industry-leading portfolio of diagnostic tests and
instruments for clinical testing and life science research.
CoaguChek­XS cobas­TaqScreen­DPX­Test cobas­b­123­POC Accu-Chek­Combo MagNA­Pure­LC2.0
330 305 278 241 236
CoaguChek Cobas AmpliScreen, cobas systems for blood Accu-Chek insulin MagNA Pure,
cobas TaqScreen gases, hospital blood delivery systems LightCycler
glucose systems
+19% * 0% * +4% * +11% * –12% *
Market segment: Market segment: Market segment: Market segment: Market segment:
Coagulation monitoring Blood screening Intensive care Insulin Delivery Systems DNA purification
and gene expression
Business area: Business area: Business area: Business unit: Business area:
Professional Diagnostics Molecular Diagnostics Professional Diagnostics Diabetes Care Applied Science
Images are not to scale.
* Year-on-year sales growth in local currencies.
07_Roche_AR10_ENG_Diagnostics.indd 61 28.01.2011 11:13:4462­
Roche Business Report 2010 Diagnostics
partners­on­new­medicines­and­their­use­in­ both­mature­and­emerging­EMEA­5­economies­(6%),­
per­­sonalised­settings­(see­also­the­R & D section­ helped­by­strong­performances­by­Professional­­
on­page­74). Diagnostics­and­Diabetes­Care.­Professional­Diag-
• To­further­accelerate growth in emerging seven nostics­and­Tissue­Diagnostics­were­the­primary­
(E7) countries 2­the­division­is­expanding­its­ growth­drivers­in­North­America­(5%).­In­Japan­(4%)­
local­organisations­and­investing­in­programmes­ overall­divisional­sales­grew­faster­than­the­market­
to­bring­products­to­local­markets­more­quickly.­ with­Professional­Diagnostics’­strong­performance­off-­
• The­division­intends­to­further­improve its prof- setting­continuing­challenges­in­Diabetes­Care.­
itability­through­a­combination­of­strong­­sales­ Increased­investment­and­strong­demand­for­immu-
growth­and­efficiency­initiatives­targeting­virtually­ noassays­and­other­leading-edge­Roche­products­
every­area­of­operations.­This­report­contains­ contributed­to­robust­above-market­growth­in­the­E7­
information­on­the­progress­made­in­2010. emerging­markets­(21%),­which­in­2010­accounted­
for­almost­13%­of­total­divisional­revenues.
Results and main business On­a­Swiss­franc­basis,­the­division’s­core­operating­
profit­for­2010­increased­26%­(30%­in­local­cur-­
developments
rencies)­to­2,202­million­Swiss­francs,­while­the­core­
operating­profit­margin­advanced­3.8­percentage­
In­2010­the­Diagnostics­Division­recorded­sales­of­ points­to­21.1%.­These­increases­largely­reflect­the­
10.4­billion­Swiss­francs,­an­increase­of­8%­in­local­ strong­performance­of­Roche’s­key­diagnostic­
currencies­over­2009­3­(4%­in­Swiss­francs;­8%­in­ ­products­as­well­as­ongoing­initiatives­to­improve­
U­­­ S dollars).­This­was­significantly­above­the­estimat-­ operational­excellence.­For­more­information­on­the­
ed­IVD­market­growth­rate­(5%)­4. ­division’s­operating­results,­see­the­Finance­Report.­
The­division­launched­a­total­of­39­tests,­which­ex­-­
panded­the­immunoassay­menu­in­infectious­dis-
Diagnostics sales increase 8%,
eases,­extended­the­molecular­test­panel­in­virology­
significantly ahead of the market. and­further­strengthened­the­tissue­assay­port-­
folio­in­oncology.­In­addition,­11­instruments­were­
launched­in­key­markets­facilitating­maximum­­
efficiency­in­state-of-the-art­testing­in­clinical­labo-­
All­five­divisional­business­areas­contributed­to­sales­ ratories,­re­search­centres­and­point-of-care­units­
growth,­led­by­Professional­Diagnostics­and­Diabetes­ ­(see­table­of­product­launches­on­page­76).­In­2011­
Care.­Immunoassays­and­blood­glucose­monitoring­ the­division­plans­to­launch­18­key­products,­includ-
systems­remained­these­businesses’­primary­growth­ ing­the­US­introduction­of­Accu-Chek­Combo­for­­
drivers.­Strong­demand­for­advanced­tissue­stain-­ the­management­of­blood­glucose­in­diabetes,­the­
ing­products­continued­to­fuel­above-market­growth­ cobas­4800­HPV­Test­for­cervical­cancer­screen-­
in­Tissue­Diagnostics.­Virology­was­the­main­con-­ ing­and­the­cobas­4800­BRAF­Mutation­Test­in­mela-
tributor­to­sustained­sales­growth­in­Molecular­Diag- noma­(see­table­of­product­launches­on­page­78).­
nostics.­Strong­sales­of­cell­analysis­and­genomics­
­systems­were­Applied­Science’s­main­growth­drivers.­ Data­from­three­clinical­studies­were­presented­at­
Instrument­placements­were­again­up­significantly­­ major­scientific­congresses:­ATHENA,­a­large­regis-
for­the­division­as­a­whole­and­were­a­major­growth­ tration­trial­investigating­the­benefits­of­HPV­testing­
driver­in­all­segments.
Sales­again­outpaced­the­market­in­all­regions.­ 2 E7 countries = Brazil, Russia, India, China, South Korea,
Growth­was­very­strong­in­Asia—Pacific­(20%)­—­ Mexico, Turkey.
­particularly­in­China­and­South­Korea­—­driven­ 3 Unless otherwise stated, all growth rates are in local currencies.
4 Market growth based on company and independent reports
mainly­by­Professional­Diagnostics.­Despite­pricing­
(to end of September 2010).
challenges,­sales­outperformed­the­market­in­­ 5 EMEA = Europe, Middle East, Africa.
07_Roche_AR10_ENG_Diagnostics.indd 62 28.01.2011 11:13:4463­
Diagnostics Roche Business Report 2010
in­screening­for­cervical­cancer,­PROTECT,­a­ran- zerland)­and­the­Diabetes­Care­R­&­D­activities­on­
domised­trial­studying­the­NT-proBNP­biomarker- insulin­delivery­systems­from­Burgdorf­(Switzerland)­
guided­approach­in­treatment­of­heart­failure,­­ to­Mann­heim­(Germany).­The­division­believes­­
and­the­STeP­trial­aiming­at­improvement­of­diabetes­ that­these­measures,­which­are­part­of­the­Group-
management­through­structured­testing.­All­three­ wide­Operational­Excellence­programm,­will­enable­­
­trials­demonstrated­the­high­medical­value­of­Roche­ it­to­enhance­system­integration,­leverage­exist-­
diagnostic­products­(see­R & D section­on­page­74). ing­capacities­and­reduce­infrastructure­costs­while­
maintaining­the­focus­on­customers­and­innovation.
Operations The­division­regularly­assesses­the­mix­of­in-sourcing­
and­out-sourcing­in­its­manufacturing­and­supply­
Roche­Diagnostics’­Business­Areas­(BAs)­are­inno- chain­operations.­In­general,­activities­which­involve­
vation­engines,­translating­our­growing­understand- proprietary­technology­or­enable­Roche­to­leverage­
ing­of­diseases­into­new­products­and­applications.­ internal­expertise­are­in-sourced.­Operations­are­
The­BA­headquarter­sites­in­Rotkreuz,­Switzerland­ ­out-sourced­when­this­offers­economies­of­scale­or­
(Professional­Diagnostics),­Mannheim,­Germany­(Dia-­ other­advantages­while­ensuring­the­continued­integ-
betes­Care),­Pleasanton,­USA­(Molecular­Diagnos- rity­of­Roche’s­products­and­services.­In­recent­years­
tics),­Penzberg,­Germany­(Applied­Science),­­­and­ the­level­of­out-sourcing­has­grown­in­line­with­sales.­
Tucson,­USA­(Tissue­Diagnostics),­are­the­division’s­
main­R­&­D­sites,­with­additional­centres­of­excel-­
lence­located­in­Branford,­USA­(454­Life­Sciences),­ Business development
­Madison,­USA­(NimbleGen),­and­Indianapolis,­USA­
(Diabetes­Care).­In­September­Roche­opened­a­new­ Collaborations­with­academia,­research­institutes­and­
Diagnostics­Operations­Complex­for­R­&­D­and­pro- other­private­and­commercial­organisations­give­
duction­in­Penzberg.­A­new­immunoassay­production­ Roche­Diagnostics­rapid­access­to­relevant­medical,­
unit­in­Mannheim­was­inaugurated­in­October. scientific­and­technological­advances.­Intellectual­
property­(IP)­exchange­is­a­strategic­component­of­
In­2010­a­lifecycle­management­approach­was­in-­ Roche’s­ability­to­offer­customers­the­most­extensive­
troduced­to­establish­a­stronger­connection­be­t­ween­ portfolio­of­tests­and­technologies­year­after­year.­
each­BA­and­its­markets.­Lifecycle­teams­are­ac-­ ­In-licensing­is­an­important­opportunity­for­Roche­to­
count­able­for­the­development,­filing,­approval­­and­ access­markers­and­technologies,­whereas­out-
launch­of­new­products­to­maximise­their­value­­­ licensing­of­IP­can­help­establish­novel­markers­and­
from­launch­to­obsolescence.­In­addition,­two­new­ technologies­from­Roche­more­rapidly­in­the­market-
global­cross-BA­functions­have­been­created­to­­ place­by­involving­more­players­to­develop­and­­
help­maintain­the­focus­on­product­profitability­and­ educate­the­market.­It­is­thus­vital­for­Roche­Diagnos-
pro­cess­efficiency.­Global­Operations­will­drive­­ tics­to­have­excellent­internal­processes­to­identify­­
operational­excellence­in­manufacturing,­supply­ IP­rapidly­and­to­maintain­close­contact­with­partner­
chain­and­direct­procurement,­while­Global­Quality­&­ companies­for­both­in-­and­out-licensing­agreements.
Regulatory­will­ensure­submission­quality­and­reduce­
time­to­approval.­The­established­Global­Platforms­ In­2010­Roche­completed­major­acquisitions­in­
and­Support­function­will­continue­to­play­a­key­role­ ­Diabetes­Care­(Medingo­Ltd.)­and­Tissue­Diagnos-
in­instrument­and­software­development­and­cus- tics­(BioImagene­Inc.)­and­entered­into­a­number­­
tomer­service.­ of­research­and­technology­collaborations­in­Diabetes­
Care­(with­InterComponentWare),­Molecular­Diag-
As­announced­in­November­over­the­next­two­to­ nostics­(with­the­German­Cancer­Research­Centre)­
three­years­Roche­Diagnostics­intends­to­transfer­ and­Applied­Science­(with­IBM­and­DNA­Electron-
the­production­of­chemical­raw­materials­and­ ics).­Moreover,­the­division­signed­over­80­licensing­
­analytics­services­from­Mannheim­to­Penzberg­­(both­ agreements,­approximately­half­of­them­in-licensing­­
in­­Germany),­blood­gas­and­electrolytes­monitor-­ IP­to­broaden­Roche’s­innovation­base­(see­Business
ing­activities­from­Graz­(Austria)­to­Rotkreuz­(Swit-­ area highlights­for­more­details).
07_Roche_AR10_ENG_Diagnostics.indd 63 28.01.2011 11:13:45Can we find
Disease area Virology / Oncology
Indication HPV (as a risk factor for cervical cancer)
Trial Registration trial ATHENA
No. of participants 47,208
No. of study sites 61
No. of countries 1 (USA)
Chantal H., a potential participant in the ATHENA trial, Basel
07_Roche_AR10_ENG_Diagnostics.indd 64 28.01.2011 11:14:15out sooner ?
Rita S., Head of Assay Development, Roche Pleasanton
07_Roche_AR10_ENG_Diagnostics.indd 65 28.01.2011 11:14:48cobas 4800 HPV Test
Creating value for patients means
proving the medical value of a diagnostic
test in a rigorous clinical trial
Biomarker
identification and
clinical validation
Collaborations with
research groups in
academia and industry
Development
Education
of diagnostic test
of healthcare
professionals
Regulatory
approval
Show sensitivity and specificity
Reimbursement
Health Successful
economics diagnostic test
on market
Demonstrate medical value
The Roche ATHENA trial enrolled over Persistent infection with high-risk human papilloma-
47,000 women, screening participants virus (HPV) is the leading cause of cervical cancer,
for cervical cell changes using both the
Pap smear and the cobas 4800 HPV implicated in more than 99% of all cases. Screening
DNA Test (for 14 high-risk HPV geno- enables early identification and removal of pre-cancer-
types). The results revealed that one
ous lesions, dramatically reducing the incidence and
in ten women of those aged 30 years or
older who tested positive for HPV ge- mortality of cervical cancer worldwide. However, many
notypes 16 or 18 were found to have cer-
studies have shown that the Pap smear, which sam-
vical pre-cancer despite normal Pap
smear tests. The cobas 4800 HPV Test ples cells from the cervix and is currently the most com-
enables physicians to identify women mon test used to detect cervical cancer, does not
with cervical pre-cancer missed using
have adequate sensitivity, and that up to 50% of pre-
cytology alone.
cancerous lesions are missed with a single Pap
smear. Thousands of women ultimately diagnosed with
cervical cancer had normal Pap smear results.
07_Roche_AR10_ENG_Diagnostics.indd 66 28.01.2011 11:14:4967­
Diagnostics Roche Business Report 2010
Business area highlights and­cobas­u­411,­a­semi-automated­urine­test­strip­
analyser.­The­rollout­of­the­new­cobas­b­123­POC­
Professional Diagnostics blood­gas­analyser­commenced­in­Europe­and­­several­
Professional­Diagnostics­is­a­leading­supplier­of­ markets­in­Latin­America­and­Asia—Pacific.­Target-
instruments,­tests,­software­and­services­for­clinical­ ing­specifically­at­the­POC­segment­and­capable­of­
laboratories­and­decentralised­testing­products­to­ delivering­many­vital­results­in­time-critical­­situa-­
support­clinical­decision­making­at­the­point­of­care­ tions,­this­instrument­is­an­important­advance­in­
(POC).­In­2010­it­had­a­15%­share­of­a­growing­­ blood­gas­analysis,­the­leading­segment­in­hospital­
global­market­worth­30­billion­US­dollars.­ POC­testing.­The­US­launch­of­cobas­b­123­POC­­
­is­expected­in­2011.­
Professional­Diagnostics’­full-year­sales­grew­­
about­twice­as­fast­as­the­global­market,­rising­11%­ Strong­growth­in­coagulation­monitoring­reinforced­
to­4,858 million­Swiss­francs­and­outpacing­market­ Roche’s­leading­position­in­this­segment.­Continued­
growth­in­all­regions.­Immunoassays­were­a­key­ strong­demand­for­portable­testing­systems,­such­as­
growth­driver,­with­sales­up­17%­in­2010.­For­a­­ the­top-selling­CoaguChek­XS­system,­and­expanded­
decade­this­segment­has­consistently­grown­at­dou- Medicare­coverage­for­home­coagulation­testing­­
ble-digit­rates,­thanks­to­a­strong­installed­base­­ in­the­US­were­key­factors­contributing­to­growth.­
and­an­ever-expanding­test­menu.­Sales­of­clinical­ Studies­have­repeatedly­shown­that­self-testing­helps­
chemistry­and­coagulation­monitoring­products­­ patients­on­anticoagulants­to­keep­their­medica-­
grew­5%­and­19%,­respectively.­ tion­within­the­therapeutic­range­and­can­minimise­
the­risk­of­complications.
In­2010­Professional­Diagnostics­launched­eight­new­
or­next-generation­immunoassays­in­the­US­or­­ Delivering­on­the­promise­of­personalised­health-
markets­recognising­the­CE­Mark,­including­six­tests­ care,­the­PROTECT­trial,­presented­at­the­American­
to­diagnose­or­monitor­infectious­diseases­—­hepa- Heart­Association­meeting­in­November,­demon-
titis­A­and­C,­HIV,­herpes­simplex­virus­(HSV-1­and­ strated­a­significant­reduction­in­total­cardiovascular­
HSV-2)­and­rubella­(see­table­of­product­launches­­ events­when­heart­failure­therapy­was­guided­by­
on­page­76).­Three­new­or­next-generation­clinical­ concen­trations­of­the­cardiac­biomarker­NT-proBNP.­
chemistry­products­were­also­introduced­in­CE­­ Because­of­this­strong­clinical­benefit,­the­trial­was­
Successful
markets.­In­2011­Professional­Diagnostics­will­expand­ stopped­early­to­allow­all­patients­access­to­this­new­
diagnostic test
on market its­immunoassay­menu­further,­with­new­assays­­ treatment­strategy­(see­R & D section­on­page­74).­
covering­a­range­of­disease­areas,­including­infec- To­further­strengthen­its­cardiology­portfolio,­Roche­
tious­diseases­and­oncology. signed­a­cross-license­agreement­with­Alere­Inc.­
­giving­each­party­semi-exclusive­worldwide­rights­for­­
Demand­for­the­cobas­8000­modular­analyser­series­ natriuretic­peptide­biomarkers­proven­for­their­diag-
remained­strong­in­2010.­First­launched­in­2009,­this­ nostic­usefulness­in­a­variety­of­cardiovascular­­
platform­for­high-throughput­testing­is­now­available­ diseases.­In­collaboration­with­the­American­College­
in­all­key­markets,­including­the­US.­Following­the­ of­Cardiology,­Professional­Diagnostics­is­developing­
introduction­of­the­cobas­e­602­immunoassay­module,­ a­web­portal­for­biomarkers,­allowing­physicians­to­
high-volume­laboratories­are­now­able­to­fully­con- access­the­latest­information­on­cardiac­biomarkers­
solidate­their­serum­work­areas.­Roche­offers­a­­com-­ and­encouraging­its­application­in­clinical­practice.­
prehensive­portfolio­of­standardised­integrated­sys-
tems­for­clinical­laboratories­of­all­types­and­sizes,­ Diabetes Care
from­the­stand-alone,­low-volume­cobas­4000­and­the­ Diabetes­Care­develops­and­commercialises­blood­
medium-volume­cobas­6000­to­the­cobas­8000­­ glucose­(BG)­monitoring­and­insulin­delivery­systems­
modular­analyser­series­for­high-volume­laboratories.­ that­enable­people­with­diabetes­to­manage­their­
condition­more­effectively.­The­goal­of­diabetes­ther-
In­the­US­Professional­Diagnostics­also­launched­the­ apy­is­to­maintain­the­BG­levels­in­a­(near-)­normal­
cobas­p­501­and­p­701­post-analytical­units,­which­ range­and­thus­avoid­diabetes-related­complications.­
automate­the­storage­and­retrieval­of­sample­tubes,­ Diabetes­Care­not­only­offers­individual­product­
07_Roche_AR10_ENG_Diagnostics.indd 67 28.01.2011 11:14:5068­
Roche Business Report 2010 Diagnostics
innovations,­but­combines­these­to­form­integrated­ acquired­micropump­specialist­Medingo,­enhancing­
solutions­that­encompass­all­areas­of­diabetes­man- its­portfolio­with­an­innovative­micropump.­This­
agement.­It­is­the­industry­leader­with­a­32%­share­­ acquisition­will­enable­Roche­to­bring­integrated­­
of­a­global­BG­monitoring­market­worth­over­8 billion­ insulin­delivery­systems­to­a­broader­range­of­people­
US­dollars.­ with­diabetes­and­offer­users­a­wider­range­of­
options­to­suit­their­needs.­
In­2010­Diabetes­Care’s­sales­rose­4%­to­2,959 mil- ­
lion­Swiss­francs.­This­was­well­above­the­global­ Diabetes­Care­remains­committed­to­exploring­and­
market­growth­rate­in­an­environment­that­remains­ developing­new­diabetes­management­concepts­­
challenging­due­to­the­uncertain­economic­recov-­ as­demonstrated­by­the­Structured­Testing­Protocol­
ery­and­general­price­pressure.­Sales­of­BG­monitor- (STeP)­clinical­study­in­type­2­diabetic­patients­­
ing­systems­(4%)­were­driven­by­Accu-Chek­Aviva­ not­using­insulin.­Presented­at­the­Annual­Meeting­­
and­Accu-Chek­Performa,­which­showed­strong­dou- of­the­European­Association­for­the­Study­of­Dia-­
ble-digit­growth,­supported­by­strong­market­up-­ betes­(EASD)­in­September,­the­STeP­study­shows­
take­of­the­sleek­versions­Accu-Chek­Aviva­Nano­and­­ that­­glycemic­control­can­be­significantly­improved­
Accu-Chek­Performa­Nano­especially­designed­for­ when­therapy­is­adjusted­on­the­basis­of­structured­
young­high-frequency­testers.­By­the­end­of­2010­ BG­monitoring­and­pattern­analysis­(see­R & D sec-
these­devices­were­available­in­36­countries­across­ tion­on­page­74).­
Europe,­Latin­America­and­Asia—Pacific.­The­Accu-
Chek­Mobile­also­posted­significant­sales­growth.­ The­visualisation­and­assessment­of­BG­and­in-­
This­BG­monitoring­system’s­strip-free­technology­is­ sulin­data­are­pivotal­to­effective­diabetes­manage-
particularly­appreciated­by­insulin-dependent­pa-­ ment,­yet­sharing­the­data­continues­to­pose­sig-­
tients­who­measure­their­blood­glucose­frequently­ nificant­challenges­for­people­with­diabetes­and­
and­thus­benefit­most­from­enhanced­testing­con- healthcare­professionals­alike.­To­address­this­issue,­
venience.­Introduced­in­2009,­the­Accu-Chek­Mobile­ Diabetes­Care­is­partnering­with­eHealth­specialist­
is­now­available­in­12­countries­in­Europe­and­­ InterComponentWare­to­develop­a­web-based­diabe-
Asia—Pacific.­In­the­EU­maltose-independent­strip­ tes­management­solution­that­improves­the­inter-­
chemistries­for­the­Accu-Chek­Aviva,­Accu-Chek­ action­between­patients­and­their­caregivers­based­
Performa,­Accu-Chek­Compact­and­Accu-Chek­ on­securely­shared,­well-structured­information.­
Mobile­product­lines­received­regulatory­approval­­
in­June­and­were­immediately­rolled­out.­ Molecular Diagnostics
Molecular­Diagnostics­develops­and­commercial-­
Diabetes­Care­posted­strong­growth­in­Europe,­Latin­ ises­advanced­diagnostic­and­blood­screening­
America­and­Asia—Pacific,­with­significant­contri- platforms­and­tests­based­on­Roche’s­proprietary­
butions­from­emerging­markets.­In­the­US­sales­de-­ real-time­polymerase­chain­reaction­(PCR)­tech-­
creased­2%­slightly­underperforming­the­market,­ nology.­With­­a­32%­market­share,­Roche­is­the­leader­
which­remained­negatively­impacted­by­the­macro- in­the­highly­competitive­molecular­diagnostics­
economic­environment,­resulting­in­price­pressures­ market,­valued­­at­4­billion­US­dollars­and­growing­
and­slow­volume­growth.­US­and­Japanese­regu-­ 7%.­This­year­marks­the­25th­anniversary­of­PCR’s­
latory­approvals­for­the­maltose-free­strip­chemistries,­ debut­to­the­scientific­community.­PCR’s­unique­
expected­in­2011,­will­enable­the­latest­additions­­ ability­to­exponentially­amplify­small­amounts­of­target­
to­the­Accu-Chek­portfolio­to­be­launched­in­the­US­ DNA­has­resulted­­in­numerous­diagnostic­tech-
and­Japan­and­are­anticipated­to­boost­sales­in­­ niques­which­would­otherwise­be­too­time­consum-
these­key­markets. ing­or­impossible­to­perform.­
Insulin­delivery­systems­posted­double-digit­sales­ Molecular­Diagnostics­continued­its­steady­per-­
growth,­driven­mainly­by­continued­strong­uptake­of­ formance­in­2010,­with­sales­advancing­4%­to­­
the­new­interactive­insulin­pump­system­Accu-Chek­ 1,189­million­Swiss­francs.­Growth­was­led­by­virol-
Combo,­now­available­in­27­countries­in­Europe,­ ogy­(2%),­which­currently­accounts­for­about­half­­
Latin­America­and­Asia—Pacific.­In­May­Diabetes­Care­ of­the­business­area’s­sales.­Demand­for­the­cobas­
07_Roche_AR10_ENG_Diagnostics.indd 68 28.01.2011 11:14:5069­
Diagnostics Roche Business Report 2010
4800­system,­launched­in­late­2009,­was­strong­with­ of­human­papillomavirus­(HPV)­DNA­testing,­includ-
the­system­now­installed­in­25­countries­in­Europe,­ ing­16/18­genotyping,­over­conventional­cytologic­
Asia—Pacific,­Latin­America­and­Canada.­cobas­4800­ Pap­testing­(see­R & D section­on­page­74).­Supported­
offers­full­automation­for­mid-­to­high-throughput­ by­the­ATHENA­results,­Roche­filed­the­HPV­test­in­
testing;­the­menu­currently­includes­dual­target­tests­ the­US­in­June,­with­approval­expected­in­the­second­
for­Chlamydia trachomatis­and­Neisseria gonorrhoeae­ half­of­2011.­This­test­received­CE­Mark­certification­
and­a­screening­and­genotyping­test­for­human­­ in­late­2009­and­experienced­a­strong­market­uptake­
papillomavirus­(HPV).­Regionally,­North­America­sales­ in­CE­markets­throughout­2010.­To­further­expand­­
showed­good­growth,­while­sales­held­steady­in­­ its­testing­potential­in­cervical­cancer,­Roche­entered­
the­EU.­Latin­America­and­Asia—Pacific­posted­excel- into­a­research­collaboration­with­the­­German­Cancer­
lent­double-digit­growth.­Strong­contribution­from­ Research­Center­(DKFZ).­Recent­findings­by­the­
the­E7­markets­was­led­by­Russia­and­Mexico. DKFZ­indicate­that­the­relative­amounts­of­specific­
RNA­markers­in­HPV-infected­cells­enable­highly­
In­2010­Molecular­Diagnostics­added­four­new­or­ accurate­discrimination­of­cervical­cancer­and­high-
next-generation­tests­to­its­portfolio­in­virology­and­ grade­from­low-grade­lesions­and­thus­facilitate­­
infectious­diseases.­Thanks­to­the­first-of-its-kind­ more­specific­prediction­of­women’s­risk­for­devel-
dual-PCR­target­HIV­viral-load­test,­which­greatly­im-­ oping­cervical­cancer.­
proves­the­ability­of­physicians­to­make­informed­
treatment­decisions,­Molecular­Diagnostics­won­­ Molecular­Diagnostics­is­building­a­best-in-class­
a­major­contract­in­South­Africa­for­over­half­a­mil- oncology­portfolio­by­securing­relevant­intellectual­
lion­tests­per­year.­Roche’s­next-generation­HBV­­ property,­developing­robust­assays­and­providing­
test,­which­received­the­CE­Mark­in­2008,­is­now­also­ complete­in vitro diagnostics­solutions­covering­­sam-
available­in­the­US.­This­test­enables­broader­geno- ple­preparation,­through­to­results­analyses­and­
type­detection­and­increased­workflow­flexibility­in­ reporting.­In­2010­Roche­obtained­a­worldwide­­co-­
the­management­of­HBV.­In­the­blood­screening­seg- exclusive­licence­from­Johns­Hopkins­University­­
ment,­the­first­duplex­assay­for­simultaneous­de-­ and­Qiagen­for­the­development­of­diagnostic­assays­
tection­of­parvovirus­B19­and­the­hepatitis­A­virus­ for­the­biomarker­phosphoinositide­3-kinase­(PI3K).­
was­successfully­launched­in­the­EU­and­other­­ The­PI3K­pathway­plays­a­major­role­in­several­­
markets­recognising­the­CE­Mark,­contributing­to­im-­ cancers,­including­colorectal,­gastric,­breast­and­
proved­safety­of­human­plasma­products.­FDA­ap-­ endometrial,­and­is­currently­a­central­focus­of­­
proval­of­this­test­is­expected­in­2011.­The­LightCycler­­ cancer­drug­deve-lopment.­Roche­has­also­obtained­
MRSA­Advanced­Test,­Roche’s­flagship­product­in­ a­license­from­Genzyme­Corporation­to­develop­a­
the­hospital-acquired­infections­market,­was­approved­ test­for­epidermal­growth­factor­receptor­(EGFR)­
and­launched­in­the­US­in­July.­Studies­indicate­that­ mutations­as­a­companion­diagnostic­for­Tarceva.­In­
the­test’s­speed­—­it­identifies­methicillin-resistant­ recent­studies­patients­with­non-small­cell­lung­­
Staphylococcus aureus­(MRSA)­carriers­in­less­than­ cancer­(NSCLC)­carrying­mutations­in­the­EGFR­gene­
two­hours,­versus­one­to­three­days­using­conven- showed­enhanced­response­to­and­may­benefit­­
tional­culture-based­methods­—­can­help­significantly­ most­from­treatment­with­Tarceva.­The­EGFR­mutation­
reduce­the­spread­of­this­potentially­deadly­microbe­ test,­along­with­further­oncology­tests­for­the­BRAF­
in­hospitals.­Screening­for­MRSA­is­one­of­the­fast- V600­mutation­and­KRAS­mutations,­are­scheduled­
est-growing­segments­in­the­North­American­molec- for­launch­on­cobas­4800­in­2011.
ular­diagnostics­market.­The­test­was­launched­in­the­
EU­and­other­markets­which­recognise­the­CE­Mark­ Applied Science
in­2009­(see­table­of­product­launches­on­page­76).­ Applied­Science­supplies­scientists­in­academia­and­
the­biotech­and­pharmaceutical­industries­with­
Data­from­ATHENA,­a­Roche-sponsored­US­registra- instruments,­reagents­and­test­kits­for­a­broad­range­
tion­trial­assessing­the­utility­of­the­cobas­4800­HPV­ of­research­applications.­The­global­life­science­
Test­in­screening­for­cervical­cancer,­were­presented­ research­market,­valued­at­8­billion­US­dollars,­grew­
at­the­International­Papillomavirus­Conference­in­ approximately­8%­in­2010.­Applied­Science­has­
Montreal.­The­data­confirm­the­increased­accuracy­ roughly­10%­share­of­this­market.
07_Roche_AR10_ENG_Diagnostics.indd 69 28.01.2011 11:14:50Have I chosen
Disease area Central Nervous System
Indication Schizophrenia
Trials 6 phase III trials
No. of patients 3,600
No. of study sites 240
No. of countries 27
Kenneth B., participant in a clinical trial with RG1678, New York
07_Roche_AR10_ENG_Diagnostics.indd 70 28.01.2011 11:15:17wisely ?
Daniela A., Research Project Leader in Central Nervous System (CNS), Roche Basel
07_Roche_AR10_ENG_Diagnostics.indd 71 28.01.2011 11:15:41RG1678 — a first-in-class GRI for schizophrenia
Creating value for patients means having
the courage to go where needs are great and
others have failed
Available therapies RG1678
— Effective against positive symptoms — Effective against negative symptoms
— Significant side effects — Potential to treat suboptimally controlled positive symptoms
— Positive symptoms often still occur in the stable phases — Fewer side effects
between acute episodes — New mechanism of action
Affecting nearly 24 million people worldwide, schizo- RG1678, a glycine reuptake inhibitor (GRI) developed
phrenia is a severe mental disorder that distorts at Roche, may be the first drug to treat the negative
the way a person thinks, acts, expresses emotions, per- symptoms of schizophrenia. Representing an entirely
ceives reality and relates to others. It is a lifelong novel approach, RG1678 normalises glutamate neu-
disease that cannot be cured. On average it shortens rotransmission by increasing synaptic levels of glycine,
life expectancy by 20 years due to the higher risk thereby targeting an important pathway in psychiatric
of suicide and also due to cardiovascular and pulmo- disorders. It has the potential to become first-in-class
nary events. Because of negative symptoms, which compound of this type for the treatment of schizophre-
usually have the greatest impact on quality of life, nia. In addition, RG1678 in combination with current
patients may be unable to live independently, hold jobs, treatments has the potential to treat suboptimally con-
establish personal relationships and manage every- trolled positive symptoms, with little or no increase
day social situations. Many drugs developed to treat in side effects. Its novel mode of action could also have
negative symptoms have failed in clinical trials, and the valu able therapeutic applications in other psychiatric
few available treatments offer only modest benefits. disorders.
07_Roche_AR10_ENG_Diagnostics.indd 72 28.01.2011 11:15:5873­
Diagnostics Roche Business Report 2010
Applied­Science­posted­4%­growth­on­sales­totalling­ quencing­is­already­on­the­horizon­and­promises­the­
868­million­Swiss­francs.­Growth­drivers­were­the­­ next­leap­in­performance.­In­June­Roche­and­IBM­
­cell­analysis­segment­(thanks­to­increased­demand­ signed­an­agreement­to­develop­a­nano­pore-based­
for­solutions­in­oncology­and­stem­cell­research),­ single­molecule­sequencer­to­directly­read­and­
genomics­(formerly­reported­as­sequencing­and­mi-­ decode­human­DNA,­based­on­IBM’s­DNA­­transistor­
croarray­businesses)­and­custom­biotech­(due­­to­ technology.­This­approach­promises­gains­­in­cost-
recovery­of­the­global­economy).­Sales­of­the­MagNA­ efficiency,­throughput,­scalability­and­speed­com-
Pure­and­LightCycler­product­lines­for­sample­pre- pared­with­other­sequencing­technologies­currently­
paration­and­quantitative­PCR­analysis­declined­due­ available­or­in­development.
to­dramatically­lower­demand­for­influenza­A­(H1N1)­
virus­testing.­All­regions­showed­sales­increases­ NimbleGen­complemented­its­offering­on­the­cyto-
except­Latin­America,­where­the­negative­effect­of­ genetics­microarray­workflow­system,­including­
decreased­H1N1­testing­was­particularly­pronounced.­ arrays­for­simultaneous­analysis­of­multiple­samples,­
Sales­in­Asia—Pacific­were­exceptionally­strong­ instruments,­reagents,­as­well­as­analysis­and­vi-­
(15%),­led­by­China­and­India. sualisation­software,­now­providing­a­comprehensive­
solution­for­high-resolution­cytogenetic­analyses­­
Sales­for­cell­analysis­systems­remained­robust,­ of­chromosomal­abnormalities.­
fuelled­by­full­integration­of­the­innovatis­product­
portfolio­and­steadily­increasing­demand­for­ Applied­Science­took­further­steps­towards­transition­
­xCELLigence­automated­real-time­cell­analysers­ of­its­products­from­pure­research­use­into­routine­
(RTCA).­In­September­Applied­Science­expanded­ diagnostic­tools­(IVDs).­A­pre-Investigational­Device­
this­product­line­by­launching­the­RTCA­HT­In-­ Exemption­(pre-IDE)­submission­for­NimbleGen’s­
strument­for­high-throughput­analysis­and­the­­ microarray­platform­has­been­filed­with­the­FDA;­its­
RTCA­­Cardio­Instrument­for­label-free­cardiotoxic-­ approval­is­the­pre-requisite­for­obtaining­FDA­­
ity­testing. clearance­for­Roche’s­cytogenetic­microarrays­­
for­use­­as­IVDs.­These­microarrays,­which­detect­­
Double-digit­increases­in­sequencing­reagent­and­ chromosomal­abnormalities,­could­spearhead­a­­
microarrays­sales­fuelled­growth­in­genomics­­ product­transition­into­IVDs­and­are­currently­under­
(17%),­helped­by­strong­worldwide­demand­for­the­ development­­to­demonstrate­their­medical­value­­
GS­­Junior­DNA­sequencer,­launched­in­May.­This­ and­diagnostic­­utility.­
medium-throughput­benchtop­version­of­the­Genome­
Sequencer­FLX­System­bridges­the­gap­between­low-­ Tissue Diagnostics
and­high-throughput­sequencing­and­offers­solutions­ Tissue­Diagnostics­(Ventana­Medical­Systems­in­
in­nearly­every­field­of­biological­research.­Thanks­­ North­America)­is­the­world’s­leading­supplier­­
to­its­size,­efficiency­and­competitive­price,­it­puts­ of­­tissue-based­cancer­diagnostics.­Its­instruments­
next-generation­sequencing­technology­within­the­ and­reagent­systems­are­used­in­histology,­cytol-­
reach­of­thousands­of­researchers­around­the­world. ogy­and­drug­discovery­laboratories­worldwide.­In­
2010­the­unit­had­a­25%­share­of­the­tissue­diag-­
In­response­to­the­worldwide­surge­in­research­ nostics­­market,­which­is­valued­at­over­2­billion­US­
projects­involving­resequencing­of­the­human­genome­ dollars­and­grew­approximately­9–10%.
to­study­diseases­in­large­populations,­Applied­
­Science­is­making­additional­investments­to­develop­ Tissue­Diagnostics­significantly­outpaced­the­­
systems­targeting­this­application.­In­November­ market­in­2010,­recording­sales­of­541­million­Swiss­
Applied­Science­entered­into­an­exclusive­partnership­ francs,­an­increase­of­17%­compared­to­the­year-­
with­DNA­Electronics­for­the­development­of­a­­ earlier­period.­Advanced­tissue­staining­—­immuno-
low-cost,­high-throughput­DNA­sequencer.­The­­sys-­ histochemistry­(IHC)­and­in situ­hybridisation­
tem­will­combine­454­Life­Sciences’­long-read­ (ISH)­—­was­the­main­growth­driver­(17%),­reflect-
sequencing­technology­with­DNA­Electronics’­inex- ing­strong­reagent­sales­and­robust­uptake­of­­
pensive,­highly­scalable­method­for­electrochemical­ the­fully­automated­BenchMark­ULTRA­system­for­
detection.­Moreover,­the­third­generation­of­se-­ simultaneous­IHC­and­ISH­testing­on­a­single­­
07_Roche_AR10_ENG_Diagnostics.indd 73 28.01.2011 11:16:0974­
Roche Business Report 2010 Diagnostics
platform.­This­system,­which­is­now­available­in­51­ has­been­very­strong,­particularly­in­developing­­
countries­worldwide,­sets­new­standards­in­terms­of­ markets.­VANTAGE,­an­advanced­workflow­manage-
random­slide­access,­user-friendliness­and­high- ment­­system­for­improved­productivity­and­patient­
quality­results.­The­business­area­performed­strongly­ safety,­launched­in­2008–2009,­continued­to­gain­
worldwide,­growing­two­to­four­times­as­fast­as­­ momentum­with­sales­more­than­doubling­compared­
the­market­in­Europe,­Latin­America­and­Asia—Pacific.­ to­­the­year-earlier­period.­
Sales­in­these­regions­benefited­from­intensified­
commercialisation­efforts­outside­the­US,­synergies­ Tissue­Diagnostics­completed­two­acquisitions:­
with­Roche­Pharmaceuticals­in­HER2­testing­in­ ­BioImagene­Inc.,­a­leader­in­digital­pathology­analy-
breast­and­gastric­cancer­and­the­introduction­of­ sis­and­workflow,­with­products­enabling­generation­
BenchMark­GX­at­an­economic­price­in­emerg-­ of­high-resolution­whole-slide­digital­images­from­
ing­markets. glass­microscope­slides­as­well­as­software­to­view,­
analyse­and­manage­tissue­images,­complementing­
In­2010­Tissue­Diagnostics­launched­15­new­anti- and­strengthening­the­offering­in­image­analysis­­
bodies­for­IHC­testing­to­support­the­diagnosis­of­ and­information­management;­and­Mariposa­Bio-
various­cancer­types­(see­table­of­product­launches­ Science,­an­innovator­in­the­field­of­antibody­produc-
on­page­76).­Six­DNA­probes­for­ISH­testing­were­ tion­to­support­Roche’s­production­of­best-in-­
added­to­the­molecular­assay­menu­in­the­EU­and­ class­antibodies.
other­markets­recognising­the­CE­Mark,­including­two­
new­molecular­DNA­tests­for­the­human­epidermal­
growth­factor­receptor­2­(HER2)­gene,­enabling­ Research and development
accurate,­timely­assessment­of­the­likelihood­of­re-­
sponse­to­treatment­with­Herceptin­in­breast­and­ In­2010­research­and­development­(R­&­D)­costs­(core­­
gastric­cancer.­A­DNA­probe­targeting­the­insulin- basis)­in­the­Diagnostics­Division­totalled­890 mil-­
like­growth­factor­1­receptor­(IGF-1R)­gene­was­ lion­Swiss­francs,­a­decline­of­2%­in­local­­currencies­
added­to­Tissue­Diagnostics’­non-small­cell­lung­ compared­to­2009.­R­&­D­costs­as­a­percentage­of­
cancer­biomarker­panel,­which­also­includes­assays­ sales­decreased­to­8.6%.­In­line­with­overall­divisional­
for­EGFR­and­Met.­Strengthening­its­position­in­ strategy,­the­focus­was­on­developing­next-gene-­
­prostate­cancer­testing,­Tissue­Diagnostics­secured­ ration­platforms­to­improve­testing­­efficiency­and­on­
the­exclusive­rights­from­AsymmetRx­Inc.­for­use­­ developing­new­tests­and­demonstrating­their­med-
of­the­p63­biomarker­and­launched­two­DNA­probes­ ical­value­with­robust­clinical­data.­Clinical­validation­
enabling­the­determination­of­ERG­genomic­rear- is­relatively­new­in­the­IVD­industry.­Besides­signif-­
rangements­on­a­single­slide.­While­the­p63­biomark- icant­investment,­it­requires­expertise­in­clinical­devel-­
er­is­the­gold­standard­for­the­differential­diagno-­ opment­and­increased­interaction­with­non-tradi-
sis­of­prostate­cancer,­ERG­genomic­rearrangements­ tional­customers­such­as­payers­and­healthcare­
have­been­shown­to­be­a­reliable­prognostic­marker­ professionals­(see­feature­on­page­66).­Being­able­­to­
of­prostate­cancer-specific­mortality­in­certain­ draw­on­Roche­Pharmaceuticals’­long-standing­ex-­
patient­groups.­ pertise­in­clinical­validation­gives­Roche­Diagnostics­
an­advantage­over­most­other­IVD­companies.
The­advanced­staining­instrument­portfolio­was­
­bolstered­worldwide­with­two­new­additions:­Dis- In­2010­three­major­clinical­trials­demonstrating­the­
covery­ULTRA,­an­automated­IHC­and­ISH­platform­ significant­medical­value­of­Roche­products­were­
designed­for­use­in­the­research­setting­and­offering­ presented­at­scientific­congresses:
improvements­in­ease­of­use,­workflow­and­system­
flexibility,­and­BenchMark­GX,­a­low-volume,­auto- Data­from­the­ATHENA­trial­were­presented­at­the­
mated­tissue­staining­instrument­designed­for­cancer­ International­Papillomavirus­Conference­in­Montreal­
diagnostics­professionals­who­want­to­expand­­ in­July.­This­Roche-sponsored­US­registration­trial,­
their­test­menu­and­adopt­automation­with­reduced­ the­largest­ever­performed­in­this­indication,­aimed­­­to­
investment.­With­placements­in­over­25­countries­­ assess­the­utility­of­the­cobas­4800­HPV­Test­in­
by­the­end­of­2010,­acceptance­of­BenchMark­GX­ screening­for­cervical­cancer.­The­data­clearly­con-
07_Roche_AR10_ENG_Diagnostics.indd 74 28.01.2011 11:16:0975­
Diagnostics Roche Business Report 2010
firmed­the­increased­accuracy­of­human­papilloma-­ therapy­adjustments­contributes­significantly­to­­a­
virus­(HPV)­DNA­testing­over­conventional­cytologic­ reduction­of­HbA1c­values,­improves­glycemic­
Pap­testing.­Out­of­47,000­women­enrolled­in­this­ ­control­and­helps­to­reduce­diabetes-specific­psy-
trial,­one­in­ten­of­those­aged­30­years­or­older­who­ chological­distress­and­depression.­While­SMBG­­
tested­positive­for­HPV­genotypes­16­or­18­were­ is­widely­accepted­as­a­core­component­of­effective­
found­to­have­cervical­pre-cancer­despite­normal­Pap­ diabetes­management­in­people­on­insulin­therapy,­
tests.­The­cobas­4800­HPV­Test­detects­14­high-­ the­value­of­SMBG­has­so­far­remained­controversial­
risk­genotypes­of­HPV,­twelve­as­a­pooled­result,­and­ for­insulin-naive­people,­representing­a­large­part­­
genotypes­16­and­18­individually.­As­demonstrated­ of­all­people­with­type­2­diabetes.­
by­ATHENA,­this­test­helps­physicians­to­recognise­
and­treat­precursors­of­cervical­cancer­earlier,­possi- In­addition­to­the­medical­value­of­IVD­tests­applied­
bly­before­it­spreads­in­the­body.­Each­year­around­ in­the­clinic,­diagnostics­today­play­a­number­of­
half­a­million­women­worldwide­are­diagnosed­with­ ­critical­roles­in­drug­development,­from­identifying­
cervical­cancer­and­more­than­250,000­succumb­­ new­therapeutic­targets­and­screening­out­un-­
to­the­disease. promising­drug­candidates­to­selecting­appropriate­
patient­populations­for­clinical­trials.­Some­may­­
Final­results­of­PROTECT­(Pro-BNP­Outpatient­Tai- also­become­companion­diagnostics­for­patient­selec-­
lored­Chronic­Heart­Failure­Therapy),­a­prospective­ tion,­response­prediction­or­therapeutic­monitor-­
randomised­clinical­trial­in­151­patients,­were­pre- ing.­Every­drug­under­development­at­Roche­has­its­
sented­at­the­American­Heart­Association­congress­ own­associated­biomarker­programme,­and­Diag-­
in­Chicago­in­November­by­the­main­study­inves-­ nostics­expertise­and­advice­are­made­available­for­
tigators­from­Harvard­University­and­Massachusetts­ each­of­these­­programmes.­In­2010­the­Diagnostics­
General­Hospital.­Promoting­a­new­paradigm­in­­ and­Pharmaceuticals­Divisions,­including­pRED,­
the­management­of­heart­failure,­the­results­demon- gRED,­Pharma­Medicines­and­Chugai,­collaborated­
strated­that­NT-proBNP-guided­heart­failure­care­ on­more­than­160 projects­across­all­disease­areas­­
was­associated­with­a­significant­56%­reduction­in­ of­interest­at­Roche.­More­than­half­of­these­projects­
total­cardiovascular­events,­such­as­worsening­­ were­in­oncology,­followed­by­inflammation,­CNS,­
heart­failure,­heart­failure­hospitalisation,­and­cardio-­ virology­and­metabolic­diseases.­In­addition,­the­
vas­cular­death,­as­compared­with­standard­treatment.­ Diagnostics­Division­collaborated­with­several­­
As­heart­failure­ranks­among­the­most­costly­chronic­ other­pharma­ceutical­companies­to­develop­com-
conditions­in­developed­countries,­reducing­the­­ panion­diagnostics­for­key­biomarkers,­particularly­­
risk­of­cardiovascular­events­not­only­contributes­to­ in­onc­ology.­
­better­patient­outcomes­but­is­also­likely­to­reduce­
healthcare­costs.­The­Roche­NT-proBNP­test­is­
­available­at­the­point-of-care­and­in­laboratories­
worldwide­where­it­runs­on­the­cobas­platforms.­It­is­
estimated­that­as­many­as­23­million­people­world-
wide­have­heart­failure­with­550,000­new­cases­diag-
nosed­each­year­in­the­US­alone­and­a­mortality­­
rate­that­exceeds­that­of­many­cancers.­
The­STeP­(Structured­Testing­Protocol)­study,­a­
prospective­12-month­clinical­trial­in­483­non-insulin-
treated­people­with­type­2­diabetes,­was­present-­
ed­at­the­Annual­Meeting­of­the­European­Association­
for­the­Study­of­Diabetes­(EASD)­in­Stockholm­­in­
September.­The­study­demonstrated­that­the­use­­of­
this­new­diabetes­management­approach­including­
structured­self-monitoring­of­blood­glucose­(SMBG),­
data­visualisation,­pattern­analysis­and­derived-
07_Roche_AR10_ENG_Diagnostics.indd 75 28.01.2011 11:16:0976­
Roche Business Report 2010 Diagnostics
Product launches
in the Diagnostics Division
Major product launches in 2010
Business area Product name Product description Market Timelines
Professional Six immunoassays in — HIV combi 27 min: for improved combined testing of EU, APAC, Q4
Diagnostics virology and infectious HIV-antigen and HIV-antibodies enabling more reliable LATAM
diseases early detection of HIV infection
— HSV-1 IgG and HSV-2 IgG: for quantitative detection EU, APAC, Q4
of IgG antibodies to HSV LATAM
— Rubella IgM: to diagnose rubella infection in women US Q1
— anti-HCV: for presumptive diagnosis of HCV infection US Q2
— anti HAV: to diagnose HAV US Q4
Two immunoassays in — free ß-HCG and PAPP-A: to evaluate a risk of trisomy EU, APAC, Q1
other disease areas 21 in pregnancy LATAM
— STAT NT-proBNP: to evaluate the risk of heart failure US Q1
Three clinical chemistry next-generation tests for HbA1c and ferritin, and new EU, APAC, Q1–2
products MultiControl ClinChem LATAM
cobas e 602 module for immunoassay module with over 80 immunoassays and a EU Q3–4
cobas 8000 modular throughput of 170 tests/hour for very high volume laboratories
analyser series
cobas b 123 POC system multi-parameter blood gas analyser for use at the EU, APAC, Q4
point of care and in laboratories LATAM
cobas c 701/ clinical chemistry and immunoassay modules for very high US Q3–4
cobas c 502/cobas e 602 volume laboratories
modules for cobas 8000
modular analyser series
cobas u 411 semi-automated urine test strip analyser US Q4
cobas p 501/cobas p 701 post-analytical units for automated storage and retrieval US Q4
of bar-coded primary and secondary sample tubes
Diabetes Care Maltose-independent for Accu-Chek Aviva, Accu-Chek Performa, EU, APAC, Q3–4
strip chemistries Accu-Chek Mobile, Accu-Chek Compact LATAM
Molecular Four molecular tests in — Cobas AmpliPrep/Cobas TaqMan Dual Target HIV-1 Test US Q3
Diagnostics virology and infectious v2.0: for simultaneous detection of two regions of the
diseases HIV genome
— LightCycler MRSA Advanced Test: automated real-time US Q3
PCR-based test for MRSA
— cobas TaqScreen DPX Test: for simultaneous quantitative EU Q3
detection of parvovirus B19 and a qualitative result for HAV
— Cobas AmpliPrep/Cobas TaqMan HBV Test v2.0: US Q4
new-generation HBV viral-load test, which enables broader
genotype detection and improved workflow flexibility
Applied Science NimbleGen CGX-6 for high-resolution analysis of chromosomal abnormalities, WW Q1
multiplex array capable of analysing six samples simultaneously
GS Junior economic benchtop next-generation sequencing system for WW Q2
smaller laboratories
NimbleGen cytogenetic complete solution for high-resolution cytogenetic analysis, WW Q2
workflow system including instruments, arrays, analysis and visualisation
software
RTCA Cardio Instrument for real-time cell analysis for functional monitoring of WW Q3
cardiotoxicity and arrhythmic effects
RTCA HT Instrument for real-time high-throughput label-free impedance-based WW Q3
cell analysis
07_Roche_AR10_ENG_Diagnostics.indd 76 28.01.2011 11:16:0977­
Diagnostics Roche Business Report 2010
Major product launches in 2010
Business area Product name Product description Market Timelines
Tissue Diagnostics Fifteen antibodies for anti-E-cadherin, anti-p63, Basal Cell Cocktail (anti-p63 and US, EU Q1–4
IHC testing in cancer anti-keratin), anti-p120 catenin, anti-cyclin D1, anti-CD44,
anti-CK5/6, anti-CAM5.2, anti-CD7, anti-CD10, anti-CK17,
anti-hENT1, anti-MOC-31, anti-GPC3, anti-CK10
One antibody for IHC anti-Helicobacter pylori EU Q1
testing in infectious
diseases
Six DNA probes for ISH DDISH HER2 Probe, SISH HER2 Probe, IGF-1R Probe, EU Q2–4
testing in cancer TOP2A Probe, 5pERG Probe, 3pERG Probe
BenchMark GX for economical low-volume automated advanced tissue EU, APAC Q2
staining
Discovery ULTRA for automated advanced tissue staining in the research setting US, EU Q1–2
black type = new product/first market launch, grey type = new product/launch in additional markets.
APAC = Asia—Pacific; EU = European Union; LATAM = Latin America; US = United States; WW = worldwide.
DDISH = dual colour dual hapten ISH; HAV = hepatitis A; HbA1c = hemoglobin 1Ac; HBV = hepatitis B; HCG = human chorionic
gonadotropin; HCV = hepatitis C; HIV = human immunodeficiency virus; HPV = human papillomavirus; HSV = herpes simplex virus;
IHC = immunohistochemistry; ISH = in situ hybridisation; MRSA = methicillin-resistant Staphylococcus aureus; NT-proBNP = N-terminal
fragment of B-type natriuretic peptide; PAPP-A = pregnancy-associated plasma protein; RTCA = real-time cell analyser;
SISH = silver ISH; STAT = short turn-around time (tests used in emergency).
07_Roche_AR10_ENG_Diagnostics.indd 77 28.01.2011 11:16:1078­
Roche Business Report 2010 Diagnostics
Key product launches planned for 2011
Business area Product name Product description Market Timelines
Professional Two immunoassays — Total Vitamin D: to measure vitamin D2 and D3 with EU H1
Diagnostics greater precision
— HE4: aid in detecting ovarian cancer EU H1
cobas c 702 module for clinical chemistry module with throughput of 2,000 tests/hour US, EU H1
cobas 8000 modular for high-volume laboratories
analyser series
cobas b 123 POC system multi-parameter blood gas analyzer for use at the US H2
point of care and in laboratories
Diabetes Care Accu-Chek Mobile LCM next-generation strip-free blood glucose monitoring system EU H2
with an integrated lancing device; significantly smaller than
current version, with enhanced functionality
Accu-Chek Nano sleek version for high-frequency users US H2
Accu-Chek Combo interactive insulin delivery system combining insulin pump US H2
and blood glucose monitoring system with broad data
management capabilities
Molecular Four molecular tests in — cobas 4800 BRAF V600 Mutation Test: for identification of EU, US H2
Diagnostics oncology and infectious the V600 mutation in the BRAF gene
diseases — cobas 4800 KRAS Mutation Test: for identification of EU H2
mutations in the KRAS gene
— cobas 4800 EGFR Mutation Test: for identification of EU H2
mutations in the EGFR gene
— cobas 4800 HPV Test: detects HPV 16 and HPV 18 individu- US H2
ally and 12 other high-risk genotypes in a pooled result
Applied Science GS G Type HLA Primer for HLA genotyping on the GS Junior System or GS FLX WW H1
Sets System
GS FLX Titanum-XL new sequencing chemistry; enables extended read lengths WW H1
on the GS FLX system (sequencing kit)
4.2M CGH and 2.1M ultra-high resolution arrays for CGH validation and combined WW H2
CGH/SNP arrays CGH/SNP validation with 4.2 million and 2.1 million features
for discovery of variations in gene copy numbers and single
nucleotides
Tissue Diagnostics ER/PR antibody for IHC to support the diagnosis of breast cancer on US H1
testing BenchMark ULTRA
HER2 Dual Colour ISH to support the diagnosis of breast cancer US H2
Probe for ISH testing
FutureView next-generation detection system for BenchMark platforms; US, EU H1
delivers greater specificity, flexible detection options and
improved turnaround time
black type = new product/first market launch; grey type = new product/launch in additional markets.
EU = European Union; US = United States; WW = worldwide.
BRAF = B-isoform of the rapidly growing fibrosarcoma oncogene; CGH = comparative genomic hybridisation; EGFR = epithelial growth
factor receptor; ER/PR = estrogene receptor/progesterone receptor; HE4 = human epididymis protein 4; HER2 = human epidermal
growth factor receptor 2; HLA = human leukocyte antigen; HPV = human papillomavirus; IHC = immunohistochemistry; ISH = in situ
hybridisation; KRAS = member of the Ras family of oncogenes; SNP = single nucleotide polymorphism.
07_Roche_AR10_ENG_Diagnostics.indd 78 28.01.2011 11:16:1079­
Diagnostics Roche Business Report 2010
Glossary In situ hybridisation (ISH) |­A­method­of­staining­
biological­tissue­samples­to­identify­the­presence­
Biomarker |­A­characteristic­that­can­be­measured­ and­copy­number­of­specific­genes­or­genetic­muta-
and­evaluated­as­an­indicator­of­a­normal­biological­ tions­in­cells;­used­in­the­diagnosis­of­cancer­and­
process,­a­disease­process­or­a­response­to­a­thera- other­diseases.
peutic­intervention.­Elevated­levels­of­the­protein­
HER2­in­cancer,­for­example,­are­a­biomarker­for­­a­ Micropump for insulin delivery |­A­next-generation­
high­probability­of­response­to­Herceptin. insulin­pump,­small,­light-weight,­discrete-to-wear­
that­delivers­insulin­without­tubing.­It­combines­­key­
Cell analysis |­Methods­of­measuring­the­properties­ features­of­durable­insulin­pumps­with­the­best­
of­cells,­including­their­size­and­shape,­cellular­ attributes­of­tube-free­patch­pumps­providing­flex-
parameters­such­as­the­presence­of­specific­proteins,­ ibility­and­freedom­for­a­broader­range­of­insulin-
and­cellular­processes­such­as­proliferation­and­ dependent­people­with­diabetes.
growth.­Cell­analysis­technologies­play­an­important­
role­in­drug­development­and­production. Microarray |­A­device­for­determining­genetic­
changes­that­may­contribute­to­human­disease­or­
CE Mark certification |­Certification­that­an­in vitro influence­treatment­response.­High-density­micro-
diagnostic­(IVD)­product­complies­with­all­safety,­ arrays­evaluate­thousands­of­DNA­and­RNA­
health­and­environmental­requirements­for­use­in­the­ sequences­at­once.
European­Union.­Certified­diagnostics­are­referred­­
to­as­CE­IVDs. Point-of-care (POC) testing |­Diagnostic­testing­
performed­at­or­near­the­site­of­patient­care­using­
Clinical chemistry |­A­branch­of­diagnostics­com- transportable­(often­handheld)­instruments­and­test­
prising­tests­that­detect­and­measure­changes­in­­ kits.­Results­are­available­immediately­helping­to­
the­chemical­composition­of­body­fluids­and­tissues­­ speed­clinical­decision-making.­
to­diagnose­or­predict­the­course­of­a­disease.
Polymerase chain reaction (PCR) |­A­laboratory­
DNA sequencing |­Methods­of­determining­the­ method­widely­used­in­research­and­industry­to­make­
order­of­nucleotides­(molecular­building­blocks)­in­ millions­of­copies­of­a­DNA­sequence­of­interest­­
genetic­material.­Knowing­an­individual’s­DNA­ very­quickly.­Real-time­PCR­simultaneously­amplifies­
sequence­can­provide­insights­into­genetic­changes­ (copies)­and­quantifies­the­targeted­DNA­molecule.
which­contribute­to­human­disease­or­influence­
­treatment­response.­High-throughput­technologies­ Virology |­In­molecular­diagnostics,­testing­to­detect­
read­thousands­of­sequences­at­once.­ certain­serious­and­prevalent­viral­infections­(e.g.­
HIV­and­hepatitis­C)­or­to­monitor­their­treatment.
Immunoassay |­A­laboratory­test­that­detects­or­
measures­a­target­substance­in­a­sample­using­­­an­
immunochemical­reaction,­in­which­an­antibody­
binds­to­a­specific­antigen.­The­target­can­be­a­drug,­
a­protein­or­a­virus,­for­example.­
Immunohistochemistry (IHC) |­A­method­of­stain-
ing­biological­tissue­samples­to­determine­the­­pres-­
ence,­level­and­location­of­specific­proteins­in­cells;­
used­in­the­diagnosis­of­cancer­and­other­­diseases.
07_Roche_AR10_ENG_Diagnostics.indd 79 28.01.2011 11:16:10Corporate Governance |
Roche’s
commitment to all stakeholders is reflected
in its operating businesses’ focus on
value creation, in a management culture
that conforms to modern standards of
corporate governance and in the Group’s
policy of communicating transparently.
Remuneration Report |
Roche’s
success depends on the abilities and
dedication of its people. Recognition of
this forms the basis of our remuneration
policy and system.
08_Roche_AR10_ENG_Corporate Governance.indd 80 28.01.2011 09:07:5781­
Corporate Governance Roche Business Report 2010
Corporate Governance
Roche­complies­with­all­relevant­corporate­gover­ At­the­AGM­on­1­March­2011,­the­Board­of­Directors­
nance­requirements,­in­particular­with­all­applicable­ will­propose­shortening­the­term­of­office­of­new­or­
laws,­the­Swiss­Stock­Exchange­(SIX­Swiss­ directors­for­re­election­from­three­to­two­years­and­
Exchange)­directives­(including­the­commentaries­ the­Board­will­nominate­Pius­Baschera,­Bruno­Gehrig,­
thereto)­and­the­Swiss­Code­of­Best­Practice­for­ Lodewijk­J.­R.­de­Vink­and­Andreas­Oeri­for­re­elec­
­Corporate­Governance­promulgated­by­the­Swiss­ tion­to­the­Board­and­Paul­Bulcke,­Peter­R.­Voser­and­
business­federation­‘economiesuisse’.­The­company’s­ Christoph­Franz­for­election­as­new­Members­of­the­
internal­governance­framework,­particularly­its­Arti­ Board.
cles­of­Incorporation­and­Bylaws,­embodies­all­the­
principles­needed­to­ensure­that­the­company’s­busi­ Walter­Frey­has­decided­to­retire­as­member­of­the­
nesses­are­managed­and­supervised­in­a­manner­ Board­of­Directors­after­ten­years­of­distinguished­
consistent­with­good­corporate­governance,­includ­ service.­The­Board­of­Directors­thanks­Walter­Frey­
ing­the­necessary­checks­and­balances.­1 for­his­long­standing­engagement­and­his­many­con­
tributions­to­Roche­which­started­already­with­his­
Our­printed­Annual­Report­contains­selected­links­to­ activities­as­a­member­of­the­Board­of­Roche­Pharma­
the­Roche­website­(www.roche.com).­Readers­are­ AG­in­Germany­from­1996­to­1998­before­becoming­
thus­provided­not­only­with­a­‘snapshot’­of­our­com­ a­Board­member­of­Roche­Holding­Ltd­in­2001.
pany­at­the­reporting­date­but­are­also­directed­to­
sources­which­they­can­consult­at­any­time­for­up­ Wolfgang­Ruttenstorfer­decided­to­resign­as­a­mem­
to­date­information­about­corporate­governance­­ ber­of­the­Board­of­Directors­of­Roche­Holding­Ltd­
at­Roche.­Whereas­each­annual­report­covers­a­sin­ after­four­years­of­service.­The­Board­of­Directors­
gle­financial­year­ending­31­December,­our­website­ thanks­Wolfgang­Ruttenstorfer­for­his­valuable­work­
contains­information­of­a­more­permanent­nature­as­ and­contribution­to­Roche.
well­as­the­latest­Roche­news.­The­company’s­Arti­
cles­of­Incorporation,­Bylaws­and­the­curricula­vitae­
of­the­members­of­the­Board­of­Directors­and­the­ Corporate Executive
Corporate­Executive­Committee­are­published­on­our­
Committee
website.
Starting­on­1­January­2010­Pascal­Soriot,­Member­of­
Board of Directors the­Corporate­Executive­Committee­since­April­2009,­
and­Daniel­O’Day­were­appointed­as­COO­Division­
At­the­92­nd­Annual­General­Meeting­(AGM)­of­ Roche­Pharmaceuticals­and­COO­Division­Roche­
Roche­Holding­Ltd,­on­2­March­2010,­shareholders­ Diagnostics­and­as­a­new­member­of­the­Corporate­
re­elected­DeAnne­Julius­and­Beatrice­Weder­di­ Executive­Committee,­respectively.­
Mauro­as­members­of­the­Board­of­Directors­for­a­
term­of­three­years­as­provided­by­the­Articles­­ Erich­Hunziker,­Chief­Financial­Officer,­Chief­Infor­
of­Incorporation.­Peter­Brabeck­Letmathe­and­Horst­ mation­Officer­and­Deputy­Head­of­the­Corporate­
Teltschik­have­decided­to­retire­as­members­of­the­ Executive­Committee,­has­decided­to­retire­from­
Board­of­Directors­after­many­years­of­distinguished­ Roche­at­the­end­of­March­2011­and­plans­to­focus­
service.­Arthur­D.­Levinson­and­William­M.­Burns­ on­a­number­of­board­memberships.­The­Board­of­
were­elected­as­new­Members­of­the­Board­for­a­ Directors­of­Roche­Holding­Ltd­thanks­Erich­Hunziker­
term­of­three­years­as­provided­by­the­Articles­of­ for­his­many­years­of­exceptional­service­and­out­
Incorporation.­At­its­organising­meeting­immediately­ standing­contributions­to­the­Group’s­success.­
following­the­2010­AGM,­the­Board­of­Directors­­
has­approved­its­committees’­structure­and­its­com­ The­Board­of­Directors­has­appointed­Alan­Hippe­to­
mittees’­memberships­as­shown­on­page­83. succeed­Erich­Hunziker­as­Chief­Financial­Officer.­
1 http://www.roche.com/about_roche/corporate_governance.htm
08_Roche_AR10_ENG_Corporate Governance.indd 81 28.01.2011 09:07:5782­
Roche Business Report 2010 Corporate Governance
Board of Directors per 31 December 2010 (from left):
Dr Franz B. Humer, Prof. Bruno Gehrig, André Hoffmann,
Dr Andreas Oeri,
Prof. Pius Baschera, Prof. Sir John Irving Bell, William M. Burns,
Lodewijk J. R. de Vink, Dr DeAnne Julius, Walter Frey,
Dr Arthur D. Levinson, Dr Wolfgang Ruttenstorfer, Prof. Beatrice Weder di Mauro.
08_Roche_AR10_ENG_Corporate Governance.indd 82 28.01.2011 09:08:1583­
Corporate Governance Roche Business Report 2010
Board of Directors
Name (year of birth) Term ends First elected
Board of Directors Dr Franz B. Humer (1946) D *, E Chairman 2012 1995
Prof. Bruno Gehrig (1946) C *, D, E Vice-Chairman 2011 2004
André Hoffmann (1958) C, D, E Vice-Chairman 2012 1996
Prof. Pius Baschera (1950) A, E 2011 2007
Prof. Sir John Irving Bell (1952) C, E 2012 2001
William M. Burns (1947) B, E 2013 2010
Lodewijk J. R. de Vink (1945) C, E 2011 2004
Walter Frey (1943) A, B, E 2011 2001
Dr DeAnne Julius (1949) B *, E 2013 2002
Dr Arthur D. Levinson (1950) C, E 2013 2010
Dr Andreas Oeri (1949) A *, E 2011 1996
Dr Wolfgang Ruttenstorfer (1950) B, E 2011 2007
Prof. Beatrice Weder di Mauro (1965) A, B, E 2013 2006
New proposed
members of the
Board of Directors,
nominated for
Paul Bulcke (1954)
election at the
Peter R. Voser (1958)
Annual General Meeting
on 1 March 2011 Dr Christoph Franz (1960)
Secretary to the
Board of Directors Dr Gottlieb A. Keller (1954)
Honorary Chairman of
the Board of Directors Dr Fritz Gerber (1929)
A Corporate Governance and Sustainability Committee.
B Audit Committee.
C Remuneration Committee.
D Presidium/Nomination Committee.
E Non-executive director.
* Committee chairperson. 1 January 2011
08_Roche_AR10_ENG_Corporate Governance.indd 83 28.01.2011 09:08:1684­
Roche Business Report 2010 Corporate Governance
Corporate Executive Committee per 31 December 2010 (from left):
Dr Severin Schwan, Dr Pascal Soriot, Daniel O’Day,
Dr Erich Hunziker, Silvia Ayyoubi, Dr Gottlieb A. Keller,
Dr Richard Scheller, Dr Jean-Jacques Garaud, Dr Dan Zabrowski,
Osamu Nagayama, Dr Stephan Feldhaus, Per-Olof Attinger.
08_Roche_AR10_ENG_Corporate Governance.indd 84 28.01.2011 09:08:4085­
Corporate Governance Roche Business Report 2010
Corporate Executive Committee
Name (year of birth) Position
Corporate Executive Committee Dr Severin Schwan (1967) CEO of the Roche Group
Dr Erich Hunziker (1953) Chief Financial and IT Officer/
Deputy Head of the Corporate Executive Committee
Dr Pascal Soriot (1959) COO Division Roche Pharmaceuticals
Daniel O’Day (1964) COO Division Roche Diagnostics
Dr Gottlieb A. Keller (1954) General Counsel
Silvia Ayyoubi (1953) Head Human Resources
As of 1 April 2011 Dr Alan Hippe (1967) Chief Financial and IT Officer
Enlarged Corporate Executive Osamu Nagayama (1947) President and CEO Chugai
Committee Dr Richard Scheller (1953) Head Genentech Research and Early Development (gRED)
Dr Jean-Jacques Garaud (1955) Head Roche Pharma
Research and Early Development (pRED)
Dr Dan Zabrowski (1959) Head of Roche Partnering
Dr Stephan Feldhaus (1962) Head Group Communications
Secretary to the Corporate
Executive Committee Per-Olof Attinger (1960)
KPMG Klynveld Peat Marwick Goerdeler SA (reporting years 2004–2008)
Statutory Auditors KPMG AG (since 2009)
of Roche Holding Ltd Auditor in charge: John A. Morris (since 2004)
Chief Compliance Officer Dr Urs Jaisli (1956)
Alan­Hippe­will­join­Roche­as­a­member­of­the­ Effective­1­August­2010­Stephan­Feldhaus­was­
­Corporate­Executive­Committee­as­of­April­2011.­ appointed­Head­Group­Communications­and­Member­
of­the­Enlarged­Corporate­Executive­Committee­
As­of­1­January­2010­Jean­Jacques­Garaud­was­ reporting­to­Severin­Schwan­and­replacing­Per­Olof­
appointed­as­Head­of­Roche­Pharma­Research­and­ Attinger,­who­took­over­a­newly­created­position­­
Early­Development­(pRED)­and­together­with­Dan­ as­Head­CEO­Office­and­Secretary­to­the­Corporate­
Zabrowski­as­Head­of­Roche­Partnering.­Both­were­ Executive­Committee­reporting­to­Severin­Schwan.
appointed­as­new­members­of­the­Enlarged­Corpo­
rate­Executive­Committee.
08_Roche_AR10_ENG_Corporate Governance.indd 85 28.01.2011 09:08:4086­
Roche Business Report 2010 Corporate Governance
Information relating to 2 Capital structure
• Information­on­Roche’s­capital­structure­is­pro­
Corporate Governance
vided­in­the­Finance­Report,­Notes­to­the­Financial­
Statements­of­Roche­Holding­Ltd­(pages­153­­
1 Group structure and shareholders and­154).­Additional­details­are­contained­in­the­
• Roche’s­operating­businesses­are­organised­into­ Articles­of­Incorporation­of­Roche­Holding­Ltd.­2
two­divisions:­Pharmaceuticals­and­Diagnostics.­ • Changes­in­equity­are­detailed­in­the­Finance­
The­Pharmaceuticals­Division­comprises­the­two­ Report,­Notes­to­the­Financial­Statements­of­
business­segments­Roche­Pharmaceuticals­and­ Roche­Holding­Ltd­(page­154).
Chugai,­whereas­Genentech­as­the­former­third­ • The­company­has­a­share­capital­of­160,000,000­
segment­has­been­integrated­into­Roche­Pharma­ Swiss­francs,­divided­into­160,000,000­fully­paid­
ceuticals.­The­Diagnostics­Division­consists­of­­ bearer­shares­with­a­nominal­value­of­1­Swiss­
the­following­five­business­areas:­Applied­Science,­ franc­each.­There­are­no­restrictions­on­the­exer­­
Diabetes­Care,­Molecular­Diagnostics,­Profes­ cise­of­the­voting­rights­of­these­shares.­Upon­
sional­Diagnostics­and­Tissue­Diagnostics.­Busi­­ deposit,­shares­can­be­voted­without­any­restric­
ness­activities­are­carried­out­through­Group­ tions.
subsidiaries­and­associated­companies.­Significant­ • There­is­no­authorised­or­conditional­capital.
subsidiaries­and­associated­companies­are­listed­ • In­addition,­702,562,700­non­voting­equity­
in­the­Finance­Report,­Note­34­to­the­Roche­Group­ securities­(NES)­have­been­issued­in­bearer­form.­
Consolidated­Financial­Statements­(‘Subsidiaries­ They­do­not­form­part­of­the­share­capital­and­
and­associates’,­page­131). confer­no­voting­rights.­Each­NES­confers­the­
• Major­shareholders­are­listed­in­the­Finance­ same­rights­as­one­share­to­participate­in­avail­­
Report,­Notes­28­and­33­to­the­Roche­Group­ able­earnings­and­in­any­liquidation­proceeds­
Consolidated­Financial­Statements­(‘Equity­ following­repayment­of­the­share­capital.­Roche’s­
attributable­to­Roche­shareholders’­and­‘Related­ NES­and­the­rights­pertaining­thereto­(including­
parties’,­pages­114­and­129)­and­in­Note­4­to­­ the­provisions­protecting­the­interests­of­NES­
the­Financial­Statements­of­Roche­Holding­Ltd­ holders)­are­described­in­§4­of­the­Articles­of­
(‘Significant­shareholders’,­page­154). Incorporation­of­Roche­Holding­Ltd.
• André­Hoffmann,­Vice­Chairman­of­the­Board­of­ • Information­on­debt­instruments­which­have­been­
Directors,­and­Andreas­Oeri,­Member­of­the­Board­ issued­and­on­outstanding­bonds­is­provided­in­
of­Directors­and­Chairman­of­the­Board’s­Corporate­ the­Finance­Report,­Note­27­to­the­Roche­Group­
Governance­and­Sustainability­Committee,­serve­­ Consolidated­Financial­Statements­(‘Debt’,­page­
in­their­respective­capacities­on­the­Board­and­its­ 108).
Committees­as­representatives­of­the­shareholders­ • Additional­information­on­employee­stock­options­
group­with­pooled­voting­rights­and­receive­the­ is­provided­in­the­Finance­Report,­Note­11­to­the­
remuneration­set­forth­in­the­Remuneration­Report­ Roche­Group­Consolidated­Financial­Statements­
on­page­93­and­in­the­Finance­Report,­Note­33­­ (‘Employee­stock­options­and­other­equity­com­­
to­the­Roche­Group­Consolidated­Financial­State­­ pensation­plans’,­page­79).
ments­(‘Related­parties’,­page­129)­and­Note­6­­ • Roche­has­issued­no­options­apart­from­employee­
to­the­Financial­Statements­of­Roche­Holding­Ltd­ stock­options,­Stock­settled­Stock­Appreciation­
(‘Board­and­Executive­remuneration’,­page­155).­ Rights­(S­SARs)­and­options­issued­in­connection­
No­other­relationships­exist­with­the­shareholders­ with­debt­instruments.
with­pooled­voting­rights. • Neither­the­options­awarded­to­employees­nor­
• There­are­no­cross­shareholdings. the­debt­instruments­which­have­been­issued­have­
any­effect­on­Roche’s­share­capital.
2 http://www.roche.com/about_roche/corporate_governance/
article_of_incorporation.htm
08_Roche_AR10_ENG_Corporate Governance.indd 86 28.01.2011 09:08:4087­
Corporate Governance Roche Business Report 2010
3 Board of Directors and Corporate Executive • The­Board­of­Directors­has­established­a­system­
Committee of­controls­which­is­continuously­monitored­by­the­
• Information­on­each­member­of­the­Board­of­ Audit­Committee­and­by­the­Corporate­Gover­
Directors­(including­the­years­in­which­they­were­ nance­and­Sustainability­Committee­and­consists­
elected­and­the­years­in­which­their­terms­end)­ of­the­following­elements:
and­on­each­member­of­the­Corporate­Executive­ —­­Report­on­financial­and­operating­risks­
Committee­is­listed­on­pages­81­to­85.­Curricula­ (risk­management­system)
vitae­and­other­information­(including­information­ —­­System­of­internal­controls­over­financial­
on­board­memberships)­are­available­on­the­ reporting­(see­pages­135­and­138­in­the­
Internet.­3­ Finance­Report)
• The­Annual­General­Meeting­elects­the­members­ —­Internal­audits
of­the­Board­of­Directors­in­staggered­elections­­ —­­Group­Compliance­Officer­and­Compliance­
in­which­each­nominee­is­voted­on­separately­(see­ officers­in­subsidiaries
§18­of­the­Articles­of­Incorporation­of­Roche­ —­­Safety,­Health­and­Environmental­Protection­
Holding­Ltd­4­and­the­Minutes­of­the­92­nd­Annual­ Department
General­Meeting­of­Roche­Holding­Ltd,­held­ —­Corporate­Sustainability­Committee
2 March­2010­5). —­­Science­and­Ethics­Advisory­Group­(SEAG),­
• With­the­exception­of­Franz­B.­Humer,­William­M.­ for­issues­relating­to­genetics­and­genetic­
Burns­and­Arthur­D.­Levinson­none­of­the­mem­­ engineering­(established­in­1999).
bers­of­the­Board­of­Directors­has­been­a­member­ • Each­year­several­black­out­periods­are­imposed­
of­Roche’s­Corporate­Executive­Committee­or­ during­which­senior­employees­are­prohibited­from­
served­in­an­executive­capacity­at­any­Group­sub­­ trading­in­company­stock.­The­following­black­out­
sidiary­during­the­three­financial­years­preceding­ periods­are­in­effect­for­2011:
the­current­reporting­period. ­ 26­December­2010­to­2­February
• The­internal­organisation­of­the­Board­of­Directors­ ­ 1­April­to­14­April
and­the­division­of­authority­and­responsibilities­ ­ 26­June­to­21­July
between­the­Board­and­management,­the­remits­ ­ 1­October­to­13­October
of­the­Board­committees­and­the­information­­ Black­out­periods­can­be­changed­by­the­Chair­
and­control­mechanisms­available­to­the­Board­­ man­of­the­Board­of­Directors­if­circumstances­
in­its­dealings­with­corporate­management­are­ warrant.
governed­by­the­Bylaws.­6­ • In­2010­the­Board­of­Directors­met­for­five­
• The­Board­of­Directors­of­Roche­Holding­Ltd­is­ meetings,­each­from­3­to­6­hours­in­length­*;­once­
organised­so­as­to­ensure­that­the­Group’s­busi­­ for­a­full­day­meeting­*;­and­once­for­a­three­day­
nesses­are­conducted­responsibly­and­with­a­
focus­on­long­term­value­creation.­To­this­end,­the­
Roche­Board­has­delegated­certain­responsibili­
ties­to­several­committees­7.­Their­composition­and­
* These figures indicate the actual length of meetings and do
chairpersons­as­of­1­January­2011­are­described­
not include the directors’ extensive pre-meeting preparations
on­page­83.­Each­committees’­authorities­and­re­­ and post-meeting follow-up activities.
sponsibilities­are­defined­in­detail­in­the­Bylaws­­ 3 http://www.roche.com/about_roche/management/
board_of_directors.htm and
of­the­Board­of­Directors.­8­
http://www.roche.com/about_roche/management/
• All­the­committees­except­the­Presidium­are­
executive_committee.htm
chaired­by­independent­directors.­ 4 http://www.roche.com/about_roche/corporate_governance/
• According­to­the­Bylaws­of­the­Board­of­Directors­ article_of_incorporation.htm
5 http://www.roche.com/about_roche/corporate_governance/
at­the­request­of­any­of­its­members­a­Board­
annual_general_meetings.htm
meeting­without­the­Chairman­present­may­be­ 6 http://www.roche.com/about_roche/corporate_governance/
convened.­The­Roche­Board­meets­once­a­year­­ article_of_incorporation.htm
to­assess­the­Chairman’s­performance.­This­ 7 http://www.roche.com/about_roche/corporate_governance/
committees.htm
meeting,­which­is­not­attended­by­the­Chairman,­
8 http://www.roche.com/about_roche/corporate_governance/
is­chaired­by­one­of­the­Vice­Chairmen. article_of_incorporation.htm
08_Roche_AR10_ENG_Corporate Governance.indd 87 28.01.2011 09:08:4088­
Roche Business Report 2010 Corporate Governance
Board and Board Committees attendance 2010
Corporate
Governance
Presidium/ and
Nomination Remuneration Audit Sustainability
Board Committee Committee Committee Committee
Number of meetings 5 5 4 5 3
F. B. Humer 5 5 – – –
B. Gehrig 5 5 4 – –
A. Hoffmann 5 5 4 – –
P. Baschera 5 – – – 2
J. I. Bell 5 – 4 – –
W. M. Burns ** 5 – – 5 –
L. J. R. de Vink 5 – 4 – –
W. Frey 5 – – 5 3
D. A. Julius 5 – – 5 –
A. D. Levinson ** 4 – 3 – –
A. Oeri 5 – – – 3
W. Ruttenstorfer 5 – – 5 –
B. Weder di Mauro 5 – – 4 2
– Not a member of that committee.
** Board and Committee member since 2 March 2010.
visit­to­a­major­subsidiary­*­which­included­a­Board­ or­the­full­Board.­10­Internal­Audit­regularly­briefs­
of­Directors­meeting­*.­The­Board­committees­met­ the­Audit­Committee­with­reference­to­ongoing­
as­follows­in­2010: audit­reports.­Members­of­Internal­Audit­attend­
—­­Presidium­of­the­Board­of­Directors/Nomination­ Audit­Committee­meetings,­as­do­external­audi­­
Committee:­five­meetings­(approx.­2­hours­ tors.­For­information­on­the­external­auditors,­see­
each­*) page­89.
—­­Remuneration­Committee:­four­meetings­9­ • Members­of­the­Corporate­Executive­Committee­
(approx.­2­to­3­hours­each­*) have­a­maximum­ordinary­notice­period­of­twelve­
—­­Audit­Committee:­five­meetings­(approx.­3­to­4­ months.
hours­each­*) • There­are­no­management­contracts­which­fall­
—­­Corporate­Governance­and­Sustainability­Com­ within­the­scope­of­Subsection­4.3­(annex)­of­the­
mittee:­three­meetings­(approx.­3­hours­each­*). SIX­Directive­on­Information­relating­to­Corporate­
• The­Board­of­Directors­regularly­conducts­a­self­ Governance.
assessment­of­its­performance.
• The­members­of­the­Corporate­Executive­Commit­ 4 Remuneration, shareholdings and loans
tee­are­invited­to­attend­for,­and­report­in­person­ All­details­regarding­remuneration,­shareholdings­
on,­those­agenda­items­concerning­them.­When­ and­loans­are­set­forth­in­the­separate­Remunera­
the­situation­warrants,­members­of­the­Enlarged­ tion­Report­on­pages­91­to­101­and­in­the­Finance­
Corporate­Executive­Committee­may­also­be­ Report,­Notes­28­and­33­to­the­Roche­Group­
invited­to­attend.­The­Board­committees­invite­the­
Chairman­of­the­Board­and­other­Corporate­ * These figures indicate the actual length of meetings and do
not include the directors’ extensive pre-meeting preparations
Executive­Committee­members­to­deliver­reports­
and post-meeting follow-up activities.
at­committee­meetings­and­may­elect­to­commis­ 9 Remuneration Committee members are not permitted to
sion­independent­expert­reports­and­call­on­­ contribute to or attend Remuneration Committee meetings at
the­services­of­consultants.­The­risk­management­ which matters concerning them are deliberated or decided.
10 Additional information is provided in the Finance Report, Note
system­is­subject­to­continuous­review,­with­
32 to the Roche Group Consolidated Financial Statements,
findings­being­presented­to­the­Audit­Committee­ ‘Risk management’, page 121.
08_Roche_AR10_ENG_Corporate Governance.indd 88 28.01.2011 09:08:4089­
Corporate Governance Roche Business Report 2010
Consolidated­Financial­Statements­(‘Equity­attri­ their­audits.­The­Audit­Committee­oversees­­
butable­to­Roche­shareholders’­and­‘Related­ and­assesses­the­auditors­and­makes­recommen­
­parties’,­pages­114­and­129)­and­are­listed­in­the­ dations­to­the­Board­(for­information­on­the­
Notes­6­and­7­to­the­Financial­Statements­of­ responsibilities­of­the­Audit­Committee,­see­Arti­
Roche­Holding­Ltd­(‘Board­and­Executive­remune­r­ cle­8.1­of­the­Bylaws­12).­The­statutory­auditors­
ation’­and­‘Board­and­Executive­shareholdings’,­ par­ticipated­in­four­meetings­of­the­Audit­Commit­
pages­155­and­157). tee­in­2010.
5 Participatory rights of shareholders The­reports­of­statutory­auditors­on­the­Consoli­
• The­participatory­rights­of­shareholders­are­ dated­Financial­Statements­and­on­the­Financial­
defined­in­Roche’s­Articles­of­Incorporation.­11­As­ Statements­can­be­found­on­pages­136­and­162,­
Roche­shares­are­issued­to­bearer,­there­are­­ respectively,­of­this­year’s­Finance­Report.
no­restrictions­on­admission­to­Annual­General­ ­
Meetings,­with­the­exception­that­shares­must­­ KPMG­received­the­following­remuneration­for­
be­deposited­within­a­specified­period­before­the­ their­services­as­statutory­auditors­of­Roche­Hold­
date­of­a­meeting­and­an­admittance­card­must­­ ing­Ltd­and­other­Roche­companies:
be­issued­in­the­shareholder’s­name,­as­provided­
in­§12­of­the­Articles­of­Incorporation.­Any­share­­
2010 2009
holder­can­elect­to­be­represented­by­another­ (millions of CHF)
shareholder­at­an­Annual­General­Meeting.­The­ Auditing services 20.8 21.9
Articles­of­Incorporation­contain­no­restrictions­­ Audit-related services 2.6 3.7
on­the­exercise­of­voting­rights,­and­the­only­quo­­ Tax consultancy services 1.5 1.3
rum­requirements­are­those­stipulated­in­§16,­­ Total 24.9 26.9
in­conformity­with­the­Swiss­Code­of­Obligations.­
• Under­§10.2­of­the­Articles­of­Incorporation,­share­­ The­statutory­auditors­are­elected­each­year­by­
holders­representing­shares­with­a­nominal­value­ the­Annual­General­Meeting.
of­at­least­1­million­Swiss­francs­can­request­the­
placement­of­items­on­the­agenda­of­an­Annual­ Ernst­&­Young­Ltd­received­the­following­remuner­
General­Meeting.­This­must­be­done­no­later­than­ ation­for­their­services­as­the­auditors­of­Chugai:
60­days­before­the­date­of­the­meeting.
2010 2009
6 Change of control and defensive measures (millions of CHF)
• The­Articles­of­Incorporation­contain­no­provisions­ Chugai audits 2.2 2.2
on­the­mandatory­bid­rule.­Swiss­law­applies. Other consulting services
• There­are­no­change­of­control­clauses.­Those­ provided to Chugai 0.1 2.2 *
components­of­remuneration­based­on­Roche­NES­ Total 2.3 4.4
would­be­terminated­in­the­event­of­an­acquisi­­
* In 2009: Genentech and Chugai.
tion,­and­vesting­period­restrictions­on­pre­exist­
ing­awards­would­be­removed,­so­that­all­such­
options­could­be­exercised­immediately. 8 Information policy
• As­provided­by­§33­of­the­Articles­of­Incorpora­
7 Relationship to statutory auditors tion­13,­corporate­notices­are­published­in­the­
At­the­Annual­General­Meeting­of­Roche­Holding­ Swiss Official Gazette of Commerce­and­in­other­
Ltd­on­2­March­2010,­the­shareholders­voted­to­ daily­newspapers­designated­by­the­Board­of­
appoint­KPMG­AG­(KPMG)­as­statutory­auditors­
(information­on­how­long­the­auditors­and­auditor­ 11 http://www.roche.com/about_roche/corporate_governance/
in­charge­have­been­serving­in­these­capacities­­ article_of_incorporation.htm
is­provided­on­page­85).­The­statutory­auditors­ 12 http://www.roche.com/about_roche/corporate_governance/
article_of_incorporation.htm
parti­cipate­in­Audit­Committee­meetings.­They­
13 http://www.roche.com/about_roche/corporate_governance/
prepare­written­and­oral­reports­on­the­results­of­ article_of_incorporation.htm
08_Roche_AR10_ENG_Corporate Governance.indd 89 28.01.2011 09:08:4090­
Roche Business Report 2010 Corporate Governance
Directors­(Basler Zeitung, Finanz und Wirtschaft, 10 Non-applicability/negative disclosure
L’Agefi, Le Temps, Neue Zürcher Zeitung).­ It­is­expressly­noted­that­any­information­not­
• Roche­reports­its­half­year­and­full­year­results­in­ ­contained­or­mentioned­herein­is­non­applicable­
business­reports­published­in­print­and­online­ or­its­omission­is­to­be­construed­as­a­negative­
formats­and­at­media­events.­In­addition,­detailed­ declaration­(as­provided­in­the­SIX­Swiss­Exchange­
first­­and­third­quarter­sales­figures­are­published­ Corpo­rate­Governance­Directive­and­the­Com­
each­year­in­April­and­October.­The­most­current­ mentary­thereto).
list­of­publication­dates­is­available­in­English­and­
German­on­the­Internet.­14­
• All­relevant­information­and­documents,­including­
all­media­releases,­investor­updates­15­and­presen­
tations­to­analyst­and­investor­conferences­are­
available­on­the­Internet.­Further­publications­can­
be­ordered­by­e­mail,­fax­or­telephone:­­
basel.webmaster­@­roche.com,­­
tel.­+41­(0)61­688­83­39,­­
fax­+41­(0)61­688­43­43.
• The­contact­address­for­Investor­Relations­is:­
F. Hoffmann­La­Roche­Ltd,­Investor­Relations,­
Group­Finance,­4070­Basel,­Switzerland;­­
tel.­+41­(0)61­688­88­80,­­
fax­+41­(0)61­691­00­14.­­
Additional­information,­including­details­on­
specific­contact­persons,­is­available­on­the­
Internet.­16
9 Chief Compliance Officer
The­Chief­Compliance­Officer­with­his­compliance­
officers­network­is­committed­to­ensuring­that­the­
Roche­Group­Code­of­Conduct­17­is­consistently­
complied­with­throughout­the­Roche­Group.­He­
also­serves­as­a­contact­person­for­shareholders,­
employees,­customers,­suppliers­and­the­general­
public­on­issues­relating­to­the­implementation­­
of­and­compliance­with­this­Code.­Employees­and­
other­parties­who­become­aware­of­violations­of­
the­Roche­Group­Code­of­Conduct­can­bring­them­
to­the­attention­of­their­managers­or­supervisors­
or­report­them­to­the­Chief­Compliance­Officer­
(Urs­Jaisli,­direct­phone­number:­­
+41­(0)61­688­40­18,­
e­mail:­urs.jaisli­@­roche.com).­­
Such­disclosures­will­be­treated­confidentially.­In­
addition,­as­of­the­end­of­2009,­employees­may­
anonymously­report­irregularities­or­complaints­­
in­their­corresponding­mother­language­via­a­
‘speak­up­hotline’.­The­Chief­Compliance­Officer­ 14 http://www.roche.com/media.htm
reports­regularly­to­the­Corporate­Governance­ 15 http://www.roche.com/investors.htm
16 http://www.roche.com/investors/contacts.htm
and­Sustainability­Committee.
17 http://www.roche.com/about_roche/corporate_governance/
code_of_conduct.htm
08_Roche_AR10_ENG_Corporate Governance.indd 90 28.01.2011 09:08:4091­
Remuneration Report Roche Business Report 2010
Remuneration Report
Summary • A­balanced­mix­of­long-­and­short-term­remunera-
Roche’s­success­depends­on­the­abilities­and­dedica- tion­components
tion­of­its­people.­Recognition­of­this­forms­the­basis­ • Market­competitiveness.
of­our­remuneration­policy­and­system.­
Base­pay,­bonuses,­blocked­non-voting­equity­securities­
One­of­the­primary­aims­of­our­remuneration­policy­is­ (NES),­awards­of­Stock-settled­Stock­Appreciation­
to­encourage­a­long-term­focus­and­align­manage- Rights­(S-SARs)­and­a­Performance­Share­Plan­(PSP)­
ment’s­interests­with­the­interests­of­Roche’s­share- support­these­principles.­These­remuneration­com-­
holders­and­holders­of­Roche’s­non-voting­equity­ ponents­are­linked­to­our­company’s­financial­perfor-­
securities­(NES). mance­and­commercial­success­and­thus­align­the­­
interests­of­Roche­employees­with­those­of­the­share-
• This­remuneration­report­will­be­submitted­sepa- holders.­
rately­for­approval­at­the­2011­Annual­General­
Meeting. The­amount­of­the­separate­components­of­remunera-
• The­remuneration­of­Corporate­Executive­Committee­ tion­for­each­individual­member­of­the­Corporate­­
members­and­other­senior­Roche­executives­is­ Executive­Committee­is­shown­in­the­individual­descrip-­
comprised­of: tion­of­the­remuneration­of­the­Corporate­Executive­
­ —­Base­salary­(fixed) Committee­in­this­report.
­ —­Bonus­(variable)
­ —­S­tock-settled­Stock­Appreciation­Rights­ Base pay
(S-SARs)­1­(variable) Base­pay­(cash­payment)­levels­are­determined­
­ —­Performance­Share­Plan­(PSP)­awards­(variable) according­to­market­data­of­the­world’s­biggest­phar-
• Under­the­PSP­2008–2010­no­NES­will­be­awarded. maceuticals­companies­3­for­specific­positions­and­
• The­S-SARs­granted­in­2006,­2007,­2008,­2009­ individual­employees’­abilities,­experience­and­perfor-­
and­2010­have­strike­prices­above­the­NES­price­­ mance­over­time.­Pay­increases­are­linked­to­individual­
as­of­31­December­2010­and­have­no­value­for­­ performance­and­also­take­into­account­prevailing­
the­recipients.­This­can­change­if­Roche’s­future­­ market­conditions­3­and­the­company’s­overall­economic­
NES­price­improves. situation.­Base­pay­and­pay­increases­are­conclusively­
• There­has­been­no­change­in­the­base­remunera- monitored­and­determined­by­the­Remuneration­­
tion­of­the­Board­of­Directors­since­2001. Committee.
Please­see­the­rest­of­this­report­for­full­details­2. Bonuses
Bonuses­(cash­payment)­are­awarded­in­recognition­­
Remuneration policy of­individual­contributions­to­value­creation­which­­
Roche­fundamentally­renewed­its­remuneration­policy­ go­beyond­normal­job­expectations,­and­they­are­
in­2004­and­reviewed­it­in­2010,­reconfirming­the­­ meant­to­be­an­incentive­to­create­or­strengthen­new­
key­principles.­It­is­part­of­a­framework­of­employee­ business­opportunities­and­strive­for­outstanding­
policies­aimed­at­motivating­and­retaining­current­ results.­Bonus­amounts­are­linked­to­Group­or­divi-
employees,­attracting­talented­new­ones­and­helping­ sional­business­performance­considering­profit,­­
all­Roche­employees­to­perform­at­consistently­­
high­levels.­Our­remuneration­policy­is­designed­to­
1 See ‘Stock options/Stock-settled Stock Appreciation Rights
foster­value­creation­and­reinforce­a­culture­of­­
(S-SARs)’, page 95, 98 and 99.
performance­and­innovation,­and­it­applies­to­non- 2 See also in the Finance Report, Note 33 to the Roche Group
managerial­employees­as­well­as­to­managers.­­ Consolidated Financial Statements (‘Related parties’, page 129)
and Notes 6 and 7 to the Financial Statements of Roche
The­key­principles­underpinning­this­policy­are:
Holding Ltd (‘Board and Executive remuneration’ and ‘Board
• Focus­on­value­creation and Executive shareholdings’, page 155 and 157).
• Pay­for­performance 3 Peer set for 2010: Abbott Laboratories, Amgen, Astellas,
• Enabling­employees­to­share­in­the­company’s­ AstraZeneca, Bayer, Becton Dickinson, Biogen Idec,
Bristol-Myers Squibb, Eli Lilly, Gilead, GlaxoSmithKline,
success
Johnson & Johnson, Merck & Co., Novartis, Pfizer,
• Fairness­and­transparency­in­remuneration­decisions Sanofi-Aventis, Takeda.
09_Roche_AR10_ENG_Remuneration Report.indd 91 28.01.2011 09:10:0992­
Roche Business Report 2010 Remuneration Report
Variable remuneration elements (bonuses, S-SARs and PSP)
in relation to fixed base pay of the Members of the Corporate Executive Committee
Bonus S-SARs PSP
Individual target value max. 100% 100% 33.33%
(in % relation to value (based on annual base pay
of base pay) measured at 1 January
of first year of cycle)
Minimum 0% 0% 0%
Maximum 200% 150% 66.66%
(in % relation to value (Cash payment) (Value development (Value development
of base pay) determined by determined by
performance of NES performance of NES
after grant) after grant)
Performance criteria Group objectives (Group Individual contributions Group performance of
and divisional business upon the Remuneration TSR in relation to
performance) and Committee’s decision at TSR performance
individual objectives its own discretion of peer set
considering profit, (see page 95 to 96)
sales growth, OPAC
(Operating Profit After
Capital Charge)
Split in %
a) Group objectives 70% n.a. –
b) Individual objectives 30% n.a. 100%
sales­growth,­OPAC­(Operating­Profit­After­Capital­ Performance Share Plan
Charge)­performance­and­to­the­achievement­of­­ The­members­of­the­Corporate­Executive­Committee­
individual­and­functional,­measurable­and­qualitative­ and­other­members­of­senior­management­(cur-­
performance­objectives.­For­reasons­of­competi-­ rently­some­120­individuals­worldwide)­participate­­
tiveness­Roche­does­not­disclose­details­of­individual­ in­the­Performance­Share­Plan­(PSP).­The­PSP­­
objectives­of­the­members­of­the­Corporate­Exec-­ was­established­in­2002­for­periods­of­three­years­­
utive­Committee.­The­Remuneration­Committee­of­the­ each­and­is­based­on­a­three-year­comparison­­
Board­of­Directors­has­defined­the­Corporate­Ex-­ of­the­total­shareholder­return­(TSR)­with­17­com-
ecutive­Committee­members­bonuses­in­December­ peting­companies­3.­In­2010­there­were­three­over-
2010­based­on­results­achieved­for­2010. lapping­performance­cycles,­(PSP­2008–2010,­­
PSP­2009–2011­and­PSP­2010–2012)­of­which­PSP­
Stock-settled Stock Appreciation Rights (S-SARs) 2008–2010­closed­on­31 December­2010.
Stock-settled­Stock­Appreciation­Rights­were­­
introduced­on­1­January­2005,­thus­establishing­a­ Details­for­the­PSP­2008–2010­calculation­and­addi-­
uniform­system­of­remuneration­throughout­Roche.­ tional­information­are­set­forth­in­‘Remuneration­­
S-SARs­entitle­holders­to­benefit­financially­from­­ of­members­of­the­Corporate­Executive­Committee,­
any­increase­in­the­value­of­Roche’s­non-voting­equity­ D. Performance­Share­Plan­(PSP)’,­page­95.
securities­between­the­grant­date­and­the­exer-­
cise­date.­Awards­are­allocated­individually­upon­the­ Remuneration of the Board of Directors and the
Remuneration­Committee’s­decision­at­its­own­dis- Corporate Executive Committee
cretion.­Detailed­information­is­available­on­page­95­ Each­year­the­Remuneration­Committee,­which­is­
and­page­98­to­99. entirely­comprised­of­independent­external­members­
of­the­Board­of­Directors,­sets­remuneration­for­the­
09_Roche_AR10_ENG_Remuneration Report.indd 92 28.01.2011 09:10:0993­
Remuneration Report Roche Business Report 2010
members­of­the­Board­of­Directors­and­the­Corporate­ neration­of­the­Chairman­of­the­Board­of­Directors,­­
Executive­Committee­(cash­payments,­bonuses,­ the­members­of­the­Corporate­Executive­Committee­­
options,­Stock-settled­Stock­Appreciation­Rights­and­ taking­into­consideration­personnel­changes.­
policy­decisions­about­pension­benefits).­The­terms­­
of­the­Performance­Share­Plan­are­determined­annually­ The­following­pages­provide­detailed­information­on­
by­the­Board­of­Directors,­acting­upon­recommen-­ the­remuneration­earned­by­each­member­of­the­
dations­from­the­Remuneration­Committee.­The­Remu- Board­of­Directors­and­by­each­member­of­the­Cor-
neration­Committee­continuously­tracks­salary­trends­ porate­Executive­Committee­for­2010.
in­the­market­of­the­world’s­biggest­pharmaceuticals­
companies­3­and­reports­to­the­Board­of­Directors.­In- 1 Remuneration
formation­on­this­committee’s­remit,­powers­and­its­ 1.1 Remuneration of members of the Board of
procedures­for­making­remuneration­decisions­can­be­ Directors |­In­2010­the­members­of­the­Board­of­
found­in­the­Bylaws­of­the­Roche­Board­of­Directors­4. Directors­5­received­the­remuneration­in­cash­shown­
Following­the­revision­of­the­remuneration­policy­
including­market­comparisons­with­the­world’s­major­ 4 http://www.roche.com/about_roche/corporate_governance/
article_of_incorporation.htm
pharmaceutical­companies­3,­the­Remuneration­
5 For a list of members, their positions and their committee
Committee­has­determined­the­bonuses­and­remu- memberships and chairmanship, see page 83.
Remuneration of members of the Board of Directors
Additional compensation 2010
Remuneration 2010 for committee members/chairs 6
(in CHF) (in CHF) Additional special compensation 2010
F. B. Humer (see page 97 7) 50,000 (Remuneration as Chairman
of the Board of Directors
see page 97 7)
B. Gehrig 400,000 8 –
A. Hoffmann 400,000 8 –
P. Baschera 300,000 30,000
J. I. Bell 300,000 30,000
W. M. Burns 250,000 9 30,000
L. J. R. de Vink 300,000 30,000
W. Frey 300,000 60,000
D. A. Julius 300,000 60,000
A. D. Levinson 250,000 9 30,000
A. Oeri 300,000 60,000
W. Ruttenstorfer 300,000 30,000
B. Weder di Mauro 300,000 60,000
Remuneration of former members of the Board of Directors
Additional compensation 2010
Remuneration 2010 for committee members/chairs 6
(in CHF) (in CHF) Additional special compensation 2010
P. Brabeck-Letmathe 50,000 10 –
H. Teltschik 50,000 10 – See page 94
6 W ith the exception of members of the Presidium and the Vice-Chairmen, Board members receive CHF 30,000/year for
each committee they serve on and CHF 60,000/year for each committee they chair.
7 See ‘G. Highest total remuneration to a member of the Board of Directors’, pages 97 and 98.
8 Remuneration for serving as Vice-Chairman of the Board.
9 Prorated remuneration for the period from March to December 2010.
10 Prorated remuneration for the period from January to March 2010.
09_Roche_AR10_ENG_Remuneration Report.indd 93 28.01.2011 09:10:0994­
Roche Business Report 2010 Remuneration Report
in­the­table­‘Remuneration­of­members­of­the­Board­ for­his­consulting­work­and­for­his­Board­member-
of­Directors’­on­page­93­for­their­Board­activities.­ ship­of­Genentech­amounting­to­342,367­US­dollars­
Remuneration­of­all­members­of­the­Board­of­Direc- (356,062­Swiss­francs).
tors­will­again­remain­unchanged­for­2011.
For­2010­the­members­of­the­Board­of­Directors­
Beside­the­cash­payments,­the­non-executive­mem- received­remuneration­totalling­14,662,589­Swiss­
bers­of­the­Board­of­Directors­were­not­awarded­any­ francs­12­(2009:­18,608,650­Swiss­francs).
shares,­non-voting­equity­securities,­Stock-settled­
Stock­Appreciation­Rights­(S-SARs)­11,­stock­options­ No­additional­remuneration­was­paid­to­members­of­
or­Restricted­Stock­Units­(RSUs)­in­2010. the­Board­of­Directors.
Horst­Teltschik­received­honoraria­amounting­to­ 1.2 Remuneration of members of the Corporate
19,635­euros­(27,096­Swiss­francs)­for­serving­on­ Executive Committee |­The­general­provisions­
the­boards­of­several­Roche­subsidiaries­in­Germany.­ assigning­authority­for­decisions­on­Corporate­Exec-
utive­Committee­remuneration­to­the­Remuneration­
William­M.­Burns­received­honoraria­amounting­to­a­ Committee­and­to­the­Board­of­Directors­are­outlined­
total­of­25,000­US­dollars­(26,000­Swiss­francs)­­ on­pages­91­to­93­of­this­remuneration­report.­
for­serving­as­a­member­of­the­Board­of­Directors­of­
Chugai­Pharamaceutical­Co.,­Ltd.­
11 See ‘Stock options/Stock-settled Stock Appreciation Rights
(S-SARs)’, page 98.
Since­his­election­to­the­Board­of­Directors­of­Roche­
12 See ‘Remuneration of members of the Board of Directors’,
Holding­Ltd­Arthur­D.­Levinson­received­payments­ page 93.
Remuneration of members of the Corporate Executive Committee
A. Base pay | in CHF
Annual salary Annual salary Annual salary
2010 2009 2008
S. Schwan 3,750,000 2,875,002 2,283,340
S. Ayyoubi 1,100,000 725,004 481,670
E. Hunziker 2,000,000 2,000,000 2,000,000
G. A. Keller 1,500,000 1,500,000 1,350,000
D. O’Day 1,000,000 * *
P. Soriot 2,000,000 1,246,878 *
Total 11,350,000
* Not a member of the Corporate Executive Committee.
Due­to­obligations­from­his­former­Roche­assignment­ B. Bonus
in­the­US,­Daniel­O’Day­received­the­following­pay- All­members­of­the­Corporate­Executive­Committee­
ments­in­2010:­Mortgage­subsidy­15,000­US­dollars­ will­receive­the­bonus­2010­as­a­cash­payment­due­
(15,600­Swiss­francs),­for­financial/tax­service­­ for­payment­at­the­end­of­April­2011.
9,796­US­dollars­(10,188­Swiss­francs).­Daniel­O’Day­
received­in­addition­82,415­Swiss­francs­for­the­ On­31­December­2010­the­Stock-settled­Stock­
schooling­of­his­children. Appreciation­Rights­granted­in­2006,­2007,­2008­­
For­2010­the­members­of­the­Corporate­Executive­
Committee­received­remuneration­totalling­
13 See ‘Remuneration of members of the Corporate Executive
38,759,516­Swiss­francs­13­(2009:­54,858,227­Swiss­
Committee’, (A.–F. and H.) excluding AHV/IV/ALV, page 94
francs). to 98.
09_Roche_AR10_ENG_Remuneration Report.indd 94 28.01.2011 09:10:0995­
Remuneration Report Roche Business Report 2010
Bonus
Bonus Bonus Bonus
for 2010 for 2009 for 2008
Total Total Total
(in CHF) (in CHF) (in CHF)
S. Schwan 3,000,000 4,675,178 3,000,000
S. Ayyoubi 1,000,000 1,637,909 500,000
E. Hunziker 2,000,000 3,606,905 2,200,000
G.A. Keller 1,000,000 1,813,506 1,000,000
D. O’Day 1,300,000 * *
P. Soriot 3,312,500 ** 2,000,000 *
Total 11,612,500
* Not a member of the Corporate Executive Committee.
** Including an additional compensation for the successful integration of Genentech amounting to 1,312,500 Swiss francs, paid in 2010.
C. Stock-settled Stock Appreciation Rights (S-SARs)
S-SARs 14 S-SARs 14 S-SARs 14
2010 2009 2008
(value in CHF 15) (value in CHF 15) (value in CHF 15)
S. Schwan 3,559,911 3,559,849 2,225,542
S. Ayyoubi 1,068,022 889,993 445,146
E. Hunziker 1,779,990 1,957,935 1,958,480
G. A. Keller 1,335,010 1,334,989 1,335,313
D. O’Day 890,030 * *
P. Soriot 1,779,990 1,401,735 *
Total 10,412,953
* Not a member of the Corporate Executive Committee.
14 S ee ‘Stock options/Stock-settled Stock Appreciation Rights (S-SARs)’, page 98.
15 B lack-Scholes value as described in ‘Stock options/Stock-settled Stock Appreciation Rights (S-SARs)’, page 98 and 99.
Values for 2008 and 2009 according to Annual Report 2009, page 79.
and­2009­most­of­which­can­be­exercised,­follow-­ each­year.­In­2010­there­were­thus­three­cycles­in­
ing­the­end­of­the­vesting­period­in­February­2010,­­ progress­(PSP­2008–2010,­PSP­2009–2011­and­PSP­
had­no­value­for­the­recipients.­16­­ 2010–2012);­As­in­the­previous­year­for­the­PSP­
2007–2009,­the­PSP­2008–2010­ended­on­31 Decem-
Members­of­the­Corporate­Executive­Committee­ ber­2010­without­any­awards­of­targeted­NES.
additionally­receive­annual­expense­allowances­of­
30,000­Swiss­francs,­totalling­180,000­Swiss­francs. Under­the­provisions­of­this­plan,­a­number­of­non-
voting­equity­securities­have­been­reserved­for­­
D. Performance Share Plan (PSP) the­participants­in­each­cycle.­The­number­of­se-­
The­members­of­the­Corporate­Executive­Committee­ curities­actually­awarded­will­depend­on­whether­­
and­other­members­of­senior­management­(currently­ and­to­what­extent­an­investment­in­Roche­securities­
some­120­individuals­worldwide)­participate­in­the­ (shares­and­NES)­outperforms­the­average­return­­
Performance­Share­Plan­(PSP).
In­2006­the­PSP­moved­to­overlapping­three-year­
16 See strike prices in table ‘Stock options and S-SARs’,
performance­cycles,­with­a­new­cycle­beginning­ page 101.
09_Roche_AR10_ENG_Remuneration Report.indd 95 28.01.2011 09:10:0996­
Roche Business Report 2010 Remuneration Report
on­an­investment­in­securities­issued­by­a­peer­set­­ At­the­end­of­the­PSP­2008–2010­cycle­(based­on­a­
of­comparator­companies­17.­Comparisons­are­based­ three-month­moving­average­at­constant­exchange­
on­the­securities’­market­prices­and­dividend­yields,­ rates)­with­distributed­dividends­totalling­13.454­bil-
i.e.­on­Total­Shareholder­Return­(TSR).­To­reduce­the­ lion­Swiss­francs­(2008:­3.967­billion­Swiss­francs;­
effect­of­short-term­market­fluctuations,­security­ 2009:­4.312­billion­Swiss­francs;­2010:­5.175­billion­
prices­are­averaged­over­the­three­months­(October­ Swiss­francs),­the­TSR­of­the­Roche­securities­­
to­December)­prior­to­the­start­of­a­performance­ (NES­and­shares)­ranked­#15,­compared­with­its­
cycle­and­over­the­three­months­(October­to­Decem- peer­set­of­companies­operating­in­the­same­in-­
ber)­at­the­end­of­the­cycle.­If­Roche­securities­­ dustry.­Therefore,­according­to­the­terms­of­the­plan,­
perform­as­well­as­or­better­than­those­of­75%­of­the­ the­participants­received­none­of­the­originally­­
peer­set­and,­in­addition,­Roche’s­TSR­increases­­ targeted­NES­(see­table­below­for­details).
at­least­10%­during­a­cycle,­the­Board­of­Directors­
can­elect­to­increase­the­maximum­NES­award­­ E. Indirect benefits
by­as­much­as­two-fold.­In­the­event­that­an­invest- Employer­contributions­made­in­2010­to­social­secu-
ment­in­Roche­securities­underperforms­the­­ rity­schemes,­pension­plans­and­a­Group-wide­
average­return­delivered­by­the­peer­companies,­ employee­stock­purchase­plan­(Roche­Connect)­in­
fewer­or­no­NES­will­be­awarded.­ respect­of­members­of­the­Corporate­Executive­­
Committee­are­shown­in­the­table­‘Indirect­benefits­
In­2010­NES­were­reserved­under­the­plan­for­mem- in­2010’­on­page­97.­
bers­of­the­Corporate­Executive­Committee­as­­
shown­in­the­table­below.­The­Board­of­Directors­will­ Roche­Connect­is­a­voluntary­stock­purchase­plan­
decide­on­the­actual­level­of­NES­or­cash­equivalent­ offering­employees­the­opportunity­to­buy­Roche­
awards­for­the­cycles­2009–2011­and­2010–2012­ non-voting­equity­securities­(NES)­up­to­an­amount­
after­the­close­of­the­2011­and­2012­financial­years,­ equal­to­10%­of­their­annual­salary­at­a­20%­dis-
respectively.­The­aim­of­the­PSP­is­to­provide­­
an­incentive­to­participants­to­achieve­steady­value­
growth.­ 17 See footnote 3, page 91.
Performance Share Plan (PSP)
2010 18 2009
Total estimated
value of
PSP awards No NES No NES
No awards of (2008–2010, awarded awarded
Target number Target number targeted number 2009–2011 in 2010 for in 2009 for
of NES for PSP of NES for PSP of NES for PSP and 2010–2012) PSP 2008–2010 PSP 2007–2009
2010–2012 2009–2011 2008–2010 (value in CHF) (value in CHF) (value in CHF)
S. Schwan 5,991 5,011 – 502,425 – –
S. Ayyoubi 1,597 1,002 – 118,688 – –
E. Hunziker 3,994 4,009 – 365,470 – –
G. A. Keller 2,995 3,006 – 274,046 – –
D. O’Day 1,997 904 – 132,479 – *
P. Soriot 3,994 2,104 – 278,475 – –
Total 20,568 16,036 – 1,671,583 – –
* Not a member of the Corporate Executive Committee.
18 Total estimated value for 2010: PSP 2008–2010: none of the originally targeted NES awarded. PSP 2009–2011 and 2010–2012: Estimated
value calculated using the year-end price as of 31 December 2010, CHF 137.00 per non-voting equity security (NES), based on the
number of NES originally targeted subject to changes in the number and value of NES awardable under the plan on 31 December 2011
and 31 December 2012, respectively, and spread over the relevant period of time, i.e. ¹⁄³ for the year 2010. The Board of Directors
will vote on the actual allocation of NES originally targeted on 31 December 2011 and 31 December 2012, respectively, according to
the TSR achieved.
09_Roche_AR10_ENG_Remuneration Report.indd 96 28.01.2011 09:10:0997­
Remuneration Report Roche Business Report 2010
Indirect benefits in 2010
Payments for
Pension funds/MGB 19 AHV/IV/ALV 20 Roche Connect tax consulting services
(in CHF) (in CHF) (in CHF) (in CHF)
S. Schwan 456,122 351,284 89,588 8,827
S. Ayyoubi 986,100 137,919 3,000 6,118
E. Hunziker 622,401 203,889 50,004 6,225
G. A. Keller 529,325 177,250 37,500 –
D. O’Day 304,350 56,524 7,294 5,918
P. Soriot 311,505 273,067 – –
Total 3,209,803 1,199,933 187,386 27,088
19 MGB: Stiftung der F. Hoffmann-La Roche AG für Mitarbeiter-Gewinnbeteiligung (employee profit-sharing foundation
supplementing occupational pension benefits).
20 AHV/IV/ALV: Swiss social security programmes providing retirement, disability and unemployment benefits.
count.­NES­purchased­under­this­plan­are­subject­to­ G. Highest total remuneration to a member of
a­holding­period,­which­is­four­years­in­Switzerland. the Board of Directors
Franz­B.­Humer­as­the­chairman­was­the­member­of­
F. Other remuneration, emoluments and loans the­Board­with­the­highest­total­remuneration­for­
In­2010­pensions­and­two­payments­for­tax­consult- 2010­(see­‘Remuneration­of­members­of­the­Board­of­
ing­services­totalling­2,118,892­Swiss­francs­were­ Directors’,­page­93).­The­Chairman’s­remuneration­
paid­to­four­former­Corporate­Executive­Committee­ consists­of­base­salary­and­bonus­awards.­As­Chair-
members.­ man­of­the­Board­after­the­handover­of­his­execu-­
tive­function­as­CEO­at­the­Annual­General­Meeting­
Members­of­the­Corporate­Executive­Committee­have­ on­4­March­2008,­he­did­not­receive­any­additional­
a­maximum­notice­period­of­twelve­months.­In­con- S-SARs­or­NES­from­new­PSP­cycles­and­was­­
nection­with­the­new­company­and­personnel­struc- no­longer­enrolled­in­any­Roche­stock­option­plan­­
ture,­members­of­the­Corporate­Executive­Committee­ or­S-SARs.
can­receive­compensation­amounting­to­one­annual­
base­pay­in­case­of­termination­of­the­contract­by­the­ According­to­the­announcement­in­the­Annual­
company­(termination­through­no­fault­and­not­based­ Report­2009,­the­Board­of­Directors­reduced­the­
on­lack­of­performance)­until­the­age­of­sixty. Chairman’s­base­salary­in­2010­to­4­million­Swiss­
Highest total remuneration to a member of the Board of Directors
2010 2009 21
(in CHF) (in CHF)
Salary 4,507,500 6,030,000
Bonus 2,200,000 4,992,018
Total 6,707,500 11,022,018
Pension funds/MGB 22 2,995,801 2,995,109
Roche Connect 75,000 75,000
Total (value) 10,033,431 23 14,353,552
21 F or detailed calculation of the remuneration as Chairman and CEO for 2009 see Annual Report 2009, page 82.
22 M GB: Stiftung der F. Hoffmann-La Roche AG für Mitarbeiter-Gewinnbeteiligung (employee profit-sharing foundation
supplementing occupational pension benefits).
23 I ncludes additional compensation for Committee members (CHF 50,000), payments for tax consulting services (CHF 49,130) and
Chugai advisory mandate USD 150,000 (CHF 156,000), not including employer contribution to AHV/IV/ALV (CHF 565,871).
09_Roche_AR10_ENG_Remuneration Report.indd 97 28.01.2011 09:10:1098­
Roche Business Report 2010 Remuneration Report
Highest total remuneration to a member of the Corporate Executive Committee
2010 2009 24
(in CHF) (in CHF)
Salary 3,750,000 2,875,002
Bonus 3,000,000 4,675,178
Total 6,750,000 7,550,180
S-SARs
(Black-Scholes value 25 at grant minus 11%) 3,559,911 3,559,849
Pension funds/MGB 26 456,122 456,941
Roche Connect 89,588 69,790
Estimated value of targeted (not awarded) NES according
to Performance Share Plan 27
(* 2009–2011, 2010–2012, no awards/value of NES of 2008–2010)
Total 502,425 * 408,793 24
Total (value) 11,396,873 28 12,101,478
24 For detailed information see Annual Report 2009, page 83.
25 Black-Scholes value as described in ‘Stock options/Stock-settled Stock Appreciation Rights (S-SARs)’, page 98 to 99.
26 MGB: Stiftung der F. Hoffmann-La Roche AG für Mitarbeiter-Gewinnbeteiligung (employee profit-sharing foundation
supplementing occupational pension benefits).
27 Basic rules and detailed calculation see ‘Remuneration of members of the Corporate Executive Committee,
D. Performance Share Plan’, page 96, footnote 18, respectively.
28 Includes an annual expense allowance (CHF 30,000), payments for tax consulting services (CHF 8,827), excluding employer
contribution to AHV/IV/ALV payments.
francs­(as­of­1 April­2010)­and­determined­at­the­­ 1.3 Security holdings |­Directors­André­Hoffmann­
end­of­2009­that­his­total­remuneration,­including­ and­Andreas­Oeri­and­members­of­the­founders’­
bonuses,­contributions­to­pension­funds­and­ad-­ families­who­are­closely­associated­with­them­belong­
ditional­compensation­(expense­allowance)­will,­ to­a­shareholder­group­with­pooled­voting­rights.­­
depending­on­the­achievement­of­objectives,­not­ At­the­end­of­2010­this­group­held­80,020,000­shares­
exceed­the­maximum­amount­of­11­million­Swiss­ (50.01%­of­issued­shares).­Detailed­information­
francs.­The­shareholders­agreed­to­this­maximum­ about­this­group­can­be­found­in­the­Finance­Report,­
amount­with­the­approval­of­the­Remuneration­ Note­33­to­the­Roche­Group­Consolidated­Financial­
Report­2009­at­the­Annual­General­Meeting­on­ Statements­(‘Related­parties’,­page­129)­and­in­­
2 March­2010.­The­effective­total­remuneration­­ the­Note­4­to­the­Financial­Statements­of­Roche­
was­8.8%­below­of­the­determined­maximum­and­ Holding­Ltd­(‘Significant­shareholders’,­page­154).­In­
30.1%­lower­than­2009. addition,­as­of­31­December­2010­the­members­­
of­the­Board­of­Directors­and­persons­closely­asso-
H. Highest total remuneration to a member of the ciated­with­them­and­the­members­of­the­Executive­
Corporate Executive Committee Committee­and­persons­closely­associated­with­­
Severin­Schwan­as­CEO­was­the­member­of­the­Cor- them­held­shares­and­NES­as­shown­in­the­table­on­
porate­Executive­Committee­with­the­highest­total­ page­100.
remuneration­for­2010­(see­‘Remuneration­of­mem-
bers­of­the­Corporate­Executive­Committee’,­A.–F.,­ 1.4 Stock options/Stock-settled Stock Apprecia-
page­94­to­page­97).­ tion Rights (S-SARs) |­At­31­December­2010­Franz­
B.­Humer­and­William­M.­Burns­(being­the­only­­
No­additional­remuneration­was­paid­to­current­or­ members­of­the­Board­of­Directors­holding­options­
former­members­of­the­Corporate­Executive­Commit- and­as­of­1­January­2005­S-SARs­due­to­their­­
tee. former­positions)­and­the­members­of­the­Corporate­
Executive­Committee­held­options­and­Stock-­
settled­Stock­Appreciation­Rights­(S-SARs;­first­
09_Roche_AR10_ENG_Remuneration Report.indd 98 28.01.2011 09:10:1099­
Remuneration Report Roche Business Report 2010
introduced­on­1­January­2005)­as­shown­in­the­table­ The­strike­prices,­expiry­dates­and­grant­values­­
‘Stock­options­and­S-SARs’­on­page­101. for­options­and­S-SARs­are­shown­in­the­table­on­
page­101.­The­numbers­of­options­and­S-SARs­­
All­of­the­options­shown­in­the­table­were­issued­by­ as­calculated­at­the­time­of­issue­have­been­entered­
Roche­as­employee­stock­options.­Each­option­­ as­values­in­the­table­‘Remuneration­of­members­­
entitles­the­holder­to­purchase­one­Roche­non-voting­ of­the­Corporate­Executive­Committee,­C.­Stock-set-
equity­security­(NES)­at­a­specified­strike­price­­ tled­Stock­Appreciation­Rights­(S-SARs)’­on­page­95.
at­grant.
Under­the­terms­of­this­multi-year­option­plan,­­
the­strike­price­for­options­shown­was­the­closing­
price­for­Roche­NES­on­the­last­day­of­trading­­
prior­to­the­Roche­Annual­Media­Conference.­All­of­
the­options­shown­are­non-tradable.­One-third­­
of­the­options­are­subject­to­a­vesting­period­of­one­
year,­one-third­have­a­vesting­period­of­two­years,­­
and­one-third­a­vesting­period­of­three­years.­
Unvested­options­lapse­without­compensation­­
if­employment­is­terminated­voluntarily­(for­reasons­
other­than­retirement),­while­vested­options­must­­
be­exercised­within­a­limited­period­of­time.­If­employ-­
ment­is­involuntarily­(layoff­or­redundancy,­job­­
elimination­or­reduction­in­force)­terminated,­granted­
but­unvested­options­vest­immediately­and­must­­
be­exercised­within­six­months­or­they­are­forfeited.­
The­fair­value­of­the­options­is­calculated­at­the­­
date­of­issue­using­the­Black-Scholes­formula­and­as­
if­the­options­were­tradable,­with­an­11%­deduction­
for­the­average­two-year­vesting­period.
The­S-SARs­shown­in­the­table­on­page­101­were­
introduced­by­Roche­on­1­January­2005­in­place­of­
stock­options.­S-SARs­entitle­holders­to­benefit­
financially­from­any­increase­in­the­value­of­Roche’s­
NES­between­the­grant­date­and­the­exercise­date.­
The­strike­price­for­S-SARs­under­the­terms­of­this­
multi-year­plan­was­the­closing­price­for­Roche­NES­
on­the­first­day­of­trading­after­the­Roche­Annual­
Media­Conference.­All­S-SARs­vest­within­three­years­
of­the­grant­date:­i.e.­one-third­vest­at­the­end­of­­
one­year,­one-third­at­the­end­of­two­years,­and­one-
third­at­the­end­of­three­years.­Vested­S-SARs­­
must­be­exercised­(converted­into­NES)­within­seven­
years­of­the­grant­date,­and­unexercised­S-SARs­
lapse­without­compensation.­The­fair­value­of­the­
options­is­calculated­at­the­date­of­issue­using­the­
Black-Scholes­formula­and­as­if­the­options­were­
tradable,­with­an­11%­deduction­for­the­average­two-
year­vesting­period.
09_Roche_AR10_ENG_Remuneration Report.indd 99 28.01.2011 09:10:10100­
Roche Business Report 2010 Remuneration Report
Security holdings (at 31 December 2010)
Close
relatives’
Shares NES security holdings Others
(number) (number) (number/type) (number)
Board of Directors
F. B. Humer 3 197,215 – S-SARs see 1.4
2500 ROGTPK Tracker-plus Cert.
Zürcher Kantonalbank on
Roche Genussschein (ROG) as underlying,
Valor 10 716 273, ISIN: CH0107162734
B. Gehrig 50 150 – –
A. Hoffmann –* 200 – 250,000 UBS Long/Short Certificates
linked to Roche Bearer Shares/
Roche Non-Voting Equity securities
(Valor: 10 690 162, ISIN: CH0106901629)
P. Baschera 1 – – –
J. I. Bell 300 1,647 – –
W. M. Burns 3 79,254 – Stock options, S-SARs see 1.4
L. J. R. de Vink – – – 31,600 American Depository Receipts (ADR),
RHHBY, US ISIN: US7711951043
W. Frey 72,500 – – –
D. A. Julius 350 – 1,550 NES –
A. D. Levinson – – – –
A. Oeri –* 307,793 250,000 UBS Long/Short Certificate
linked to Roche Bearer Shares/
Roche Non-Voting Equity securities
(Valor: 10 690 162, ISIN: CH0106901629)
W. Ruttenstorfer 1,000 – – –
B. Weder di Mauro 200 – – –
Total 74,407 586,259 1,550 NES
Corporate Executive Committee
S. Schwan 3 35,978 570 NES Stock options, S-SARs see 1.4
S. Ayyoubi 3 12,213 – Stock options, S-SARs see 1.4
E. Hunziker 3 62,458 – Stock options, S-SARs see 1.4
G. A. Keller 1,253 31,278 70 NES S-SARs see 1.4
D. O’Day 3 220 – S-SARs see 1.4
P. Soriot 2 6,314 – S-SARs see 1.4
Total 1,267 148,461 640 NES
* Shares held by the shareholders group with pooled voting rights not listed.
09_Roche_AR10_ENG_Remuneration Report.indd 100 28.01.2011 09:10:10101­
Remuneration Report Roche Business Report 2010
Stock options and S-SARs
Number of stock options and S-SARs held by current and former members
of the Corporate Executive Committee on 31 December 2010 (S-SARs first issued in 2005)
2010 29 2009 29 2008 29 2007 29 2006 29 2005 29 2004 30 Total
Corporate Execu-
tive Committee
S. Schwan 154,443 175,362 105,576 29,190 15,696 4,983 30 1,864 487,114
S. Ayyoubi 46,335 43,842 21,117 3,243 2,517 3,957 2,360 123,371
E. Hunziker 77,223 96,450 92,907 48,651 26,160 34,074 20,915 396,380
G. A. Keller 57,918 43,842 63,345 24,327 15,696 – – 205,128
D. O’Day 38,613 21,762 20,133 10,269 5,856 – – 96,633
P. Soriot 77,223 69,051 63,345 29,190 23,544 – – 283,989
+
21,636
Total 451,755 450,309 366,423 144,870 111,105 43,014 25,139 1,592,615
Former Corporate
Executive Commit-
tee members
F. B. Humer None 31 None 31 None 31 48,651 52,317 42,589 – 143,557
W. M. Burns None 32 109,602 105,576 48,651 26,160 34,074 – 324,063
Strike price (CHF) 175.50 145.40 195.80 229.60 195.00 123.00 129.50
196.50
Market price per NES 137.00
on 31 December 2010
(CHF)
Expiry date 4.2.2017 5.2.2016 31.1.2015 8.2.2014 2.2.2013 3.2.2012 3.2.2011
2.1.2013
Grant value per 23.05 20.30 21.08 36.59 34.02 20.89 31.92
option and 37.02
(starting in 2005)
per S-SAR in CHF
(Black-Scholes value
minus 11%)
29 S-SARs.
30 Stock options.
31 A s of 2008 Franz B. Humer does not receive any additional S-SARs. Franz B. Humer received stock options and
S-SARs as a Member of the Corporate Executive Committee until 2007.
32 A s of 2010 Wiliam M. Burns does not receive any additional S-SARs. William M. Burns received stock options and
S-SARs as a Member of the Corporate Executive Committee until 2009.
09_Roche_AR10_ENG_Remuneration Report.indd 101 28.01.2011 09:10:10Corporate Responsibility |
In
2010 the Dow Jones Sustainability Indexes
named Roche ‘Supersector Leader’ in
healthcare for the second consecutive year.
Sustainability is at the core of our business
practices and this positioning reflects
our commitment to running our business
in a way that is ethical, responsible and
creates long-term value for stakeholders.
During the year we made progress on
our long-term diversity and energy goals
and introduced new programmes to
increase access to our products.
10_Roche_AR10_ENG_Corporate Responsibility Part1.indd 102 28.01.2011 11:54:14103­
Corporate Responsibility Roche Business Report 2010
Corporate responsibility in brief
We­focus­on­developing­new­medicines­and­diag­ the­sixth­annual­sustainability­workshop,­attended­­
nostics­that­address­unmet­medical­need­and­help­ by­sustainability­experts­from­around­the­Group.­
patients­lead­longer,­better­lives.­Discovering­­ Access­to­medicines­and­diagnostics­and­the­value­­
and­developing­these­products­remains­our­greatest­ of­our­products­and­services­remained­high­on­­
responsibility. the­agenda­this­year,­while­a­working­group­dis­
cussed­our­new­KPIs.
The­nature­of­our­business­means­we­always­think­
long­term.­It­takes­eight­to­twelve­years­to­bring­our­ More on the Web
medicines­to­market,­so­being­sustainable­is­critical­ • Sustainability principles:
for­our­success,­as­well­as­for­our­customers,­sup­­ www.roche.com/principles
• CSC Charter: www.roche.com/csr_committees
pliers­and­partners.­We­aim­to­balance­the­needs­of­
• KPIs: www.roche.com/sus-kpi.pdf
individuals,­society­and­the­environment­in­our­work,­
and­to­be­a­rewarding­employer­that­attracts­talented­
people.­Our­values­of­integrity,­courage­and­passion­
guide­employees­to­do­the­right­thing­in­their­work.
Our approach Roche management of sustainability
We­focus­on­the­corporate­responsibility­issues­that­
are­most­relevant­to­our­stakeholders­and­have­the­ Board of Directors
greatest­potential­to­impact­our­business.­We­monitor­
our­progress­using­key­performance­indicators­(KPIs)­
Corporate
for­each­issue.­During­2010­we­revised­our­KPIs­to­ Executive
align­them­with­our­strategic­framework,­ensure­they­ Committee
support­our­long­term­business­strategy­and­goals,­
and­further­integrate­responsible­behaviour­through­
out­the­business. Board Committee
for Corporate Governance
and Sustainability
The­updated­KPIs­measure­the­value­we­create­for­
four­main­stakeholder­groups:­employees,­patients,­
investors­and­society.­We­report­against­several­of­
Corporate Sustainability Committee (CSC)
these­KPIs,­plus­additional­performance­measures,­ Core Team and Working Team
throughout­this­Annual­Report­and­on­our­website.­
In­2010­we­were­named­‘Supersector­Leader’­in­
healthcare­for­the­second­year­running­in­the­Dow­ Key material sustainability topics
Jones­Sustainability­Indexes­(DJSI),­in­recognition­­
of­our­commitment­to­sustainable­practices.­We­use­
this­index­and­other­analyses­to­evaluate­our­perfor­
mance,­and­to­identify­areas­where­we­can­improve­
or­learn­from­others.­
Managing corporate responsibility
A network of more than 150 colleagues from
At­Roche,­corporate­responsibility­is­an­integral­part­
all relevant Corporate and Divisional Functions
of­everyone’s­work­and­is­coordinated­by­our­Cor­­
porate­Sustainability­Committee­(CSC),­as­shown­in­
the­diagram.­The­CSC­identifies­and­assesses­sig­­
nificant­social,­ethical­and­environmental­risks­and­
opportunities,­and­develops­and­revises­corporate­
positions­and­guidelines­on­related­topics.­It­met­for­
mally­four­times­in­2010­and,­in­September,­hosted­
10_Roche_AR10_ENG_Corporate Responsibility Part1.indd 103 28.01.2011 11:54:14104­
Roche Business Report 2010 Corporate Responsibility
Stakeholder engagement
We­aim­to­create­value­for­our­stakeholders­through­ believe­in­two­way­dialogue­where­both­parties­learn­
the­medical­benefits­our­products­provide,­our­­ from­each­other.­The­table­shows­examples­from­
daily­business­activities,­and­specific­activities­with­ 2010,­and­there­is­further­information­on­our­website.
each­group.­We­regularly­seek­stakeholders’­views­
when­formulating­business­strategy,­setting­priorities­ More on the Web
including­those­relating­to­Corporate­Responsibil­­ • Stakeholder engagement:
ity­(CR),­and­throughout­product­development.­We­ www.roche.com/stakeholder_engagement
Stakeholder engagement in 2010
Stakeholder group Examples of engagement Results of engagement
Patients and — Ran workshops for patient groups in several — Better understanding of patients’ needs so
patient groups countries, including France and Germany we can help them manage their disease
— Reviewed informed consent forms with — Consent forms easier for patients to read
patient advocacy group, EGAN and understand
Healthcare — Market research and needs assessment — Improved understanding of customer needs
professionals among HCPs in US and top five EU countries — Over 3,000 HCPs participated in American
(HCPs) — Virtual conference services for HCPs Society of Clinical Oncology virtual conference
Governments, — Participated in industry initiatives on topics — Development of effective public health poli-
regulators and such as biosimilars cies and regulations, and shared learnings
industry — Developed guidelines for misuse of com- — Roche and WADA signed a memorandum of
pounds with the World Anti-Doping Agency understanding
Healthcare payers — Worked with payers to develop methods to — Development of tools to assess cost-
evaluate and compare the effectiveness of effectiveness
medicines — Improved understanding among payers of
— Developed a pricing toolkit and computer the value of our products and services
models in association with payers
Employees — Group-wide programmes to promote our — Increased awareness and understanding of
strategic framework the strategic framework among the global
— Ran management town hall meetings at work force
major sites
Investors — Attended over 70 investor meetings and — Improved investor understanding of our busi-
conferences ness model, strategy and late-stage pipeline
Suppliers and — Worked with key suppliers to commit to our — Minimised supply chain risks
business partners new Supplier Code of Conduct — Extended supplier audits to business critical
— Began aligning supplier audit protocols with service providers (indirect spend)
those of other PSCI members
Non-governmental — Worked with the Access to Medicines Index — Ensure recognition for our access
organisations on its 2010 ranking programmes
— Engaged with Amnesty International, — Launched project with the Chinese Ministry
Declaration of Bern and others on organ of Health to establish an organ donation
donation in China system
Communities — Donated time, money and expertise to — Help to reduce health inequalities
causes such as AIDS orphans in Malawi — Maintain positive relationships with
and clean water in Uganda communities
— Contributed to local communities through — Support the next generation of scientists
initiatives such as Roche Genetics Education
Programme
Media — Over 120 corporate press releases and trade — Maintain a positive media image and protect
news updates our reputation
10_Roche_AR10_ENG_Corporate Responsibility Part1.indd 104 28.01.2011 11:54:14105­
Corporate Responsibility Roche Business Report 2010
Patients
Excellence­in­science­is­furthering­our­understanding­ Our­health­economists­and­reimbursement­managers­
of­the­mechanisms­of­disease.­We­are­using­this­ work­with­national­and­local­health­authorities­to­
knowledge­to­develop­medically­differentiated­new­ demonstrate­the­economic­and­health­benefits­of­our­
therapies­and­help­improve­patients’­quality­of­life.­ products­and­services­within­each­healthcare­sys­
Furthermore,­by­fitting­treatments­to­patients­and­ tem.­We­engage­with­payers­and­providers­through­
achieving­better­outcomes,­personalised­healthcare­ out­a­product’s­lifecycle,­and­provide­guidance­on­
makes­more­efficient­use­of­healthcare­budgets. how­to­assess­the­value­of­our­products­and­services­
through­evaluations­such­as­HTAs.­In­markets­such­
We­can­increase­this­contribution­to­society­by: as­the­UK,­we­have­developed­models­that­assess­the­
• demonstrating­the­medical­and­economic­value­ costs­and­clinical­consequences­of­certain­thera­­
of­our­products pies­compared­with­different­treatment­options,­to­
• helping­to­improve­global­access­to­healthcare help­payers­and­healthcare­providers­make­in­­
• running­safe­and­ethical­clinical­trials formed­choices.
• ensuring­patient­safety­
• building­relationships­with­patients­groups We­work­with­payers­to­agree­pricing­arrangements­
• listening­and­responding­to­customers’­views. that­suit­their­needs.­Our­approach­considers­a­
range­of­options­for­reaching­a­mutually­agreeable­
The value of medicines and diagnostics price,­such­as­volume­based­and­other­discounts,­
Healthcare­payers­have­to­balance­medical­need­and­ price­capping,­cost­sharing­and­payment­by­results.­
clinical­impact­with­the­cost­of­new­medicines­and­­ This­work­was­particularly­important­for­main­­
the­allocation­of­scarce­budgets.­This­has­led­to­the­ taining­access­to­our­products­in­2010,­when­many­
development­of­a­variety­of­methods­for­determin­­ governments­focused­on­reducing­healthcare­­
ing­appropriate­coverage­and­reimbursement­rates­­ budgets­or­restricting­their­growth,­to­help­manage­
by­examining­the­clinical,­economic,­social­and­­ public­finances.
ethical­implications­of­a­medical­technology.­These­
are­broadly­termed­Health­Technology­Assess­­ Our­positions­on­personalised­healthcare,­assessing­
ments­(HTAs).­Different­providers­use­different­HTAs,­ the­value­of­our­products­and­services,­and­pricing­
resulting­in­varying­healthcare­priorities,­delivery­­ describe­our­approach­in­more­detail­and­are­available­
and­access­levels. on­our­website.
It­is­essential­that­payers­can­assess­our­products­ Global access to healthcare
using­objective,­consistent­and­open­processes,­ The­provision­of­healthcare­is­a­shared­responsibility,­
which­consider­the­full­cycle­of­care­as­well­as­clini­ and­lack­of­access­to­medicines­and­diagnostics­is­
cal­and­economic­value,­for­individual­patients­and­­ one­of­many­systemic­causes­of­healthcare­inequality.­
for­society.­For­this­reason,­we­have­a­global­depart­ Other­barriers­include­lack­of­disease­awareness,­­
ment­that­sets­and­maintains­prices­for­our­portfolio,­ low­levels­of­diagnosis,­and­limited­healthcare­infra­
throughout­the­product­lifecycle.­It­also­ensures­our­ structure­and­budgets.
clinical­trials­assess­the­cost­effectiveness­as­well­­
as­efficacy.­ We­have­an­important­role­to­play­in­tackling­the­­
global­healthcare­challenge.­We­work­with­govern­
When­setting­the­price­for­a­new­test­or­drug,­we­look­ ments,­healthcare­providers,­the­media,­patient­
at­the­medical­benefit­it­provides,­and­compare­its­ groups­and­non­governmental­organisations­(NGOs)­
lifecycle­value­with­the­available­alternatives.­Many­of­ to­increase­access­and­tackle­these­wider­problems.­
our­products­help­reduce­treatment­times­and­the­
need­for­surgery­or­palliative­care,­minimise­hospital­ Health­needs­in­developing­countries­and­emerging­
stays,­prevent­disease­from­returning,­and­speed­ markets­differ­from­those­in­the­developed­world.­­
patients’­return­to­work.­The­associated­savings­are­ We­create­tailored­programmes­to­boost­access­to­our­
also­taken­into­account.­Additionally,­we­consider­ products,­plus­research­and­development­(R­&­D)­
local­reimbursement­models,­population­size­and­ models­for­the­discovery­of­new­products­for­these­
prevalence­of­the­disease,­and­level­of­unmet­need. regions.­We­are­committed­to­finding­sustainable­­
10_Roche_AR10_ENG_Corporate Responsibility Part1.indd 105 28.01.2011 11:54:15106­
Roche Business Report 2010 Corporate Responsibility
and­impactful­ways­to­make­a­long­term­difference­to­
healthcare.­The­illustration­shows­some­of­our­pro­
grammes­to­increase­access­to­healthcare,­and­there­
40
are­further­details­on­our­website.
new drug leads selected
Access for those most in need |­The­World­Health­
by OneWorld Health to investigate
Organization­(WHO)­lists­many­of­our­drugs­as­ as potential new treatments for
childhood diarrhoea
essential­medicines.­These­and­our­other­products­
are­available­through­doctors,­hospitals,­laborato­­
ries­and­pharmacies­in­over­160­countries­—­mainly­
in­those­with­established­healthcare­systems.­­ 47,000
However,­around­a­third­of­the­world’s­population­
does­not­have­adequate­access­to­healthcare.­ patients received free medicines
through the Genentech
Access to Care Foundation
Poorer­countries­suffer­the­highest­levels­of­disease­
and­have­the­weakest­healthcare­systems.­Many­face­
a­critical­shortage­of­healthcare­professionals­and­
facilities,­as­well­as­low­levels­of­understanding­of­the­
1,100,000
causes,­prevention­and­treatment­of­disease.­We­­
aim­to­provide­sustainable­access­to­healthcare­in­
infants tested for HIV
these­countries­based­on: through the AmpliCare Initiative
• Sustainable­patent­and­pricing­policies
• Partnerships­with­governments,­NGOs­and­others
• Education,­training­and­knowledge­transfer
• R­&­D­into­diseases­with­unmet­medical­needs.
We­have­not­filed­or­enforced­patents­for­any­of­our­
19,500
medicines­in­the­Least­Developed­Countries­(LDCs)­
defined­by­the­United­Nations­since­2001.­In­2010­­
employees participated in the annual Children’s
we­expanded­this­policy­to­include­the­Low­Income­
Walk to support care centres and provide educational
Countries­(LICs)­defined­by­the­World­Bank,­cover­­ opportunities for AIDS orphans in Malawi, as well
as local community activities
ing­another­six­countries.­In­addition,­we­do­not­file­
or­enforce­patents­for­any­antiretroviral­HIV­medi­
cines­in­sub­Saharan­African­(sSA)­countries.
We­supply­two­HIV­medicines­at­no­profit­prices­in­
the­LDCs­and­sSA,­and­we­provide­these­medicines­ develops­new­markets­for­our­products­and­services­
at­reduced­prices­in­lower­middle­income­countries.­ in­the­longer­term.
Valcyte,­our­medicine­for­AIDS­related­cytomegalo­­
virus­retinitis,­is­available­at­reduced­prices­for­NGO­ In­2010­we­joined­forces­with­the­International­
led­AIDS­treatment­programmes­in­the­LDCs,­LICs,­ Atomic­Energy­Agency­(IAEA)­to­launch­EDUCARE,­
sSA,­and­lower­middle­income­countries.­ a­major­new­programme­to­improve­cancer­care­­
in­Africa.­Cancer­kills­more­people­each­year­in­devel­­
We­focus­on­developing­partnerships­with­govern­ oping­countries­than­AIDS,­malaria­and­tuberculo­­
ments­and­NGOs­in­these­countries.­Our­aim­is­to­ sis­combined,­yet­there­is­very­little­oncology­invest­
estab­lish­programmes­that­raise­awareness,­train­ ment.­The­programme­is­establishing­an­online­­
healthcare­providers,­and­improve­infrastructure.­This­ university­offering­comprehensive­training­in­several­
approach­increases­the­capabilities­of­healthcare­ areas­of­cancer­management,­and­a­network­for­­
systems­so­they­can­start­to­sustainably­meet­patient­ doctors­to­share­knowledge­and­experience­with­their­
needs.­This­increases­access­to­healthcare,­and­ peers.­Roche­is­providing­financial­support,­con­­
10_Roche_AR10_ENG_Corporate Responsibility Part1.indd 106 28.01.2011 11:54:15107­
Corporate Responsibility Roche Business Report 2010
11,000,000 treatment courses of anti-influenza medicine
Tamiflu donated to WHO for countries most in
need, two sublicensing agreements reached and
the Tamiflu Reserves Programme established for
developing countries
3–12
months employees can go on secondment to
55 contribute their skills and expertise to help
make a difference in health services in LDCs
countries where Roche does
not file or enforce patents for
83% of HIV-infected patients
any of its medicines
eligible for no-profit or
reduced-price Roche medicines
4 pilot countries selected for online
university courses in oncology
under the EDUCARE initiative in
sSA, in partnership with IAEA
13
45,000 AIDS technology agreements
reached with companies in LDCs
and sSA for on-site technical help
people reached each year in to manufacture generic versions
rural South Africa by the of Roche’s HIV medicine saquinavir
Phelophepa Healthcare train
450 2,000
employees participated in the annual Children’s children supported in sSA in monitoring orphaned children given primary healthcare
Walk to support care centres and provide educational their diabetes through a partnership plus other services and assistance through
opportunities for AIDS orphans in Malawi, as well with Novo Nordisk’s ‘Changing Diabetes Re & Act and support to the UNICEF & ECPP
as local community activities in Children’ programme AIDS Orphan programmes
sultation­and­expertise.­In­2010­we­identified­suitable­ patients­and­their­families.­In­2010­we­took­part­in­
sites­for­pilot­programmes­in­Ghana,­Zambia,­Tan­­ workshops­for­healthcare­workers­in­Cameroon­­
zania,­and­Uganda,­where­we­will­begin­training­pro­ and­Uganda,­and­participated­in­the­Diabetes­Leader­
grammes­in­2011. ship­Forum­Africa­2010.­More­than­260­participants­
from­32­sub­Saharan­African­countries­attended­this­
We­also­have­a­number­of­programmes­for­increasing­ event,­to­discuss­the­appropriate­response­to­the­
access­to­diagnostic­tests.­We­are­a­partner­in­Novo­ increasing­burden­of­diabetes­and­other­non­commu­
Nordisk’s­Changing­Diabetes­in­Children­programme,­ nicable­diseases­in­Africa.
along­with­the­World­Diabetes­Foundation­and­sev­
eral­African­governments.­More­than­450­children­in­ A­number­of­our­partnerships­improve­research­into­
Africa­were­enrolled­in­the­programme­by­the­end­­ neglected­diseases­of­the­developing­world.­For­
of­2010.­They­received­education­in­diabetes­care­and­ example,­in­2010­we­launched­a­research­fellowship­
access­to­insulin­and­diabetes­supplies­provided­­ together­with­the­WHO’s­programme­for­research­
by­Roche.­We­also­help­to­train­healthcare­workers,­ and­training­into­tropical­diseases­(TDR),­the­Gates­
10_Roche_AR10_ENG_Corporate Responsibility Part1.indd 107 28.01.2011 11:54:15108­
Roche Business Report 2010 Corporate Responsibility
Foundation­and­the­International­Federation­of­Phar­
maceutical­Manufacturers­and­Associations­(IFPMA).­
Boosting cancer care in Morocco
This­fellowship­gives­researchers­from­developing­
countries­first­hand­experience­of­state­of­the­art­ In Morocco, our partnership with the Lalla Salma
processes­and­techniques,­to­help­improve­their­ Association Against Cancer (ALSC) has helped
research­and­clinical­development­expertise. increase cancer awareness and access to treat-
ment, and led to the launch of the first national
Roche­ranked­sixth­in­the­2010­Access­to­Medicines­ cancer plan.
Index,­an­independent­ranking­of­20­research­­ This plan includes the construction of new cancer
focused­pharmaceutical­companies­based­on­106­ centres, expanded screening programmes, and
indicators.­We­are­pleased­with­this­score,­partic­­ education and awareness initiatives.
ularly­as­the­index­focused­on­diseases­outside­our­ We also partner with ALSC to provide access to our
areas­of­specialty,­and­so­did­not­take­into­account­ cancer treatments for the eight million Moroccans
our­EDUCARE­cancer­initiative­or­diagnostics­access­ living below the poverty line, who otherwise fall
programmes.­ outside the healthcare system. ALSC buys the
drugs at a much reduced price, and Roche donates
Access in emerging markets |­Improving­health­ the money received to help strengthen healthcare
care­standards­in­middle­income­countries­present­­ infrastructure in the country. In 2010 1,300 cancer
a­substantial­market­opportunity­for­Roche.­The­­ patients received free treatment as a result of this
market­research­agency­IMS­estimates­that­by­2012,­ partnership. Our efforts are paying dividends, as
the­value­of­emerging­markets­will­equal­roughly­ the market for cancer treatments has more than
80%­of­US­market­value­and­exceed­that­of­Western­ quadrupled in the last five years.
Europe.­Our­emerging­markets­strategy­focuses­­ At a special ceremony in November 2010, Roche
on­speeding­up­regulatory­approvals­and­supporting­ accepted the International Award from Princess
market­development,­primarily­in­major­emerging­ Lalla Salma for our efforts.
economies­such­as­Brazil,­China,­India­and­Russia.
Every­country’s­healthcare­system­is­at­a­different­
stage­of­development­and­has­different­needs.­We­
work­with­governments­in­each­country­to­help­ such­as­cancer,­hepatitis­C­and­rheumatoid­arthritis.­
establish­appropriate­policies,­processes­and­pro­ In­2010­we­negotiated­commercial­access­pro­
grammes,­such­as­disease­awareness,­local­clin­­ grammes­in­middle­income­countries­for­our­hepatitis­
ical­trials­and­training­for­healthcare­professionals.­ drug­Pegasys,­as­well­as­for­our­cancer­drugs­
­Avastin,­Herceptin,­MabThera­and­Tarceva.­
We­also­develop­specific­pricing­programmes­for­
individual­emerging­markets,­where­many­patients­ For­example,­India­has­a­high­hepatitis­C­infection­
cannot­afford­long­term­treatment­for­diseases­­ rate,­coupled­with­low­levels­of­diagnosis­and­limited­
Impact of our HIV access programmes
HIV-infected patients HIV-infected patients living
living in countries eligible in countries eligible for
for no-profit medicines reduced-price medicines
68 % 83 %
10_Roche_AR10_ENG_Corporate Responsibility Part1.indd 108 28.01.2011 11:54:16109­
Corporate Responsibility Roche Business Report 2010
access­to­treatment.­Counterfeit­medicines­present­ trials­in­countries­where­we­do­not­plan­to­market­the­
further­challenges.­Our­Pharmaceuticals­and­Diag­ medicine­being­tested.­We­incorporate­the­Inter­­
nostics­Divisions­have­set­up­screening­camps,­blood­ national­Conference­on­Harmonisation­(ICH)­—­Good­
banks­and­dialysis­clinics­to­help­overcome­these­ Clinical­Practice­(GCP)­guidelines­into­our­clinical­­
problems.­We­have­also­engaged­supply­chain­secu­ trial­programmes,­and­train,­monitor­and­audit­all­
rity­experts­Kezzler­to­provide­encryption­software­ those­involved­to­ensure­compliance.­In­2010­we­
that­enables­consumers­to­verify­that­their­medicine­ revised­the­information­we­provide­to­patients­taking­
is­genuine­when­they­buy­it,­using­their­mobile­phone.­ part­in­Roche­trials­with­help­from­the­European­
Cost­assistance­programmes­are­available­in­India­ Genetic­Alliances­Network­(EGAN),­to­make­it­
based­on­the­recommendation­of­the­treat­ing­doctor.­ clearer­and­easier­to­understand.
As­a­result­of­these­combined­efforts,­the­number­­
of­patients­receiving­Pegasys­and­our­cancer­drugs­ Clinical trials
has­dramatically­increased.­
2010 2009 2008
Access in the developed world |­Even­in­countries­ Number of clinical trials 1,429 1,552 1,596
with­advanced­healthcare­systems,­many­people­­ Number of healthcare
cannot­afford­treatment­or­the­insurance­to­pay­for­­ centres involved 30,006 31,447 29,886
it.­In­the­United­States,­Genentech­helps­patients­­ Number of patients in
to­access­our­medicines,­regardless­of­their­ability­ phase I–IV clinical trials 327,804 302,063 277,674
to­pay.­
Roche and Genentech.
Genentech­Access­Solutions­helps­insured­patients­
navigate­the­complexities­of­health­insurance­­ People­can­search­for­clinical­trials­to­take­part­in­­
coverage­by­explaining­what­their­policy­covers­and­ or­learn­from­the­results­of­completed­trials­at­­
what­they­need­to­pay­for,­and­by­helping­them­­ www.roche­trials.com.­As­of­31­December­2010­­
find­payment­support­programmes­where­possible.­­ the­website­contained­details­of­842­protocols­­
In­2010­we­assisted­more­than­107,000­people. and­385­trial­results.­These­studies­cover­more­than­
100­conditions­including­Alzheimer’s­disease,­
The­Genentech­Access­to­Care­Foundation­(GATCF)­ asthma,­around­30­cancers,­cardiovascular­disease,­
provides­free­medicines­to­uninsured­and­underin­ depression,­diabetes,­hepatitis,­HIV/AIDS,­influenza­
sured­patients­who­meet­certain­financial­and­medi­ and­obesity.­The­website­had­194,241­visitors­in­
cal­criteria.­In­2010­GATCF­provided­free­medicines­­ 2010.­Details­of­our­clinical­trials­are­also­available­
to­more­than­47,000­patients. through­the­International­Federation­of­Pharma­­
ceutical­Manufacturers­and­Associations­(IFPMA)­
Safe and ethical clinical trials clinical­trials­portal,­and­the­US­National­Institutes­­
Clinical­trials­are­essential­to­demonstrate­that­new­ of­Health’s­global­registry.­
medicines­are­safe­and­effective­and­that­diagnostic­
tests­provide­useful­data.­They­also­provide­impor­ We­store­biological­material­used­in­clinical­trials,­
tant­information­about­the­cost­effectiveness­of­­ such­as­tissue,­organs,­blood­and­other­bodily­fluids,­
a­treatment­and­how­this­improves­quality­of­life.­In­ in­human­specimen­repositories,­or­‘biobanks’.­­
addition,­trials­provide­participating­hospitals­with­ This­material­is­invaluable­for­learning­more­about­
educational,­financial­and­medical­support,­and­give­ diseases­and­exploring­possible­treatments.­­
patients­access­to­the­latest­therapies.­Patients­ They­also­contain­sensitive­information­about­the­
receive­free­treatment­during­the­trial,­and­until­the­ person­providing­the­sample.­We­are­dedicated­­
drug­is­available­through­the­healthcare­system­if­­ to­protecting­donors’­privacy­and­ensuring­they­are­
no­approved­alternative­exists.­ fully­informed­about­how­their­sample­and­data­­
will­be­used­before­they­agree­to­take­part­in­a­trial.­
We­have­strict­policies­and­processes­to­ensure­the­ We­apply­equally­strict­measures­to­all­personal­data­
safety,­well­being­and­legal­rights­of­people­taking­ about­customers,­suppliers­and­employees,­in­line­
part­in­clinical­trials.­In­addition,­we­do­not­perform­ with­our­directive­on­the­protection­of­personal­data.
10_Roche_AR10_ENG_Corporate Responsibility Part1.indd 109 28.01.2011 11:54:16Can I handle
Disease area Oncology
Indication First-line metastatic colorectal cancer
Trial AVEX (Avastin in the Elderly with Xeloda), MO19286
No. of patients 280 — fully recruited
No. of study sites 54
No. of countries 10
Daisy D., St. Michael’s Hospital, Oncology Clinical Research Group, Toronto
10_Roche_AR10_ENG_Corporate Responsibility Part1.indd 110 28.01.2011 11:54:43this ?
Jane A., Senior International Clinical Trial Manager, Roche Basel
10_Roche_AR10_ENG_Corporate Responsibility Part1.indd 111 28.01.2011 11:55:07Phase IV clinical trials with Avastin in advanced colorectal cancer
Creating value for patients means doing
post-approval trials so an effective medicine
can benefit an even wider population
Increasing the
number of patients
who can benefit
from Avastin
ML18147 (TML) 2012 * 820
ML20907 (CAIRO3) 2013 * 780
ML21768 (AIO0207) 2013 * 760
Duration of treatment
ML19033 (NordicACT) 2012 * 249
MO18420 (DREAM) 2013 * 640
ML21662 (TRIBE) 2014 * 450
New chemotherapy
combinations
Avastin
MO19286 (AVEX) 2012 * 280
MO18725 (OLIVIA) 2014 * 80
Special populations
* First results Number
expected of patients
in trial
Nearly a million patients have been treated with Avastin since it was first launched
in 2004, and this breakthrough cancer medicine is being developed further in
an extensive clinical trial programme. Cancer treatment is constantly evolving as
oncologists try new drug combinations. Phase IV clinical trials, conducted after
a medicine has entered the market, can generate valuable new insights, even for
a drug as thoroughly studied as Avastin.
Phase IV trials provide important additional information on safety and efficacy
in the ‘real-life’ setting of routine oncology practice, and on the use of Avastin in
special populations, such as the elderly. Many phase IV trials are further evalu-
ating Avastin in patients with metastatic colorectal cancer. Some are designed to
determine the optimal duration of treatment, while others are investigating new
combinations of Avastin with other medicines.
10_Roche_AR10_ENG_Corporate Responsibility Part1.indd 112 28.01.2011 11:55:08113­
Corporate Responsibility Roche Business Report 2010
Organ transplantation |­In­2010­an­NGO­raised­ We­investigate­all­reported­side­effects­to­find­out­
concerns­that­organs­used­in­two­Roche­clinical­trials­ whether­our­product­caused­them.­If­there­is­a­link,­
in­China­may­have­been­harvested­without­consent,­ we­re­evaluate­whether­the­benefits­of­the­medicine­
and­possibly­from­executed­prisoners.­The­trials­into­ or­test­still­outweigh­the­risks.­We­also­have­proce­
the­use­of­the­immunosuppressant­CellCept­in­­ dures­in­place­to­promptly­inform­patients,­physicians,­
organ­transplants­involve­298­patients­at­16­accred­ healthcare­providers­and­regulators­of­any­new­prod­
ited­transplant­centres,­and­are­being­carried­out­­ uct­safety­information.­We­update­product­labelling­
to­establish­whether­the­standard­CellCept­dose­will­ and­information­with­new­safety­information­as­
safely­and­effectively­prevent­organ­rejection­in­­ required­and,­when­necessary,­write­to­healthcare­
people­of­Chinese­origin.­ providers­with­updated­advice­on­the­use­of­our­
products.
For­clinical­trials­in­China­we­follow­the­same­scien­
tific,­medical­and­ethical­standards­as­in­all­other­ We­have­a­strict­product­recall­process­to­ensure­we­
countries.­We­support­a­worldwide­ban­on­any­use­of­ can­withdraw­products­rapidly­on­the­rare­occasions­
organs­from­executed­prisoners,­as­well­as­on­the­ that­quality­problems­do­arise.­In­2010­there­were­no­
death­penalty.­However,­as­in­many­countries,­Chi­ recalls­involving­the­public.
nese­legislation­prevents­pharmaceutical­companies­
from­determining­the­origin­of­transplant­organs.­ Patient advocacy
Transparency­is­essential­when­pharmaceutical­com­
We­will­complete­the­two­trials­but­have­no­plans­to­ panies­partner­with­patient­advocates.­We­declare­
carry­out­further­transplantation­trials­in­China­at­­ our­patient­group­partnerships­on­our­website,­along­
this­stage.­Any­future­trials­will­continue­to­adhere­to­­ with­a­short­description­of­the­partnership’s­activi­
the­Declaration­of­Istanbul­on­Organ­Trafficking­and­ ties.­We­also­declare­significant­or­meaningful­non­­
Transplant­Tourism­and­the­WHO­Guiding­Principles­ financial­support,­as­guided­by­the­European­Fed­­
on­Human­Cell,­Tissue­and­Organ­Transplantation.­ eration­of­Pharmaceutical­Industries­and­Associations­
(EFPIA).­Our­position­statement­and­guidelines­for­
We­contributed­to­changes­in­Chinese­legislation­in­ working­with­patient­groups­describe­our­approach­
2007.­As­a­result­of­these­changes,­the­number­of­ and­are­available­on­our­website.­
transplants­from­living­donors­has­increased.­Efforts­
to­introduce­a­system­for­people­in­China­to­sign­
their­consent­to­donate­an­organ­are­also­having­a­
Patient groups are important
positive­effect.­We­strongly­believe­that­organ­do­­
nation­by­freely­consenting­donors­is­the­most­effec­
partners for Roche. They give us
tive­way­to­contribute­to­an­ethical­and­sustainable­
solution­in­this­area­of­medical­practice.­We­welcome­­
insight into the challenges facing
all­support­in­this­area,­to­improve­the­situation­for­
patients­in­need­of­organs.
patients and their families,
Patient safety and share our interest in helping
Any­medicine­may­cause­side­effects­in­some­
patients.­Our­priority­is­to­make­sure­the­benefits­ patients to understand and
­outweigh­the­risks.­We­have­robust­processes­in­­
all­countries­to­monitor­how­patients­react­to­our­ manage their condition.
­medicines.­We­regularly­analyse­medicines­against­
various­reference­databases­to­help­us­spot­poten­­
tial­safety­risks.­All­products­in­clinical­development­
have­a­safety­management­plan,­and­all­marketed­ Examples­of­our­patient­advocacy­in­2010­include­
medicines­have­a­risk­management­plan­reviewed­ running­workshops­in­Frankfurt,­Germany,­and­Brus­
and­approved­by­major­health­authorities. sels,­Belgium,­to­help­patient­groups­improve­the­
support­they­provide­people­living­with­disease.­In­
10_Roche_AR10_ENG_Corporate Responsibility Part1.indd 113 28.01.2011 11:55:09114­
Roche Business Report 2010 Corporate Responsibility
France,­the­Roche­Foundation­organised­a­Chronic­ Chugai­also­supports­efforts­to­raise­disease­aware­
Disease­Meeting­in­May­2010.­This­event,­which­will­ ness.­In­June­2010­the­company­held­an­event­to­
now­be­held­annually,­brought­together­almost­­ promote­the­importance­of­early­detection­and­treat­
300­patients,­patient­representatives­and­healthcare­ ment­of­rheumatoid­arthritis,­which­affects­around­
professionals­to­discuss­ways­to­improve­quality­of­­ 700,000­people­in­Japan.­Awareness­days­in­eight­
life­for­patients­with­chronic­disease.­The­Foundation­­ Japanese­cities­brought­attention­to­the­impor­­
also­launched­a­new­patient­testimony­website,­­ tance­of­detecting­colon­cancer­early.­For­the­second­
www.lavoixdespatients.fr,­which­publishes­patient­ year­running,­the­campaign­used­a­giant­inflatable­
experiences­and­shares­them­through­links­to­­ colon­with­information­posted­on­the­walls,­for­visitors­
social­networks­such­as­Facebook­and­Twitter.­ to­walk­through­and­learn­how­to­help­prevent­­
colon­cancer­during­daily­life.­In­December­Chugai­
Patient education and awareness sponsored­an­event­run­by­the­cancer­charity­­
Our­responsibilities­do­not­stop­once­we­have­sup­ Medicine­and­Humour,­which­helps­patients­and­
plied­a­product.­We­also­help­healthcare­professionals­ their­families­to­manage­the­disease.
and­patients­to­fully­understand­their­disease­and­
treatment­options,­how­to­use­our­products­correctly,­ More on the Web
and­any­other­services­available­for­improving­out­ • Personalised healthcare: www.roche.com/phc_in_r_d
comes. • Roche position statements on PHC, access to medicines and
diagnostics, pricing, neglected diseases, and working with
patient groups:
Examples­include­the­Accu­Chek­Connect­website­
www.roche.com/policies_guidelines_and_positions
and­coaching­programmes,­which­help­diabetic­ • Access to medicines report: www.roche.com/
patients­to­link­their­behaviour­to­their­condition.­We­ access_to_healthcare
• Programmes in LDCs: www.roche.com/
also­provide­support­services­for­our­cancer­medi­
programmes_in_least_developed_and_developed_countries
cines,­including­calls­from­trained­oncology­nurses­to­ • Programmes in developed countries:
help­patients­manage­their­therapy,­treatment­diaries­ www.GenentechAccessSolutions.com
• Roche trials and patient safety: www.roche-trials.com;
to­record­and­learn­from­their­experiences,­patient­
www.roche.com/clinical_trials;
treatment­calendars­and­appointment­reminders.­
www.roche.com/managing_medication_safety
• List of patient groups supported:
Our­Bag­of­Hope­programme­partners­with­the­­ www.roche.com/patient-groups
• Accu-Chek Connect: www.accu-chekconnect.com
Juvenile­Diabetes­Research­Foundation­(JDRF)­to­
• International Federation of Pharmaceutical Manufacturers and
distribute­bags­containing­information­and­dia­­
Associations (IFPMA) clinical trials portal:
betes­supplies­to­newly­diagnosed­type­1­diabetics.­ www.ifpma.org/clinicaltrials
To­date,­this­project­has­helped­nearly­100,000­ • US National Institutes of Health’s global registry:
www.clinicaltrials.gov
patients­to­adjust­to­life­with­their­condition.­In­2010­
Roche­received­JDRF’s­Chancellor’s­Award­for­­
this­work.
In­addition,­we­help­healthcare­professionals­and­
patient­groups­to­produce­newsletters­and­magazines,­
information­packs,­guides­for­friends,­family­and­­
caregivers.­We­also­supply­needle­boxes,­counselling­
hotlines­and­education­programmes.­For­example,­­
we­have­partnered­with­the­European­Genetics­Alli­
ances­Network­to­produce­a­series­of­simple­leaflets­
in­several­languages,­which­answer­patients’­ques­
tions­on­topics­such­as­clinical­trials­and­bio­banks.­
These­are­available­at­www.biomedinvo4all.com.­­
In­2010­we­added­leaflets­on­Personalised­Health­
care­and­the­Social­and­Psychological­Aspects­­
of­Diagnostic­Testing.
10_Roche_AR10_ENG_Corporate Responsibility Part1.indd 114 28.01.2011 11:55:09115­
Corporate Responsibility Roche Business Report 2010
People
Our­pursuit­of­excellence­in­science­provides­direc­ As­changing­demographics­and­talent­shortages­con­
tion­and­purpose­during­challenging­economic­times.­ tinue­to­impact­the­labour­market,­competition­for­
More­than­ever,­we­rely­on­our­people­to­develop­­ highly­skilled­and­experienced­employees­remains­an­
and­deliver­innovative­products­to­patients­and­there­ ongoing­challenge.­We­are­constantly­stepping­up­
by­contribute­to­the­future­of­healthcare. our­practices­to­source­and­attract­the­best­talent­in­
the­healthcare­industry.
It­is­the­commitment­of­our­80,653­employees,­and­
their­demonstration­of­our­values­of­integrity,­courage­ Personal­and­professional­development­is­very­impor­
and­passion,­that­make­a­real­difference­in­the­lives­ tant­to­our­employees­and­a­priority­in­an­innovation­
of­patients. driven­company­like­ours.­This­remains­the­case­dur­
ing­the­significant­organisational­changes­currently­
As­a­company­dedicated­to­innovation­and­science,­­ underway.­We­strive­for­our­people­to­reach­their­full­
a­highly­skilled,­passionate­and­motivated­workforce­ potential­and­support­them­at­every­stage.
is­at­the­core­of­who­we­are­and­what­we­do.­We­
want­to­be­a­truly­great­place­to­work­for­today’s­most­ We­believe­in­rewarding­achievement­and­commit­
talented­people,­by­giving­them­the­chance­to­make­ ment­with­fair­and­attractive­compensation.­This­
their­mark,­providing­an­environment­where­they­can­ approach­contributes­significantly­to­attracting,­reward­
grow­and­recognising­them­for­their­achievements. ing,­recognising­and­retaining­the­right­­people.­
Selected external awards and recognitions (with top rankings)
Rank 2010 Award Roche site
1 Science Magazine’s Top Employer Survey Genentech
1 Universum — The Swiss Professional Survey 2010 Roche Basel
‘Health/medicine sector’
1 CRF Institute Roche Germany
‘Top employer for engineers’
1 CRF Institute Roche Switzerland
‘Top employer for Switzerland’
3 San Francisco Business Times Genentech
‘Best Places to Work in the Bay Area’
4 Fast Company Magazine’s Genentech
‘World’s Most Innovative Companies 2010’
4 San Diego’s Best Places to Work Genentech
4 Great Places to Work — Denmark Roche Denmark
Best Pharma Company/Best Multinational Company/
Best medical company
5 Science Magazine Top Employers Survey Roche Basel
7 Fortune’s ‘100 Best Companies to Work For’ Genentech
‘Large Companies’
8 Great Places to Work — Austria Roche Vienna
‘Best Employers with 50–250 Employees’
8 Great Places to Work — Spain Roche Madrid
‘Best Workplaces 2010’
9 JRA Best Workplaces — New Zealand Roche Auckland
‘Small to Medium Sized Business Category’
9 Great Places to Work — Urugay Roche Urugay
‘1 st place amongst pharmaceutical companies’
10_Roche_AR10_ENG_Corporate Responsibility Part1.indd 115 28.01.2011 11:55:09116­
Roche Business Report 2010 Corporate Responsibility
People­from­diverse­backgrounds­bring­a­range­­ has­been­named­best­employer­in­the­healthcare­
of­perspectives­to­their­work,­helping­to­drive­inno­­ industry­by­Science­magazine­for­eight­of­the­last­nine­
vation.­This­is­why­we­value­the­experience­of­all­ years,­and­in­2010­Roche­rose­from­17­th­to­5­th­place­
employees­and­foster­an­inclusive­working­environ­ in­the­same­survey.­Survey­participants­gave­both­
ment­in­which­everyone­feels­respected­regardless­­ companies­high­ratings­for­being­innovative­leaders­
of­age,­background­or­gender,­where­they­can­ in­the­healthcare­industry­and­for­doing­important,­
develop­their­careers­and­see­the­positive­impact­­ high­quality­research.­Activities­in­the­field­of­social­
of­their­work.­ responsibility­were­also­rated­highly­and­contrib­­
uted­to­the­positive­results.­Roche­was­also­recog­
The­way­we­implement­the­organisational­changes­ nised­in­rankings­by­Universum,­Top­Employer,­and­
taking­place­as­part­of­our­recently­announced­­ the­Great­Place­to­Work­Institute­™.­
Operational­Excellence­programme­will­test­our­com­
mitment­to­remaining­a­great­place­to­work.­ Championing diversity
In­2010­Roche’s­Executive­Committee­committed­to­
Being a great place to work increasing­the­percentage­of­female­leaders­in­key­
Roche­was­recognised­as­an­attractive­employer­by­­ positions­by­50%­by­2014.­Key­positions­are­defined­
a­number­of­awards­in­2010.­For­example,­Genentech­ as­those­roles­that­are­critical­to­business­delivery,­
drive­significant­value,­and­have­the­greatest­breadth­
and­depth­of­responsibility.­Key­positions­are­closely­
Programmes to ensure diversity in the workforce linked­to­organisational­structure.­We­will­therefore­
revise­our­current­list­of­around­400­positions­to­
reflect­the­recent­changes­that­have­taken­place.
Global and local leadership
programmes to­develop­inclusive­
Given­the­commitment­to­increase­female­leaders­­
leadership­behaviours­and­foster­a­
culture­of­diversity in­key­positions,­we­have­replaced­our­previously­
reported­women­in­senior­leadership­metric­(based­
on­approximately­2,000­positions),­with­the­per­­
Sponsored employee affinity centage­of­women­in­key­positions.­The­baseline­for­
groups, associations and net-
this­new­metric­was­13%­women­in­key­positions­­
works to­provide­support,­exchange­
of­ideas­and­share­learnings in­December­2009.­We­are­already­seeing­a­positive­
impact­from­the­various­actions­taken­to­support­
women­in­leadership,­with­an­increase­of­women­in­
Programmes to improve under-
key­positions­to­16%­in­December­2010.­
standing of­the­needs­of­employees­
with­disabilities­and­to­increase­
number­of­hires Gender diversity
2010 2009 2008
Mobility programmes to­promote­
Women in total
international­transfer­of­employees­
across­the­globe workforce 46% 46% 46%
Women in management 37% 37% 37%
Women in top
120 executives 15% 9% 8%
Attraction and sourcing pro-
cesses and standards to­ensure­ Women in
diversity­of­candidate­pools key positions 16% 13% NA
Gender­is­only­one­element­of­our­commitment­to­
diversity,­and­we­do­not­tolerate­discrimination­of­any­
Programmes focusing on older
employees which­value­their­ form,­as­stated­in­our­global­Employment­Policy.­­
expierience­and­retain­knowledge Our­approach­is­to­embed­diversity­in­all­our­main­
processes­and­objectives.­Our­Human­Resources­
10_Roche_AR10_ENG_Corporate Responsibility Part1.indd 116 28.01.2011 11:55:11117­
Corporate Responsibility Roche Business Report 2010
function­has­measures­and­goals­in­all­key­processes­ applications­*­for­specific­jobs,­and­registered­
relating­to­recruiting,­developing,­promoting­and­­ 167,800­new­candidates­*­to­the­Roche­Group­Talent­
recognising­employees,­to­support­a­diverse­work­ Pool­—­a­database­of­job­seekers­interested­in­
force­and­inclusive­environment.­In­the­context­of­­ becoming­Roche­employees.­
our­diversity­goal,­we­have­extended­our­range­of­
programmes­and­initiatives­to­encourage­and­safe­­ Advertising­roles­internally­also­offers­greater­op­­
guard­employee­diversity,­and­support­a­number­of­ portunities­for­Roche­employees,­as­by­joining­the­
employee­associations­and­networks.­These­include­ Roche­Talent­Pool­they­are­notified­by­e­mail­as­­
Roche­Basel’s­Family­and­Careers­and­Women­in­ soon­as­we­post­a­position­matching­their­prefer­
Leadership­groups,­Genentech­Women­Profession­­ ences­and­skills.
als­(GWP)­and­Genentech­Out­&­Equal­(GO­&­E),­
Strengthening­Ties­Across­Generations­Seniors­ We­regularly­conduct­a­global­survey­to­gauge­the­
(STAGES),­and­African­Americans­in­Biotechnology­ effectiveness­of­our­recruitment­services­and­train­­
(AAIB).­ our­recruiters­worldwide­on­the­latest­methods­and­
strategies.­Throughout­the­year,­a­small­group­of­­
Fostering innovation our­recruitment­specialists­attended­business­con­­
Innovation­is­the­core­of­our­business,­and­is­driven­ ferences­and­events­at­top­international­business­
by­diverse­approaches,­ideas­and­experiences.­Our­ schools­to­give­prospective­employees­the­chance­to­
talent­management­processes­are­all­designed­to­ learn­more­about­our­company­and­for­us­to­add­­
recognise­and­drive­innovation.­In­addition­we­con­ targeted­talent­to­our­pipeline­for­the­future.­These­
duct­a­broad­array­of­specific­and­localised­activi­­ and­many­other­initiatives,­combined­with­the­work­­
ties.­Our­Pharma­Research­and­Early­Development­ of­our­professional­recruitment­teams­around­the­
research­organisation­introduced­a­scientific­career­ globe,­ensure­our­pool­of­diverse­and­talented­candi­
ladder­in­2010­and­sponsored­a­major­recognition­ dates­continues­to­grow.
programme,­the­Leo­Sternbach­Awards­for­Innovation­
in­Chemistry.­This­year,­the­award­recognised­ In­2010­Roche­scored­amongst­the­top­companies­­
Dr Brad­Graves­and­his­team­for­new­classes­of­com­ on­talent­attraction­and­retention­in­the­Dow­Jones­
pounds­in­the­area­of­cancer­treatment.­Research­ Sustainability­Indexes.­
organisations­at­both­Roche­and­Genentech­partici­
pate­in­internal­and­external­science­conferences­ The­Talent­Selection­Survey­shows­a­10­point­in­­
and­write­publications­in­prestige­journals.­In­2010­ crease­in­the­percentage­of­Roche­recruitment­­
Roche­published­more­than­1,200­sientific­articles,­­ managers­who­believe­their­new­hire­performs­well­
of­which­nearly­60­were­in­high­impact­journals­such­ compared­with­their­peers.­This­places­us­above­­
as­Nature,­Cell,­Science­and­the­New England Jour- the­benchmark­in­this­external­survey­of­over­75­mul­
nal of Medicine.­Our­Post­doc­fellowship­programme­ tinational­corporations,­and­suggests­that­we­are­
awards­grants­to­our­best­scientists,­enabling­them­­ successfully­attracting­top­talent.
to­conduct­exploratory­research,­and­strengthening­
our­R­&­D­talent­pipeline.­Several­Genentech­scien­ Developing employees |­In­2010­we­enhanced­our­
tists­received­prestigious­external­science­awards­in­ support­for­employees­to­develop­functional,­profes­
2010,­among­them­Dr­Richard­Scheller,­who­received­ sional­and­leadership­skills.­This­year­71%­of­our­
the­Kavli­Prize­in­Neuroscience,­and­Dr­Napoleone­ employees­took­part­in­career­development­planning­
Ferrara,­who­won­the­Lasker­DeBakey­Clinical­Medi­ discussions.­In­addition,­we­work­with­employees­
cal­Research­Award. individually­to­guide­their­development­according­to­
their­needs,­interests­and­specialities.­Consistent­
Attracting employees |­To­attract­talent,­we­ global­training­materials­now­reflect­our­development­
continue­to­leverage­our­strong­and­differentiating­ philosophy,­which­is­based­on­employee­engage­
employer­brand­through­careers­websites­in­91­ ment,­individual­growth­and­organisational­success.­
countries.­These­sites­had­approximately­1.7­million­
visitors­in­2010.­In­addition,­the­Genentech­career­
website­had­1.2­million­visits.­We­received­266,110­ * Excluding Genentech, Ventana and Chugai.
10_Roche_AR10_ENG_Corporate Responsibility Part1.indd 117 28.01.2011 11:55:11118­
Roche Business Report 2010 Corporate Responsibility
Our­leadership­development­programmes­instil­what­­ Leadership pipeline
it­means­to­be­a­leader­at­Roche,­and­equip­managers­
to­live­up­to­these­expectations.­To­increase­the­con­ 2010
sistency­of­these­programmes­worldwide,­in­2010­we­ Number of high-potential leaders 4,681
created­a­global­framework­for­leadership­develop­ Percentage of women
ment­to­be­implemented­in­phases­by­2013.­This­effort­ high-potential leaders 38%
will­be­supported­by­the­continuing­rollout­of­a­glob­ Percentage of women
al­Learning­Management­System,­and­will­provide­ in leadership programmes 32%
easier­access­to­learning­and­development­support. Internal staffing rate of key positions
(Top 120) 85%
Our­business­is­becoming­increasingly­global,­and­
this­year­we­introduced­a­partnership­with­Global­ We­completed­our­suite­of­global­leadership­pro­
English,­a­service­that­provides­online­business­Eng­ grammes­with­the­introduction­of­a­module­for­global­
lish­training.­The­on­demand­service­gives­employees­ employees­with­high­potential­in­the­longer­term.­
access­to­fast,­cost­effective­and­intensive­language­ Global­programmes­are­now­available­for­high­poten­
courses.­To­date,­over­1,200­employees­from­38­coun­­ tial­leaders­at­all­career­stages.­We­have­also­
tries­have­used­the­service. enhanced­our­suite­of­programmes­by­updating­con­
tent­to­focus­on­inclusive­behaviour­and­cultural­
Our­Diagnostics­and­European­Pharmaceuticals­affili­ awareness,­as­well­as­to­build­greater­collaboration­
ates­offered­nearly­38,300­courses­in­2010­through­ and­understanding­across­divisions,­regions­and­
our­common­training­model,­whether­online­or­class­ functions.­Finally,­we­have­improved­the­way­we­
room­based­training­sessions,­with­almost­45,800­ select­participants,­set­learning­goals­and­measure­
employees­taking­part. the­effectiveness­of­the­programmes.­
Learning and development Our­leadership­development­programme­proved­suc­
cessful­when­several­outstanding­internal­leaders­
2010 2009 2008 stepped­into­critical­roles­during­the­organisational­
Total training changes­that­took­place­this­year.­The­internal­fill­
investment rate­for­all­positions­is­45%,­and­85%­for­the­top­120­
(million CHF) 150 146 139 executive­positions.
Training spend per
employee (CHF) 1,829 1,794 1,734 In­2010­the­Dow­Jones­Sustainability­Indexes­rated­
Total number of Roche­as­the­best­company­in­the­Healthcare­sector­
training hours (million) 1.87 2.16 2.4 for­human­capital­development,­contributing­to­our­
Average training hours position­as­healthcare­supersector­leader.
per employee 23 26 29
Number of postdocs, International mobility |­We­consider­international­
students and interns * 780 656 565 experience­to­be­an­important­aspect­in­the­pro­­
fessional­development­of­future­leaders.­In­2010­we­
* Excluding Chugai.
saw­a­marked­increase­in­the­number­of­new­inter­­
national­assignments,­from­247­in­2009­to­364­in­
Developing tomorrow’s leaders |­In­2010­we­con­ 2010.­This­was­partly­due­to­the­Genentech­integra­
tinued­our­progress­in­identifying­and­developing­ tion­and­resulting­exchange­of­talented­employees­
high­potential­leaders­capable­of­taking­on­critical­ between­California­and­other­parts­of­the­world.­Our­
senior­roles­in­the­short,­medium­and­long­term.­ 626­expatriates­and­cross­boundary­employees­rep­
resent­55­different­nationalities,­and­27%­are­women.­
Moving­abroad­can­be­stressful,­so­we­try­to­make­
the­experience­as­smooth­as­possible.­In­April­2010­
we­launched­revised­international­assignment­­
10_Roche_AR10_ENG_Corporate Responsibility Part1.indd 118 28.01.2011 11:55:11119­
Corporate Responsibility Roche Business Report 2010
policies,­offering­additional­flexibility­to­assignees.­ During­2011­and­2012,­our­goal­is­to­roll­out­our­glob­
We­now­also­offer­a­childcare­allowance­and­in­­ ally­aligned­compensation­strategy,­supported­by­­
creased­spousal­support.­In­addition,­we­introduced­ the­new­Global­Performance­Management­principles.­
a­standard­healthcare­programme­for­global­assign­ The­new­common­approach­will­ensure­our­company­
ees,­which­has­come­into­effect­on­1­January­2011.­ remains­competitive­and­sustainable,­and­continues­
This­programme­offers­competitive­health­insurance­ to­create­value­for­all­stakeholders.­By­maintaining­a­
to­assignees­and­their­families­through­a­leading­ strong­link­between­performance­and­compensation,­
specialist­provider.­ we­will­preserve­employees’­opportunity­to­share­in­
our­success.­
Rewarding and recognising employees
Performance management |­In­2010,­92%­of­our­ Benefits |­Benefits­are­an­important­part­of­the­
employees­took­part­in­performance­management­ total­reward­package­we­offer­our­employees.­Most­
­discussions­with­their­managers­to­reach­a­shared­ programmes­are­tailored­to­local­markets­and­regu­­
understanding­of­their­performance­objectives­and­ lations,­but­typical­examples­include­financial­support­
achievements­through­the­year­and­determine­com­ for­employees­and­their­dependents­upon­retirement­
pensation. and­in­case­of­illness,­disability­or­death.­These­bene­­
fits­usually­supplement­local­state­systems.­We­also­
As­the­mobility­of­our­employees­increases­and­many­ offer­wellness­programmes­that­encourage­a­healthy­
leaders­manage­organisations­across­country­bor­ lifestyle,­and­benefits­that­support­employees’­work/
ders,­we­are­working­to­align­our­performance­man­ life­balance.­Over­91%­of­affiliates­offer­extensive­ben­
agement­principles­globally­in­2011­and­2012.­The­ efits­plans.­Most­go­beyond­state­schemes,­and­
new­common­approach­will­put­greater­emphasis­on­ include­free­access­to­a­wide­range­of­medical­ser­
an­ongoing­dialogue­between­employees­and­man­ vices.­
agers.­We­believe­this­continuous­two­way­feedback­
process­will­contribute­to­timely­input­about­ideas­­ In­2010­we­worked­to­make­affiliates’­benefit­pro­
for­improvement,­better­employee­development­and­ grammes­consistent­within­countries.­This­will­ensure­
ultimately­maximise­scientific­innovation­and­busi­ employees­are­treated­equally­and­improve­efficien­­
ness­results. cy­by­consolidating­vendors.­In­the­United­States,­­
our­combined­workforce­of­24,000­employees­will­all­
Compensation |­Our­total­remuneration­investment­ enjoy­the­same­attractive­and­competitive­benefit­­
in­2010­amounted­to­approximately­11.9­billion­Swiss­ programmes­from­1­January­2011.­In­the­United­King­
francs.­ dom,­we­have­extended­our­flexible­benefits­pro­
gramme­to­cover­all­Pharmaceuticals­and­Diagnostics­
Our­base­pay­packages­reward­performance­and­ employees­from­1­April­2011.­
commitment,­while­our­bonus­schemes­incentivise­
employees­for­innovation­and­outstanding­results­­ In­addition,­we­have­introduced­a­global­assistance­
that­support­our­strategic­objectives.­Bonuses­reflect­ programme­to­support­employees­and­their­families­
both­individual­and­team­achievements,­as­well­as­ while­travelling­abroad.­This­will­provide­access­­
overall­business­performance.­ to­medical­and­security­information­and­emergency­
assistance­from­1­January­2011.­
We­want­employees­to­share­in­our­success.­Through­
Roche­Connect,­employees­in­most­countries­can­ During­2010,­we­continued­to­closely­monitor­the­
purchase­non­voting­equity­securities­at­a­discount­ status­of­our­major­pension­funds.­Alongside­some­
of­up­to­20%.­In­2010,­16,824­employees­in­42­coun­ cash­injections,­we­initiated­changes­in­several­­
tries­took­part­in­this­programme.­This­represents­ local­pension­plans.­Some­of­our­major­pension­funds­
approximately­37%­of­eligible­employees,­and­securi­ removed­early­retirement­incentives­and­have­intro­
ties­worth­61­million­Swiss­francs­were­purchased­­ duced­more­flexible­retirement­models­in­anticipation­
in­2010.­Additionally,­15,410­managers­and­employees­ of­an­ageing­workforce.
received­non­voting­equity­securities­through­the­
Roche­Long­Term­Plan.
10_Roche_AR10_ENG_Corporate Responsibility Part1.indd 119 28.01.2011 11:55:12120­
Roche Business Report 2010 Corporate Responsibility
Aligning human resources processes More on the Web:
Over­the­course­of­2011,­Genentech­and­our­North­ • Employees: www.roche.com/employees
American­pharmaceutical­operations­will­be­incorpo­ • Group policies, positions and guidelines:
www.roche.com/policies_guidelines_and_positions
rated­into­our­Common­HR­Information­Solution­
• Global careers portal: http://careers.roche.com
(CHRIS).­CHRIS­enables­globally­aligned­processes­
• Employment policy: www.roche.com/employment_policy.pdf
that­have­been­adjusted­to­reflect­the­best­prac­­ • Core standards: www.roche.com/commitments
tices­of­both­Genentech­and­the­rest­of­the­Roche­
Group.­Currently,­CHRIS­covers­181­affiliates­and­
representative­offices­and­77%­of­Roche­employees.­
Human rights and labour relations
The­Roche­Employment­Policy­governs­human­rights­
and­labour­relations.­The­Chief­Compliance­Officer­
monitors­implementation­and­compliance­with­this­
policy­and­serves­as­a­contact­for­all­employees.­
We­respect­the­right­of­employees­to­freedom­of­as­­
sociation­and­collective­bargaining.­More­than­7,030­
of­our­employees­are­trade­union­members­and­­
over­32,110­are­members­of­organisations­that­freely­
represent­them­(in­countries­where­this­is­legal).­­
The­Roche­Europe­Forum­represents­the­interests­of­
almost­35,800­employees­in­26­countries.­
Our­directive­on­the­protection­of­personal­data­
ensures­that­we­safeguard­employee­information­and­
comply­with­relevant­local­legislation.­
A­dedicated­Employee­Relations­Officer­monitors­the­
level­of­employee­engagement­and­ensures­that­
appropriate­programmes­and­policies­are­in­place­to­
ensure­fair,­transparent­and­respectful­treatment­­
of­employees,­including­during­the­implementation­­
of­our­Operational­Excellence­programme.­We­­
will­manage­this­programme­carefully,­keeping­em­­
ployees­well­informed­throughout,­supporting­­
them­through­the­changes­and­ensuring­those­leav­
ing­the­company­are­treated­with­fairness,­dignity,­­
and­in­a­socially­responsible­way.­Our­locally­defined­
severance­packages­typically­include­a­range­of­
measures­to­reflect­the­different­needs­of­those­af­­
fected.­Measures­include­severance­pay­with­­
options­to­convert­to­time,­outplacement­services,­
counselling,­careers­fairs­and­centres,­retraining­­
and­redeployment­options,­as­well­as­an­increased­
focus­on­internal­recruitment­and­opportunities.
10_Roche_AR10_ENG_Corporate Responsibility Part1.indd 120 28.01.2011 11:55:12121­
Corporate Responsibility Roche Business Report 2010
Key figures Employees (FTE) by function
Our employees 2010 2009 2008
Roche­employs­80,653­people­in­108­countries,­­ Servicing 15,160 13,408 12,292
clustered­in­five­main­regions.­Our­workforce­­ Manufacturing &
represents­more­than­131­nationalities,­with­24%­­ Logistics 14,770 16,395 15,381
of­employees­working­in­R­&­D.­ Marketing &
Distribution 27,536 28,682 28,426
Research &
Roche employees worldwide Development 19,039 18,894 18,518
(Full-Time Equivalents/FTE) General &
Administration 4,148 4,128 5,463
2010 2009 2008 Total 80,653 81,507 80,080
Europe 35,811 35,310 34,570
North America 23,695 25,412 25,823
Asia 14,964 14,169 13,065 Staffing rates
Latin America 4,633 4,930 4,988
Australia 858 891 887 2010 2009 2008
Africa 692 795 747 New hires 8,279 8,192 9,169
Total 80,653 81,507 80,080 Internal staffing rate 45% 29% 35%
External staffing rate 55% 71% 65%
Employees (FTE) by operating divisions
Retaining employees
2010 2009 2008 In­2010­staff­turnover­increased­from­7%­to­9.5%.­
Pharma 1 46,335 48,181 2 47,551 Driver­of­the­increase­is­the­first­wave­of­employer­
Chugai 6,852 6,632 6,590 related­terminations­as­part­of­Operational­Excel­­
Diagnostics 26,194 25,508 2 25,404 lence­in­Australia,­Latin­America­and­North­America.
Other 1,272 1,186 2 535
Total 80,653 81,507 80,080
Turnover *
1 Including Genentech.
2 2009 restated to reflect consolidation of Finance and IT
into Other. 2010 2009 2008
Total 9.5% 7.0% 9.9%
Employees by contract types Europe 5.7% 5.1% 9.5%
North America 12.3% 7.8% 10.4%
2010 2009 2008 Asia 10.0% 7.2% 8.1%
Regular (FTE) 78,537 79,632 78,216 Latin America 19.3% 13.4% 14.3%
Fixed Term (FTE) 2,116 1,876 2,184 Australia 20.2% 10.9% 15.1%
Full Time (headcount) 76,767 77,866 76,058 Africa 16.8% 18.3% 11.1%
Part Time (headcount) 4,845 4,562 4,342
* Regular and temporary employees under Roche contract.
Reasons for leaving
2010 2009 2008
Employee-initiated 46% 51% 56%
Employer-initiated 44% 40% 24%
Neutral 10% 9% 20%
10_Roche_AR10_ENG_Corporate Responsibility Part1.indd 121 28.01.2011 11:55:12122­
Roche Business Report 2010 Corporate Responsibility
Society
Our­responsibility­extends­beyond­the­healthcare­ Breakdown of giving by area | in 2010
products­we­provide­to­patients­and­the­well-being­of­
our­employees.­We­are­also­committed­to­supporting­
the­welfare­of­communities­in­which­we­operate.­ Humanitarian
and social projects 87%
Our­donation­programmes­seek­to­give­back­to­com- Science
munities­in­four­strategic­areas:­humanitarian­and­ and education 6%
social­projects;­science­and­education;­arts­and­cul- Arts and culture 4%
ture;­and­community­and­environment.­In­each­­ Community
area,­we­support­programmes­that­meet­the­criteria­ and environment 3%
defined­by­our­policy­on­philanthropic­donations­­
and­non-commercial­sponsorship,­as­well­as­pro-
grammes­that­we­believe­will­make­a­lasting,­­ Launching­a­programme­or­contributing­to­a­cause­is­
tangible­difference.­ only­the­first­step­in­Roche’s­social­engagement.­We­
carefully­consider­what­we­want­our­philanthropy­to­
A rigorous approach achieve,­and­continually­monitor­progress­towards­
To­create­real­change,­we­have­developed­­ the­desired­impact.­Therefore,­we­track­the­outcomes­
a­targeted­strategy­which­hinges­on­four­criteria:­ of­our­projects,­not­just­the­initial­investment.
• Innovative:­applies­creative­and­effective­
solutions­to­society’s­challenges­ Sample philanthropic impacts
• Sustainable:­delivers­enduring­effects­in­ Patient and — 2,000 orphaned children given
a­dynamic,­resource-constrained­world­ community health primary healthcare in Malawi
• Collaborative:­draws­on­the­strengths­and­ outreach — Courses for 200 community
capacities­of­respective­partners health workers held in South
• Outcome-driven:­provides­tangible­long-term­ African villages
benefits­to­the­people­involved Community rebuilding — 53 bore holes rehabilitated
and strengthening in Uganda
We­make­most­of­our­contributions­locally,­so­that­ — 18 primary school classrooms
each­business­unit­can­best­address­the­needs­of­its­ built and furnished in Malawi
own­community.­Our­businesses­conceive­and­­ Education — 100 students receive
implement­their­community­activities­to­provide­the­ enhancement and secondary scholarships;
greatest­possible­impact­given­the­specific­chal- opportunity 6 receive post-secondary
lenge­and­available­capabilities.­ assistance in Malawi
— 6 students enrolled in 6-week
Some­issues­call­for­global­intervention.­In­such­ international research
cases,­we­work­with­our­international­network­­ exchange in Germany and the
of­partners­to­support­projects­that­will­meet­socie- United States
ty’s­most­critical­needs.­These­projects­do­not­often­
make­headlines,­but­nevertheless­help­to­resolve­­ Humanitarian and social projects
fundamental­obstacles­to­good­health,­such­as­a­lack­ Improving­well-being­is­at­the­core­of­Roche’s­philos-
of­basic­medical­supplies­or­trained­healthcare­­ ophy.­Humanitarian­and­social­projects­account­for­
professionals.­By­mobilising­our­resources­and­expe- the­largest­portion­of­our­giving­—­and­focus­on­sup-
rience­across­our­four­strategic­areas,­we­aim­to­ porting­the­most­vulnerable­members­of­society,­
make­a­notable­difference. often­children.
Managing impact Employee­participation­in­our­programmes­amplifies­
Developing­and­managing­our­philanthropic­activities­ their­impact.­For­example,­19,500­employees­from­
requires­careful­coordination.­Principles­and­priori- more­than­100­affiliates­participated­in­the­2010­
ties­are­set­at­the­Group­level,­and­implemented­lo-­ annual­Children’s­Walk.­They­generated­over­1.2­mil-
cally­by­business­units­and­partners.­ lion­Swiss­francs,­including­matching­funds­from­­
11_Roche_AR10_ENG_Corporate Responsibility Part2.indd 122 28.01.2011 09:17:41123­
Corporate Responsibility Roche Business Report 2010
the­company.­This­year,­65%­of­this­money­will­go­to­ rily­through­the­1,600­teachers­Roche­helped­train.­
support­day­care­centres­in­Malawi­that­provide­ This­year,­we­also­expanded­our­Roche Genetics­
food,­shelter,­education­and­skills­training­to­AIDS­ Education­Programme,­providing­teaching­materials­
orphans.­The­remaining­35%­will­support­local­­ for­secondary­teachers­in­the­Basel­region.­With­­
charities­that­support­vulnerable­children,­selected­ four­laboratory­workshops­and­two­Talking­Science­
by­affiliates. workshops,­the­school-based­training­model­raises­
understanding­and­interest­in­genetics.
It­is­important­that­employees­see­the­impact­of­their­
efforts.­Each­year,­nine­of­the­most­successful­local­ Arts and culture
Children’s­Walk­fundraisers­visit­the­programmes­we­ Innovation­comes­in­many­forms.­We­see­a­strong­
support,­to­reaffirm­our­commitment­and­witness­­ creative­connection­between­science­and­the­arts.­In­
the­difference­we­make­in­Malawi.­They­then­return­ partnership­with­the­Lucerne­Festival,­the­Cleveland­
home­and­act­as­ambassadors­for­the­walk­and­its­ Orchestra­and­Carnegie­Hall,­we­regularly­commission­
objectives. new­works­from­contemporary­composers.­This­
August,­we­welcomed­the­world­premiere­of­Toshio­
Access­to­healthcare­should­be­universal,­but­in­many­ Hosokawa’s­orchestral­piece­‘Woven­Dreams’,­and­
countries­this­is­not­the­case.­We­have­a­number­­ announced­our­sixth­commission­to­composer­Sofia­
of­programmes­that­help­to­build­infrastructure,­pro- Gubaidulina.­We­provide­further­support­for­crea-­
vide­basic­healthcare­or­transfer­knowledge­and­ tivity­and­expression­through­monthly­Roche­’n’­Jazz­
expertise. events,­where­we­bring­together­the­local­communi-
ty­with­world-class­musicians­to­explore­modern,­
For­example,­the­Roche-sponsored­Phelophepa­ inventive­music.­Now­in­its­fifth­year,­Roche­’n’­Jazz­
health­train­delivers­health­supplies­and­services­to­ has­entertained­more­than­15,000­people­with­per-
poor­and­remote­South­African­communities.­In­­ formances­by­55­ensembles.
2010­—­the­train’s­16­th­year­—­Roche­refurbished­the­
primary­health­coach,­improving­ventilation,­privacy,­ Community and environment
and­disabled­access. We­believe­that­individual­well-being­is­closely­tied­­
to­healthy­communities.­For­example,­in­Kuala­Lumpur­
Science and education Roche­has­established­a­community-based­reha-­
Excellence­in­science­is­critical­for­Roche.­We­aim­to­ bilitation­project­with­Malaysia’s­Department­of­Social­
inspire­future­generations­of­scientists­who­will­­ Welfare.­The­project­provides­occupational­therapy­
drive­the­discovery­of­new­treatments­and­diagnostics­ for­children­with­mental,­physical,­developmental­or­
for­today’s­unmet­medical­needs. emotional­conditions­in­rural­communities.­This­­
helps­the­children­improve­basic­motor­functions­and­
We­provide­young­scientists­with­opportunities­to­ reasoning­abilities,­and­therefore­to­lead­indepen-
expand­their­experience­in­the­field­through­our­ dent­and­productive­lives.
International­Roche­Postdoc­Fellowship­Program.­In­
2010­we­built­up­the­programme­to­100­positions­ More on the Web
with­two-year­grants,­expandable­up­to­four­years­ • Roche social programmes: www.roche.com/society
based­on­scientific­merit.­These­are­for­joint­R­&­D­ • Roche ’n’ Jazz: www.roche-n-jazz.net
• Roche Re & Act: www.react.roche.com
projects­with­partner­universities,­including­the­first­
postdocs­approved­in­China­and­Japan.­In­2011,­
additional­programmes­are­planned.
Science­and­health­matters­often­involve­ethical­con-
siderations.­Roche­Nutley­supports­the­New­Choices,­
New­Responsibilities­programme,­which­introduces­
middle-­and­high-school­students­to­bioethics.­The­
curriculum­supplement­has­reached­approximately­
40,000­students­since­its­introduction­in­1990­prima-
11_Roche_AR10_ENG_Corporate Responsibility Part2.indd 123 28.01.2011 09:17:42124­
Roche Business Report 2010 Corporate Responsibility
Responsible practices
Our­reputation­is­one­of­our­most­valuable­assets.­­ Roche.­We­asked­local­managers­to­implement­a­
It­is­vital­that­all­employees­comply­with­laws,­regula- comprehensive­anti-corruption­compliance­pro-
tions­and­internal­standards­to­fulfil­our­commit-­ gramme,­and­launched­a­global­Roche­Marketing­
ment­to­act­with­integrity.­This­is­the­minimum­our­ and­Sales­Compliance­Questionnaire­to­further­­
stakeholders­expect.­For­these­reasons,­we­judge­ promote­the­importance­of­good­business­conduct.­­
ourselves­not­only­on­our­results,­but­also­on­how­­ We­will­continue­these­meetings­throughout­2011.­
we­achieve­them.
Risk and crisis management
Integrity and compliance Our­Risk­Management­Charter­defines­our­risk­man-
The­Roche­Group­Code­of­Conduct­sets­clear­ex-­ agement­approach­and­responsibilities.­It­is­available­
pectations­for­our­people.­It­guides­employees­on­ on­our­website­along­with­a­list­of­risks­to­our­busi-
correct­business­behaviour,­how­to­act­with­integrity,­ ness.­We­use­stakeholder­feedback­to­help­identify­
and­how­to­speak­up­in­case­of­compliance­con- and­assess­social,­environmental­and­ethical­risks­
cerns.­ and­opportunities,­and­include­the­most­significant­in­
the­Group­risk­management­process.­We­have­in-­
We­encourage­employees­to­speak­to­their­line­man- troduced­a­new­system­to­determine­exposure­from­
ager,­the­local­compliance­officer­or­the­Chief­­ sales­and­marketing­risks­that­are­not­yet­fully­miti-
Compliance­Officer.­They­can­also­report­compliance­ gated.
concerns­anonymously­using­the­SpeakUp­telephone­
line­and­web­service.­Launched­in­December­2009,­ The­Group­and­all­subsidiaries­have­established­crisis­
SpeakUp­operates­in­47­languages­and­98­countries,­ management­teams­to­ensure­we­act­quickly­in­an­
making­it­available­to­almost­70,000­employees.­ emergency.­These­teams­regularly­rehearse­different­
Between­1­December­2009­and­31­December­2010,­ crisis­scenarios,­alerts­and­escalation­procedures.­­
122­reports­were­made­via­the­system.­Roughly­­ We­are­using­our­experience­of­our­pandemic­pre-
half­were­general­comments­about­Roche’s­business,­ paredness­plan­in­response­to­the­H1N1­influenza­
which­are­not­classed­as­non-compliances.­The­­ pandemic­in­2009­to­strengthen­our­business­conti-
other­half­related­to­alleged­violations­of­the­Code­of­ nuity­procedures­globally.
Conduct.­Analysis­of­the­issues­reported­shows­that­
employees­are­using­the­SpeakUp­Line­responsibly.­ Sustainable supply chain
We­spent­around­18­billion­Swiss­francs­in­2010­with­
In­2010,­110­material­business­ethics­incidents­were­ 3rd­parties­on­raw­materials,­active­pharmaceuti-­
reported­in­total,­including­seven­cases­reported­ cal­ingredients­and­other­direct­spend,­plus­indirect­
through­the­SpeakUp­line.­After­investigating­each­ spend­like­contract­R­&­D,­licences,­laboratory­sup-
incident­and­taking­corrective­action­where­nec- plies,­equipment,­consultancy,­marketing­services­
essary,­we­terminated­61­employment­contracts­as­­ and­others.­Ensuring­that­the­companies­supply-­
a­result­of­unethical­behaviour.­ ing­these­products­and­services­act­responsibly­is­­
an­essential­part­of­sustainable­procurement.
We­carried­out­various­activities­to­strengthen­­
compliance­in­2010.­We­updated­our­online­training­ Roche­is­a­member­of­the­Pharmaceutical­Supply­
programmes­on­our­Code­of­Conduct­and­on­anti-­ Chain­Initiative­(PSCI)­and­endorses­the­PSCI­Princi-
trust­issues­by­clearly­listing­the­options­available­for­ ples,­which­set­standards­for­suppliers­in­the­areas­­
reporting­concerns.­In­2010­we­began­rolling­out­­ of­ethics,­labour,­health­and­safety,­the­environment,­
a­more­user-friendly­online­training­programme,­called­ and­related­management­systems.­Our­Supplier­Code­
Roche­Behaviour­in­Business­(RoBiB),­and­set­a­­ of­Conduct,­introduced­in­2009,­incorporates­these­
target­for­95%­of­employees­to­complete­it­in­2011. Principles,­as­well­as­other­important­topics­such­­
as­innovation,­financial­security­and­supplier­diversity.­
We­held­several­meetings­for­local­compliance­offi- At­the­end­of­2010­the­majority­of­key­suppliers­­
cers­to­share­best­practice­in­2010.­We­now­use­the­ had­provided­their­written­commitment­to­the­Supplier­
Genentech’s­tagline­‘Compliance­is­good­business’­­ Code,­which­is­now­included­in­new­supplier­con-
to­communicate­a­consistent­message­throughout­ tracts.­
11_Roche_AR10_ENG_Corporate Responsibility Part2.indd 124 28.01.2011 09:17:42125­
Corporate Responsibility Roche Business Report 2010
Roche supplier assessment — prioritisation
Direct spend Indirect spend Priority for
auditing and
Contract manufacturers CROs, R & D laboratories improvement
API manufacturers 3 rd -Party waste management
Hazardous-chemical manufacturers Animals
Temp labour, Logistics services
Chemicals/Biotech raw materials
Construction, Marketing services
Primary packaging
Fleet services, Travel, Facility management
Informatics, General & admin services
Secondary packaging Consulting services, Engineering services
Equipment
In­May­2010­we­introduced­online­training­to­teach­ contract­research­companies,­temporary­labour­
procurement­staff­how­to­encourage­sustainability­ agencies,­marketing­agencies,­logistics­providers­
among­our­suppliers.­The­training­is­available­on­our­ and­other­service­providers.­The­majority­of­sup-­
intranet­in­Chinese,­English,­German­and­Spanish.­ pliers­met­our­standards,­while­findings­requiring­
More­than­3,000­employees­have­taken­the­course­to­ action­related­mainly­to­labour­conditions,­health­­
date.­Some­classroom­training­sessions­were­also­ and­safety.­We­will­work­with­suppliers­to­correct­
held.­Our­pharmaceutical­division­introduced­a­new­ problems­found­and­provide­training­to­prevent­
Procurement­Code­of­Conduct­to­guide­procure- future­issues.
ment­managers­in­responsible­sourcing.
As­part­of­our­work­with­the­PSCI,­we­have­begun­to­
We­will­continue­to­implement­both­the­Supplier­and­ align­our­supplier­sustainability­audit­protocol­with­
Procurement­Codes­of­Conduct­during­2011.­We­also­ those­of­other­member­companies.­This­will­promote­
plan­to­work­with­selected­high-impact­suppliers­to­ transparency­and­enable­us­to­share­audit­findings,­
measure­and­reduce­their­environmental­footprints,­ reducing­bureaucracy­and­duplication­of­effort.­We­
following­a­pilot­project­with­a­logistics­supplier. have­successfully­piloted­the­aligned­audit­proto-­
col­with­two­suppliers­so­far.
We­monitor­compliance­with­our­sustainability­re-
quirements­at­critical­suppliers­using­internal­and­ Responsible research
external­audits.­We­take­a­risk-based­approach­­ Our­business­model­relies­on­scientific­excellence­and­
to­prioritise­the­companies­to­audit,­which­factors­­ a­detailed­understanding­of­the­mechanisms­of­­
in­risk­levels­by­industry­as­well­as­previous­sus-­ disease,­so­we­can­translate­scientific­breakthroughs­
tainability­performance.­ into­innovative­medicines­and­diagnostics­that­make­
a­difference.­However,­ethical­questions­inevitably­
In­2010­we­conducted­36­audits­in­the­direct­spend­ arise­as­we­explore­the­potential­of­cutting-edge­tech-
area­(e.g.­API,­chemicals­and­biologicals­suppliers,­ nologies.­We­carefully­consider­and­manage­any­­
contract­manufacturers).­For­the­first­time,­we­began­ concerns­to­make­sure­we­maintain­our­integrity­while­
audits­of­critical­service­providers.­We­audited­27­ making­sure­that­no­opportunities­are­lost.­
ksiR
The Roche Supplier Code of Conduct demands high ethical standards from suppliers. It further demands high
standards on social responsibility, safety, health, environment and management systems. It also demands cooperation
with suppliers on additional important topics such as innovation, economic sustainability and supplier diversity.
11_Roche_AR10_ENG_Corporate Responsibility Part2.indd 125 28.01.2011 09:17:42126­
Roche Business Report 2010 Corporate Responsibility
Ethics in R & D |­We­have­clear­policies­and­pro- We­provide­regular­online­ethics­training­for­em-­
cedures­in­place­to­preserve­high­ethical­standards­­ ployees­and­in­April­2010­launched­a­new­online­
in­our­research­and­development­(R &­D)­activities.­ module­based­on­case­studies.­
Our­position­on­clinical­research­defines­these­stan-
dards­and­clarifies­our­views­on­specific­areas­of­­ Animal welfare |­We­take­public­concern­about­ani-
concern.­ mal­research­very­seriously.­We­promote­the­use­of­
alternative­methods­and­work­hard­to­identify­options­
Employees­who­encounter­an­ethical­dilemma­in­­ other­than­the­use­of­animals.­However,­animal­test-
their­work,­and­cannot­resolve­this­with­their­immedi- ing­remains­indispensable­to­biomedical­research­for­
ate­colleagues,­can­contact­our­Global­Ethics­Liai-­ scientific­and­legal­reasons.­Regulatory­authorities­
son­Office.­In­2010­this­office­received­and­resolved­ require­all­healthcare­companies­to­test­the­safety­and­
23­queries,­without­the­need­for­escalation.­The­­ efficacy­of­new­drugs­in­animals­before­they­can­be­
vast­majority­related­to­informed­consent­and­the­use­ used­in­humans.­
of­samples­from­biobanks.­The­Global­Ethics­Liaison­
Office­consults­experts­within­and­outside­the­com- In­2010­we­used­502,105­animals­in­our­research,­­
pany­to­broker­a­solution­as­needed.­ a­slight­increase­on­2009.­For­the­first­time,­we­also­
report­the­number­of­animals­used­by­contractors­
In­2010­we­merged­our­external­Science­and­Ethics­ carrying­out­research­on­our­behalf­—­55,913.­Around­
Advisory­Group­(SEAG)­with­the­Clinical­Research­ 97%­of­all­animals­were­mice­and­rats.
Ethics­Advisory­Group­(CREAG)­to­form­one­indepen-­
dent­body­that­advises­us­on­ethical­issues­in­our­ We­follow­and­promote­the­3Rs­approach­to­animal­
R­&­D­activities.­The­new­SEAG­comprises­external­ research.­This­means­we­replace­animal­tests­where­
experts­in­ethics,­law­and­social­science,­as­well­as­ possible,­reduce­the­number­of­animals­used,­and­
patient­advocates.­It­will­continue­to­provide­advice­ refine­tests­and­animal­welfare­standards.­All­em­-
as­required­and­meet­formally­once­a­year.­ ployees­and­contractors­who­perform­animal­research­
for­us­are­required­to­meet­or­exceed­applicable­laws­
and­industry­standards.
Key activities in 2011
Access Employee Diversity Philanthropy Suppliers
to healthcare engagement
Increase­percentage­­ Systematically­collect­­ Continue­implementation­­
Expand­successful­­ Achieve­positive­ratings of­women­in­key­positions­ and­report­outcomes­of­ of­both­the­Procurement­­
access­programmes­in­ in­employee­engagement­ (50%­increase­from­­ affiliate­philanthropic­­ and­Supplier­Code­of­­
developing­countries­­ surveys­(80%­positive­ 2009­to­2014) activities­and­corporate­­ Conduct­
to­other­countries ratings­by­end­2014) signature­programmes
11_Roche_AR10_ENG_Corporate Responsibility Part2.indd 126 28.01.2011 09:17:44127­
Corporate Responsibility Roche Business Report 2010
We­use­incentives,­training­and­communications­to­ with­animals.­The­committee­covers­Roche­research­
promote­the­3Rs.­These­include­the­Roche­3Rs­­ facilities­in­Europe­and­the­USA,­and­will­include­our­
Award­for­employees­globally,­which­next­takes­place­ Shanghai­site­and­Chugai­from­2011.
in­2011.­This­year­we­began­work­on­a­3Rs­database­
for­sharing­good­practices­throughout­the­Group,­ Innovation and new technologies |­Breakthroughs­
which­will­be­launched­in­2011. in­science­create­opportunities­for­new­drug­dis-­
covery,­development­and­delivery.­For­example,­stem­
Roche­was­one­of­the­founders­of­the­new­Swiss­ cells­and­their­applications­offer­tremendous­poten-
Charter­on­Animal­Welfare,­adopted­in­2010­by­Inter- tial­for­relieving­chronic­pain­and­even­curing­serious­
pharma,­the­association­of­research-based­phar- conditions­such­as­arthritis,­diabetes­and­Parkinson’s­
maceutical­companies­in­Switzerland.­The­Charter­­ disease.­In­particular,­the­discovery­of­induced­plurip-­
commits­us­to­consistently­high­standards­of­ani-­ otent­stem­cells­derived­from­adult­cells­provides­an­
mal­welfare­through­a­programme­of­auditing,­em-­ alternative­to­embryonic­stem­cells,­opening­up­addi-
ployee­training,­stakeholder­dialogue,­promotion­­ tional­opportunities­in­this­promising­field.­
of­the­3Rs­and­management­of­external­contractors.­
We­will­report­our­progress­in­implementing­the­ We­are­involved­in­stem­cell­research­partnerships,­
Charter.­ including­the­Institute­for­Stem­cell­Therapy­and­Ex-­
ploration­of­Monogenic­diseases­(iSTEM)­in­France­
Our­Animal­Welfare­Ethics­Committee­became­fully­ and­the­Massachusetts­General­Hospital­and­Harvard­
operational­and­met­four­times­in­2010.­The­commit- University­in­the­United­States.­In­2009­we­estab-
tee­has­developed­recommendations­for­the­use­­ lished­Stem­Cells­for­Research­(SCR)­in­Basel­and­
of­contractors­for­animal­research­and­will­examine­ Nutley­to­develop­our­expertise­in­this­area.­This­
all­new­studies­using­non-human­primates­(NHPs),­ group­focuses­on­drug­discovery,­pre-clinical­safety­
particularly­those­carried­out­by­contractors.­The­ testing­and­disease­modelling.
committee­has­created­a­questionnaire­to­help­re-­
searchers­submit­NHP­studies­for­examination.­It­also­ We­are­committed­to­responsible­and­transparent­
advises­employees­on­best­practices­when­working­ stem­cell­research.­We­have­therefore­established­
Customer relation- Responsible CR reporting Green IT Energy efficiency
ship management marketing
Evaluate­and­implement­ Promote­best­practices­of­ Reduce­energy­con-
Provide­added­value­ Apply­the­new­Sales­&­­ improved­IT­systems­­ use­of­virtual­IT­to­reduce­ sumption­and­improve­
through­customer­satis- Marketing­Compliance­ for­reporting­on­key­con- energy­consumption­and­ energy­efficiency­­
faction­assessments­­ Questionnaire­Group-wide­ tributions­to­healthcare­­ solutions­to­reduce­travel­ (10%­reduction­from­­
to­meet­or­exceed­ institutions,­patient­organi- and­enable­expanded­ 2009­to­2014)
­customer­expectations sations,­and­individual­ communication
HCPs
11_Roche_AR10_ENG_Corporate Responsibility Part2.indd 127 28.01.2011 09:17:45128­
Roche Business Report 2010 Corporate Responsibility
Animals used in research (Roche and contract Responsible marketing
research organisations) | in 2010 Strict­regulations­and­industry­guidelines­govern­­
the­sale­and­marketing­of­medicines­and­diagnostics,­
to­make­sure­they­are­prescribed,­administered­­
Mice and Rats 97.1% and­used­correctly,­and­that­patients­understand­the­
Other rodents benefits­and­risks­of­taking­them.­
and rabbits 1.1%
Dogs 0.3% However,­regulations­vary­from­country­to­country,­
Primates 0.5% even­within­Europe.­In­2010­Roche­and­other­corpo-
Other (fish, frogs) 1.0% rate­members­of­the­European­Federation­of­Phar-­
maceutical­Industry­Associations­(EFPIA)­developed­
a­Leadership­Statement­which­provides­guidance­­
in­five­sensitive­areas.­These­relate­to:­patient­infor-­
binding­principles­for­stem­cell­research­in­consul-­ mation;­training­for­medical­sales­representatives;­­
tation­with­internal­and­external­stakeholders,­which­ the­provision­of­medical­samples­to­healthcare­pro-
we­will­publish­in­2011. fessionals;­organising­meetings­for­healthcare­­
professionals;­and­relationships­with­patient­organi-
In­partnership­with­biopharmaceutical­company­ sations.­Roche­has­fully­committed­to­following­­
­Halozyme,­we­are­exploring­a­new­method­of­drug­ this­guidance.­In­addition,­our­Chief­Compliance­Offi-­
­delivery­that­could­make­it­possible­to­give­biological­ cer­joined­EFPIA’s­new­Trust­Reputation­and­Com-­
medicines­such­as­Herceptin­and­MabThera/­ pliance­Policy­Committee.­
Rituxan­by­subcutaneous­injection­rather­than­intra-
venously.­Halozyme’s­Enhanze­technology­allows­ Roche­managers­are­responsible­for­ensuring­all­
subcutaneous­injection­of­large­volumes­of­medicine­ marketing­activity­under­their­control­complies­­
in­just­three­to­five­minutes,­making­it­more­con-­ with­our­Code­of­Conduct­and­industry­marketing­
venient­and­cost­effective­than­intravenous­delivery. codes.­In­2010­we­launched­the­Roche­Marketing­
Working with stakeholders to make the best product
Regulators and policy makers Physicians and healthcare providers
– Input into regulatory filings – Clinical trial design, participation
– Clinical trial design and results publication
Product
– Shape treatment guidelines – Feedback on product performance
and profile
– Input into training and education material
– Shape treatment guidelines
Patients and patient groups Payers and reimbursers
– Market research on patients needs – Health outcome studies
– Focus groups on product profile (e.g. ease of use) – Determination of medical value
– Co-develop support, awareness and – Reimbursement programmes
educational material
– Training for patient groups
11_Roche_AR10_ENG_Corporate Responsibility Part2.indd 128 28.01.2011 09:17:46129­
Corporate Responsibility Roche Business Report 2010
and­Sales­Compliance­Questionnaire­(RMSCQ),­to­ tions­and­policies­for­public­health­as­well­as­for­
help­managers­assess­how­well­their­operations­­ more­general­areas,­such­as­the­assessment­of­the­
perform­on­sensitive­compliance­topics.­All­General­ value­of­healthcare­and­our­work­with­public­­
Managers­have­to­sign­a­declaration­that­confirms­ health­organisations,­think­tanks­and­academics.­
their­compliance.­We­also­ran­refresher­training­on­
responsible­marketing­for­global­product­strategy­ One­example­is­our­contribution­to­the­European­
teams­in­the­pharmaceutical­business.­2011­we­will­ Commission­Process­on­Corporate­Responsibility­in­
carry­out­refresher­courses­on­antitrust­issues­and­ the­field­of­pharmaceuticals.­This­process­was­
anti-corruption. launched­in­2010­to­improve­transparency­and­busi-
ness­ethics,­access­to­medicines­in­developing­­
Customer relationship management countries,­and­pricing­and­reimbursement­systems­­
Our­customers­range­from­patients,­healthcare­pro- in­Europe.­We­are­also­participating­in­a­project­­
fessionals,­hospitals­and­reference­laboratories­to­ to­develop­market­access­for­biosimilar­drugs.­
public­and­private­healthcare­payers.­It­is­important­
to­manage­these­relationships­in­a­professional­­ In­2010­we­developed­guidelines­for­sharing­infor-
and­transparent­way.­We­consider­their­needs­and­ mation­on­the­potential­of­misuse­of­drugs­in­sports,­­
views­when­developing­our­products­and­services. in­association­with­the­World­Anti-Doping­Agency­
(WADA).­Roche­and­WADA­signed­a­memorandum­
We­focus­on­building­strategic,­long-term­partner- of­understanding­describing­the­process­to­follow­
ships­with­healthcare­administrators,­as­well­as­spe- when­suspicion­arises.­WADA­presented­Roche­with­
cialists­in­individual­disease­areas.­This­helps­us­­ an­award­in­recognition­of­our­role­in­this­area.
gain­a­broader­overview­of­patient­needs­across­all­
areas­of­healthcare,­and­enables­us­to­offer­a­full­ We­also­contribute­to­policy­development­through­
range­of­appropriate­pharmaceutical­and­diagnostic­ our­membership­of­industry­bodies­such­as­the­­
products.­This­approach­aligns­more­closely­with­­ European­Diagnostics­Manufacturers­Association­
our­vision­for­personalised­healthcare,­and­will­im-­ (EDMA),­the­European­Biopharmaceutical­Enter-
prove­customer­service,­identify­additional­oppor-­ prises­(EBE),­the­International­Federation­of­Pharma-
tunities­and­create­efficiencies­and­cost­savings.­ ceutical­Manufacturers­and­Associations­(IFPMA),­
and­the­European­Federation­of­Pharmaceutical­In-
For­example,­Genentech­employs­Thought­Leader­ dustry­Associations­(EFPIA).­In­2010­EFPIA­approved­
Liaisons,­who­work­with­external­medical­experts­to­ four­priority­areas­for­the­next­two­years.­These­re-
ensure­we­understand­their­opinions­and­establish­ late­to:­improving­the­effectiveness­of­health­technol-
lasting,­mutually­beneficial­partnerships. ogy­assessments;­strengthening­intellectual­proper-­
ty­frameworks;­enhancing­ethics,­trust­and­reputation;­
We­carry­out­comprehensive­market­research­and­ and­attracting­more­R­&­D­to­the­European­Union.­
analysis­to­better­understand­the­needs­of­specific­ Through­EFPIA,­we­contributed­to­updates­to­Euro-
customer­groups­and­markets.­In­2010­indepen-­ pean­Union­(EU)­legislation­aimed­at­strength-­
dent­research­among­246­cancer­specialists­in­the­ ening­systems­for­monitoring­the­safety­of­medicines,­
United­States­and­five­European­countries­showed­ in­particular­to­protect­against­counterfeit­medi-­
that­Roche’s­customer­retention­in­these­markets­­ cines­and­ensure­patients­receive­reliable­information­
is­90%­—­compared­with­an­average­rate­of­72%­ on­prescription­medicines.­This­work­will­continue­­
among­our­peers.­In­addition­to­product­efficacy,­­ in­2011.
the­main­drivers­of­customer­retention­was­found­to­
be­the­sales­representative’s­conduct,­knowledge­­ We­have­contributed­to­the­revision­of­the­EU­Direc-
and­expertise,­and­the­information­and­support­pro- tive­on­the­Protection­of­Animals­used­for­Scientific­
vided­for­patients­and­clinicians. Purposes­since­the­process­began­in­2001.­The­Direc-
tive­aims­to­balance­the­needs­of­research­and­pa-
Public policy tients­with­animal­welfare.­Significant­new­provisions­
We­share­our­views­and­expertise­with­governments­ include­a­mandatory­ethical­review­process­and­­
and­regulators­to­help­develop­effective­laws,­regula- the­development­and­implementation­of­alternative­­
11_Roche_AR10_ENG_Corporate Responsibility Part2.indd 129 28.01.2011 09:17:46130­
Roche Business Report 2010 Corporate Responsibility
methods­that­tangibly­improve­animal­welfare.­The­ cesses­that­are­difficult­to­reproduce.­Copies­of­a­bio-
Directive­will­apply­in­all­EU­member­states­from­ logical­product­are­therefore­similar­but­not­identi-­
November­2012. cal­to­the­original.­These­‘biosimilar’­products­cannot­
be­considered­generic­medicines,­or­approved­­
We­contributed­to­responses­from­EDMA­and­EBE­­ based­on­the­limited­data­set­most­regulatory­bodies­
to­a­European­Commission­consultation­on­in vitro­di- accept­for­generics.
agnostics­(IVDs)­in­2010.­We­support­the­Commis-
sion’s­proposed­risk-based­classification­system­for­ We­support­the­development­of­a­clear­regulatory­
IVDs,­as­long­as­manufacturers­are­given­enough­ framework­for­the­approval­of­biosimilar­products,­
time­to­adjust­to­the­increase­in­development­costs­­ which­compares­them­with­the­original­drug.­The­
it­will­incur.­More­clarity­is­needed­on­proposed­ European­Medicines­Agency­has­established­such­a­
requirements­for­providing­clinical­evidence­for­high- system,­and­published­additional­draft­guidelines­on­
risk­IVDs.­Also­through­EDMA,­we­contributed­to­ similar­biological­medicinal­products­containing­mon-
the­European­Commission’s­review­of­the­medical­de- oclonal­antibodies­for­review.­The­US­Congress­intro-
vices­sector,­which­identified­major­challenges­relat- duced­a­legislative­process­for­approving­biosimilars­
ing­to­competitiveness,­innovation­and­patient­access.­ as­part­of­the­healthcare­reforms­in­March­2010.­For­
countries­where­there­is­no­specific­framework­for­
Combating counterfeits |­Counterfeit­medical­prod- approving­biosimilars,­we­believe­that­regulatory­
ucts­are­illegal­and­a­serious­global­public­health­ authorities­should­follow­the­World­Health­Organi-
problem.­They­endanger­patients,­undermine­confi- zation­(WHO)­Guidelines­on­Evaluation­of­Similar­
dence­in­the­healthcare­industry,­breach­intellectual­ Biotherapeutic­Products,­where­a­comparison­with­an­
property­rights,­and­waste­healthcare­budgets.­We­ original­biological­product­is­required­to­establish­
work­with­relevant­stakeholders­to­improve­product­ similarity.­In­2010­we­engaged­with­regulatory­author-­
security,­strengthen­and­enforce­existing­laws,­train­ ities­and­biosimilar­manufacturers­around­the­world­
local­officials­and­educate­the­public.­Through­EFPIA,­ to­promote­the­WHO­guidelines­as­the­minimum­stan-­
we­have­contributed­to­the­proposed­European­Com- dard.­We­will­continue­to­do­so­to­ensure­similar­
mission­Directive­on­Counterfeiting.­ ­versions­of­our­biotherapeutic­products­brought­to­
market­are­safe­and­effective.­An­updated­position­­
Eliminating­counterfeits­requires­a­comprehensive,­ on­biosimilars­is­available­on­our­website.
universal­approach­across­the­pharmaceutical­indus-
try.­This­should­include­standardised­product­seriali- Political contributions |­Roche­does­not­fund­in-
sation­and­universal­safety­features.­2010­saw­the­ dividual­politicians.­Employees­in­the­USA­can­make­
conclusion­of­an­EFPIA­pilot­project­of­one­potential­ personal­contributions­through­Roche’s­Good­Gov-
approach:­a­system­for­verifying­that­medicines­dis- ernment­Committee­(GGC)­and­Genentech’s­Genen-
pensed­in­pharmacies­are­genuine.­On­each­pack,­a­ PAC.­Both­are­voluntary­political­action­committees­
unique­barcode­smaller­than­a­fingernail­holds­a­ (PAC).­In­2010­employees­donated­340,899­US­dol-
­random­serial­number,­and­the­product­code,­batch­ lars­to­political­campaigns­through­these­PACs.
number,­and­expiry­date.­Before­dispensing­a­medi-
cine,­pharmacists­scan­the­barcode­to­check­it­is­ More on the Web
authentic.­Pharmacists­in­25­stores­scanned­and­ver- • All position papers: www.roche.com/
policies_guidelines_and_positions
ified­almost­100,000­packs­from­14­manufacturers,­
• Responsible marketing, risk management and compliance:
including­Roche.­The­results­show­that­the­technol-
www.roche.com/business_integrity_and_responsible_ marketing
ogy­is­a­feasible,­cost-effective­and­secure­means­­ www.roche.com/risk_management_and_compliance
of­enhancing­patient­safety­and­supply­chain­security. • The Pharmaceutical Industry Principles for Responsible Supply
Chain Management: http://pharmaceuticalsupplychain.org
• Patents, counterfeiting and biosimilars:
Biosimilar products |­Unlike­traditional­medicines­ www.roche.com/medical_value_patents_and_pricing;
which­contain­small­molecules­produced­by­chemical­ www.roche.com/patents
• New products and technologies:
synthesis,­biological­medical­products­have­complex­
www.roche.com/csr_research_and_development
molecular­structures.­They­are­produced­from­living­
www.roche.com/innovation_and_technologies
systems­using­sophisticated­manufacturing­pro-
11_Roche_AR10_ENG_Corporate Responsibility Part2.indd 130 28.01.2011 09:17:47131­
Corporate Responsibility Roche Business Report 2010
Safety, security, health
and environmental protection
Roche­is­dedicated­to­good­health.­We­are­as­com- supplement­these­courses.­In­2010­we­expanded­­
mitted­to­preserving­the­safety­and­well-being­of­­ the­number­of­languages­our­online­SHE­training­is­­
our­employees­and­the­environment­as­we­are­to­im-­ available­in,­bringing­the­total­to­13­and­ensuring­­
proving­health­and­quality­of­life­for­patients. all­Roche­employees­can­understand­the­materials.­
This­enabled­53,000­employees­to­access­the­pro-
Managing SHE gramme­and­41%­of­these­have­participated.­In­2011­
Good­safety,­security,­health­and­environmental­(SHE)­ we­will­expand­this­programme­to­Genentech­
management­is­essential­to­our­business.­We­em-­ employees.­
ploy­a­team­of­20­dedicated­people­at­our­headquar-
ters­in­Basel,­which­is­complemented­by­a­team­of­­ Security
13­in­the­United­States.­While­over­600­full-time­em-­ The­vision­of­security­at­Roche­is­to­protect­our­em-
ployees­support­our­SHE­programme­across­our­ ployees­and­visitors,­physical­assets,­intellectual­
sites,­maintaining­good­performance­is­every­em-­ property­and­products­from­harm­or­loss.­Our­global­
ployee’s­responsibility.­ network­of­site­security­officers­worked­with­Roche’s­
Chief­Security­Officer­in­2010­on­supply­chain­securi-­
Each­site­identifies­its­specific­SHE­risks­and­oppor- ty,­travel­security,­incident­management,­and­training.
tunities,­and­communicates­these­according­to­local­
preferences.­This­ensures­that­colleagues­under- We­have­launched­a­pilot­project­in­Latin­America­to­
stand­and­adhere­to­our­SHE­policy­and­guidelines.­ systematically­assess­transport­security­risks­in­our­
supply­chain­such­as­trucks­being­intercepted,­and­
Our­policy­is­to­internally­audit­critical­sites­such­as­ implement­additional­security­measures­as­neces-­
chemical­and­pharmaceutical­manufacturing­facilities­ sary.­We­have­also­improved­the­help­available­for­
every­three­years,­and­all­other­relevant­sites­period-­ employees­should­emergency­situations­arise­during­
ically­according­to­risk.­These­audits­rate­SHE­per-­ business­travel.­This­includes­security­analysis­before­
formance­according­to­internal­standards,­and­stipu-­ travelling­to­dangerous­countries,­and­a­security­and­
late­future­improvements.­We­have­incorporated­ medical­advice­service­for­use­during­travel.
Genentech­sites­into­the­corporate­SHE­audit­pro-
gramme­and­these­are­now­assessed­against­the­ Regional­security­risks­need­tailored­solutions.­In­
same­standards­as­other­Roche­operations.­ 2010­the­Group­security­team­chaired­a­series­of­re-­
gional­security­workshops­to­reinforce­this­approach.­
SHE audits For­example,­a­workshop­in­Indianapolis,­United­
States,­enabled­participants­to­exchange­insights­and­
2010 2009 2008 experiences­in­the­areas­of­intellectual­property­pro-
Worldwide audits 24 27 25 tection,­workforce­violence­and­supply­chain­security.
First-time audits 4 2 2
Health and safety
In­2010­we­visited­24­sites,­four­for­the­first­time.­Of­
the­20­sites­previously­audited,­almost­all­had­im-­ 2010 2009 2008
proved­their­performance.­Recommended­improve- Roche accident rate 0.065 0.074 0.078
ments­in­2010­include­increased­training­on­topics­ Occupational accidents 432 392 474
such­as­emergency­management,­business­continu- Occupational illnesses 184 227 270
ity,­and­safe­driving.­As­we­expect­similarly­high­­ Work-related fatalities 0 0 0
SHE­standards­from­our­suppliers,­our­procurement­ Work-related accidents
department­conducts­SHE­audits­at­third­party­­ per million working
locations­and­issues­follow-uprecommendations.­ hours 2.97 2.92 3.42
Training­is­at­the­core­of­our­SHE­strategy.­Local­ Employee­health­and­safety­is­one­of­our­foremost­
managers­provide­tailored­training­through­lectures­ priorities.­We­have­rigorous­policies­to­safeguard­
and­courses­customised­to­site-specific­SHE­risks.­ their­well-being,­and­expect­the­same­standards­from­
Regular­regional­SHE­conferences­and­workshops­ our­contractors.
11_Roche_AR10_ENG_Corporate Responsibility Part2.indd 131 28.01.2011 09:17:47132­
Roche Business Report 2010 Corporate Responsibility
Investments­in­SHE­training­appear­to­be­paying­­ Total environmenttal impact — eco-balance
off.­We­have­reduced­work-related­accidents­per­mil-
lion­working­hours­by­36%­since­2005.­Employees­ Use of resources energy 14,495 TJ
reported­432­occupational­accidents­in­2010,­a­10%­ raw materials 67,529 t
increase­in­frequency­compared­with­last­year.­How- water 19,667,601 t
ever,­the­average­severity­—­the­resulting­number­of­ Emissions air
lost­days­—­decreased­4%.­Overall,­the­Roche­acci- VOC 164 t
dent­rate­—­a­measure­that­combines­frequency­with­ SO 7 t
2
severity­—­improved­by­approximately­11%.­Occupa- NO 262 t
x
tional­illness­improved­in­both­incidence­and­severity,­ CO 1,070,794 t
2
with­184­cases­reported. halogenated
hydrocarbons 3,796 t
Our­occupational­accident­and­illness­profile­remains­ particles 33 t
consistent,­with­slips,­falls­and­repetitive­strains­­ water
representing­the­majority­of­work-related­complaints­ TOC 242 t
in­2010.­There­were­no­major­accidents­this­year­—­ heavy metals 0.463 t
for­the­third­consecutive­year. phosphorus 33 t
nitrogen 136 t
Though­we­are­pleased­with­this­positive­trend,­we­ Landfilled waste inert waste 1,226 t
recognise­the­need­to­remain­vigilant.­We­have­ construction waste 14,900 t
installed­defibrillators­in­central­locations­at­almost­ reactor waste 7,208 t
all­sites,­and­continue­to­support­our­employees’­ mio impact points
well-being,­both­during­and­outside­of­work­hours.­ Eco-balance per employee 7.17
Many­Roche­sites­organise­campaigns­to­reduce­
accidents­outside­the­workplace,­such­as­selling­pro-
tective­sports­equipment,­and­running­motorcycle­ Eco-efficiency rate (EER)
safety­courses.­
2010 2009 2008
Environmental footprint Sales (million CHF) 47,473 49,051 45,617
Our­total­environmental­footprint­is­comprised­of­ Environmental
many­individual­impacts,­including­energy­use,­water­ Expenditure
and­waste.­We­measure­our­total­impact­using­the­ (million CHF) 194 186 209
‘eco-balance’­metric­developed­by­the­Swiss­Agency­ Environmental damage
for­the­Environment­(BAFU).­This­weights­the­im- (10 9 environmental
pacts­of­air­and­water­emissions,­landfill­waste,­pri- damage units) 591,592 572,983 564,328
mary­energy,­and­raw­material­usage­to­calculate­a­ EER 0.414 0.460 0.387
total­footprint.­We­also­calculate­impact­per­employee­
so­we­can­measure­our­progress­as­the­business­ We­assess­the­efficiency­of­our­environmental­in-
grows.­We­set­ourselves­a­target­to­improve­our­eco- vestments­and­running­costs­by­comparing­sales­fig-
balance­by­10%­from­2005­levels­by­2015. ures­with­our­total­environmental­expenditures­and­
impact,­as­calculated­according­to­the­BAFU­method-
We­are­pleased­to­have­reached­this­goal­early,­and­ ology.­Our­resulting­eco-efficiency­rate­(EER)­has­
now­plan­to­improve­our­eco-balance­a­further­­ decreased­to­0.414,­a­10%­change­from­2009.­­
15%­from­2010­levels­by­2020.­This­year,­in­keeping­ There­is­a­detailed­definition­at­www.roche.com/
with­an­updated­BAFU­eco-balance­methodology,­­ fact_sheet_eco_efficiency.pdf.­
we­have­included­additional­parameters­such­as­­­
water­use,­resulting­in­an­eco-balance­of­7.17.­
11_Roche_AR10_ENG_Corporate Responsibility Part2.indd 132 28.01.2011 09:17:47133­
Corporate Responsibility Roche Business Report 2010
Energy and climate change Greenhouse gas emissions | CO2 equivalent
As­Roche’s­greenhouse­gas­emissions­result­mainly­
from­energy­use,­our­climate­and­energy­strategies­ 2010 2009 2008
are­inextricably­linked.­ Total emissions
(million tonnes) 1.077 1.053 1.062
Our­priority­is­to­reduce­emissions­while­remaining­a­ Total emissions
viable,­profitable­company.­We­plan­to­do­this­by­ per million CHF of sales
increasing­energy­efficiency­and­switching­to­sustain- (tonnes) 22.69 21.47 23.28
able­energy.­Through­a­Group­directive,­we­have­­
developed­a­systematic­approach­for­conserving­en-
ergy.­This­includes­measures­such­as­designing­­ Energy use | terajoules
new­plants­and­buildings­to­be­more­energy­efficient,­
and­optimising­and­retrofitting­existing­assets.­The­ 2010 2009 2008
directive­covers­all­aspects­of­our­business,­from­pur- Total energy use 14,495 13,898 13,662
chasing­and­operations,­to­research,­marketing,­ Total energy use
administration,­and­transport.­ per million CHF of sales 0.305 0.283 0.299
Total energy use per
In­2005­we­set­a­goal­to­improve­energy­efficiency­­ employee 0.176 0.176 0.178
—­measured­as­consumption­per­employee­—­by­10%­
by­2010.­With­an­improvement­of­7.4%­in­five­years,­ Employee­awareness­and­motivation­will­also­be­criti-
we­missed­this­goal.­This­shortcoming­is­largely­due­ cal­to­achieving­our­goals.­We­are­fortunate­to­have­
to­recent­acquisitions­and­corresponding­increases­­ innovative­and­dedicated­employees.­Our­annual­Re-
in­business­travel,­which­have­raised­our­overall­ sponsible­Care­Award­recognises­this­by­encour-
energy­consumption.­The­energy­efficiency­of­build- aging­employees­to­collaborate­on­ideas­for­energy-
ings,­plants­and­machinery­has­improved­by­more­ saving­projects.­This­year­we­rewarded­sites­that­
than­20%­during­this­period. included­remarkable­projects­in­their­energy­reduc-
tion­plans.­We­recognised­eleven­sites­for­on-site­
We­are­firmly­committed­to­improving­our­perfor- energy­conservation­projects,­and­five­received­
mance.­This­year­we­defined­plans­for­a­further­10%­ awards­for­projects­involving­their­fleets­and­flights.­
efficiency­improvement­by­2014,­from­2009­levels.­­
In­the­longer­term,­we­aim­to­reduce­usage­by­20%­ While­we­are­reducing­the­amount­of­fuel­we­use­­
per­employee­by­2020,­from­2010­levels.­Achieving­ to­heat,­cool­and­run­our­buildings­and­manufacturing­
these­goals­will­require­significant­learning­and­in- sites,­business­travel­is­proving­more­of­a­challenge.­
vestment.­We­are­improving­our­energy­measurement­ Business­air­travel­is­increasing,­and­now­represents­
and­management­processes,­defining­accountabili- almost­17%­of­overall­energy­use.­Introduced­in­
ties,­and­developing­frameworks­for­communication­ 2009,­our­policy­of­using­only­cars­that­emit­a­maxi-
and­knowledge-sharing.­ mum­120­grammes­of­CO ­per­kilometre­in­our­
2
European­Pharma­fleet­by­2012­is­bearing­fruit,­and­
Each­business­unit­and­site­will­need­to­contribute­if­ has­improved­fuel­consumption­efficiency­by­4%­­
we­are­to­reach­our­energy­efficiency­goals.­This­year­ in­one­year.
we­asked­the­58­largest­energy-consuming­sites­
across­the­business­to­create­energy­reduction­action­ While­efficiency­measures­will­play­a­large­role­in­
plans.­The­response­has­been­very­positive,­resulting­ reaching­our­energy­target,­we­must­also­consider­the­
in­total­potential­savings­of­1,400­terajoules­per­year.­ types­of­fuel­we­use.­Our­long-term­strategy­is­to­
A­significant­proportion­of­these­savings­come­from­ continue­to­replace­fossil­fuels­with­sustainable­ener-
retrofitting­refrigeration,­heating,­ventilation­and­air- gy­sources­wherever­practical­and­feasible.­As­a­
conditioning­systems.­We­are­confident­that­success- Group,­our­goal­is­to­increase­the­proportion­of­sus-
fully­implementing­the­submitted­plans­will­achieve­ tainable­energy­we­use­to­20%­by­2020.­
our­2014­goal,­and­will­closely­monitor­implementa-
tion­of­the­plans­to­make­sure­they­stay­on­track.
11_Roche_AR10_ENG_Corporate Responsibility Part2.indd 133 28.01.2011 09:17:47134­
Roche Business Report 2010 Corporate Responsibility
Energy use by type | % acquired­sites­will­work­towards­separate­timelines­
to­give­them­the­same­time­frame­as­operations­
Fuel used by involved­in­the­original­process­(for­Genentech­thus­
company vehicles 10.0 the­target­to­be­met­is­2022).
Oil 1.6 Achieving­these­targets­will­require­significant­
investment.­Though­we­are­searching­for­alternatives,­
Fuel due to business there­are­currently­no­viable­substitutes­in­some­cir-
air travel 16.7 cumstances.­We­will­continue­to­examine­alternatives­
and­work­with­refrigeration­suppliers­to­make­further­
Grid electricity 29.0 reductions­in­the­future.
District heating 3.8 Emissions to air | tonnes
Waste/ 2010 2009 2008
Renewable energy 1.2 VOCs 164 177 213
Particulates 33 27 27
Natural gas 37.7 Nitrogen oxides 262 286 193
Sulphur dioxide 7 9 10
Halogenated hydrocarbons | tonnes Our­manufacturing­operations­emit­volatile­organic­
compounds­(VOCs),­particulates,­nitrogen­oxides­
2010 2009 2008 (NO x)­and­sulphur­dioxide­(SO 2).­These­contribute­to­
various­forms­of­pollution,­including­air­pollution,­
smog,­and­acid­rain.­We­minimise­emissions­to­air­
Holdings 205.2 179.8 144.6 wherever­possible­through­a­variety­of­technologies­
and­practices.­Flue­gas­scrubbers­reduce­NO­and­
x
SO .­VOCs­are­reduced­through­various­incineration­
2
Emissions 3.8 6.5 3.4 and­freezing­processes.­Though­still­under­investi-
gation­in­Switzerland­and­the­US,­the­latter­may­­
It­has­been­challenging­to­reduce­emissions­of­ also­reduce­energy­use.­The­table­shows­our­emis-
chemical­refrigerants­that­are­either­ozone-depleting,­ sions­to­air­in­2010.­Particulates,­NO ­and­SO ­
x 2
such­as­CFCs­and­HCFCs,­or­have­a­high­global­ fluctuate­from­year­to­year,­but­always­at­very­low­
warming­potential,­such­as­HFCs.­The­volume­of­ levels.
refrigerant­holdings­reported­significantly­increased­
in­2010­as­Genentech’s­figures­include­rented­­ Waste | tonnes
or­leased­buildings­and­equipment­for­the­first­time.
2010 2009 2008
We­committed­to­phase­out­all­CFCs­and­HCFCs­from­ General waste
our­operations­by­2010,­and­all­halogenated­hydro- produced 27,249 19,828 42,823
carbon­refrigerants­by­2015.­Though­we­have­made­ General waste per
significant­progress­—­a­100%­reduction­of­halons­ million CHF of sales 0.57 0.40 0.94
and­an­82%­reduction­of­fully­halogenated­com- Chemical waste
pounds­in­seven­years­excluding­Genentech­sites­—­ produced 29,020 27,605 31,295
our­recent­acquisitions­and­lack­of­technical­solu- Chemical waste per
tions­for­some­applications­have­made­this­goal­un-­ million CHF of sales 0.61 0.56 0.69
realistic.­In­consultation­with­our­engineers,­sites,­
and­business­representatives,­we­decided­to­revise­ Roche’s­increased­waste­production­this­year­
our­goal.­We­now­plan­to­reduce­halogenated­­ reflects­a­number­of­operational­changes.­The­37%­
refrigerants­at­Roche­sites­by­90%­by­2015.­Newly­ increase­in­general­waste­includes­large­amounts­­
11_Roche_AR10_ENG_Corporate Responsibility Part2.indd 134 28.01.2011 09:17:48135­
Corporate Responsibility Roche Business Report 2010
of­construction­waste­from­demolished­buildings­­ our­operations­discharged­463­kilogrammes­of­heavy­
in­Mannheim,­Germany,­and­Belleville,­USA.­Chem-­­ metals,­into­watercourses,­primarily­flushed­out­­
ical­waste­increased­slightly­in­line­with­higher­­ from­metal­pipes.­We­discharge­these­pollutants­only­
production­volumes. if­this­fully­complies­with­all­relevant­regulations,­
including­pre-treatment­requirements.­We­are­striving­
Water to­reduce­total­wastewater­toxicity­by­10%­between­
2015­and­2020,­and­are­currently­developing­analyti-
2010 2009 2008 cal­methods­and­performance­measures­to­help­us­
Water withdrawn achieve­this.
(million cubic metres) 19.6 18.6 21.0
Water used Biodiversity
(million cubic metres) 3.6 2.8 2.4 Pharmaceuticals­and­the­natural­world­have­been­
Wastewater discharged closely­linked­for­centuries.­Nature­holds­much­­
to treatment plant inspiration­and­potential­for­treating­illness,­and­we­
(million cubic metres) 6.3 5.2 7.3 must­guard­against­species­loss.­We­support­the­
Organic matter principles­of­resource­stewardship­as­defined­in­the­
discharged to water- Convention­on­Biological­Diversity­(CBD).­
courses after treatment
(tonnes) 242 154 592 The­winners­of­Roche’s­2010­ECOmpetition­award­
Heavy metals have­found­a­surprisingly­simple,­yet­effective­way­to­
discharged to water- counter­the­prevalence­of­invasive­plant­species.­­
courses after treatment Our­Colorado­site­recently­welcomed­a­herd­of­moun-
(kilogrammes) 463 426 545 tain­goats­with­an­appetite­for­the­weeds­threat-­
­ening­the­local­ecosystem.­Compared­with­harsh­
Water­availability­is­increasingly­critical­for­Roche­ chemicals­or­labour-intensive­alternatives,­the­goats­
and­for­society,­and­varies­geographically.­While­ provide­a­low-impact­and­cost-effective­means­to­
Roche­currently­has­no­high-usage­operations­in­ solving­a­significant­environmental­challenge.­
areas­of­water­scarcity,­we­adapt­conservation­and­
reduction­programmes­according­to­local­conditions­ Pharmaceuticals in the environment (PiE)
and­needs.­For­example,­our­Californian­sites­use­ Traces­of­pharmaceutical­products­make­their­way­
drought-resistant­landscaping.­At­other­sites,­we­col- into­the­environment,­primarily­through­natural­­
lect­and­recycle­water­from­our­cooling­towers,­ processes­following­normal­patient­use.­Manufactur-
­creating­a­closed-loop­system­that­reduces­water­use. ing­and­improper­disposal­by­patients­also­con­­-­
trib­ute­a­small­proportion.­Current­evidence­suggests­
We­carefully­manage­both­water­use­and­wastewater­ that­exposure­to­these­low-level­concentrations­in­
discharges.­Our­withdrawal­and­consumption­in-­ surface,­ground­and­drinking­water­does­not­pose­any­
creased­in­2010­due­largely­to­the­inclusion­of­two­ harm­to­human­health,­but­we­recognise­the­need­­
new­sites.­This­year,­our­operations­withdrew­19.6­ for­further­research­into­the­effects­and­support­sci-
million­cubic­metres­of­water.­Reducing­total­with- en­tific­work­in­this­field.
drawal­is­an­important­part­of­our­overall­environ-
mental­target,­and­our­revised­method­for­calculating­ The­risks­to­aquatic­life­are­thought­to­be­greater.­
environmental­impact­(eco-balance)­now­includes­ Studies­to­date­do­not­suggest­any­short-term­
water­usage­to­reflect­this. effects­from­exposure­to­low-level­concentrations­of­
pharmaceuticals,­but­more­research­is­being­con-
We­carefully­control­the­quality­of­water­emissions.­­ ducted­to­evaluate­the­potential­impact­of­long-term­
In­2010­we­discharged­6.3­million­cubic­metres­to­­ exposure.
treatment­plants.­After­treatment,­we­discharged­242­
tonnes­of­organic­matter­—­an­increase­primarily­ We­consider­the­entire­lifecycle­of­our­drugs,­and­
caused­by­the­acquisition­of­a­substantial­Singapore­ take­steps­to­minimise­releases­into­the­environment­
biotech­operation.­In­line­with­low-level­fluctuations,­ at­all­stages.­We­design­our­manufacturing­sites­to­
11_Roche_AR10_ENG_Corporate Responsibility Part2.indd 135 28.01.2011 09:17:48136­
Roche Business Report 2010 Corporate Responsibility
reduce­the­risk­of­active­ingredients­entering­waste-
water,­and­use­financial­incentives­to­encourage­­
customers­to­return­unused­product­for­proper­dis-
posal.­
Compliance and incidents
We­meet­all­local­laws­or­regulations­as­a­mini-­
mum,­but­set­our­sights­higher.­Our­Group­policies­­
are­often­more­rigorous­than­external­standards.­­
We­received­no­significant­SHE­fines­in­2010­for­the­
eighth­consecutive­year.
However,­we­paid­three­small­fines­this­year­for­minor­
infractions.­These­related­to­a­water­quality­viola­-­
tion,­a­physical­defect­in­a­storage­tank,­and­exces-
sive­use­of­a­boiler.­While­none­of­these­incidents­
presented­a­significant­risk­to­our­employees­or­the­
local­community,­we­take­all­incidents­seriously.­­
We­have­taken­steps­to­correct­each­problem­and­
prevent­similar­incidents­from­occurring­in­future.
More on the Web
• SHE performance and goals: www.roche.com/she_performance
• Environmental protection: www.roche.com/environment
• SHE policy: www.roche.com/safety_health_and_environmental_
protection.pdf
• Group fact sheets, positions, policies and guidelines:
www.roche.com/policies_guidelines_and_positions
• Genentech sustainability report:
www.gene.com/gene/about/environmental
11_Roche_AR10_ENG_Corporate Responsibility Part2.indd 136 28.01.2011 09:17:48137­
Independent Assurance Report Roche Business Report 2010
Independent Assurance Report
To­the­Corporate­Governance­and­Sustainability­Committee­of The­Roche­Corporate­Governance­and­Sustainability­Committee­
Roche­Holding­Ltd,­Basel­(‘Roche’). is­responsible­for­both­the­subject­matter­and­the­criteria.­­
­ Our­responsibility­is­to­provide­a­conclusion­on­the­subject­mat-
We­have­performed­assurance­procedures­to­provide­assurance­ ter­based­on­our­assurance­procedures­in­accordance­with­­
on­the­following­aspects­of­the­2010­corporate­responsibility­ the­International­Standard­on­Assurance­Engagements­(ISAE)­
reporting­of­Roche. 3000.
Subject matter Main assurance procedures
Data­and­information­disclosed­in­the­corporate­responsibility­ Our­assurance­procedures­included­the­following­work:
reporting­of­Roche­and­its­consolidated­subsidiaries,­excluding­ • Evaluation of the application of Group guidelines |­
Chugai­Pharmaceutical­Co.,­Ltd.,­for­the­business­year­ended­­ Reviewing­the­application­of­the­Roche­internal­corporate­
31­December,­2010­on­the­following­aspects: responsibility­reporting­guidelines;
•­ The­management­and­reporting­processes­with­respect­to­ • Site visits |­Visiting­selected­sites­of­Roche’s­Pharmaceuti-
the­corporate­responsibility­reporting­and­to­the­preparation­ cals­and­Diagnostics­Divisions­in­Germany,­Hungary,­­
of­SHE­and­people­key­figures­as­well­as­the­control­ Russia­and­the­US.­The­selection­was­based­on­quantitative­
environment­in­relation­to­the­data­aggregation­of­these­­ and­qualitative­criteria;­­
key­figures; Interviewing­personnel­responsible­for­internal­corporate­
•­ The­SHE­key­figures­in­the­tables­on­pages­131­to­136­ responsibility­reporting­and­data­­collection­at­the­sites­­
and­some­selected­people­key­figures­disclosed­on­pages­ we­visited­and­at­the­Group­level­to­determine­the­under-
115­to­121­of­the­Roche­Business­Report­2010. standing­and­application­of­Roche­internal­corporate­
responsibility­guidelines;­
Criteria • Assessment of the key figures |­Performing­tests­on­
•­ The­Roche­Group­internal­corporate­responsibility­reporting­ a­sample­basis­of­evidence­supporting­selected­SHE­and­
guidelines­based­on­the­Responsible­Care­programme­ people­key­figures­(Roche­accident­rate,­energy­con-
Health,­Safety­and­Environmental­Protection­reporting­guide-­ sumption,­CO­emissions­related­to­energy­consumption,­
2
­lines­published­by­the­European­Chemical­Industry­Council­ release­of­halogenated­hydrocarbons,­use­of­water,­­
CEFIC­and­the­‘Sustainability­Reporting­Guidelines­G3’­pub-­ fines­in­relation­to­safety­and­environmental­protection,­
lished­on­October­2006­by­the­Global­Reporting­Initiative­ headcount/FTE­data,­staff­turnover­and­senior­manage-
(GRI);­and ment­positions)­concerning­completeness,­accuracy,­­
•­ The­defined­procedures­by­which­SHE­and­people­key­ adequacy­and­consistency;
figures­are­gathered,­collated­and­aggregated­internally. • Review of the documentation and analysis of relevant
policies and basic principles |­Reviewing­the­relevant­
Responsibility and methodology documentation­on­a­sample­basis,­­including­group­sustain-
The­accuracy­and­completeness­of­corporate­responsibility­indi- ability­policies,­­management­and­reporting­structures­­
cators­are­subject­to­inherent­limitations­given­their­nature­­ and­­documentation.
and­methods­for­determining,­calculating­and­estimating­such­ • Assessment of the processes and data con solidation |­
data.­Our­assurance­report­should­therefore­be­read­in­con-­ Reviewing­the­appropriateness­of­the­management­and­
nection­with­Roche’s­internal­guidelines,­definitions­and­proce- reporting­processes­for­corporate­responsibility­reporting;­
dures­on­the­reporting­of­its­corporate­responsibility­perfor- and­Assessing­the­consolidation­process­of­data­at­the­
mance. group­level.
11_Roche_AR10_ENG_Corporate Responsibility Part2.indd 137 28.01.2011 09:17:48138­
Roche Business Report 2010 Independent Assurance Report
Conclusions The Global Reporting
In­our­opinion
Initiative sustainability
•­ The­internal­corporate­responsibility­reporting­guidelines­
are­being­applied­properly; reporting guidelines
•­ The­internal­reporting­system­to­collect­and­aggregate­
SHE­and­people­key­figures­is­functioning­as­designed­and­
With­this­years’­Annual­Report­we­continue­our­approach­­
provides­an­appropriate­basis­for­its­disclosure.
of­aligning­our­sustainability­reporting­to­the­guidelines­of­the­­
Global­Reporting­Initiative­(GRI).
Based­on­our­work­described­in­this­report­and­the­assess-
ment­of­criteria,­nothing­has­come­to­our­­attention­that­causes­
As­for­the­last­three­Annual­Reports,­Roche­is­of­the­opinion­
us­to­believe­that­the­corporate­responsibility­information­­
that­the­A+­level­of­the­GRI­G3­guidelines­applies­to­its­Annual­
mentioned­in­the­subject­matter­and­­disclosed­with­the­corpo-
Report­2010.­This­was­checked­with­and­confirmed­by­the­
rate­responsibility­reporting­in­the­Roche­Business­Report­
GRI.
2010­does­not­give­a­fair­­picture­of­Roche’s­performance.
Details­of­how­we­report­against­each­indicator­can­be­found­­
Zurich,­21­January­2011
at­www.roche.com/reporting_and_indices
PricewaterhouseCoopers­AG
Dr­Thomas­Scheiwiller­ ­­­Stephan­Hirschi
Severin­Schwan
11_Roche_AR10_ENG_Corporate Responsibility Part2.indd 138 28.01.2011 09:17:49Published by Cautionary statement regarding forward-looking
F. Hoffmann-La Roche Ltd statements
4070 Basel, Switzerland This Annual Report contains certain forward-looking state-
Tel. +41 (0)61 688 11 11 ments. These forward-looking statements may be identified
Fax +41 (0)61 691 93 91 by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’,
‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar
expressions or by discussion of, among other things, strategy,
Media Office
goals, plans or intentions. Various factors may cause actual
Group Communications
results to differ materially in the future from those reflected in
4070 Basel, Switzerland
forward-looking statements contained in this Annual Report,
Tel. +41 (0)61 688 88 88 among others: (1) pricing and product initiatives of competi-
Fax +41 (0)61 688 27 75 tors; (2) legislative and regulatory developments and eco-
nomic conditions; (3) delay or inability in obtaining regulatory
Investor Relations approvals or bringing products to market; (4) fluctuations in
currency exchange rates and general financial market condi-
4070 Basel, Switzerland
tions; (5) uncertainties in the discovery, development or
Tel. +41 (0)61 688 88 80
marketing of new products or new uses of existing products,
Fax +41 (0)61 691 00 14
including without limitation negative results of clinical trials
or research projects, unexpected side effects of pipeline or
World Wide Web marketed products; (6) increased government pricing pres-
www.roche.com sures; (7) interruptions in production; (8) loss of or inability
to obtain adequate protection for intellectual property rights;
Corporate Sustainability Committee (9) litigation; (10) loss of key executives or other employees;
and (11) adverse publicity and news coverage.
Tel. +41 (0)61 688 40 18
E-mail: corporate.sustainability@roche.com
The statement regarding earnings per share growth is not
a profit forecast and should not be interpreted to mean
To order publications
that Roche’s earnings or earnings per share for 2010 or any
Tel. +41 (0)61 688 83 39 subsequent period will necessarily match or exceed the
Fax +41 (0)61 688 43 43 historical published earnings or earnings per share of Roche.
E-mail: basel.webmaster@roche.com
All trademarks mentioned enjoy legal protection.
Next Annual General Meeting:
Links to third party pages are provided for convenience only.
1 March 2011
We do not express any opinion on the content of any third-
party pages and expressly disclaim any liability for all third-
party information and the use of it.
The Roche Annual Report is published in German and English.
Printed on non-chlorine bleached, FSC-certified paper.
The Roche Annual Report is issued by
F. Hoffmann-La Roche Ltd, Basel, Group Communications.
On the cover: Jone F. (USA), a participant in
the phase III EMILIA trial, is receiving treat-
ment with T–DM1 for advanced HER2-positive
breast cancer.
12_Roche_AR10_ENG_Imprint.indd 139 28.01.2011 15:55:3312_Roche_AR10_ENG_Imprint.indd 140 28.01.2011 09:19:19Key figures
Roche Group Index 2008 = 100
Sales mCHF Free cash flow mCHF
2010 47,473 4,699
2009 49,051 8,893
2008 45,617 4,979
Research and development 2 mCHF Total dividend mCHF F. Hoffmann-La Roche Ltd
2010 9,050 5,6933
4070 Basel, Switzerland
2009 9,509 5,175
2008 8,704 4,313
© 2011
Operating profit 2 mCHF Number of employees
All trademarks are legally protected.
2010 16,591 80,653
2009 16,272 81,507
www.roche.com
2008 15,068 80,080
Income taxes 2 mCHF Total employee remuneration mCHF
2010 3,135 11,934
2009 3,287 12,080
2008 3,604 11,129
Net income mCHF Patients on clinical trials 4
2010 8,891 327,804
2009 8,510 302,063
2008 10,844 277,674
Core Earnings per Share CHF Eco-efficiency rate 5
2010 12.78 0.414
2009 12.34 0.46
2008 11.17 0.387
Price development of non-voting equity security (Genussschein) | in CHF
2008 2009 2010
300
250
200
150
100
Roche non-voting equity security Swiss Market Index (rebased)
1 Key figures indexed to 2008 = 100. Figures for 2008 as in Annual Report 2009.
2 Core results. For a full index of Global Reporting Initiative (GRI)
3 Proposed by the Board of Directors. indicators used in the report see:
4 Development phase I to IV. www.roche.com/reporting_and_indices
5 For calculation of the Eco-Efficiency Rate see:
7 000 898 E www.roche.com/environment
00_Roche_AR10_ENG_Key figures.indd 1 28.01.2011 11:41:21
Roche
|
Annual
Report
2010
626 x 297 210 11 210 195
2010 Roche Annual Report
Creating value
for patients
00_Roche_AR10_UG_ENG.indd 1 00_Roche_AR10_ENG_Front Cover.indd 1 27.01.2011 20:09:22 28.01.2011 11:45:52